0001193125-17-093838.txt : 20170323 0001193125-17-093838.hdr.sgml : 20170323 20170323170509 ACCESSION NUMBER: 0001193125-17-093838 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 26 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170323 DATE AS OF CHANGE: 20170323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GALAPAGOS NV CENTRAL INDEX KEY: 0001421876 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-37384 FILM NUMBER: 17710377 BUSINESS ADDRESS: STREET 1: GEN DE WITTELAAN L11 A3 CITY: 2800 MECHELEN STATE: C9 ZIP: 00000 MAIL ADDRESS: STREET 1: GEN DE WITTELAAN L11 A3 CITY: 2800 MECHELEN STATE: C9 ZIP: 00000 20-F 1 d333278d20f.htm 20-F 20-F
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 20-F

 

 

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2016

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

OR

 

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report                     

Commission file number 001-37384

 

 

GALAPAGOS NV

(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)

 

 

Belgium

(Jurisdiction of incorporation or organization)

Generaal De Wittelaan L11 A3

2800 Mechelen, Belgium

(Address of principal executive offices)

Onno van de Stolpe

Chief Executive Officer

Galapagos NV

Generaal De Wittelaan L11 A3

2800 Mechelen, Belgium

Tel: +32 15 342 900 Fax: +32 15 342 901

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

Title of each class

 

Name of each exchange on which registered

American Depositary Shares, each representing one
ordinary share, no par value per share
  The Nasdaq Stock Market LLC
Ordinary shares, no par value per share*   The Nasdaq Stock Market LLC*

* Not for trading, but only in connection with the registration of the American Depositary Shares.

Securities registered or to be registered pursuant to Section 12(g) of the Act. None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

Ordinary shares, no par value per share: 46,256,078 as of December 31, 2016

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    ☒  Yes    ☐  No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    ☐  Yes    ☒  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days    ☒  Yes    ☐  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.    ☐  Yes    ☒  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  ☒                                           Accelerated filer  ☐                                           Non-accelerated filer  ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S. GAAP  ☐  

International Financial Reporting Standards as issued

by the International Accounting Standards Board  ☒

           Other  ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.    ☐  Item 17    ☐  Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ☐  Yes    ☒  No

 

 

 


Table of Contents

TABLE OF CONTENTS

 

             Page  

INTRODUCTION

     1  

PART I

     3  
Item 1  

Identity of Directors, Senior Management and Employee.

     3  
Item 2  

Offer Statistics and Expected Timetable.

     3  
Item 3  

Key Information.

     3  
  A.  

Selected Financial Data

     3  
  B.  

Capitalization and Indebtedness

     5  
  C.  

Reasons for the Offer and Use of Proceeds

     5  
  D.  

Risk Factors

     5  
Item 4  

Information on the Company.

     47  
  A.  

History and Development of the Company

     47  
  B.  

Business Overview

     48  
  C.  

Organizational Structure.

     96  
  D.  

Property, Plants and Equipment.

     96  
Item 4B  

Unresolved Staff Comments.

     97  
Item 5  

Operating and Financial Review and Prospects.

     97  
  A.  

Operating Results

     107  
  B.  

Liquidity and Capital Resources

     120  
  C.  

Research and Development

     124  
  D.  

Trend Information

     124  
  E.  

Off-Balance Sheet Arrangements

     125  
  F.  

Tabular Disclosure of Contractual Obligations

     125  
  G.  

Safe Harbor.

     126  
Item 6  

Directors, Senior Management and Employees.

     126  
  A.  

Directors and Senior Management.

     126  
  B.  

Compensation.

     130  
  C.  

Board Practices.

     139  
  D.  

Employees.

     143  
  E.  

Share Ownership.

     143  
Item 7  

Major Shareholders and Related Party Transactions

     143  
  A.  

Major Shareholders.

     143  
  B.  

Related Party Transactions.

     145  
  C.  

Interests of Experts and Counsel.

     149  
Item 8  

Financial Information

     149  
  A.  

Consolidated Statements and Other Financial Information.

     149  
  B.  

Significant Changes.

     149  
Item 9  

The Offer and Listing.

     150  
  A.  

Offer and Listing Details.

     150  
  B.  

Plan of Distribution.

     151  
  C.  

Markets.

     151  


Table of Contents
             Page  
  D.  

Selling Shareholders.

     151  
  E.  

Dilution.

     151  
  F.  

Expenses of the Issue.

     152  
Item 10  

Additional Information.

     152  
  A.  

Share Capital.

     152  
  B.  

Memorandum and Articles of Association.

     152  
  C.  

Material Contracts.

     152  
  D.  

Exchange Controls.

     152  
  E.  

Taxation.

     152  
  F.  

Dividends and Paying Agents.

     162  
  G.  

Statement by Experts.

     162  
  H.  

Documents on Display.

     162  
  I.  

Subsidiary Information.

     162  
Item 11  

Quantitative and Qualitative Disclosures About Market Risk.

     162  
Item 12  

Description of Securities Other than Equity Securities.

     164  
  A.  

Debt Securities.

     164  
  B.  

Warrants and Rights.

     164  
  C.  

Other Securities.

     165  
  D.  

American Depositary Shares.

     165  

PART II

     167  
Item 13  

Defaults, Dividend Arrearages and Delinquencies.

     167  
Item 14  

Material Modifications to the Rights of Security Holders and Use of Proceeds.

     167  
Item 15  

Controls and Procedures.

     167  
Item 16  

Reserved.

     168  
Item 16A    

Audit Committees Financial Expert.

     168  
Item 16B    

Code of Business Conduct and Ethics.

     168  
Item 16C    

Principal Accountant Fees and Services.

     169  
Item 16D    

Exemptions from the Listing Standards for Audit Committees.

     170  
Item 16E    

Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

     170  
Item 16F    

Change in Registrant’s Certifying Accountant.

     170  
Item 16G    

Corporate Governance.

     170  
Item 16H    

Mine Safety Disclosure.

     171  

PART III

     172  
Item 17  

Financial Statements.

     172  
Item 18  

Financial Statements.

     172  
Item 19  

Exhibits.

     172  

SIGNATURES

  

EXHIBIT INDEX

  

 

ii


Table of Contents

INTRODUCTION

Unless otherwise indicated, “GLPG,” “the company,” “our company,” “we,” “us,” and “our” refer to Galapagos NV and its consolidated subsidiaries.

We own various trademark registrations and applications, and unregistered trademarks, including GALAPAGOS, FIDELTA, and our corporate logo. All other trade names, trademarks and service marks referred to in this annual report on Form 20-F, or this annual report, are the property of their respective owners. Trade names, trademarks and service marks of other companies appearing in this annual report are the property of their respective holders. Solely for convenience, the trademarks and trade names in this annual report may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Our audited consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Our consolidated financial statements are presented in euros. All references in this annual report to “$,” “US$,” “U.S.$,” “U.S. dollars,” “dollars,” and “USD” mean U.S. dollars and all references to “€” and “euros” mean euros, unless otherwise noted. Throughout this annual report, references to “ADSs” mean American Depositary Shares or ordinary shares represented by American Depositary Shares, as the case may be.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than present and historical facts and conditions contained in this annual report, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this annual report, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

 

    the initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;

 

    our ability to advance product candidates into, and successfully complete, clinical trials;

 

    our reliance on the success of our product candidate filgotinib and certain other product candidates;

 

    the timing or likelihood of regulatory filings and approvals;

 

    our ability to develop sales and marketing capabilities;

 

    the commercialization of our product candidates, if approved;

 

    the pricing and reimbursement of our product candidates, if approved;

 

    the implementation of our business model, strategic plans for our business, product candidates and technology;

 

    the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

 

    our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;


Table of Contents
    cost associated with defending intellectual property infringement, product liability, and other claims;

 

    regulatory development in the United States, Europe, and other jurisdictions;

 

    estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

 

    the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;

 

    our ability to maintain and establish collaborations or obtain additional grant funding;

 

    the rate and degree of market acceptance of our product candidates if approved by regulatory authorities;

 

    our financial performance;

 

    developments relating to our competitors and our industry, including competing therapies;

 

    our ability to effectively manage and anticipated growth;

 

    our ability to attract and retain qualified employees and key personnel;

 

    statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance; and

 

    other risks and uncertainties, including those listed in the section of this annual report titled “Item 3.D.—Risk Factors.”

You should refer to the section of this annual report titled “Item 3.D.—Risk Factors” for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

This annual report contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this annual report is generally reliable, such information is inherently imprecise.

Please see the Glossary of Terms on page 87 for definitions of scientific and other terms used in this annual report.

 

2


Table of Contents

PART I

 

Item 1 Identity of Directors, Senior Management and Employee.

Not applicable.

 

Item 2 Offer Statistics and Expected Timetable.

Not applicable.

 

Item 3 Key Information.

 

A. Selected Financial Data

Our consolidated audited financial statements have been prepared in accordance with IFRS, as issued by the IASB. We derived the selected statements of consolidated operations data, selected statements of consolidated financial position and selected statements of consolidated cash flows, each as of December 31, 2012, 2013, 2014, 2015 and 2016 from our consolidated audited financial statements. This data should be read together with, and is qualified in its entirety by reference to, “Item 5—Operating and Financial Review and Prospects” as well as our financial statements and notes thereto appearing elsewhere in this annual report. Our historical results are not necessarily indicative of the results to be expected in the future.

 

Consolidated statement of operations:    Year ended December 31,  
     2016     2015     2014     2013     2012  
     (Euro, in thousands, except share and per share data)  

Revenues

   129,519     39,563     69,368     76,625     74,504  

Other income

     22,093       21,017       20,653       19,947       17,722  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues and other income

     151,612       60,579       90,021       96,572       92,226  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Service cost of sales

             (5,584

Research and development expenditure

     (139,573     (129,714     (111,110     (99,380     (80,259

General and administrative expenses

     (21,744     (19,127     (13,875     (12,353     (12,118

Sales and marketing expenses

     (1,785     (1,182     (992     (1,464     (1,285

Restructuring and integration costs

     —         —         (669     (290     (2,506
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     (163,103     (150,023     (126,646     (113,487     (101,751
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating loss

     (11,491     (89,444     (36,624     (16,915     (9,526
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Fair value re-measurement of share subscription agreement

     57,479       (30,632     —         —         —    

Other financial income

     9,950       1,987       2,291       2,182       3,103  

Other financial expenses

     (1,692     (1,539     (867     (1,402     (1,176
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income / loss (-) before tax

     54,246       (119,627     (35,201     (16,135     (7,599
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income taxes

     (235     1,218       (2,103     (676     164  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income / loss (-) from continuing operations

     54,012       (118,410     (37,303     (16,811     (7,435
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income from discontinued operations

     —         —         70,514       8,732       1,714  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income / loss (-)

   54,012     (118,410   33,211     (8,079   (5,721
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

3


Table of Contents
Consolidated statement of operations:    Year ended December 31,  
     2016      2015     2014     2013     2012  
     (Euro, in thousands, except share and per share data)  

Net income / loss (-) attributable to:

           

Owners of the parent

     54,012        (118,410     33,211       (8,079     (5,721
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Basic income / loss (-) per share

   1.18      (3.32   1.10     (0.28   (0.22
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Diluted income / loss (-) per share

   1.14      (3.32   1.10     (0.28   (0.22
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Basic income/ loss (-) per share from continuing operations

   1.18      (3.32   (1.24   (0.58   (0.28
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Diluted income/ loss (-) per share from continuing operations

   1.14      (3.32   (1.24   (0.58   (0.28
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average number of shares - Basic (in ‘000 shares)

     45,696        35,700       30,108       28,787       26,545  

Weighted average number of shares - Diluted (in ‘000 shares)

     47,308        35,700       30,108       28,787       26,545  

 

Condensed consolidated statement of financial position:                                   
     December 31,  
     2016      2015      2014      2013      2012  
     (Euro, in thousands)  

Cash and cash equivalents

   973,241      340,314      187,712      138,175      94,369  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total assets

     1,083,338        442,514        270,467        287,374        94,369  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Share capital

     223,928        185,399        157,274        154,542        139,347  

Share premium account

     649,135        357,402        114,182        112,484        72,876  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total equity / net assets

     758,701        364,999        206,135        167,137        118,447  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total non-current liabilities

     220,846        5,103        3,976        7,678        7,867  

Total current liabilities

     103,791        72,412        60,356        112,559        109,014  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities

     324,637        77,515        64,332        120,237        116,881  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities and equity

   1,083,338      442,514      270,467      287,374      235,328  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

Condensed consolidated statement of cash flows:                               
     2016     2015     2014     2013     2012  
     (Euro, in thousands)  

Cash and cash equivalents at beginning of the period

   340,314     187,712     138,175     94,369     32,277  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash flows generated / used (-) in operating activities

     239,403       (114,590     (75,555     1,846       65,873  

Net cash flows generated / used (-) in investing activities

     (7,287     (4,297     120,606       (11,988     (6,437

Net cash flows generated in financing activities

     395,996       271,370       4,214       54,495       2,265  

Effect of exchange rate differences on cash and cash equivalents

     4,816       118       271       (548     391  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of the period

   973,241     340,314     187,712     138,175     94,369  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

4


Table of Contents

Exchange Rate Information

The following table sets forth, for each period indicated, the low and high exchange rates of U.S. dollars per euro, the exchange rate at the end of such period and the average of such exchange rates on the last day of each month during such period, based on the noon buying rate of the Federal Reserve Bank of New York for the euro. As used in this document, the term “noon buying rate” refers to the rate of exchange for the euro, expressed in U.S. dollars per euro, as certified by the Federal Reserve Bank of New York for customs purposes. The exchange rates set forth below demonstrate trends in exchange rates, but the actual exchange rates used throughout this annual report may vary.

 

     Year ended December 31,  
     2012      2013      2014      2015      2016  

High

     1.3463        1.3816        1.3927        1.2015        1.1516  

Low

     1.2062        1.2774        1.2101        1.0524        1.0375  

Rate at end of period

     1.3186        1.3779        1.2101        1.0859        1.0552  

Average rate per period

     1.2859        1.3281        1.3297        1.1096        1.1070  

The following table sets forth, for each of the last six months, the low and high exchange rates for euros expressed in U.S. dollars and the exchange rate at the end of the month based on the noon buying rate as described above.

 

     September
2016
     October
2016
     November
2016
     December
2016
     January
2017
     February
2017
 

High

     1.1271        1.1212        1.1121        1.0758        1.0794        1.0802  

Low

     1.1158        1.0866        1.0560        1.0375        1.0416        1.0551  

Rate at end of period

     1.1238        1.0962        1.0578        1.0552        1.0794        1.0580  

On December 31, 2016, the noon buying rate of the Federal Reserve Bank of New York for the euro was €1.00 = US$1.0552. Unless otherwise indicated, currency translations in this annual report reflect the December 31, 2016 exchange rate.

On March 17, 2017, the noon buying rate of the Federal Reserve Bank of New York for the euro was €1.00 = $1.0742.

 

B. Capitalization and Indebtedness

Not applicable.

 

C. Reasons for the Offer and Use of Proceeds

Not applicable.

 

D. Risk Factors

Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the U.S. Securities and Exchange Commission, or the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this annual report and our other SEC filings. See “Special Note Regarding Forward-Looking Statements” above.

 

5


Table of Contents

Risks Related to Product Development, Regulatory Approval and Commercialization

We are heavily dependent on the success of our product candidate filgotinib. We are also dependent on the success of our other product candidates, such as our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972 and MOR106. We cannot give any assurance that any product candidate will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized.

Filgotinib is currently undergoing Phase 3 studies in rheumatoid arthritis, or RA, and in Crohn’s disease, or CD, and a Phase 2b/3 trial in ulcerative colitis, or UC, by our collaboration partner Gilead. Our business and future success is substantially dependent on our ability to develop, obtain regulatory approval for, and then successfully commercialize our product candidate filgotinib, either alone or in a partnership. Our business and future success also depend on our ability to develop successfully, obtain regulatory approval for, and then successfully commercialize our other product candidates, such as our cystic fibrosis, or CF, candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972 and MOR106. We completed Phase 2 trials in certain mutations of CF with potentiator GLPG1837 in 2016; we completed a Phase 1 trial and submitted an application for a Phase 2 safety and pharmacokinetics study in 2016 for GLPG2222, a CF corrector candidate; we initiated a Phase 1 trial in May 2016 for GLPG2451, a CF corrector candidate; we initiated a Phase 1 trial in November 2016 with GLPG2737, a CF corrector candidate; we initiated a Phase 2a trial for idiopathic pulmonary fibrosis, or IPF, with GLPG1690 in April 2016; we plan to initiate a Phase 1b trial with GLPG1972 in osteoarthritis, or OA, patients in 2017; and we initiated a Phase 1b trial in April 2016 with MOR106, a human monoclonal antibody, in patients with atopic dermatitis, or AtD. Our product candidates will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions (if regulatory approval can be obtained at all), securing sources of commercial manufacturing supply, building of, or partnering with, a commercial organization, substantial investment and significant marketing efforts before any revenues can be generated from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, the EMA, or any other comparable regulatory authority, and we may never receive such regulatory approval for any of our product candidates. We cannot assure you that our clinical trials for filgotinib, our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972 or MOR106 will be completed in a timely manner, or at all, or that we will be able to obtain approval from the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or any other comparable regulatory authority for any of these product candidates. We cannot be certain that we will advance any other product candidates into clinical trials. If any of filgotinib, our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972 or MOR106 or any future product candidate is not approved and commercialized, we will not be able to generate any product revenues for that product candidate. Moreover, any delay or setback in the development of any product candidate could adversely affect our business and cause the price of the ADSs or our ordinary shares to fall.

Due to our limited resources and access to capital, we must and have in the past decided to prioritize development of certain product candidates; these decisions may prove to have been wrong and may adversely affect our revenues.

Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. As such, we are currently primarily focused on the development of filgotinib, our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972, and MOR106. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular compounds, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the pharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected.

 

6


Table of Contents

The regulatory approval processes of the FDA, the EMA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA, the EMA and other comparable regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Our product candidates could fail to receive regulatory approval for many reasons, including the following:

 

    the FDA, the EMA or other comparable regulatory authorities may disagree with the design or implementation of our clinical trials;

 

    we may be unable to demonstrate to the satisfaction of the FDA, the EMA or other comparable regulatory authorities that a product candidate is safe and effective for its proposed indication;

 

    the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or other comparable regulatory authorities for approval;

 

    we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

 

    filgotinib and our other product candidates (except for our CF program) are developed to act against targets discovered by us, and because our product candidates are novel mode of action products, they carry an additional risk regarding desired level of efficacy and safety profile;

 

    the FDA, the EMA or other comparable regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials;

 

    the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application, or NDA, supplemental NDA, biologics license application, or BLA, or other submission or to obtain regulatory approval in the United States, Europe or elsewhere;

 

    the FDA, the EMA or other comparable regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies or such processes or facilities may not pass a pre-approval inspection; and

 

    the approval policies or regulations of the FDA, the EMA or other comparable regulatory authorities may change or differ from one another significantly in a manner rendering our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of future clinical trial results may result in our or our collaboration partners’ failure to obtain regulatory approval to market filgotinib, GLPG1837, GLPG2222, GLPG1690, GLPG1972 and/or other product candidates, which would harm our business, results of operations and prospects significantly. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. In certain jurisdictions, regulatory authorities may not approve the price we intend to charge for our products. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

We have not previously submitted an NDA, a BLA, a marketing authorization application, or any similar drug approval filing to the FDA, the EMA or any comparable regulatory authority for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory

 

7


Table of Contents

approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, to a significant extent, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights or share in revenues from the exercise of such rights. If the markets for patient subsets that we are targeting (such as RA, CD, UC, or CF) are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.

In connection with our global clinical trials, local regulatory authorities may have differing perspectives on clinical protocols and safety parameters, which impacts the manner in which we conduct these global clinical trials and could negatively impact our chances for obtaining regulatory approvals or marketing authorization in these jurisdictions, or for obtaining the requested dosage for our product candidates, if regulatory approvals or marketing authorizations are obtained.

In connection with our global clinical trials, we are obliged to comply with the requirements of local regulatory authorities in each jurisdiction where we execute and locate a clinical trial. Local regulatory authorities can request specific changes to the clinical protocol or specific safety measures that differ from the positions taken in other jurisdictions. For example, in our DARWIN Phase 2 clinical trials for filgotinib in subjects with RA, we agreed with the FDA to exclude the 200 mg filgotinib daily dose for male subjects enrolled in the United States pending further data to demonstrate a wider exposure margin in patients versus the safe exposure in animal studies, while there is no such restriction by health authorities outside the United States. We cannot assure you that this view will not be adopted by other regulatory authorities in later stage trials or at the marketing authorization stage, if filgotinib successfully completes the registrational trials. Even if filgotinib does receive regulatory approval or marketing authorization, the FDA or other regulatory authorities may impose dosing restrictions that differ from the approved dosing regimen in other jurisdictions, and these differences could have a material adverse effect on our ability to commercialize our products in these jurisdictions.

Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate, and we may be required to include labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings.

If the FDA, EMA or any other comparable regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration requirements and continued compliance with current good manufacturing practices, or cGMPs, and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

 

    restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;

 

    fines, untitled or warning letters or holds on clinical trials;

 

8


Table of Contents
    refusal by the FDA, the EMA or any other comparable regulatory authority to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals or licenses;

 

    product seizure or detention, or refusal to permit the import or export of products; and

 

    injunctions or the imposition of civil or criminal penalties.

The policies of the FDA, the EMA and other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

Filgotinib, if approved, may be subject to box warnings, labeling restrictions or dose limitations in certain jurisdictions, which could have a material adverse impact on our ability to market filgotinib in these jurisdictions.

Based on pre-clinical findings, we expect that filgotinib, if approved, may have a labeling statement warning female patients of child-bearing age to take precautionary measures of birth control to protect against pregnancy, similar to warnings included with other frequently used medications in RA, such as methotrexate, or MTX.

In addition, there may be dose limitations imposed for male patients who are prescribed filgotinib, if approved. In connection with the DARWIN clinical program, we agreed with the FDA to exclude the 200 mg filgotinib daily dose for male subjects in the United States; males received a maximum daily dose of 100 mg in the U.S. sites in these trials. This limitation was not imposed by any other regulatory agency in any other jurisdiction in which the Phase 2 DARWIN clinical program is being conducted. We agreed to this limitation because in both rat and dog toxicology studies, filgotinib induced adverse effects on the male reproductive system and the FDA determined there was not a sufficient safety margin between the filgotinib exposure at the no-observed-adverse-effect-level observed in these studies and the anticipated human exposure at the 200 mg daily filgotinib dose. Accordingly, in connection with the DARWIN 3 open-label, long-term extension clinical trial, in the United States, male subjects are dosed at 100-mg-daily-dose only. Male participants in this study and their partners are required to use highly effective contraceptive measures for the duration of the study and during a washout period thereafter. As an additional safety measure, we monitor clinical laboratory changes in hormone levels for subjects in the DARWIN 3 clinical trial.

Recently generated nonclinical data showed filgotinib did not induce any macroscopic or microscopic findings in the male reproductive system in animals with higher filgotinib exposure versus previous studies.

The Phase 3 FINCH program, led by our collaboration partner Gilead, is evaluating 100 mg and 200 mg filgotinib in both males and females in major RA patient populations worldwide. Men and women in both the Phase 2b/3 SELECTION and Phase 3 DIVERSITY trials in UC and CD, respectively, will be randomized to receive placebo, 100 mg or 200 mg filgotinib. In these SELECTION and DIVERSITY trials in the United States, males may receive 200 mg only if they failed conventional therapy, anti-TNF and vedolizumab. The filgotinib Phase 3 programs will also contain a dedicated male patient testicular safety study.

Even if filgotinib does receive regulatory approval or marketing authorization, the FDA or other regulatory authorities may impose dosing restrictions that differ from the approved dosing regimen in other jurisdictions.

Box warnings, labeling restrictions, dose limitations and similar restrictions on use could have a material adverse effect on our ability to commercialize filgotinib in those jurisdictions where such restrictions apply.

 

9


Table of Contents

Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials as well as data from any interim analysis of ongoing clinical trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development. We have never completed a Phase 3 trial or submitted an NDA or BLA.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Although product candidates may demonstrate promising results in early clinical (human) trials and pre-clinical (animal) studies, they may not prove to be effective in subsequent clinical trials. For example, testing on animals may occur under different conditions than testing in humans and therefore the results of animal studies may not accurately predict human experience. Likewise, early clinical studies may not be predictive of eventual safety or effectiveness results in larger-scale pivotal clinical trials. The results of pre-clinical studies and previous clinical trials as well as data from any interim analysis of ongoing clinical trials of our product candidates, as well as studies and trials of other products with similar mechanisms of action to our product candidates, may not be predictive of the results of ongoing or future clinical trials. For example, the positive results generated to date in pre-clinical studies and Phase 1, Phase 2a and Phase 2b clinical trials for filgotinib in RA or Phase 2 clinical trials for CD do not ensure that later clinical trials will continue to demonstrate similar results or observations, including the Phase 3 studies in RA, UC, and CD currently ongoing. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and earlier clinical trials. In addition to the safety and efficacy traits of any product candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials, and it is possible that we will as well. Based upon negative or inconclusive results, we or our collaboration partners may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval.

We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:

 

    obtaining regulatory approval to commence a trial;

 

    reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

 

    obtaining Institutional Review Board, or IRB, or ethics committee approval at each site;

 

    obtaining regulatory concurrence on the design and parameters for the trial;

 

    obtaining approval for the designs of our clinical development programs for each country targeted for trial enrollment;

 

    recruiting suitable patients to participate in a trial, which may be impacted by the number of competing trials that are enrolling patients;

 

    having patients complete a trial or return for post-treatment follow-up;

 

    clinical sites deviating from trial protocol or dropping out of a trial;

 

    adding new clinical trial sites;

 

    manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of comparator drug for use in clinical trials; or

 

    the availability of adequate financing and other resources.

 

10


Table of Contents

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such trials are being conducted, or by the FDA, the EMA or other comparable regulatory authorities, or recommended for suspension or termination by the Data Monitoring Committee, or the DMC, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the EMA or other comparable regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, including those seen in the class to which our product candidates belong, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, manufacturing issues or lack of adequate funding to continue the clinical trial. For example, it is possible that safety issues or adverse side effects could be observed in trials for filgotinib in RA, CD and UC and other potential indications; for our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737) in CF; for GLPG1690 in IPF; for GLPG1972 in OA; or for MOR106 in AtD, which could result in a delay, suspension or termination of the ongoing trials of filgotinib (in one or more indications), our CF candidates, GLPG1690, GLPG1972 or MOR106. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

If filgotinib, our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972, MOR106 or any other product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business would be materially harmed. For example, if the results of ongoing or future trials for filgotinib do not achieve the primary efficacy endpoints or demonstrate unexpected safety findings, the prospects for approval of filgotinib, as well as the price of the ADSs or our ordinary shares and our ability to create shareholder value could be materially and adversely affected.

In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase 2, Phase 3 or other clinical trials we or any of our collaboration partners may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. If we are unable to bring any of our current or future product candidates to market, our ability to create long-term shareholder value will be limited.

We initiated our first clinical study in 2009, and for eight of our compounds, Phase 2 studies have been initiated. Phase 3 studies in RA and CD and a Phase 2b/3 trial in UC have been initiated by our collaboration partner Gilead for filgotinib.

The rates at which we complete our scientific studies and clinical trials depend on many factors, including, but not limited to, patient enrollment.

Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. With respect to clinical development of our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), the availability of, for example, Kalydeco® (ivacaftor), which is a drug developed by Vertex to be used to treat patients with a certain mutation of CF, may cause patients to be less willing to participate in our clinical trial in regions in which

 

11


Table of Contents

therapy has been approved. Since CF is a competitive market in certain regions such as the United States and the European Union with a number of product candidates in development, patients may have other choices with respect to potential clinical trial participation and we may have difficulty in reaching our enrollment targets. In addition, the relatively limited number of patients worldwide (estimated to be 80,000) may make enrollment more challenging. Any of these occurrences may harm our clinical trials and by extension, our business, financial condition and prospects.

We may not be successful in our efforts to use and expand our novel, proprietary target discovery platform to build a pipeline of product candidates.

A key element of our strategy is to use and expand our novel, proprietary target discovery platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect the price of the ADSs or our ordinary shares.

Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, healthcare payors, patients and the medical community.

Even if we obtain regulatory approval for one or more of our product candidates, the product may not gain market acceptance among physicians, healthcare payors, patients and the medical community, which is critical to commercial success. Market acceptance of any product candidate for which we receive approval depends on a number of factors, including:

 

    the efficacy and safety as demonstrated in clinical trials;

 

    the timing of market introduction of the product candidate as well as competitive products;

 

    the clinical indications for which the product candidate is approved;

 

    acceptance by physicians, the medical community and patients of the product candidate as a safe and effective treatment;

 

    the convenience of prescribing and initiating patients on the product candidate;

 

    the potential and perceived advantages of such product candidate over alternative treatments;

 

    the cost of treatment in relation to alternative treatments, including any similar generic treatments;

 

    the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;

 

    relative convenience and ease of administration;

 

    the prevalence and severity of adverse side effects; and

 

    the effectiveness of sales and marketing efforts.

If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors, patients and the medical community, we will not be able to generate significant revenues, and we may not become or remain profitable.

 

12


Table of Contents

We currently have no marketing and sales organization. To the extent any of our product candidates for which we maintain commercial rights is approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell any product candidates, or generate product revenues.

We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to independently commercialize any product candidates that receive marketing approval and for which we maintain commercial rights, we would have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development of filgotinib, GLPG1837, GLPG2451, GLPG2222, GLPG2737, GLPG1690, GLPG1972, MOR106 or any other product candidates for which we maintain commercial rights, we may elect to build a targeted specialty sales force which will be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. With respect to our product candidates, we may choose to partner with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. In the instance of filgotinib, under our collaboration agreement with Gilead, if we exercise our co-promotion option with respect to licensed products, we would assume a portion of the co-promotion effort in the United Kingdom, Germany, France, Italy, Spain, the Netherlands, Belgium, and/or Luxembourg and share equally in the net profit and net losses in these territories instead of receiving royalties in those territories during the period of co-promotion. In the instance of our CF portfolio of drugs aimed at a triple combination therapy, under our collaboration agreement with AbbVie, if we exercise our co-promotion option with respect to a licensed product, we would assume a portion of the co-promotion effort in the Netherlands, Belgium and Luxembourg and share in the net profit and net losses in these territories instead of receiving royalties in those territories during the period of co-promotion. If we are unable to enter into collaborations with third parties for the commercialization of approved products, if any, on acceptable terms or at all, or if any such partner does not devote sufficient resources to the commercialization of our product or otherwise fails in commercialization efforts, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted.

Coverage and reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance.

There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. To the extent that we retain commercial rights following clinical development, we would seek approval to market our product candidates in the United States, the European Union and other selected jurisdictions. Market acceptance and sales of our product candidates, if approved, in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that coverage and adequate reimbursement will be available for any of our product candidates, if approved. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, any of our product candidates, if approved. If reimbursement is not available or is available on a limited basis for any of our product candidates, if approved, we may not be able to successfully commercialize any such product candidate. Reimbursement by a third-party payor may depend upon a number of factors, including, without limitation, the third-party payor’s determination that use of a product is:

 

    a covered benefit under its health plan;

 

    safe, effective and medically necessary;

 

    appropriate for the specific patient;

 

13


Table of Contents
    cost-effective; and

 

    neither experimental nor investigational.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost- effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement or to have pricing set at a satisfactory level. If reimbursement of our future products, if any, is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability.

In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. Any negotiated prices for any of our product candidates, if approved, covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain outside of the Medicare Part D prescription drug plan. Moreover, while Medicare Part D applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment under Medicare Part D may result in a similar reduction in payments from non-governmental payors.

In certain countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our product candidates to other available therapies. If reimbursement of any of our product candidates, if approved, is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such country.

The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.

Legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for any of our product candidates, if approved, that could materially affect the opportunity to commercialize.

The United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our product candidates profitably, if approved. Among policy-makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future.

 

14


Table of Contents

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:

 

    the demand for any of our product candidates, if approved;

 

    the ability to set a price that we believe is fair for any of our product candidates, if approved;

 

    our ability to generate revenues and achieve or maintain profitability;

 

    the level of taxes that we are required to pay; and

 

    the availability of capital.

In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or, collectively, the ACA, became law in the United States. The goal of the ACA is to reduce the cost of healthcare and substantially change the way healthcare is financed by both governmental and private insurers. The ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of any of our product candidates, if they are approved. Provisions of the ACA relevant to the pharmaceutical industry include the following:

 

    an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs;

 

    an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively;

 

    a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D;

 

    extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

 

    expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers’ Medicaid rebate liability;

 

    expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;

 

    requirements under the federal Open Payments program and its implementing regulations for the disclosure by certain drug, biologic product, device and medical supply manufacturers of payments made to physicians and teaching hospitals and of ownership or investment interests held by physicians and their immediate family members in these manufacturers;

 

    expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;

 

    a licensure framework for follow-on biologic products; and

 

    a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013. In January 2013, then President Obama signed into law the American Taxpayer Relief

 

15


Table of Contents

Act of 2012, which, among other things, reduced Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding.

As a result of the 2016 election in the United States, there is great political uncertainty concerning the fate of the ACA and other healthcare laws. The United States Congress is expected to draft legislation to repeal parts of the ACA, but it is uncertain when such legislation would be passed and whether Congress would replace the law and what any replacement law would encompass. We cannot predict any initiatives that may be adopted in the future.

We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our drug discovery and development efforts may target diseases and conditions that are already subject to existing therapies or that are being developed by our competitors, many of which have substantially greater resources, larger research and development staffs and facilities, more experience in completing pre-clinical testing and clinical trials, and formulation, marketing and manufacturing capabilities than we do. As a result of these resources, our competitors may develop drug products that render our products obsolete or noncompetitive by developing more effective drugs or by developing their products more efficiently. Our ability to develop competitive products would be limited if our competitors succeeded in obtaining regulatory approvals for product candidates more rapidly than we were able to or in obtaining patent protection or other intellectual property rights that limited our drug development efforts. Any drug products resulting from our research and development efforts, or from our joint efforts with collaboration partners or licensees, might not be able to compete successfully with our competitors’ existing and future products, or obtain regulatory approval in the United States, European Union or elsewhere. Further, we may be subject to additional competition from alternative forms of treatment, including generic or over-the-counter drugs.

In the field of RA, therapeutic approaches have traditionally relied on disease-modifying anti-rheumatic drugs, or DMARDS, such as MTX and sulphasalazine as first-line therapy. These oral drugs work primarily to suppress the immune system and, while effective in this regard, the suppression of the immune system leads to an increased risk of infections and other side effects. Accordingly, in addition to DMARDS, monoclonal antibodies targeting tumor necrosis factor, or TNF, like AbbVie’s Humira, or IL-6 like Roche’s Actemra, have been developed. These biologics, which must be delivered via injection, are currently the standard of care as first- and second-line therapies for RA patients who have an inadequate response to DMARDS. In November 2012, Xeljanz (tofacitinib citrate), marketed by Pfizer, was approved by the FDA as an oral treatment for the treatment of adult patients with RA who have had an inadequate response to, or who are intolerant of, MTX. Xeljanz is the first Janus kinase, or JAK, inhibitor for RA approved for commercial sale in the United States. We are aware of other JAK inhibitors in development for patients with RA, including a once-daily JAK1/2 inhibitor called baricitinib which is being developed by Lilly, is approved by the EMA for RA and expected to be approved by the FDA for RA as early as March 2017, a JAK3/2/1 inhibitor called ASP015k which is being developed in Japan by Astellas, and a JAK inhibitor called ABT-494 which is being developed in Phase 3 in RA by AbbVie. Filgotinib, a selective JAK1 inhibitor, was developed in collaboration with AbbVie until AbbVie terminated the collaboration agreement on September 25, 2015. On December 16, 2015, we entered into a collaboration agreement with Gilead, under which Gilead initiated a Phase 3 trial for filgotinib in August 2016. We expect that filgotinib, which we are developing to treat patients with moderate to severe RA who have an inadequate response to MTX, will compete with all of these therapies. If generic or biosimilar versions of these therapies are approved we would expect to also compete against these versions of the therapies.

In the field of inflammatory bowel disease, or IBD, first line therapies are oral (or local) treatments with several low-cost generic compounds like mesalazine, more effective in UC and azathioprine, more effective in CD. Steroids like budesonide are used in both UC and CD. Companies like Santarus have developed controlled-

 

16


Table of Contents

release oral formulation with the aim to have local intestinal delivery of budesonide thereby limiting systemic side effects. For more advanced therapy, monoclonal antibodies with various targets such as TNF and more recently, integrins by vedoluzimab (Entyvio), marketed by Takeda, are approved. We are also aware of other biologics in clinical development for these indications, such as: ustekinumab, developed by Johnson & Johnson, which is in Phase 3 clinical trials and RPC1063, which is being developed by Celgene and has shown efficacy in a Phase 2 trial in UC. There are also several novel oral treatments being explored in Phase 2 and Phase 3, including Pfizer’s Xeljanz, which has been filed for approval in UC. The large number of treatments for UC, and somewhat less for CD, presents a substantial level of competition for any new treatment entering the IBD market. Gilead, under our collaboration agreement, initiated a Phase 3 trial for filgotinib for CD in December 2016 and a Phase 2b/3 trial for filgotinib for UC in December 2016. We expect that filgotinib, which we are developing to treat patients with moderately to severely active CD and UC, will compete with all of these therapies. If generic or biosimilar versions of these therapies are approved we would expect to also compete against these versions of the therapies.

In the field of CF, all but two of the approved therapies to treat CF patients have been designed to treat the symptoms of the disease rather than its cause. Kalydeco, marketed by Vertex, is currently the only approved therapy to address the cause of Class III mutation CF. Kalydeco is a CF transmembrane conductance regulator, or CFTR, potentiator to treat CF in patients with a Class III (G551D) mutation of the CFTR gene. Vertex also markets Orkambi, which is Kalydeco and lumacaftor, a corrector molecule for patients with a Class II (F508del) mutation of the CFTR gene, a broader patient population. Vertex obtained FDA approval in July 2015 for Orkambi in the United States and obtained European Commission Marketing Authorization for Orkambi in Europe in November 2015. We are also aware of other companies, including Novartis, Nivalis, Pfizer, Proteostasis and ProQR, and not-for-profit organizations like Flatley Discovery Lab, which are actively developing product candidates for the treatment of CF. These typically target the CFTR protein as potentiators, correctors, or other modulators of its activity. On September 23, 2013, we entered into a global collaboration agreement with AbbVie, focused on the discovery, worldwide development and commercialization of potentiator and corrector molecules for the treatment of CF. On April 28, 2016, we expanded this collaboration to provide for the potential development and commercialization of triple combination products consisting of a potentiator molecule, a corrector 1 molecule and a corrector 2 molecule to treat specified populations of patients with CF. We expect that our CF portfolio of drugs aimed at a triple combination therapy will compete with all these therapies. If generic or biosimilar versions of these therapies are approved we would expect to also compete against these versions of the therapies.

In the field of IPF there are two approved disease modifying drugs: pirfenidone (Esbriet), marketed by Roche, and nintedanib (Ofev), marketed by Boehringer Ingelheim. These drugs prolong life for IPF patients by months, leaving an unmet medical need for those developing disease-modifying drugs in this field.

In the field of OA, there are currently no disease-modifying drugs approved. Current treatment involves weight loss, physical therapy, and pain management.

In the field of AtD, generic drugs are approved standard of care, including immunomodulators cyclosporine and mycophenolate mofetil and topical treatments. There are disease-modifying biologics in currently in development.

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or other comparable regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of certain side effects. In such an event, our trials could be suspended or terminated and the FDA, the EMA or comparable regulatory authorities could order us to cease

 

17


Table of Contents

further development of or deny approval of our product candidates for any or all targeted indications. The drug- related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

If one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

 

    regulatory authorities may withdraw approvals of such product;

 

    regulatory authorities may require additional warnings on the label;

 

    we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

 

    we could be sued and held liable for harm caused to patients; and

 

    our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.

Combination therapies involve unique adverse events that could be exacerbated compared to adverse events from monotherapies or could lead to unfavorable drug-drug interactions.

Combination therapies, such as using our wholly-owned product candidates as well as third-party agents, involve unique adverse events that could be exacerbated compared to adverse events from monotherapies or could lead to unfavorable drug-drug interactions. These types of adverse events could be caused by our product candidates or drug interactions and could also cause us, our collaboration partners or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable regulatory authority. For example, we or our collaboration partners may voluntarily suspend or terminate clinical trials if at any time one of our product candidates, or a combination therapy including any of them presents an unacceptable safety risk to the clinical trial patients. This, in turn, could prevent us or our collaboration partners from commercializing our product candidates. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events.

Risks Related to Our Financial Position and Need for Additional Capital

We are a clinical-stage company with no approved products and no historical product revenues, which makes it difficult to assess our future prospects and financial results.

We are a clinical-stage biotechnology company and we have not yet generated any product income. Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. Our operations to date have been limited to developing our technology and undertaking pre-clinical studies and clinical trials of our product candidates, including filgotinib, our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972 and MOR106. We may not have the ability to overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical area. Consequently, the ability to predict our future operating results or business prospects is more limited than if we had a longer operating history or approved products on the market.

We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.

We have incurred significant operating losses since our inception in 1999. We have incurred net profits of €33.2 million for the year ended December 31, 2014, net losses of €118.4 million for the year ended

 

18


Table of Contents

December 31, 2015 and net profits of €54.0 million for the year ended December 31, 2016. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders’ equity and working capital. In April 2014, we sold our service division for net proceeds of €130.8 million, which explains the net profits recorded in 2014. In January 2016, Gilead made an equity investment in Galapagos through a subscription of new ordinary shares, which resulted in a positive non-cash fair value gain of €57.5 million in the financial result of 2016, contributing significantly to net profits recorded in 2016. We expect to continue incurring significant research, development and other expenses related to our ongoing operations, and to continue incurring operating losses for the foreseeable future. We also expect these losses to increase, due to higher costs of later stage development, as we continue our development of, and to seek regulatory approvals for, our product candidates.

We do not anticipate generating revenues from sales of products for the foreseeable future, if ever. If any of our product candidates fail in clinical trials or do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.

If one or more of our product candidates is approved for commercial sale and we retain commercial rights, we anticipate incurring significant costs associated with commercializing any such approved product candidate. Therefore, even if we are able to generate revenues from the sale of any approved product, we may never become profitable. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of expenses and when we will be able to achieve or maintain profitability, if ever.

We will require substantial additional funding, which may not be available to us on acceptable terms, or at all.

Our operations have consumed substantial amounts of cash since inception. We are currently conducting clinical trials for filgotinib, our CF candidates (including GLPG1837, GLPG2451, GLPG2222, and GLPG2737), GLPG1690, GLPG1972 and MOR106. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive. We will require substantial additional future capital in order to complete clinical development and, if we are successful, to commercialize any of our current product candidates. If the FDA, or any other comparable regulatory agency, such as the EMA, requires that we perform studies or trials in addition to those that we currently anticipate with respect to the development of our product candidates, or repeat studies or trials, our expenses would further increase beyond what we currently expect, and any delay resulting from such further or repeat studies or trials could also result in the need for additional financing.

Our existing cash and cash equivalents will not be sufficient for us to complete advanced clinical development of any of our product candidates or, if applicable, to commercialize any product candidate that is approved. Accordingly, we will continue to require substantial additional capital to continue our clinical development activities and potentially engage in commercialization activities. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our product candidates. The amount and timing of our future funding requirements will depend on many factors, including but not limited to:

 

    the progress, costs, results of and timing of our ongoing and planned clinical trials;

 

    our ability to reach milestones under our existing collaboration arrangements and enter into additional collaborative agreements for the development and commercialization of our product candidates;

 

    the willingness of the FDA, EMA and other comparable regulatory authorities to accept our clinical trials and pre-clinical studies and other work as the basis for review and approval of product candidates;

 

    the outcome, costs and timing of seeking and obtaining regulatory approvals from the FDA, EMA and other comparable regulatory authorities;

 

 

19


Table of Contents
    whether our collaboration partners continue to collaborate with us on the development and commercialization of our product candidates;

 

    the number of product candidates and indications that we pursue, whether developed from our novel, proprietary target discovery platform, otherwise developed internally or in-licensed;

 

    the timing and costs associated with manufacturing our product candidates for clinical trials and other studies and, if approved, for commercial sale;

 

    our need to expand our development activities and, potentially, our research activities;

 

    the timing and costs associated with establishing sales and marketing capabilities;

 

    market acceptance of any approved product candidates;

 

    the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;

 

    the cost to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

 

    the extent to which we may be required to pay milestone or other payments under our in-license agreements and the timing of such payments;

 

    our need and ability to hire additional management, development and scientific personnel; and

 

    our need to implement additional internal systems and infrastructure, including financial and reporting systems.

Some of these factors are outside of our control. Based upon our current expected level of operating expenditures and our existing cash and cash equivalents, we believe that we will be able to fund our operating expenses and capital expenditure requirements at least for the next two to three years. This period could be shortened if there are any significant increases beyond our expectations in spending on development programs or more rapid progress of development programs than anticipated. Accordingly, we expect that we will need to raise substantial additional funds in the future. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain funding from equity offerings or debt financings, including on a timely basis, we may be required to:

 

    seek collaboration partners for one or more of our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available;

 

    relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves; or

 

    significantly curtail one or more of our research or development programs or cease operations altogether.

Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our product candidates or technologies.

We may seek additional funding through a combination of equity offerings, debt financings, collaborations and/or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of the ADSs or our ordinary shares. The incurrence of additional indebtedness and/or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in certain additional restrictive covenants, such as limitations on our ability to

 

20


Table of Contents

incur additional debt and/or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, issuance of additional equity securities, or the possibility of such issuance, may cause the market price of the ADSs or our ordinary shares to decline. In the event that we enter into collaborations and/or licensing arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves or potentially reserve for future potential arrangements when we might be able to achieve more favorable terms.

Risks Related to Our Reliance on Third Parties

We may not be successful in maintaining development and commercialization collaborations, and any collaboration partner may not devote sufficient resources to the development or commercialization of our product candidates or may otherwise fail in development or commercialization efforts, which could adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.

The collaboration arrangements that we have established, and any collaboration arrangements that we may enter into in the future may not ultimately be successful, which could have a negative impact on our business, results of operations, financial condition and growth prospects. If we partner with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. It is possible that a collaboration partner may not devote sufficient resources to the development or commercialization of our product candidate or may otherwise fail in development or commercialization efforts, in which event the development and commercialization of such product candidate could be delayed or terminated and our business could be substantially harmed. In particular, we are heavily dependent on Gilead for its further development of our product candidate filgotinib and on AbbVie for its further development of our triple combination product candidate for the treatment of CF. Gilead and AbbVie may not devote sufficient resources or give sufficient priority to the filgotinib program or CF collaboration, respectively. Our collaborators may not elect to advance the product candidates on which we collaborate. Gilead may not be successful in the further development and commercialization of filgotinib, even when they do devote resources and prioritize their efforts for filgotinib. AbbVie may not be successful in the further development and commercialization of our potential triple combination product for the treatment of CF.

In addition, the terms of any collaboration or other arrangement that we establish may not be favorable to us or may not be perceived as favorable, which may negatively impact the trading price of the ADSs or our ordinary shares. In some cases, we may be responsible for continuing development of a product candidate or research program under a collaboration and the payment we receive from our collaboration partner may be insufficient to cover the cost of this development. Moreover, collaborations and sales and marketing arrangements are complex and time consuming to negotiate, document and implement and they may require substantial resources to maintain.

We are subject to a number of additional risks associated with our dependence on collaborations with third parties, the occurrence of which could cause our collaboration arrangements to fail. Conflicts may arise between us and collaboration partners, such as conflicts concerning the interpretation of clinical data, the achievement of milestones, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration. If any such conflicts arise, a collaboration partner could act in its own self-interest, which may be adverse to our best interests. Any such disagreement between us and a collaboration partner could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating sufficient revenues to achieve or maintain profitability:

 

    reductions in the payment of royalties or other payments we believe are due pursuant to the applicable collaboration arrangement;

 

21


Table of Contents
    actions taken by a collaboration partner inside or outside our collaboration which could negatively impact our rights or benefits under our collaboration including termination of the collaboration for convenience by the partner; or

 

    unwillingness on the part of a collaboration partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities.

If our collaborations on research and development candidates do not result in the successful development and commercialization of products or if one of our collaboration partners terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop product candidates.

We may not be successful in establishing development and commercialization collaborations, which could adversely affect, and potentially prohibit, our ability to develop our product candidates.

Developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products are expensive. Accordingly, we have sought and may in the future seek to enter into collaborations with companies that have more resources and experience. If we are unable to obtain a collaboration partner for our product candidates, we may be unable to advance the development of our product candidates through late-stage clinical development and seek approval in any market. In situations where we enter into a development and commercial collaboration arrangement for a product candidate, we may also seek to establish additional collaborations for development and commercialization in territories outside of those addressed by the first collaboration arrangement for such product candidate. If any of our product candidates receives marketing approval, we may enter into sales and marketing arrangements with third parties with respect to otherwise unlicensed or unaddressed territories. There are a limited number of potential collaboration partners, and we expect to face competition in seeking appropriate collaboration partners. If we are unable to enter into any development and commercial collaborations and/ or sales and marketing arrangements on acceptable terms, or at all, we may be unable to successfully develop and seek regulatory approval for our product candidates and/or effectively market and sell approved products, if any.

We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

We have relied upon and plan to continue to rely upon CROs to monitor and manage data for our pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and we control only certain aspects of their activities. We and our CROs also rely upon clinical sites and investigators for the performance of our clinical trials in accordance with the applicable protocols and applicable legal and regulatory requirements and scientific standards. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol and applicable legal and regulatory requirements and scientific standards, and our reliance on CROs as well as clinical sites and investigators does not relieve us of our regulatory responsibilities. We, our CROs, as well as the clinical sites and investigators are required to comply with current GCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, investigators and clinical sites. If we, any of our CROs or any of the clinical sites or investigators fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon

 

22


Table of Contents

inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. We also cannot assure you that our CROs, as well as the clinical sites and investigators, will perform our clinical trials in accordance with the applicable protocols as well as applicable legal and regulatory requirements and scientific standards, or report the results obtained in a timely and accurate manner. In addition to GCPs, our clinical trials must be conducted with product produced under cGMP regulations. While we have agreements governing activities of our CROs, we have limited influence over the actual performance of our CROs as well as the performance of clinical sites and investigators. In addition, significant portions of the clinical trials for our product candidates are and will continue to be conducted outside of Belgium, which will make it more difficult for us to monitor CROs as well as clinical sites and investigators and perform visits of our clinical sites, and will force us to rely heavily on CROs to ensure the proper and timely conduct of our clinical trials in accordance with the applicable protocols and compliance with applicable regulations, including GCPs. Failure to comply with applicable protocols and regulations in the conduct of the clinical trials for our product candidates may require us to repeat clinical trials, which would delay the regulatory approval process.

Some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.

If any of our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our pre-clinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure (including by clinical sites or investigators) to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenues could be delayed significantly.

Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

We rely completely on third parties to manufacture our pre-clinical and clinical drug supplies and we intend to rely on third parties to produce commercial supplies of any approved product candidate.

If, for any reason, we were to experience an unexpected loss of supply of our product candidates or placebo or comparator drug used in certain of our clinical trials, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our pre-clinical and clinical drug supplies and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers or other third-party manufacturers to manufacture our product candidates are subject to the FDA’s, EMA’s and other comparable regulatory authorities’ pre-approval inspections that will be conducted after we submit our NDA or BLA to the FDA or the required approval applications to any other relevant regulatory authority. We do not control the implementation of the manufacturing process of, and are completely dependent on, our contract manufacturers or other third-party

 

23


Table of Contents

manufacturers for compliance with cGMP regulatory requirements for manufacture of both active drug substances and finished drug products. If our contract manufacturers or other third-party manufacturers cannot successfully manufacture material that conforms to applicable specifications and the strict regulatory requirements of the FDA, EMA or others, we will not be able to secure and/or maintain regulatory approvals for our products manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers or other third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or other comparable regulatory authority finds deficiencies at these facilities for the manufacture of our product candidates or if it withdraws any approval because of deficiencies at these facilities in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have access to a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a contract manufacturer or other third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Additionally, if we receive regulatory approval for our product candidates, we may experience unforeseen difficulties or challenges in the manufacture of our product candidates on a commercial scale compared to the manufacture for clinical purposes.

We expect to continue to depend on contract manufacturers or other third-party manufacturers for the foreseeable future. We currently obtain our supplies of finished drug product through individual purchase orders. We have not entered into long-term agreements with our current contract manufacturers or with any alternate fill/ finish suppliers. Although we intend to do so prior to any commercial launch in order to ensure that we maintain adequate supplies of finished drug product, we may be unable to enter into such an agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business.

We rely on clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.

As part of our strategy to mitigate development risk, we seek to develop product candidates with validated mechanisms of action and we utilize biomarkers to assess potential clinical efficacy early in the development process. This strategy necessarily relies upon clinical data and other results obtained by third parties that may ultimately prove to be inaccurate or unreliable. Further, such clinical data and results may, at times, be based on products or product candidates that are significantly different from our product candidates. If the third-party data and results we rely upon prove to be inaccurate, unreliable or not applicable to our product candidates, we could make inaccurate assumptions and conclusions about our product candidates and our research and development efforts could be materially adversely affected.

Risks Related to Our Intellectual Property

Our ability to compete may decline if we do not adequately protect our proprietary rights.

Our commercial success depends on obtaining and maintaining proprietary rights to our product candidates for the treatment of RA, CD, UC, CF and other diseases, as well as successfully defending these rights against

 

24


Table of Contents

third-party challenges. We will only be able to protect our product candidates, and their uses from unauthorized use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent protection for our product candidates is uncertain due to a number of factors, including:

 

    we may not have been the first to make the inventions covered by pending patent applications or issued patents;

 

    we may not have been the first to file patent applications for our product candidates or the compositions we developed or for their uses;

 

    others may independently develop identical, similar or alternative products or compositions and uses thereof;

 

    our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;

 

    any or all of our pending patent applications may not result in issued patents;

 

    we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity;

 

    any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties;

 

    our compositions and methods may not be patentable;

 

    others may design around our patent claims to produce competitive products which fall outside of the scope of our patents; or

 

    others may identify prior art or other bases which could invalidate our patents.

Even if we have or obtain patents covering our product candidates or compositions, we may still be barred from making, using and selling our product candidates or technologies because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions or products that are similar or identical to ours. If a patent owned by a third party covers one of our product candidates or its use, this could materially affect our ability to develop the product candidate or sell the resulting product if approved. Because patent applications are not published until 18 months from their priority date, there may be currently pending applications unknown to us that may later result in issued patents that our product candidates or compositions may infringe. Additionally, because the scope of claims in pending patent applications can change, there may be pending applications whose claims do not currently cover any of our product candidates but may be altered such that one or more of our product candidates are covered when the resulting patent issues. These patent applications may have priority over patent applications filed by us.

Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. For example, others may be able to develop a product that is similar to, or better than, ours in a way that is not covered by the claims of our patents.

Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. Moreover, in some circumstances, we do not

 

25


Table of Contents

have the right to control the preparation, filing or prosecution of patent applications, or to maintain the patents, covering technology subject to our collaboration or license agreements with third parties. For example, under our collaboration agreement with AbbVie for CF, AbbVie has the right to control prosecution and maintenance of any patent rights covering inventions that are jointly discovered or developed by us and AbbVie and patent rights that we control which relate to the compounds or products subject to the collaboration. In addition, in some circumstances, our counterparty has the right to enforce the patent rights subject to the applicable agreement without our involvement or consent or to otherwise control the enforcement of such patent rights. For example, under our collaboration agreement with AbbVie for CF, AbbVie controls the enforcement of the patent rights subject to the agreement, although we may elect to participate in such enforcement proceedings and under our collaboration agreement with Gilead, Gilead controls any litigation on our patents for filgotinib. Therefore, these patents and patent applications may not be prosecuted or enforced in a manner consistent with the best interests of our business.

Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could harm our results of operations.

Pharmaceutical patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position.

The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office, or USPTO, the European Patent Office, and other foreign counterparts are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. Certain U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to reexamination proceedings, post-grant review and/or inter partes review in the USPTO. European patents and other foreign patents may be subject also to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, reexamination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes.

In addition, changes in or different interpretations of patent laws in the United States, Europe, and other jurisdictions may permit others to use our discoveries or to develop and commercialize our technology and products without providing any compensation to us, or may limit the number of patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. and European laws and those countries may lack adequate rules and procedures for defending our intellectual property rights.

If we fail to obtain and maintain patent protection and trade secret protection of our product candidates, we could lose our competitive advantage and competition we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability.

Developments in patent law could have a negative impact on our business.

From time to time, courts and other governmental authorities in the United States, Europe and other jurisdictions may change the standards of patentability and any such changes could have a negative impact on our business.

 

26


Table of Contents

For example, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a “first-to-invent” system to a “first-to-file” system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what impact, if any, the America Invents Act will have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend any patents that may issue from our patent applications, all of which could have a material adverse effect on our business.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to patent protection, because we operate in the highly technical field of development of therapies, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. It is our policy to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party’s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations.

In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or a third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets, with protection varying across Europe and in other countries. Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.

We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.

Filing, prosecuting and defending patents on our product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries could be less extensive than those in the United States and Europe, assuming that rights are obtained in the United States and Europe. Furthermore, even if patents are granted based on our European patent applications, we may not choose to perfect or maintain our rights in all available European countries. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States and Europe. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries, or from selling or importing products made using our inventions. The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority dates of each of our patent applications.

 

27


Table of Contents

Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States and Europe. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.

The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.

Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States, Europe and other jurisdictions may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

We may be subject to claims by third parties asserting ownership or commercial rights to inventions we develop or obligations to make compensatory payments to employees.

Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have written agreements with collaboration partners that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with collaboration partners with respect to joint inventions or inventions made by our collaboration partners that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaboration partner’s materials where required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaboration partner’s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business.

 

28


Table of Contents

While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing or obtaining such an agreement with each party who, in fact, develops intellectual property that we regard as our own. In addition, such agreements may be breached or may not be self-executing, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.

Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.

We employ individuals who were previously employed at universities, pharmaceutical companies or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business.

Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. We cannot assure you that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties.

There is significant litigation in the pharmaceutical industry regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our product candidates, technologies or activities infringe the intellectual property rights of others. If our development activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs or compositions. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our products. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and the price of the ADSs or our ordinary shares. Any legal action against us or our collaboration partners could lead to:

 

    payment of substantial damages for past use of the asserted intellectual property and potentially treble damages, if we are found to have willfully infringed a party’s patent rights;

 

    injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell our product candidates; or

 

29


Table of Contents
    us or our collaboration partners having to enter into license arrangements that may not be available on commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business and financial condition. As a result, we could be prevented from commercializing current or future product candidates.

Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects.

Issued patents covering our product candidates could be found to be invalid or unenforceable if challenged in court.

If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering our product candidate, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements in most jurisdictions, including lack of novelty, obviousness or non-enablement. In the United States, grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.

Risks Related to Our Organization, Structure and Operation

Our future success depends on our ability to retain the members of our executive committee and to attract, retain and motivate qualified personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our industry has experienced a high rate of turnover of management personnel in recent years. Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, especially our executive committee comprised of: Onno van de Stolpe, our chief executive officer; Bart Filius, our chief financial officer; Piet Wigerinck, our chief scientific officer; and Andre Hoekema, our senior vice president of corporate development, whose services are critical to the successful implementation of our product candidate acquisition, development and regulatory strategies. We are not aware of any present intention of any of these individuals to leave our company. In order to induce valuable employees to continue their employment with us, we have provided warrants that vest over time. The

 

30


Table of Contents

value to employees of warrants that vest over time is significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.

Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us at any time, with or without notice. The loss of the services of any of the members of our executive committee or other key employees and our inability to find suitable replacements could harm our business, financial condition and prospects. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior, mid-level, and senior scientific and medical personnel.

We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we have to offer. If we are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize product candidates will be limited.

If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.

We expect that if our drug discovery efforts continue to generate product candidates, our clinical product candidates continue to progress in development, and we continue to build our development, medical and commercial organizations, we will require significant additional investment in personnel, management and resources. Our ability to achieve our research, development and commercialization objectives depends on our ability to respond effectively to these demands and expand our internal organization, systems, controls and facilities to accommodate additional anticipated growth. If we are unable to manage our growth effectively, our business could be harmed and our ability to execute our business strategy could suffer.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our product candidates, if approved.

We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our products. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to stop development or, if approved, limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

 

    delay or termination of clinical trials;

 

    injury to our reputation;

 

    withdrawal of clinical trial participants;

 

    initiation of investigations by regulators;

 

    costs to defend the related litigation;

 

31


Table of Contents
    a diversion of management’s time and our resources;

 

    substantial monetary awards to trial participants or patients;

 

    decreased demand for our product candidates;

 

    product recalls, withdrawals or labeling, marketing or promotional restrictions;

 

    loss of revenues from product sales; and

 

    the inability to commercialize any our product candidates, if approved.

Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our product candidates. We currently carry clinical trial liability insurance at levels which we believe are appropriate for our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

Risks from the improper conduct of employees, agents, contractors, or collaboration partners could adversely affect our reputation and our business, prospects, operating results, and financial condition.

We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaboration partners that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation.

In particular, our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and U.S. Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaboration partners, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.

 

32


Table of Contents

We could be subject to liabilities under environmental, health and safety laws or regulations, or fines, penalties or other sanctions, if we fail to comply with such laws or regulations or otherwise incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws, regulations, and permitting requirements, including those governing laboratory procedures, decontamination activities and the handling, transportation, use, remediation, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals, radioactive isotopes and biological materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials or wastes either at our sites or at third-party disposal sites. In the event of such contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations or permitting requirements. These current or future laws, regulations and permitting requirements may impair our research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions.

Any future relationships with customers and third-party payors may be subject, directly or indirectly, to applicable anti-kickback laws, fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.

If we obtain FDA, EMA or any other comparable regulatory authority approval for any of our product candidates and begin commercializing those products in the United States, European Union or other jurisdiction, our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to health information privacy and security regulation of the European Union, the United States and other jurisdictions in which we conduct our business. For example, the laws that may affect our ability to operate include:

 

    the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs;

 

    U.S. federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

 

    the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

 

   

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which imposes certain obligations,

 

33


Table of Contents
 

including mandatory contractual terms, on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and

 

    analogous state and laws and regulations in other jurisdictions, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and state and laws in other jurisdiction governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations or other sanctions. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws and regulations, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government funded healthcare programs.

We must maintain effective internal control over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business, investor confidence and market price.

We must maintain effective internal control over financial reporting in order to accurately and timely report our results of operations and financial condition. We often use estimates and assumptions concerning the future, especially when performing impairment tests on (in)tangible assets. We perform these tests whenever there is an impairment indicator. In addition, because we are a U.S. public company, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires, among other things, that we assess the effectiveness of our disclosure controls and procedures annually and the effectiveness of our internal control over financial reporting at the end of each fiscal year.

We are no longer an “emerging growth company” and we will no longer be able to avail ourselves of exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies.” For example, the Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and the effectiveness of our disclosure controls and procedures quarterly. Section 404 of the Sarbanes-Oxley Act (“Section 404”) requires us to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on, and our independent registered public accounting firm potentially to attest to, the effectiveness of our internal control over financial reporting. We previously availed ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404. However, we are no longer able to avail ourselves of this exemption. Our independent registered public accounting firm is now required to undertake an assessment of our internal control over financial reporting, and as a result the cost of our compliance with Section 404 will correspondingly increase. The rules governing the standards that must be met for our management to assess our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on management’s review of internal control over financial reporting. Our compliance with applicable provisions of Section 404 will require that we incur substantial accounting expense

 

34


Table of Contents

and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of the ADSs or our ordinary shares could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. Furthermore, investor perceptions of our company may suffer if deficiencies are found, and this could cause a decline in the market price of the ADSs or our ordinary shares. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our stated operating results and harm our reputation. If we are unable to implement these requirements effectively or efficiently, it could harm our operations, financial reporting, or financial results and could result in an adverse opinion on our internal control over financial reporting from our independent registered public accounting firm.

Our information technology systems could face serious disruptions that could adversely affect our business.

Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners and delays in our research and development work. The loss of product development or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of our product candidates could be delayed.

Business interruptions could delay us in the process of developing our product candidates.

Loss of our laboratory facilities through fire or other causes could have an adverse effect on our ability to continue to conduct our business. We currently have insurance coverage to compensate us for such business interruptions; however, such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any significant property or casualty loss to our facilities.

We may undertake strategic acquisitions in the future and any difficulties from integrating such acquisitions could adversely affect our share price, operating results and results of operations.

We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources, result in loss of key personnel and could prove to be more difficult or expensive than we predict. The diversion of our management’s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness.

As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the

 

35


Table of Contents

past, whether as a result of unidentified risks or liabilities, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.

In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in-process research and development charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular periods.

Our collaboration arrangements with our strategic partners may make us an attractive target for potential acquisitions under certain circumstances.

Under certain circumstances, due to the structure of our collaboration arrangements with our strategic partners, our strategic partners may prefer to acquire us rather than paying the milestone payments or royalties under the collaboration arrangements, which may bring additional uncertainties to our business development and prospects.

Our international operations subject us to various risks, and our failure to manage these risks could adversely affect our results of operations.

We face significant operational risks as a result of doing business internationally, such as:

 

    fluctuations in foreign currency exchange rates;

 

    potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement;

 

    potential changes to the accounting standards, which may influence our financial situation and results;

 

    becoming subject to the different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations;

 

    reduced protection of, or significant difficulties in enforcing, intellectual property rights in certain countries;

 

    difficulties in attracting and retaining qualified personnel;

 

    restrictions imposed by local labor practices and laws on our business and operations, including unilateral cancellation or modification of contracts;

 

    rapid changes in global government, economic and political policies and conditions, political or civil unrest or instability, terrorism or epidemics and other similar outbreaks or events, and potential failure in confidence of our suppliers or customers due to such changes or events; and

 

    tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other trade barriers.

Recent developments relating to the United Kingdom’s referendum vote in favor of withdrawal from the European Union could adversely affect us.

The United Kingdom held a referendum on June 23, 2016 in which a majority voted for the United Kingdom’s withdrawal from the European Union (referred to as “Brexit”). As a result of this vote, negotiations

 

36


Table of Contents

are expected to commence to determine the terms of the United Kingdom’s withdrawal from the European Union as well as its relationship with the European Union going forward, including the terms of trade between the United Kingdom and the European Union. The effects of Brexit have been and are expected to continue to be far-reaching. Brexit and the perceptions as to its impact may adversely affect business activity and economic conditions in Europe and globally and could continue to contribute to instability in global financial and foreign exchange markets. Brexit could also have the effect of disrupting the free movement of goods, services and people between the United Kingdom and the European Union; however, the full effects of Brexit are uncertain and will depend on any agreements the United Kingdom may make to retain access to European Union markets.

In addition, we expect that Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the United Kingdom determines which European Union laws to replicate or replace. If the United Kingdom were to significantly alter its regulations affecting the pharmaceutical industry, we could face significant new costs. It may also be time-consuming and expensive for us to alter our internal operations in order to comply with new regulations. Altered regulations could also add time and expense to the process by which our product candidates receive regulatory approval in the United Kingdom and European Union. Similarly, it is unclear at this time what impact Brexit will have on our intellectual property rights and the process for obtaining, maintaining and defending such rights. It is possible that certain intellectual property rights, such as trademarks, granted by the European Union will cease being enforceable in the United Kingdom absent special arrangements to the contrary, and we are required to refile our trademarks and other intellectual property applications domestically in the United Kingdom.

Lastly, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership in the European Union. Given these possibilities and others we may not anticipate, as well as the lack of comparable precedent, the full extent to which our business, results of operations and financial condition could be adversely affected by Brexit is uncertain.

If we are unable to use tax loss carryforwards to reduce future taxable income or benefit from favorable tax legislation, our business, results of operations and financial condition may be adversely affected.

At December 31, 2016, we had cumulative carry forward tax losses of €230.9 million in Belgium, €61.5 million in France (when taking into account pending tax litigation effect), and €18.7 million related to the other entities of our company. These are available to carry forward and offset against future taxable income for an indefinite period in Belgium and France, but approximately €17.8 million of these tax loss carryforwards in Switzerland, Croatia, the United States and the Netherlands will expire between 2018 and 2030. If we are unable to use tax loss carryforwards to reduce future taxable income, our business, results of operations and financial condition may be adversely affected. As a company active in research and development in Belgium and France, we have benefited from certain research and development incentives including, for example, the Belgian research and development tax credit and the French research tax credit (crédit d’impôt recherche). These tax credits can be offset against Belgian and French corporate income tax due, respectively. The excess portion may be refunded as from the end of a five-year fiscal period for the Belgian research and development incentive, and at the end of a three-year fiscal period for the French research and development incentive. The research and development incentives are both calculated based on the amount of eligible research and development expenditure. The Belgian tax credit represented €4.3 million for the year ended December 31, 2014, €5.4 million for the year ended December 31, 2015 and €5.7 million for the year ended December 31, 2016. The French tax credit amounted to €7.8 million for the year ended December 31, 2014, €8.7 million for the year ended December 31, 2015 and €9.5 million for the year ended December 31, 2016. The Belgian and/or French tax authorities may audit each research and development program in respect of which a tax credit has been claimed and assess whether it qualifies for the tax credit regime. The tax authorities may challenge our eligibility for, or our calculation of, certain tax reductions and/or deductions in respect of our research and development activities and, should the Belgian and/or French tax authorities be successful, we may be liable for additional corporate income tax, and penalties and interest related thereto, which could have a significant impact on our results of operations and future cash flows. Furthermore, if the Belgian and/or the French government decide to eliminate, or reduce

 

37


Table of Contents

the scope or the rate of, the research and development incentive benefit, either of which it could decide to do at any time, our results of operations could be adversely affected.

As a company active in research and development in Belgium, we also expect to benefit in the future from the “patent income deduction” or the replacing “innovation deduction” in Belgium. The patent income deduction regime allows, in the case of taxable income, gross profits attributable to revenue from patented products to be taxed at a lower rate than other revenues, i.e., 6.8%. The innovation deduction regime allows net profits attributable to revenue from among others patented products (or products for which the patent application is pending) to be taxed at a lower rate than other revenues, i.e., 5.1%. When taken in combination with tax losses carried forward and research and development incentives mentioned above, we expect that this will result in a long-term low rate of corporation tax for us. The innovation deduction applies as of July 1, 2016, although subject to various conditions, the patent income deduction can continue to apply until June 30, 2021 at the latest.

Our inability to qualify for such advantageous tax legislation, as well as the aforementioned future alteration of the Belgian patent income deduction regime, as well as any other unexpected adverse changes of Belgian tax legislation, may adversely affect our business, results of operations and financial condition.

We may be forced to repay the technological innovation grants if we fail to comply with our contractual obligations under the applicable grant agreements.

We have received several technological innovation grants to date, totaling €26.8 million as of December 31, 2016, to support various research programs from an agency of the Flemish government to support technological innovation in Flanders. These grants carry clauses which require us to maintain a presence in the Flemish region for a number of years and invest according to pre-agreed budgets. If we fail to comply with our contractual obligations under the applicable technological innovation grant agreements, we could be forced to repay all or part of the grants received. Such repayment could adversely affect our ability to finance our research and development projects. In addition, we cannot ensure that we will then have the additional financial resources needed, the time or the ability to replace these financial resources with others.

We may be exposed to significant foreign exchange risk.

We incur portions of our expenses, and may in the future derive revenues, in currencies other than the euro, in particular, the U.S. dollar. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the euro. Therefore, for example, an increase in the value of the euro against the U.S. dollar could be expected to have a negative impact on our revenue and earnings growth as U.S. dollar revenue and earnings, if any, would be translated into euros at a reduced value. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows.

The instability of the euro or the inability of countries to refinance their debts could have a material adverse effect on our revenue, profitability and financial position.

As a result of the credit crisis in Europe, in particular in Greece, Italy, Ireland, Portugal and Spain, the European Commission created the European Financial Stability Facility, or the EFSF, and the European Financial Stability Mechanism, or the EFSM, to provide funding to Eurozone countries in financial difficulties that seek such support. In March 2011, the European Council agreed on the need for Eurozone countries to establish a permanent stability mechanism, the European Stability Mechanism, which was established on September 27, 2012 to assume the role of the EFSF and the EFSM in providing external financial assistance to Eurozone countries. Despite these measures, concerns persist regarding the debt burden of certain Eurozone countries and their ability to meet future financial obligations and the overall stability of the euro. An extended

 

38


Table of Contents

period of adverse development in the outlook for European countries could reduce the expenditures on drugs through reduced volumes and lower prices, which could have negative impact on the development and commercialization of our product candidates. In addition, the European credit crisis could affect the availability and cost of debt, if and when needed by us to finance our operations and research and development. These potential developments, or market perceptions concerning these and related issues, could affect our financial position, results of operations and cash flow.

The requirements of being a U.S. public company may strain our resources and divert management’s attention.

We are required to comply with various corporate governance and financial reporting requirements under the Sarbanes-Oxley Act of 2002, the Exchange Act, and the rules and regulations adopted by the SEC and the U.S. Public Corporation Accounting Oversight Board, or PCAOB. Further, compliance with various regulatory reporting requires significant commitments of time from our management and our directors, which reduces the time available for the performance of their other responsibilities. Our failure to track and comply with the various rules may materially adversely affect our reputation, ability to obtain the necessary certifications to financial statements, lead to additional regulatory enforcement actions, and could adversely affect the value of the ADSs or our ordinary shares.

If a claim is introduced by Charles River with regard to our former service division, our results of operations and financial condition may be adversely affected.

On March 13, 2014, we announced the signing of a definitive agreement to sell the service division operations to Charles River Laboratories International, Inc., or CRL, for a total consideration of up to €134 million. CRL agreed to pay us an immediate cash consideration of €129 million. The potential earn-out of €5 million due upon achievement of a revenue target 12 months after transaction closing has not been obtained. Approximately 5% of the total consideration, including price adjustments, was being held on an escrow account. Following common practice, we have given customary representations and warranties with customary caps and limitations which are capped and limited in time (since April 1, 2016, CRL can only introduce a claim covered by the Tax Deed (during a period of 5 years), other claims related to the sale cannot be submitted anymore). If Charles River makes a claim with respect to the sale of the service division, we could incur significant costs and expenses associated with the claim. To date, four claims have been introduced by CRL, which have all been settled for a total amount of €1.3 million. On January 17, 2017 an amount of €4.1 million was released from the escrow account. The release of the remaining balance of the escrow account will be possible after final agreement between the parties on the amounts at stake.

The audit report included in this annual report is prepared by an auditor who is not inspected by the PCAOB, and, as such, you are deprived of the benefits of such inspection.

Auditors of companies that are registered with the SEC and traded publicly in the United States, including our auditors, must be registered with the PCAOB and are required by the laws of the United States to undergo regular inspections by the PCAOB to assess their compliance with the laws of the United States and professional standards. Although our auditors are registered with the PCAOB, because our auditors are located in Belgium, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the Belgian authorities, our auditors are not currently inspected by the PCAOB. This lack of PCAOB inspections in Belgium currently prevents the PCAOB from regularly evaluating audits and quality control procedures of any auditors operating in Belgium, including our auditors. The inability of the PCAOB to conduct inspections of auditors in Belgium makes it more difficult to evaluate the effectiveness of our auditors’ audit procedures or quality control procedures as compared to auditors outside of Belgium that are subject to PCAOB inspections. As a result, investors may be deprived of the benefits of PCAOB inspections.

 

39


Table of Contents

Risks Related to Ownership of Our Ordinary Shares and ADSs

The market price of the ADSs could be subject to wide fluctuations.

The market price of the ADSs could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:

 

    actual or anticipated fluctuations in our financial condition and operating results;

 

    actual or anticipated changes in our growth rate relative to our competitors;

 

    competition from existing products or new products that may emerge;

 

    announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;

 

    failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;

 

    issuance of new or updated research or reports by securities analysts;

 

    fluctuations in the valuation of companies perceived by investors to be comparable to us; share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;

 

    additions or departures of key management or scientific personnel;

 

    disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;

 

    changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and any announcements relating to coverage policies or reimbursement levels;

 

    announcement or expectation of additional debt or equity financing efforts;

 

    sales of the ADSs by us, our insiders or our other shareholders; and

 

    general economic and market conditions.

These and other market and industry factors may cause the market price and demand for the ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of our capital shares. In addition, the stock market in general, and biotechnology and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.

Share ownership is concentrated in the hands of our principal shareholders and management, which may have the effect of delaying or preventing a change of control of our company.

Our executive officers, directors, current 5% or greater shareholders and their affiliated entities, including Gilead, together beneficially own approximately 33% of our ordinary shares, including shares in the form of ADSs. This concentration of ownership might have the effect of delaying or preventing a change of control of our company that other shareholders may view as beneficial.

Fluctuations in the exchange rate between the U.S. dollar and the euro may increase the risk of holding the ADSs.

Our shares currently trade on Euronext Brussels and Euronext Amsterdam in euros, while the ADSs trade on NASDAQ in U.S. dollars. Fluctuations in the exchange rate between the U.S. dollar and the euro may result in temporary differences between the value of the ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit such differences.

 

40


Table of Contents

In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the euro, the U.S. dollar equivalent of the proceeds that a holder of the ADSs would receive upon the sale in Belgium of any shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in euros on our shares represented by the ADSs could also decline.

If securities or industry analysts do not publish research or publish inaccurate research or unfavorable research about our business, the price of the ordinary shares and ADSs and trading volume could decline.

The trading market for the ordinary shares and ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. If no or few securities or industry analysts cover our company, the trading price for the ordinary shares and ADSs would be negatively impacted. If one or more of the analysts who covers us downgrades the ordinary shares and ADSs or publishes incorrect or unfavorable research about our business, the price of the ordinary shares and ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, or downgrades the ordinary shares and ADSs, demand for the ordinary shares and ADSs could decrease, which could cause the price of the ordinary shares and ADSs or trading volume to decline.

We have no present intention to pay dividends on our ordinary shares in the foreseeable future and, consequently, your only opportunity to achieve a return on your investment during that time is if the price of the ADSs appreciates.

We have no present intention to pay dividends in the foreseeable future. Any recommendation by our board of directors to pay dividends will depend on many factors, including our financial condition (including losses carried-forward), results of operations, legal requirements and other factors. Furthermore, pursuant to Belgian law, the calculation of amounts available for distribution to shareholders, as dividends or otherwise, must be determined on the basis of our non-consolidated statutory accounts prepared in accordance with Belgian accounting rules. In addition, in accordance with Belgian law and our articles of association, we must allocate each year an amount of at least 5% of our annual net profit under our non-consolidated statutory accounts to a legal reserve until the reserve equals 10% of our share capital. Therefore, we are unlikely to pay dividends or other distributions in the foreseeable future. If the price of the ADSs declines before we pay dividends, you will incur a loss on your investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends.

Our shareholders residing in countries other than Belgium may be subject to double withholding taxation with respect to dividends or other distributions made by us.

Any dividends or other distributions we make to shareholders will, in principle, be subject to withholding tax in Belgium at a rate of 30%, except for shareholders which qualify for an exemption of withholding tax such as, among others, qualifying pension funds or a company qualifying as a parent company in the sense of the Council Directive (90/435/EEC) of July 23, 1990, or the Parent-Subsidiary Directive, or that qualify for a lower withholding tax rate or an exemption by virtue of a tax treaty. Various conditions may apply and shareholders residing in countries other than Belgium are advised to consult their advisers regarding the tax consequences of dividends or other distributions made by us. Our shareholders residing in countries other than Belgium may not be able to credit the amount of such withholding tax to any tax due on such dividends or other distributions in any other country than Belgium. As a result, such shareholders may be subject to double taxation in respect of such dividends or other distributions. Belgium and the United States have concluded a double tax treaty concerning the avoidance of double taxation, or the U.S.-Belgium Tax Treaty. The U.S.-Belgium Tax Treaty reduces the applicability of Belgian withholding tax to 15%, 5% or 0% for U.S. taxpayers, provided that the U.S. taxpayer meets the limitation of benefits conditions imposed by the U.S.-Belgium Tax Treaty. The Belgian withholding tax is generally reduced to 15% under the U.S.-Belgium Tax Treaty. The 5% withholding tax applies in case where the U.S. shareholder is a company which holds at least 10% of the shares in the company. A 0% Belgian withholding tax applies when the shareholder is a company which has held at least 10% of the shares in

 

41


Table of Contents

the company for at least 12 months, or is, subject to certain conditions, a U.S. pension fund. The U.S. shareholders are encouraged to consult their own tax advisers to determine whether they can invoke the benefits and meet the limitation of benefits conditions as imposed by the U.S.-Belgium Tax Treaty.

Future sales of ordinary shares or ADSs by existing shareholders could depress the market price of the ordinary shares and ADSs.

If our existing shareholders sell, or indicate an intent to sell, substantial amounts of ordinary shares or ADSs in the public market, the trading price of the ADSs could decline significantly. As of March 15, 2017, 39,495,377 shares were eligible for sale in the public market, 563,485 of which shares are held by directors, executive officers and other affiliates and are subject to volume limitations under Rule 144 under the Securities Act . In addition, the ordinary shares subject to outstanding warrants will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. We have filed registration statements on Form S-8 with the SEC covering ordinary shares available for future issuance under our warrant plans. Sales of a large number of the shares issued under these plans in the public market could have an adverse effect on the market price of the ADSs.

We are a Belgian public limited liability company, and shareholders of our company may have different and in some cases more limited shareholder rights than shareholders of a U.S. listed corporation.

We are a public limited liability company incorporated under the laws of Belgium. Our corporate affairs are governed by Belgian corporate law. The rights provided to our shareholders under Belgian corporate law and our articles of association differ in certain respects from the rights that you would typically enjoy as a shareholder of a U.S. corporation under applicable U.S. federal and state laws.

Under Belgian corporate law, other than certain limited information that we must make public and except in certain limited circumstances, our shareholders may not ask for an inspection of our corporate records, while under Delaware corporate law any shareholder, irrespective of the size of its shareholdings, may do so. Shareholders of a Belgian corporation are also unable to initiate a derivative action, a remedy typically available to shareholders of U.S. companies, in order to enforce a right of our company, in case we fail to enforce such right ourselves, other than in certain cases of director liability under limited circumstances. In addition, a majority of our shareholders present or represented at our meeting of shareholders may release a director from any claim of liability we may have, including if he or she has acted in bad faith or has breached his or her duty of loyalty, provided, in some cases, that the relevant acts were specifically mentioned in the convening notice to the meeting of shareholders deliberating on the discharge. In contrast, most U.S. federal and state laws prohibit a company or its shareholders from releasing a director from liability altogether if he or she has acted in bad faith or has breached his or her duty of loyalty to the company. Finally, Belgian corporate law does not provide any form of appraisal rights in the case of a business combination. Please see the section of this annual report titled “Item 10.B.—Memorandum and Articles of Association.”

As a result of these differences between Belgian corporate law and our articles of association, on the one hand, and the U.S. federal and state laws, on the other hand, in certain instances, you could receive less protection as an ADS holder of our company than you would as a shareholder of a listed U.S. company.

Takeover provisions in Belgian law may make a takeover difficult.

Public takeover bids on our shares and other voting securities, such as warrants or convertible bonds, if any, are subject to the Belgian Act of April 1, 2007 and to the supervision by the Belgian Financial Services and Markets Authority, or FSMA. Public takeover bids must be made for all of our voting securities, as well as for all other securities that entitle the holders thereof to the subscription to, the acquisition of or the conversion into voting securities. Prior to making a bid, a bidder must issue and disseminate a prospectus, which must be approved by the Belgian FSMA. The bidder must also obtain approval of the relevant competition authorities, where such approval is legally required for the acquisition of our company.

 

42


Table of Contents

The Belgian Act of April 1, 2007 provides that a mandatory bid will be triggered if a person, as a result of its own acquisition or the acquisition by persons acting in concert with it or by persons acting on their account, directly or indirectly holds more than 30% of the voting securities in a company that has its registered office in Belgium and of which at least part of the voting securities are traded on a regulated market or on a multilateral trading facility designated by the Royal Decree of April 27, 2007 on public takeover bids. The mere fact of exceeding the relevant threshold through the acquisition of one or more shares will give rise to a mandatory bid, irrespective of whether or not the price paid in the relevant transaction exceeds the current market price.

There are several provisions of Belgian company law and certain other provisions of Belgian law, such as the obligation to disclose important shareholdings and merger control, that may apply to us and which may make an unfriendly tender offer, merger, change in management or other change in control, more difficult. These provisions could discourage potential takeover attempts that third parties may consider and thus deprive the shareholders of the opportunity to sell their shares at a premium (which is typically offered in the framework of a takeover bid).

Holders of the ADSs are not treated as shareholders of our company, do not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise your right to vote.

Holders of the ADSs are not treated as shareholders of our company, unless they withdraw our ordinary shares underlying the ADSs. The depositary, or its nominee, is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as shareholders of our company, other than the rights that they have pursuant to the deposit agreement.

Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (1) the notice of the meeting or solicitation of consent or proxy sent by us and (2) a statement as to the manner in which instructions may be given by the holders.

Holders of ADSs may instruct the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. We cannot guarantee ADS holders that they will receive the voting materials in time to ensure that they can instruct the depositary to vote their ordinary shares or to withdraw their ordinary shares so that they can vote them themselves. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that ADS holders may not be able to exercise their right to vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested.

We may not be able to complete equity offerings without cancellation or limitation of the preferential subscription rights of our existing shareholders, which may as a practical matter preclude us from timely completion of offerings.

In accordance with the Belgian Companies Code, our articles of association provide for preferential subscription rights to be granted to our existing shareholders to subscribe on a pro rata basis for any issue for cash of new shares, convertible bonds or warrants that are exercisable for cash, unless such rights are cancelled or limited either by resolution of our shareholders’ meeting or by our board of directors in the framework of the authorized capital, as described below. On April 26, 2016, our shareholders authorized our board to increase our share capital (possibly with cancellation or limitation of the preferential subscription rights of our existing

 

43


Table of Contents

shareholders at the discretion of our board), subject to certain limitations, for a period of five years. We refer to this authority for our board to increase our share capital as our authorized capital. As of the date of this annual report, our board of directors may decide to issue up to 8,557,345 ordinary shares pursuant to this authorization, without taking into account however subsequent issuances under our warrant programs or otherwise. Please see the section of this annual report titled “Item 10.B.—Memorandum and Articles of Association.” Absent renewal by our shareholders of this authorization of the board or absent cancellation or limitation by our shareholders of the preferential subscription rights of our existing shareholders, the requirement to offer our existing shareholders the preferential right to subscribe, pro rata, for new shares being offered may as a practical matter preclude us from timely raising capital on commercially acceptable terms or at all.

Shareholders may not be able to participate in equity offerings we may conduct from time to time.

If we conduct equity offerings in the future, certain shareholders, including those in the United States, may, even in the case where preferential subscription rights have not been cancelled or limited, not be entitled to exercise such rights, unless the offering is registered or the shares are qualified for sale under the relevant regulatory framework. As a result, there is the risk that investors may suffer dilution of their shareholdings should they not be permitted to participate in preference right equity or other offerings that we may conduct in the future.

Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.

ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders’ meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.

As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of ADSs or our ordinary shares.

We are a “foreign private issuer,” as defined in the SEC’s rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act. In addition, our officers and directors are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on Euronext Brussels and Euronext Amsterdam and voluntarily report our results of operations on a quarterly basis, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. domestic issuers and will not be required to file quarterly reports on Form 10-Q or current reports on Form 8-K under the Exchange Act. Accordingly, there is and will continue to be less publicly available information concerning our company than there would be if we were not a foreign private issuer.

 

44


Table of Contents

As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from NASDAQ corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards.

As a foreign private issuer listed on the NASDAQ Global Select Market, we are subject to corporate governance listing standards. However, rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in Belgium, which is our home country, may differ significantly from corporate governance listing standards. For example, neither the corporate laws of Belgium nor our articles of association require a majority of our directors to be independent and we could include non-independent directors as members of our nomination and remuneration committee, and our independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present. Currently, we intend to follow home country practice to the maximum extent possible. Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers. See the sections of this annual report titled “Item 6—Directors, Senior Management and Employees” and “Item 16G—Corporate Governance.”

We may lose our foreign private issuer status in the future, which could result in significant additional cost and expense.

While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter and, accordingly, the next determination will be made with respect to us on June 30, 2017.

In the future, we would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if more than 50% of our securities are held by U.S. residents and more than 50% of the members of our executive committee or members of our board of directors are residents or citizens of the United States, we could lose our foreign private issuer status.

The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP, rather than IFRS, in U.S. dollars rather than euros and modify certain of our policies to comply with corporate governance practices associated with U.S. domestic issuers. Such conversion of our financial statements to U.S. GAAP will involve significant time and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies.

It may be difficult for investors outside Belgium to serve process on, or enforce foreign judgments against, us or our directors and senior management.

We are a Belgian public limited liability company. Less than a majority of the members of our board of directors and members of our executive committee are residents of the United States. All or a substantial portion of the assets of such non-resident persons and most of our assets are located outside the United States. As a result, it may not be possible for investors to effect service of process upon such persons or on us or to enforce against them or us a judgment obtained in U.S. courts. Original actions or actions for the enforcement of judgments of U.S. courts relating to the civil liability provisions of the federal or state securities laws of the United States are not directly enforceable in Belgium. The United States and Belgium do not currently have a multilateral or bilateral treaty providing for reciprocal recognition and enforcement of judgments, other than

 

45


Table of Contents

arbitral awards, in civil and commercial matters. In order for a final judgment for the payment of money rendered by U.S. courts based on civil liability to produce any effect on Belgian soil, it is accordingly required that this judgment be recognized or be declared enforceable by a Belgian court in accordance with Articles 22 to 25 of the 2004 Belgian Code of Private International Law. Recognition or enforcement does not imply a review of the merits of the case and is irrespective of any reciprocity requirement. A U.S. judgment will, however, not be recognized or declared enforceable in Belgium if it infringes upon one or more of the grounds for refusal that are exhaustively listed in Article 25 of the Belgian Code of Private International Law. Actions for the enforcement of judgments of U.S. courts might be successful only if the Belgian court confirms the substantive correctness of the judgment of the U.S. court and is satisfied that:

 

    the effect of the enforcement judgment is not manifestly incompatible with Belgian public policy;

 

    the judgment did not violate the rights of the defendant;

 

    the judgment was not rendered in a matter where the parties transferred rights subject to transfer restrictions with the sole purpose of avoiding the application of the law applicable according to Belgian international private law;

 

    the judgment is not subject to further recourse under U.S. law;

 

    the judgment is not compatible with a judgment rendered in Belgium or with a subsequent judgment rendered abroad that might be enforced in Belgium;

 

    a claim was not filed outside Belgium after the same claim was filed in Belgium, while the claim filed in Belgium is still pending;

 

    the Belgian courts did not have exclusive jurisdiction to rule on the matter;

 

    the U.S. court did not accept its jurisdiction solely on the basis of either the nationality of the plaintiff or the location of the disputed goods; and

 

    the judgment submitted to the Belgian court is authentic.

In addition to recognition or enforcement, a judgment by a federal or state court in the United States against us may also serve as evidence in a similar action in a Belgian court if it meets the conditions required for the authenticity of judgments according to the law of the state where it was rendered. The findings of a federal or state court in the United States will not, however, be taken into account to the extent they appear incompatible with Belgian public policy.

We may be at an increased risk of securities class action litigation.

Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

We believe that we should not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for the 2016 taxable year and we do not anticipate being a PFIC for the current taxable year, but this conclusion is a factual determination that is made annually and thus may be subject to change. If we were a PFIC, this could result in adverse U.S. tax consequences to certain U.S. holders.

Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest, and gains

 

46


Table of Contents

from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Our status as a PFIC depends on the composition of our income and the composition and value of our assets (for which purpose the total value of our assets may be determined in part by reference to the market value of the ADSs and our ordinary shares, which are subject to change) from time to time. If we are a PFIC for any taxable year, U.S. holders of the ADSs may suffer adverse tax consequences, including having gains realized on the sale of the ADSs treated as ordinary income, rather than capital gain, losing the preferential rate applicable to dividends received on the ADSs by individuals who are U.S. holders, and having interest charges apply to distributions by us and the proceeds of sales of the ADSs. See “Item 10.E.—Taxation—Certain Material U.S. Federal Income Tax Considerations to U.S. Holders—Passive Foreign Investment Company Considerations.”

Based upon the expected value of our assets, including any goodwill, and the expected composition of our income and assets, we believe that we should not be a PFIC for the 2016 taxable year and we do not anticipate that we will be a PFIC with respect to the current taxable year. However, our status as a PFIC is a fact-intensive determination made on an annual basis, and we cannot provide any assurances regarding our PFIC status for the current, prior or future taxable years. We do not currently intend to provide the information necessary for U.S. holders to make a “qualified electing fund,” or QEF, election if we are treated as a PFIC for any taxable year, and prospective investors should assume that a QEF election will not be available.

We believe that we were not a controlled foreign corporation, or CFC, for U.S. federal income tax purposes for the 2016 taxable year. If we were to qualify as a CFC, this could result in adverse U.S. federal income tax consequences to certain U.S. holders.

Each “Ten Percent Shareholder” (as defined below) in a non-U.S. corporation that is classified as a “controlled foreign corporation,” or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder’s pro rata share of the CFC’s “Subpart F income” and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents and royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for United States federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A “Ten Percent Shareholder” is a United States person (as defined by the U.S. Internal Revenue Code of 1986, as amended (the “Code”)) who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote of such corporation. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain.

We do not believe that we were a CFC for the taxable year ended December 31, 2016. However, we cannot provide any assurances regarding our status as a CFC for the 2016 taxable year or any future taxable years.

 

Item 4 Information on the Company.

 

A. History and Development of the Company

Our legal and commercial name is Galapagos NV. We are a limited liability company incorporated in the form of a naamloze vennootschap / société anonyme under Belgian law. We were incorporated in Belgium on June 30, 1999 for an unlimited duration. We are registered with the Register of Legal Entities (Antwerp, division Mechelen) under the enterprise number 0466.460.429. Our principal executive and registered offices are located at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium and our telephone number is +32 15 34 29 00. Our agent for service of process in the United States is CT Corporation System.

 

47


Table of Contents

Our fiscal year ends December 31. We also maintain a corporate website at www.glpg.com. Information contained on, or that can be accessed through, our website does not constitute a part of this annual report. We have included our website address in this annual report solely as an inactive textual reference.

Our actual capital expenditures for the years ended December 31, 2014, 2015 and 2016 amounted to €2.8 million, €6.7 million, and €4.8 million respectively. These capital expenditures primarily consisted of laboratory equipment and leasehold improvements. We expect our capital expenditures to increase in absolute terms in the near term as we continue to advance our research and development programs and grow our operations. We anticipate our capital expenditure in 2017 to be financed from the cash flows from operating activities and cash reserves . For more information on our capital expenditures, see the section of this annual report titled “Item 6.B.—Liquidity and Capital Resources—Capital Expenditures.”

 

B. Business Overview

We are a clinical-stage biotechnology company specialized in the discovery and development of medicines with novel modes of action, addressing disease areas of high unmet medical need. Our pipeline comprises programs ranging from discovery to Phase 3 clinical trials in inflammation, cystic fibrosis, fibrosis, osteoarthritis and other indications. Our highly flexible platform is applicable across many therapeutic areas. Our clinical stage programs include: filgotinib, which is currently in Phase 3 trials in rheumatoid arthritis (RA), Crohn’s disease (CD), and ulcerative colitis (UC); our cystic fibrosis (CF) portfolio of drugs aimed at a triple combination therapy for 90% of CF patients, for which we plan to initiate patient clinical trials by mid-2017; GLPG1690, our fully proprietary autotaxin inhibitor, which is currently in a Phase 2a trial for idiopathic pulmonary fibrosis (IPF); GLPG1972 for osteoarthritis (OA), which is expected to be dosed in a Phase 1b trial in U.S. patients in 2017; and MOR106, which is currently being dosed in atopic dermatitis (AtD) patients in a Phase 1b trial. Except for our CF program, these programs are derived from our proprietary target discovery platform.

We have collaborations with Gilead for filgotinib, with AbbVie for CF, with Servier for GLPG1972, and with MorphoSys for MOR106. For more information on our collaborations, see “—Collaborations.” The following table summarizes key information on our lead development programs as of the date of this annual report:

 

LOGO

 

48


Table of Contents

Lead Programs

Filgotinib: Selective JAK1 Inhibitor with a Potential Best-in-class Product Profile

Based on results from our Phase 2 trials, we believe that filgotinib is a promising candidate for the treatment of RA, CD and potentially other inflammatory diseases. We are party to an exclusive collaboration agreement with Gilead to develop and commercialize filgotinib in multiple diseases. Under the terms of the collaboration, Gilead is primarily responsible for development and seeking regulatory approval of the licensed product. We are required to use commercially reasonable efforts as requested by Gilead to assist Gilead with certain development activities. Gilead initiated Phase 3 clinical programs in RA and CD and a Phase 2b/3 program in UC in 2016.

Our Filgotinib Program in RA

RA is a chronic autoimmune disease that affects 2.9 million patients (of which approximately 1.5 million are being treated with biologics) in the United States and Europe. RA is characterized by inflammation and degeneration of the joints. Patients suffer from pain, stiffness, and restricted mobility due to a persistent inflammation of multiple joints, ultimately resulting in irreversible damage of the joint cartilage and bone. According to GlobalData, sales of RA therapeutics across the 10 main healthcare markets was $19.5 billion in 2015, with the current market being dominated by injectable, biological therapies. Biologics, mostly TNF therapies, need to be injected and often lose their effect over time, so there continues to be a considerable unmet need with regard to efficacy, safety, and convenience of use with existing treatments.

New oral therapies that target the Janus kinase, or JAK, signaling pathway are emerging to treat inflammatory diseases; JAK inhibitors, however, are associated with a range of side effects, including aberrations in low-density lipoprotein, or LDL, cholesterol and red blood and NK cell counts. In a human whole blood assay we demonstrated that filgotinib, with a 30-fold selectivity for JAK1 over JAK2, was more selective for JAK1 than any other compound known to us to be either approved for sale or in clinical development. We believe the high selectivity of filgotinib for JAK1 may allow for a positive efficacy profile, with an improved safety profile for filgotinib due to the improved selectivity over JAK2 and JAK3.

 

LOGO

Our Clinical Program for Filgotinib for RA

Clinical trials to date have shown that filgotinib is well-tolerated, with atherogenic index improvement and absence of anemia. We believe its once-a-day oral dosage and its low risk for drug-drug interactions make it convenient for patient use.

We reported final 24-week data from DARWIN 1 and DARWIN 2 Phase 2b dose-range finding clinical trials in 2015. Both trials were double-blind, placebo-controlled for 24 weeks of treatment in patients with moderate to severe rheumatoid arthritis who showed an inadequate response to methotrexate. DARWIN 1 (594 patients) evaluated filgotinib as an addition to methotrexate, as once- and twice-daily administration (qd and bid dosing, respectively) at three daily dose levels. DARWIN 2 (283 patients) evaluated filgotinib as once-daily

 

49


Table of Contents

monotherapy administration (qd dosing) at three dose levels. Both trials achieved the primary endpoints (ACR20). Below are the ACR50 and ACR70 scores at 12 and 24 weeks for 100 and 200 mg qd in both DARWIN 1 and DARWIN 2:

 

LOGO

Overall, there was no statistically relevant difference between the once-daily and twice-daily dosing regimens in DARWIN 1. Both trials showed a rapid onset of activity, as of week one for ACR and DAS28(CRP) responses. In DARWIN 1 (200 mg bid) and in DARWIN 2 (100 mg qd) up to 50% of the patients reached low disease activity or remission. The 100 mg and 200 mg qd doses achieved similar levels of activity overall.

Safety data in both trials was similarly promising. In dose groups including placebo in both studies, 3.9% of patients stopped treatment during the trial for safety reasons. In DARWIN 1 patients reporting serious (2.5% overall) and non-serious treatment-emergent adverse events were evenly spread over the dose groups including placebo. Serious infections were reported in six patients, including one death on active treatment in the second half of the trial and for which the Data Safety Monitoring Board did not see a reason to pause or change the trial. No opportunistic infections were reported. Herpes zoster infection occurred in five patients, equally spread over placebo and filgotinib groups. In DARWIN 2 a higher discontinuation rate for safety was observed for placebo (5.6%) during the first 12 weeks of the trial compared to filgotinib treated patients (2.5%) up to week 24. Similar incidence of serious and non-serious treatment-emergent adverse events was reported, evenly spread over the dose groups including placebo. A higher rate of infections was observed in filgotinib (19% over 24 weeks) compared to placebo (10% up to week 12), with serious infections remaining limited (1.4% of filgotinib patients). No malignancies, tuberculosis, major adverse cardiac events, opportunistic infections, or deaths were reported in DARWIN 2.

On the basis of pre-clinical findings, males in the United States were restricted by the FDA to the 100 mg dose for DARWIN 1 and 2. Male reproductive hormones consequently were monitored in male patients taking 200 mg in DARWIN 1 and 2 outside the United States. No clinically significant changes or discontinuations were observed for male reproductive hormones in either trial.

Consistent with its selective JAK1 inhibition, filgotinib treatment led to an improvement in hemoglobin (DARWIN 1 up to 0.5 g/dL, or a 4% increase from baseline, DARWIN 2 up to 0.4 g/dL, or 3.6% increase from baseline). In DARWIN 1, all lipid fractions including HDL and LDL increased, with the largest percentage increase in HDL, while in DARWIN 2 similar increases in LDL and HDL were maintained. Neutrophil levels remained stable after initial decline to mid-normal range at week four. Neither lymphocytes nor liver enzymes were impacted by treatment with filgotinib in either study.

 

50


Table of Contents

Filgotinib’s improvement in hemoglobin shown in DARWIN 1 and 2 potentially differentiates it when compared to impact on hemoglobin shown by other JAK inhibitors in RA trials:

 

LOGO

Filgotinib’s lack of impact on natural killer (NK) cells shown in DARWIN 1 and 2 potentially differentiates it when compared to the impact on NK cells shown by other JAK inhibitors in RA trials:

 

LOGO

Of the patients who have completed DARWIN 1 and DARWIN 2 and were eligible to continue, approximately 98% elected to participate in the DARWIN 3 follow-up trial. DARWIN 3 is a multi-center, open-label, long-term follow-up safety and efficacy trial of subjects who have completed either DARWIN 1 or DARWIN 2. All subjects have started the trial at the same dose level, either at 200 mg once per day or at 100 mg twice per day (except for males in the U.S. sites of these trials who receive a maximum daily dose of 100 mg), depending on the regimen administered during the preceding trial, with DARWIN 1 subjects continuing to use filgotinib in combination with MTX.

 

51


Table of Contents

FINCH Phase 3 Program with Filgotinib in RA

In August 2016, our collaboration partner Gilead initiated the FINCH global Phase 3 program investigating the efficacy and safety of 100 mg and 200 mg filgotinib once daily, in RA patient populations, ranging from early stage to biologic-experienced patients:

FINCH 1 is a 52-week, randomized, placebo- and adalimumab-controlled trial in combination with methotrexate (MTX) in an expected 1,650 patients who have had inadequate response to MTX. The primary endpoint is ACR20 at week 12. American College of Rheumatology 20% (ACR20) response rate signifies a 20% or greater improvement in the number of swollen and tender joints as well as a 20% or greater improvement in three out of five other disease-activity measures. ACR50 and ACR70 reflect the same, respectively for 50% and 70% response rates. The study will also include radiographic assessment at weeks 24 and 52.

FINCH 2 is a 24-week, randomized, placebo-controlled trial in an expected 423 patients who are on conventional disease-modifying anti-rheumatic drugs (cDMARD), and have had an inadequate response to biological treatment. The primary endpoint is ACR20 at week 12.

FINCH 3 is a 52-week, randomized trial in an expected 1,200 MTX-naïve patients to study filgotinib in combination with MTX, as well as monotherapy. The primary endpoint is ACR20 at week 24. Radiographic progression will also be assessed.

Gilead will perform a single dedicated male patient safety study concurrent to all Phase 3 programs. This study is expected to include RA, CD, and UC patients.

Our Filgotinib Program in Inflammatory Bowel Disease (IBD)

IBD includes CD and UC. We observed high activity and a favorable safety profile in a Phase 2 trial with filgotinib in CD. The profile we saw with filgotinib in this CD patient trial leads us to believe the product candidate may show activity and tolerability in UC patient studies as well. IBD affects approximately 2 million patients (of which approximately 0.5 million are being treated with biologics) in the United States and Europe, and the market for IBD therapies is approximately $9 billion today, according to GlobalData. Current treatments are dominated by anti-TNF agents, with new biologic products gaining some ground in second line treatment.

CD is an IBD of unknown cause, resulting in chronic inflammation of the gastrointestinal (GI) tract with a relapsing and remitting course. Today, only 10% of CD patients achieve prolonged clinical remission. There are currently no highly effective oral therapies approved for CD and, similar to RA, treatment is dominated by injectable, biologic treatments including anti-TNF therapies. Anti-TNF agents have improved the management of CD; however, not all patients respond to these drugs, and secondary loss of response is reported in up to 50% of patients per year in placebo-controlled trials. There continues to be a considerable unmet need with these existing treatments. Dysregulation of the JAK signaling pathway has also been associated with CD, and we believe that filgotinib, with its high selectivity for JAK1, is a highly attractive candidate for the treatment of CD. By inhibiting JAK1 but not JAK2, unwanted effects such as anemia may be prevented. This absence of anemia is of particular importance to IBD patients, who frequently experience fecal blood loss.

Increased activity and focus from pharmaceutical companies has led to more clinical trials of oral therapies in CD. For example, AbbVie is conducting a Phase 2 trial with upadacitinib (pan-JAK inhibitor) which should read out in 2017. Celgene announced Phase 1b results with GED-0301 (SMAD-7), which showed early activity but limited endoscopic improvement. Celgene is also investigating ozanimod (S1P 1 and 5 receptor modulator) in Phase 2 in CD, with topline results expected in 2017. After two Phase 2 trials, Pfizer announced Xeljanz (pan-JAK inhibitor) will not be developed further in CD.

Our Clinical Program with Filgotinib in CD

Our FITZROY Phase 2 trial (174 patients) evaluated filgotinib once-daily versus placebo in patients with moderate to severely active CD and mucosal ulceration. Patients recruited were either anti-TNF naïve or

 

52


Table of Contents

anti-TNF failures. FITZROY was the first trial in CD to require endoscopic confirmation of lesions at entry, and also to include a placebo control on endoscopy. The trial comprised two parts, each of 10 weeks duration: the first part investigated the safety and efficacy of filgotinib 200 mg once daily versus placebo, while the second part of the study investigated continued treatment through 20 weeks in an observational exploratory design. The FITZROY trial achieved the primary endpoint of clinical remission at 10 weeks: the percentage of patients achieving a Crohn’s Disease Activity Index (CDAI) score lower than 150 was statistically significantly higher in patients treated with filgotinib (47%) versus patients receiving placebo (23%). The share of patients achieving 100-points clinical response (60%) also was significant versus those receiving placebo (41%). Improvement in quality of life, histopathology, endoscopy assessment and biomarkers of inflammatory activity were also observed at week 10. Overall mean change in histopathology scores at week 10 for patients treated with filgotinib (-3.5) versus placebo (-0.6) was significantly different, confirming the clinical responses in the tissues of patients. More patients on filgotinib showed >50% improvement in SES-CD (endoscopy) scores versus placebo patients at week 10:

 

LOGO

Clinical responses were maintained from week 10 to week 20. Non-responders in the placebo arm from the first ten weeks received filgotinib 100 mg in the second ten weeks and showed improvement in clinical remission during the second part of the trial.

Overall, in the FITZROY study at 20 weeks of treatment, filgotinib demonstrated a favorable safety profile consistent with the DARWIN studies in RA. An increase in hemoglobin was also observed in FITZROY, without difference between filgotinib and placebo. No clinically significant changes from baseline in neutrophils or liver function tests were observed.

Gilead initiated a Phase 3 trial (DIVERSITY) with filgotinib in CD in November 2016. The DIVERSITY Phase 3 trial investigates efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo in patients with moderately to severely active disease including those with prior antibody therapy failure. Gilead will recruit approximately 1,300 patients from the United States, Europe, Latin America, Canada, and Asia/Pacific regions. Men and women in the DIVERSITY trial will be randomized to receive placebo, 100 mg or 200 mg filgotinib. In the United States, males may receive 200 mg if they failed at least one anti-TNF and vedolizumab, a monoclonal anti-integrin antibody marketed by Takeda.

In March 2017, Gilead initiated a Phase 2 study in small bowel CD and a Phase 2 study in fistulizing CD.

 

53


Table of Contents

Our Clinical Program with Filgotinib in UC

UC is an inflammatory bowel disease resulting in ulcerations and inflammation of the colon and rectum. Unlike CD, UC involves damaging inflammation of only the colon and rectum. Although the introduction of anti-TNF biologics has improved the treatment of some patients, only 33% of patients will achieve long-term remission, and many patients lose their response to treatment over time. The medical need for improved efficacy is high and could likely be achieved by a new mechanism of action.

Increased activity and focus from potential competitors has led to more clinical trials of oral therapies in UC. Pfizer showed activity with Xeljanz (pan-JAK inhibitor) in Phase 3 UC trials and has filed for approval. AbbVie is conducting a Phase 2 trial with ABT-494 (pan-JAK inhibitor) which should read out in 2017. Celgene is investigating ozanimod (S1P 1 and 5 receptor modulator) in Phase 3 and GED-0301 (SMAD-7) in Phase 2 in UC.

Gilead initiated the SELECTION Phase 2b/3 trial in UC with filgotinib in December 2016. SELECTION investigates efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo in patients with moderately to severely active disease including those with prior antibody therapy failure. Gilead will recruit approximately 1,300 patients from the United States, Europe, Latin America, Canada, and Asia/Pacific regions. The SELECTION Phase 2b/3 trial in UC will include a futility analysis, serving as the Phase 2b part of this integrated Phase 2b/3 study. Men and women in SELECTION will be randomized to receive placebo, 100 mg or 200 mg filgotinib. In the United States, males may receive 200 mg if they failed at least one anti-TNF and vedolizumab.

Our CF Program

CF is a rare, life-threatening, genetic disease affecting the lungs and the digestive system, impacting approximately 80,000 patients worldwide with approximately 30,000 patients in the United States. CF patients carry a defective cystic fibrosis transmembrane conductance regulator, or CFTR, gene and are classified based on their specific mutation of the CFTR gene. The Class II mutation is present in approximately 90% of CF patients, with Orkambi being the only approved therapy for the underlying cause of CF in this mutation. Kalydeco is a disease-modifying treatment for Class II mutations, representing 4% of total CF patients. The market for CF therapies is robust and growing. According to Vertex Pharmaceuticals, approximately 9,000 patients were treated with Vertex therapies in 2016, and this they expect to grow to approximately 75,000 patients by 2024. Combined sales of Kalydeco and Orkambi were approximately $1.7 billion in 2016.

Despite the approval of Kalydeco and Orkambi, there is need for better therapies to improve pulmonary function for a large majority of the patient population. Though many pediatric patients have normal lung function at the time of diagnosis, physicians generally believe that earlier treatments can have downstream benefits for the patient by slowing the deterioration in lung function.

Two types of disease-modifying CFTR modulators have the current focus of CF drug developers. Potentiator molecules aim to restore the flow of ions through an activated CFTR by influencing the channel’s opening. Corrector molecules aim to overcome defective protein processing by restoring proper folding of CFTR and allowing for increased cell surface expression. In order to improve CFTR function meaningfully for the largest patient group with Class II and other mutations, we believe a combination of medicines will be required, comprising a potentiator and two novel corrector (which we refer to as C1 and C2) molecules.

 

54


Table of Contents

In pre-clinical cellular assay studies, we consistently observed that combinations of potentiator, C1, and C2 correctors restore close to healthy CFTR function in lung epithelial cells and organoids cultured from Class II and Class III/IV patients, both homozygous and heterozygous for F508del, respectively:

 

LOGO

These results are suggestive of a compelling therapeutic option for these patients. We believe that our CF combination therapy may address the unmet need in both homozygous and heterozygous Class II patients, based on these in vitro results.

We aim to evaluate a once-daily, oral, triple combination CF therapy in patients starting in mid-2017, with additional trials with novel CF compounds initiating throughout 2017. We have developed a portfolio of lead and follow-on compounds from which to select the best potentiator and corrector molecules for our triple combination therapy:

 

LOGO

Our Clinical Program for CF

Our most advanced product candidate, potentiator GLPG1837, was the first potentiator since Kalydeco to show comparable results in G551D patients in the SAPHIRA 1 Phase 2a trial in late 2016.

SAPHIRA 1 was an open-label study of three doses of GLPG1837 in 26 patients with the G551D mutation. Of these patients, 25 patients were on stable Kalydeco treatment at screening and agreed to a one week washout prior to the start of dosing GLPG1837. One patient was naïve to Kalydeco. All subjects received GLPG1837 125 mg bid (twice-daily) for 7 days, immediately followed by 250 mg bid for 7 days and subsequently by 500 mg bid for 14 days.

 

55


Table of Contents

A statistically significant dose dependent decrease in sweat chloride concentration was observed. At the 500 mg bid dose, sweat chloride decreased from a mean value of 98 mmol/L at baseline to 66 mmol/L (p <0.0001). For those patients exceeding the predicted target concentration, sweat chloride changed from a mean value of 94 mmol/L at baseline to 52 mmol/L. Below is an illustration of the changes in sweat chloride at increasing pre-dose exposures of GLPG1837 in blood plasma from SAPHIRA 1 in G551D patients who had washed out of Kalydeco prior to being treated with GLPG1837:

 

LOGO

Twenty-five patients were on stable treatment with Kalydeco prior to this study. For these patients, mean percent predicted FEV1 (ppFEV1) levels were 74% at screening (prior to Kalydeco washout). The one week wash-out resulted in a 5.4% mean decrease in absolute ppFEV1. At the end of treatment with GLPG1837, the ppFEV1 levels returned to the Kalydeco pre-washout levels. The figure below illustrates this restoration of ppFEV1 to screening levels, after washout and treatment with GLPG1837 in SAPHIRA 1:

 

LOGO

Overall GLPG1837 was well tolerated in SAPHIRA 1, with observed treatment emergent adverse events being predominantly mild or moderate, and typical for a CF patient population. One patient dropped out of the study due to an increase in non-cardiac creatine phosphokinase.

We believe that SAPHIRA 1 represents a clinical validation of our in vitro systems, reinforcing our confidence in our approach to get to a triple combination therapy.

 

56


Table of Contents

We initiated a Phase 1 trial for a second potentiator candidate GLPG2451 in May 2016. Follow-on potentiator GLPG3067 entered Phase 1 in March 2017. GLPG1837 has a twice-daily dosing profile, while GLPG2451 has potential for once-daily dosing.

We reported that GLPG2222, the first early binding (C1) corrector, showed favorable safety and tolerability in Phase 1 trials in healthy volunteers in June 2016. GLPG2222 was tested in single ascending doses up to 800 mg, and in multiple ascending doses up to 600 mg qd for 14 days in a double-blind, randomized, placebo-controlled study. The product candidate was shown to be well-tolerated and no emerging safety signals observed in the dose range studied. Absorption of GLPG2222 was rapid and favorable. Pharmacokinetics of GLPG2222 support once-daily dosing regimens to be explored in further development. We believe GLPG2222 is well positioned for selection for the first triple combination therapy in 2017 and will be further explored in the clinic throughout the year to improve our understanding of dosing for the triple combination, including a Phase 2 trial on top of Kalydeco in Class III mutation patients initiated in January 2017. We dosed the first healthy volunteer with a combination of GLPG2451 and GLPG2222 in February 2017. Backup C1 corrector GLPG2851 will enter Phase 1 trials in 2017.

We initiated a Phase 1 trial for our first late binding (C2) corrector GLPG2737, the final component needed for a triple combination therapy, in November 2016. Topline results from this trial are expected in Q2 2017. We are developing follow-on C2 correctors which are expected to enter Phase 1 in 2017.

Our IPF Programs

IPF is a chronic, relentlessly progressive fibrotic disorder of the lungs that typically affects adults over the age of 40. According to GlobalData, IPF affects approximately 109,000 patients in the United States and Europe and, as such, we have received orphan designation for our product candidate GLPG1690 in this indication from the European Commission and we intend to seek orphan designation in the United States for our product candidates in IPF. The clinical prognosis of patients with IPF is poor, as the median survival at diagnosis is two to four years. Currently, no medical therapies have been found to cure IPF. The medical treatment strategy aims to slow disease progression and improve quality of life. Lung transplantation may be an option for appropriate patients with progressive disease and minimal comorbidities.

Regulatory agencies have approved Esbriet and Ofev for the treatment of mild to moderate IPF. Both Esbriet and Ofev have been shown to slow the rate of functional decline in IPF and are gaining ground as the standard of care worldwide. Combined sales of both drugs reached $1.1 billion in 2016, with 74% of global revenues being in the United States. These regulatory approvals represent a major breakthrough for IPF patients; yet neither drug improves lung function, and the disease in most patients on these therapies continues to progress. Moreover, the adverse effects associated with these therapies are considerable (e.g., diarrhea, liver function test abnormalities with Ofev, nausea and rash with Esbriet). Therefore, there is still a large unmet medical need as IPF remains a major cause of morbidity and mortality. GlobalData estimates global sales of approved IPF drugs will grow to nearly $2.4 billion in 2022.

GLPG1690 is a potent and selective inhibitor of autotaxin (ATX) and is fully proprietary to us. We identified ATX as a potential target for IPF, after finding the target using an inflammation assay in our target discovery platform. Pharmacology and translational studies published by other parties since then suggest that ATX may also play a role in metabolic disease, arthritic pain, oncology, and lung disease. We evaluated GLPG1690 in a pre-clinical lung fibrosis model (bleomycin-treated mice) and observed effects on reducing the fibrotic score, numerically favoring GLPG1690 over Esbriet.

GLPG1690 completed a Phase 1 first-in-human trial in February 2015. In this trial, GLPG1690 was shown to be well-tolerated in up to 1000 mg daily dose and demonstrated a favorable pharmacokinetic profile.

 

57


Table of Contents

Moreover, in this trial GLPG1690 demonstrated the ability to reduce plasma lysophosphatidic acid (LPA) levels on a sustained basis, implying ATX engagement.

We are currently conducting a Phase 2a trial (called FLORA) in IPF patients. FLORA is fully recruited and we expect topline results in the second half of 2017. This randomized, placebo-controlled double-blind trial includes up to 24 patients with IPF from 17 centers in Europe and evaluates treatment with 600mg of GLPG1690 for 12 weeks. Primary objectives are to assess safety, tolerability, and pharmacokinetics and pharmacodynamics of GLPG1690 in IPF patients. Target engagement will be measured by LPA in plasma and bronchoalveolar lavage fluid, both at baseline and through 12 weeks of treatment. Secondary objectives include the evaluation of lung function, changes in disease biomarkers and quality of life.

In June 2016, we nominated a second product candidate for IPF, GLPG2938, with an undisclosed novel mechanism of action. This candidate is expected to enter Phase 1 trials in 2017.

Our OA Program

Sometimes called degenerative joint disease or degenerative arthritis, OA is the most common chronic condition of the joints. OA can affect any joint, but it occurs most often in the small joints of the fingers, knees, hips, lower back and neck, and the bases of the thumb and big toe. According to GlobalData, OA will be the fourth leading cause of disability by the year 2020. There are limited data on the total prevalence of OA. GlobalData estimates that diagnosed cases will grow from approximately 117 million cases in 2016 to approximately 131 million cases by 2024, with cases affecting hand, knee, and hip in that order of prevalence.

In normal joints, a firm, rubbery material called cartilage covers the end of each bone. Cartilage provides a smooth, gliding surface for joint motion and acts as a cushion between the bones. In OA, the cartilage breaks down, causing pain, swelling and problems moving the joint. As OA worsens over time, bones may break down and develop growths called spurs. Bits of bone or cartilage may chip off and float around in the joint. In the body, an inflammatory process occurs and cytokines (proteins) and enzymes develop that further damage the cartilage. In the final stages of OA, the cartilage wears away and bone rubs against bone leading to joint damage and more pain.

Although OA occurs in people of all ages, it is most common in people older than 65. Common risk factors include obesity, previous joint injury, over-use of the joint, and weak thigh muscles. One in two adults will develop symptoms of knee OA during their lives. One in four adults will develop symptoms of hip OA by age 85. Current treatments for OA include weight loss, physical therapy, pain and anti-inflammatory medicines, and surgery, all of which address only the symptoms of the disease. There are currently no disease-modifying therapies available for OA, with drug sales for OA patients amounting to approximately $4 billion in generic painkillers in 2016.

GLPG1972 has a novel mode of action with potential application in OA and was discovered by us under our collaboration agreement with Servier, a French pharmaceutical company.

In June 2016, we announced that GLPG1972, a first-in-class product candidate aimed at treating OA, was shown to be safe and well tolerated in healthy human volunteers in a Phase 1 first-in-human trial. In this trial, dosing with GLPG1972 reduced a cartilage breakdown biomarker by up to 60% in these volunteers within two weeks. In 2017, we intend to conduct a Phase 1b patient clinical trial of GLPG1972 in the United States, where we retained full commercial rights. Additional data resulting from the ongoing nonclinical program expected in the second quarter of 2017 is expected to enable our collaboration partner Servier to decide on the exercise of the option to license the compound for further development into OA patient trials outside the United States.

 

58


Table of Contents

Our AtD Programs

AtD, also known as atopic eczema, is a chronic pruritic (itching) inflammatory skin disease that most frequently starts in early childhood, often persists into adulthood, but may also have an adult onset. According to GlobalData, sales of AtD therapies in the seven major healthcare markets may reach $4 billion in 2016, with 35 million patients diagnosed with the disease and 10 million patients being treated in those markets. The main features of AtD are the impairment of the skin barrier and dysfunction of the immune system accompanied with dry skin and severe pruritus that is associated with cutaneous hyperactivity to various environmental stimuli. The pruritus (itching) may lead to sleep loss, anxiety, depression and impaired social life and is therefore considered as highest therapeutic need in AtD. Generic drugs are the approved standard of care, including immunomodulators cyclosporine and mycophenolate mofetil and topical treatments. There are disease-modifying biologics in currently in development.

MOR106 is a human monoclonal antibody designed to selectively target IL-17C in clinical development worldwide. IL-17C is a target discovered by us and has been shown to be distinct from other members of the IL-17 cytokine family, playing an important and pro-inflammatory role in certain skin disorders. MOR106 potently inhibits the binding of IL-17C to its receptor and thus inhibits its biological activity.

MOR106 arises from a strategic discovery and co-development alliance between us and MorphoSys, in which both companies contribute their core technologies and expertise.

We are currently evaluating MOR106 in a randomized, double-blind, placebo-controlled Phase 1 trial, with the aim to evaluate safety and tolerability. As secondary endpoints, the trial will assess pharmacokinetics and potential immunogenicity of MOR106.

The first part of the trial was conducted in a single center in 56 healthy volunteers, evaluating single ascending doses (SAD) as intravenous infusion compared to placebo. MOR106 showed favorable safety and PK results when administered to healthy volunteers in the ongoing trial. Subsequently investigation was started of multiple ascending doses (MAD) compared to placebo in approximately 24 patients with moderate to severe AtD in several European centers. Topline results of the complete trial, including the MAD part in patients and further results from the SAD part in healthy volunteers, are expected in the second half of 2017.

In June 2016, we nominated a second product candidate for AtD, GLPG2534, with a novel mechanism of action, which is different from the target of MOR106. This small molecule candidate is fully proprietary to us and is expected to enter Phase 1 trials in 2017.

For a breakdown of our total revenues by activity and geographic market, please see “Note 3—Segment information—Geographical information” in our consolidated financial statements appended to this annual report.

Our Strategy

We seek to develop a robust portfolio of breakthrough therapies. Our ambition is to become a fully integrated biopharmaceutical company focused on the development and commercialization of novel medicines. Our strategy is to leverage our unique and proprietary target discovery platform, which facilitates discovery and development of therapies with novel modes of action which address the root causes of the disease.

Key elements of our strategy include:

 

    Rapidly advance the development and commercialization of filgotinib with our collaboration partner Gilead in RA, CD, UC, and potentially other inflammatory diseases

Based on the results from our Phase 2 clinical trials, we believe that filgotinib is a promising candidate for the treatment of RA, CD, UC and potentially other inflammatory diseases. Our collaboration partner Gilead

 

59


Table of Contents

initiated Phase 3 clinical programs in RA, CD and UC in 2016. We retained an option to co-promote filgotinib with Gilead in the UK, Germany, France, Italy, Spain, the Netherlands, Belgium, and Luxembourg; exercising this option would enable us to build a commercial organization and further progress our ambition to become a fully integrated biopharmaceutical company.

 

    Collaborate with our collaboration partner AbbVie to develop a CF franchise of triple combination oral therapies

In order to address the unmet need in CF patients with Class II and other mutations in the CFTR gene, we aim to develop a triple combination therapy comprising a potentiator and two corrector molecules. Our most advanced product candidate for this triple combination therapy, potentiator GLPG1837, showed promising activity, with observed treatment emergent adverse events being predominantly mild or moderate, in CF patients with the Class III mutation of the CFTR gene in a Phase 2 trial late in 2016. This trial also provided data necessary to validate our in vitro assays and dosing modelling for developing a successful triple combination therapy. We initiated a Phase 1 trial for a second potentiator candidate GLPG2451 in May 2016. We reported positive topline results from a Phase 1 trial for our C1 corrector candidate, GLPG2222, in June 2016 and initiated a Phase 2 trial on top of Kalydeco in Class III mutation patients in January 2017. We initiated a Phase 1 trial for our C2 corrector GLPG2737 in November 2016. We dosed the first healthy volunteer with a combination of GLPG2451 and GLPG2222 in February 2017. We aim to evaluate a once-daily, oral, triple combination therapy in CF patients starting in mid-2017, with additional trials with novel CF compounds initiating throughout 2017. We initiated a Phase 1 study with potentiator GLPG3067 in March 2017. We have an exclusive collaboration agreement with AbbVie to jointly discover, develop, and commercialize these novel CF modulators.

 

    Advance GLPG1690 in patient clinical trials in IPF

We have completed the enrollment of IPF patients in a Phase 2a trial evaluating target and disease biomarker changes during three months’ treatment with autotaxin inhibitor GLPG1690 or placebo, and we intend to disclose topline results of this trial in the second half of 2017. We have worldwide development and commercialization rights for GLPG1690.

 

    Advance GLPG1972 in OA patient clinical trials in the United States

In June 2016, we announced that a Phase 1 first-in-human trial of GLPG1972, a novel mechanism of action product candidate for the treatment of OA, showed the product candidate reduced a cartilage breakdown biomarker in healthy volunteers up to 60% within two weeks. We retain all development and commercialization rights to this compound in the United States, and we intend to initiate clinical trials of GLPG1972 in the United States in 2017. Additional data resulting from an ongoing nonclinical program expected in the second quarter of 2017 will enable our collaboration partner Servier to make a decision regarding exercising its option to license the compound for further development in OA patient trials outside the United States.

 

    Advance MOR106 in AtD patient clinical trials with our collaboration partner MorphoSys

In April 2016, we initiated a Phase 1 first-in-human trial and in October 2016, we announced first dosing of an AtD patient with MOR106, a novel human monoclonal antibody medicine in development with MorphoSys, in a Phase 1b trial. MOR106 targets IL17-C, a novel antibody target discovered by us. MorphoSys and we share costs and potential benefits equally in this collaboration. Topline data from the Phase 1b trial with MOR106 are expected in the second half of 2017.

 

    Maximize and capture the value of our target discovery platform by becoming a fully integrated biotechnology company

Our platform has yielded many new mode-of-action investigational therapies across multiple therapeutic areas. Our most mature pre-clinical programs are GLPG2534 for AtD and GLPG2938 for IPF, both of which we plan to take into Phase 1 trials in 2017. Additionally, we are exploring the potential of development programs

 

60


Table of Contents

and pre-clinical product candidates in ankylosing spondylitis, psoriatic arthritis, lupus, nonalcoholic steatohepatitis, type 2 diabetes, and hepatitis B. We aim to initiate a Phase 3 trial every other year, while conducting three proof-of-concept trials, delivering eight new validated targets and three pre-clinical product candidates every year. We aim to select promising programs for internal development and commercialization to capture greater value for shareholders and establish ourselves as a fully integrated biopharmaceutical company.

Our Proprietary Target Discovery Platform

Our target discovery platform provides a significant and substantial competitive advantage in our portfolio of novel mode of action product candidates as it:

 

    closely mimics the in vivo situation through the use of primary human cell with relevant trigger and readout for a specific disease phenotype

 

    identifies the optimal point to intervene in a disease pathway by knocking down of a given protein in these assays

 

    enables us to rapidly analyze all of the drugable genome and select pharmaceutically tractable protein targets directly by their ability to regulate key disease biology

Our product candidate filgotinib acts on a target whose role in the specific disease was discovered by us using our discovery platform and we believe is a proof of success of this approach. Filgotinib acts on JAK1 and we believe has potential for a best-in-class profile in Phase 3 clinical trials in RA, CD, and UC.

The human genome is made up of tens of thousands of genes which code for the proteins that make up the human body. Nearly all chronic diseases and disorders are caused by a disruption in the normal function of certain proteins. The main goal of pharmaceutical companies is to design drugs that alter the activity of these proteins so that normal function returns and the cause of the disease is minimized or eliminated. One of the main obstacles in discovering new drugs is to understand exactly which of the body’s thousands of proteins play a key role in a particular disease. Once these proteins are discovered, they become targets for drug design. Finding these targets is one of the critical steps in the drug discovery process. Our approach to target discovery is unique as our discovery platform focuses on target identification using primary human cells, which we believe provides a good system to study the effect that a protein might have on the disease in the human body.

In order to study proteins in human cells, we take advantage of the distinctive properties of adenoviruses. Adenovirus is the virus that causes the common cold and has the capability to infect almost every type of human cell. The adenoviruses we work with have been engineered to act as a shuttle vehicle, allowing the delivery of specific pieces of DNA into human cells. Additionally, these viruses have been made replication incompetent, meaning they do not replicate in the human cell they infect, and so do not interfere with the processes in the cell. We engineered the viruses to carry small pieces of DNA, specific for individual human genes. When the virus enters the cell, this DNA piece leads to the production of a short sequence of RNA that is processed in the cell to become “short interfering RNA,” or siRNA, which specifically interferes with the mRNA of the protein it was designed for. By using these viruses, we can cause the cells to block, or “knock-down,” the production of a certain protein, mimicking what a small molecule drug does in the human body. We built a collection with these adenoviruses, now in excess of 20,000 viruses, that addresses over 6,000 drugable genes.

Our drug discovery research is based on the targets discovered using this technology. Once a target is validated, it is tested against large collections of chemical small molecules to identify chemical structures that interact with the target and block or activate protein production. These chemical structures are then optimized to obtain “drug-like” characteristics followed by testing of the product candidate in the clinic.

We believe that this discovery approach may increase the chances of success in bringing new mode of action drugs to the market. Since 2009, we have generated 32 pre-clinical candidates of which 24 have novel modes of action. Of these, 15 have entered the clinic, 11 with novel modes of action.

 

61


Table of Contents

In addition to our pipeline of molecules in the clinic, we have multiple discovery programs which are advancing toward clinical development. Further to targets and molecules in RA, IBD, and CF, we are exploring new modes of action in OA, metabolic diseases, fibrosis, Hepatitis B virus, and immune inflammation.

Intellectual Property

The proprietary nature of, and protection for, our product candidates, their methods of use, and our platform technologies are an important part of our strategy to develop and commercialize novel medicines. We have obtained patents relating to certain of our product candidates, and are pursuing additional patent protection for them and for our other product candidates and technologies. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Additionally, we have registered and unregistered trademarks, including amongst others our company name.

Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important products, technologies, inventions and know-how related to our business and our ability to defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the proprietary position of our development programs.

As of March 24, 2017, patent rights held by Galapagos NV relating to our product candidates include the following:

Filgotinib Product Candidate: We have four U.S. patents relating to filgotinib, one pending U.S. patent application, one patent granted via the EPO and counterpart patent applications that are pending in Australia, Canada, Europe and other foreign countries. The four issued U.S. patents, and any additional patents that may be granted based on our pending U.S. and foreign patent applications, are currently expected to expire in 2030, not including any potential extensions for the marketed product that may be available via supplementary protection certificates or patent term extensions. In addition, we have one granted U.S. patent and two pending U.S. applications, with counterpart applications pending in other foreign countries, which are directed to certain physical forms, including polymorphic forms and compositions, of our filgotinib product candidate, and patents, if granted, based on these patent applications are estimated to expire in 2035, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions. We also have a pending application under the Patent Cooperation Treaty, or PCT, related to the use of our filgotinib product candidate in cardiovascular disorders, and a pending PCT application related to the specific use of our filgotinib product candidate at particular doses in inflammatory conditions. Any patents, if granted, based on these patent applications are estimated to expire in 2036. We additionally have rights in six pending U.K. applications which relate to methods of treatment using filgotinib in additional indications. Any patents, if granted, based on these patent applications are estimated to expire in 2037. We also have two pending U.K. applications related to the use of combinations of filgotinib with other Galapagos proprietary compounds. Any patents, if granted, based on these patent applications are estimated to expire in 2038. We have additional patents and pending patent applications directed to the use of compounds related to our filgotinib product candidate and these patents, and patents that may be issued based on these pending patent applications, are currently expected to expire from 2029 to 2033, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG1837 Product Candidate: We have two issued U.S. patents relating to GLPG1837, one pending U.S. patent application and counterpart foreign patent applications that are pending in Australia, Canada, Europe and other foreign countries. Patents, if any, that issue based on these pending patent applications are estimated to expire in 2034, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG2222 Product Candidate: We have rights in one pending U.S. patent application, a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating

 

62


Table of Contents

to GLPG2222. Patents, if any, that issue based on these pending patent applications are estimated to expire in 2035, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG2451 Product Candidate: We have rights in one pending U.S. patent application, a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to GLPG2451. Patents, if any, that issue based on these pending patent applications are estimated to expire in 2036, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG2737 Product Candidate: We have rights in a pending U.S. patent application, a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to GLPG2737. Patents, if any, that issue, based on this pending patent application are estimated to expire in 2036, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG3067 Product Candidate: We have rights in a pending U.S. patent application relating to GLPG3067. Patents, if any, that issue, based on this pending patent application are estimated to expire in 2037, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG2851 Product Candidate: We have rights in a pending U.S. patent application, a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to GLPG2851. Patents, if any, that issue, based on this pending patent application are estimated to expire in 2036, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG3221 Product Candidate: We have rights in a pending U.S. patent application relating to GLPG3221. Patents, if any, that issue, based on this pending patent application are estimated to expire in 2037, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG1690 Product Candidate: We have two issued U.S. patents relating to GLPG1690, one pending U.S. patent application and counterpart foreign patent applications that are pending in Australia, Canada, Europe and other foreign countries. Patents, if any, that issue based on these pending patent applications are estimated to expire in 2034, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG1972 Product Candidate: We have rights, jointly with our alliance partner Servier, in a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to GLPG1972. Patents, if any, that issue based on these pending patent applications are estimated to expire in 2035, not including any potential extensions that may be available for the marketed product via supplementary protection certificates or patent term extensions.

MOR106 Product Candidate: We have rights in a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to MOR106. Patents, if any, that issue based on this pending patent application are estimated to expire in 2037, not including any potential extension that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG2534 Product Candidate: We have a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to GLPG2534. Patents, if any, that issue

 

63


Table of Contents

based on this pending patent application are estimated to expire in 2036, not including any potential extension that may be available for the marketed product via supplementary protection certificates or patent term extensions.

GLPG2938 Product Candidate: We have a pending patent application under the PCT, as well as patent applications pending in Taiwan and other foreign countries relating to GLPG2938. Patents, if any, that issue based on this pending patent application are estimated to expire in 2037, not including any potential extension that may be available for the marketed product via supplementary protection certificates or patent term extensions.

We also own or have rights in patents relating to our target discovery platform.

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing the application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office, or USPTO, in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed co-owned patent. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. However, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. In certain foreign jurisdictions similar extensions as compensation for regulatory delays are also available. The actual protection afforded by a patent varies on a claim by claim and country to country basis for each applicable product and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.

Furthermore, the patent positions of biotechnology and pharmaceutical products and processes like those we intend to develop and commercialize are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in such patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries can diminish our ability to protect our inventions, and enforce our intellectual property rights and more generally, could affect the value of intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.

The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our ability to maintain and solidify our proprietary position for our product candidates and technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether any of the patent applications that we may file or license from third parties will result in the issuance of any patents. The issued patents that we own or may receive in the future, may be challenged, invalidated or circumvented, and the rights granted under any issued patents may not provide us with proprietary protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may be able to independently develop and commercialize similar drugs or duplicate our technology, business model or strategy without infringing our patents. Because of the extensive time required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent.

We may rely, in some circumstances, on trade secrets and unpatented know-how to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our consultants, scientific advisors and contractors and invention assignment agreements with our employees. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security

 

64


Table of Contents

measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaboration partners use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

Our commercial success will also depend in part on not infringing the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our product candidates may have a material adverse impact on us. If third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention if the patent applications were filed before March 16, 2013, or in derivation proceedings to determine inventorship for patent applications filed after such date.

In addition, substantial scientific and commercial research has been conducted for many years in the areas in which we have focused our development efforts, which has resulted in third parties having a number of issued patents and pending patent applications relating to such areas. Patent applications in the United States and elsewhere are generally published only after 18 months from the priority date. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made. Therefore, patent applications relating to drugs similar to our current product candidates and any future drugs, discoveries or technologies we might develop may have already been filed by others without our knowledge. For more information on these and other risks related to intellectual property, see “Item 3.D.—Risk Factors—Risks Related to Our Intellectual Property.”

Collaborations

We have entered into multiple collaboration agreements with pharmaceutical partners, which have generated approximately $896 million in cash at December 31, 2016 to fund discovery and development. We expect to continue to collaborate selectively with pharmaceutical and biotechnology companies to leverage our discovery platform and accelerate product candidate development. Our current alliances include the following alliances with AbbVie and Gilead:

Amended and Restated Collaboration with AbbVie for CFTR Modulators (CF)

On September 23, 2013, we entered into a global collaboration agreement with AbbVie focused on the discovery and worldwide development and commercialization of potentiator and corrector molecules for the treatment of CF. In connection with our entry into the collaboration agreement we received a one-time, non-refundable, non-creditable upfront payment in the amount of $45 million. On April 28, 2016, we and AbbVie entered into the amended and restated agreement which expanded the parties’ CF collaboration by amending and restating the collaboration agreement to, among other things, increase the remaining total milestones under the amended and restated agreement up to approximately $600 million from $350 million. As amended, the collaboration will provide for the potential development and commercialization of triple combination products consisting of a potentiator molecule, a corrector 1 molecule and a corrector 2 molecule to treat specified populations of patients with CF. As of the date of this annual report, we have achieved $57.5 million as milestones under this agreement (of which $50 million has been paid to date), in addition to the $45 million upfront payment.

The collaboration is managed by a set of joint committees comprised of equal numbers of representatives from each party. The joint steering committee oversees and coordinates the overall conduct of the collaboration. The joint research committee, or JRC, oversees and coordinates the discovery phase of the collaboration. The joint development committee, or JDC, oversees and coordinates the development phase of the collaboration. The

 

65


Table of Contents

joint commercialization committee will oversee and develop the strategies for commercialization of co-promoted licensed products in the Netherlands, Belgium and Luxembourg if we elect to exercise our co-promotion option, as described below.

Under the terms of the collaboration, both parties are required to use commercially reasonable efforts to identify and deliver a specified number of potentiator molecules which may be used in combination with a corrector molecule as a dual combination product, a specified number of corrector 1 molecules to be used in combination with a potentiator molecule and a corrector 2 molecule as a triple combination product and a specified number of corrector 2 molecules which may be used in combination with a potentiator molecule and a corrector 1 molecule as a triple combination product. The parties are also required to use commercially reasonable efforts to identify and deliver a specified number of backup molecules for each of the molecules described above. Each of the above molecules is to be measured against agreed-to success criteria.

If (i) the JRC determines that a potentiator molecule, a corrector 1 molecule and/or a corrector 2 molecule have met certain specified criteria by a specified date, or AbbVie otherwise decides to continue development of such molecule(s), and (ii) an investigational new drug application has been accepted for such molecules(s), then we and AbbVie will develop and approve (through the JDC) a plan in connection with development of such molecule and, when appropriate, combination product(s) including such molecule, with the goal of achieving agreed-to proof of concept criteria. We are generally responsible for the costs of such development activities at our expense up to an agreed cost cap, and then each party will be responsible for the excess costs associated with its respective agreed upon development activities.

If the applicable proof of concept criteria are met or AbbVie otherwise decides to continue development, we and AbbVie will develop and approve (through the JDC) a plan in connection with Phase 3 clinical trials for the molecule or molecules, in which we are responsible for a specified percentage of the costs.

Subject to certain exceptions, following approval, AbbVie will have the sole right to commercialize licensed products worldwide, except in China and South Korea, in which we will have the sole right to commercialize licensed products, and further subject to our co-promotion option in the Netherlands, Belgium and Luxembourg. We will be solely responsible for obtaining regulatory and other approvals required for commercialization of licensed products in China and South Korea.

Under the amended and restated agreement, we are still eligible to receive up to $567.5 million in total additional payments for developmental, regulatory and sales-based milestones. In March 2017, we achieved a $7.5 million milestone, for which the payment is not yet received to date. In addition, we will be eligible to receive tiered royalties ranging from the mid-teens to 20% on net sales of licensed products payable on a product-by-product basis. The royalties payable to us under the amended and restated agreement may be reduced under certain circumstances, including if generic competition on an active ingredient of a licensed product in a particular territory results in market share losses of a certain amount. Our right to receive royalties under the amended and restated agreement expires, on a product-by-product and country-by-country basis, on the later of (1) the last day that at least one valid patent claim subject to the amended and restated agreement and covering the licensed product exists, (2) the expiry of a mutually agreed upon time period after the first commercial sale of the licensed product in the applicable country, or (3) the expiration of regulatory exclusivity for the licensed product in the applicable country. In the event we exercise our co-promotion option with respect to a licensed product, we would assume a portion of the co-promotion effort in The Netherlands, Belgium and Luxembourg and share in the net profit and net losses in these territories instead of receiving royalties in those territories during the period of co-promotion.

Under the amended and restated agreement, subject to certain exceptions, neither party may directly or indirectly (including by means of licensing, acquisition or otherwise), on its own or through a third party, research, develop, commercialize or manufacture any molecule, compound or product that has as one of its primary mechanisms of action modulation of the activity of the CF transmembrane conductance regulator.

 

66


Table of Contents

The amended and restated agreement will expire upon the expiration of the longest royalty term applicable to licensed products under the agreement as described above. Either party may terminate the amended and restated agreement on a country-by-country basis in their respective jurisdictions if they are unable to secure or maintain regulatory approval for the licensed product. After certain discovery activities, but before the first commercial sale of any licensed product by AbbVie, AbbVie may terminate the amended and restated agreement for convenience in its entirety or on a country-by-country basis upon prior written notice to us. Either we or AbbVie may terminate the agreement for the other party’s uncured material breach; however, if such breach relates solely to a breach with respect to our diligence obligations in China or South Korea or AbbVie’s commercialization diligence obligations in the United States, France, Italy, Spain, the United Kingdom or Germany, we or AbbVie may only terminate the amended and restated agreement with respect to such country. Either party may terminate the amended and restated agreement in the event of specified insolvency events involving the other party.

If the amended and restated agreement terminates due to our material breach or as a result of a change of control, all rights and licenses granted to AbbVie will become exclusive or non-exclusive at AbbVie’s sole option, irrevocable, unrestricted and perpetual, and AbbVie will provide consideration for such rights and licenses in an amount to be mutually agreed between us and AbbVie. If the amended and restated agreement terminates in its entirety for any other reason, all rights and licenses granted by either party will terminate, and we will have an exclusive option to obtain an exclusive or non-exclusive license from AbbVie under certain intellectual property rights to exploit the licensed product that is the subject of development or commercialization at the time of termination. If we exercise such option, we and AbbVie will then negotiate a transition agreement which will, in most termination cases, include reasonable financial consideration to AbbVie.

If the amended and restated agreement is terminated in a specific territory because of AbbVie’s material, uncured breach in such territory, or due to an inability by AbbVie to obtain regulatory approval, all rights and licenses granted by us will be deemed amended not to include such territory, and we will have specified rights for, and AbbVie will take specified actions to assist us in continuing the development, manufacture and commercialization of the licensed product in such territory. If the amended and restated agreement is terminated in a specific territory because of our material, uncured breach in such territory, or because of our inability to obtain regulatory approval, all rights and licenses granted to AbbVie with respect to that country will become exclusive or non-exclusive at AbbVie’s sole option, irrevocable, unrestricted and perpetual, and AbbVie will provide consideration for such rights and licenses in an amount to be mutually agreed between us and AbbVie. In addition, AbbVie will have specified rights for, and we will take specified actions to assist AbbVie in, continuing the development, manufacture and commercialization of the licensed product in such territory.

Either party may, without the consent of the other party, assign the amended and restated agreement to an affiliate or successor. Any other assignment requires written consent of the other party. However, with respect to an assignment to an affiliate, the assigning party will remain responsible. If we undergo a change in control prior to the first commercial sale of a product, AbbVie has the right to terminate the amended and restated agreement. At any time, if we undergo a change in control, AbbVie may disband all joint committees and undertake exclusive control of their activities, terminate our right to co-promote and/or terminate our rights and licenses in connection with development and sale of any product in China and South Korea.

Exclusive Collaboration Agreement with Gilead for Filgotinib

In September 2015, our exclusive collaboration with AbbVie for JAK1 inhibitors was terminated, following which we regained all unencumbered rights to filgotinib.

In December 2015, we entered into a global collaboration agreement with Gilead to develop and commercialize filgotinib for the treatment of inflammatory indications. On January 13, 2016, the parties announced that the U.S. Federal Trade Commission provided early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and we closed this transaction on January 19, 2016.

 

67


Table of Contents

In connection with our entry into the collaboration agreement, we received an upfront payment of $725 million consisting of a one-time, non-refundable, non-creditable license fee in the amount of $300 million and a $425 million equity investment. All payments by Gilead to us are made in U.S. dollars. As of the date of this annual report, we have received an additional $60 million as payments under this agreement.

In addition, we will be eligible to receive development and regulatory milestone-based payments of up to $695 million and sales-based milestone payments of up to $600 million. We will be eligible to receive tiered royalty percentages starting at 20% on global net sales of licensed products. The royalties payable to us under the collaboration agreement may be reduced under certain circumstances. Our right to receive royalties under the collaboration agreement continues, on a country-by-country basis, until the later to occur of certain specified events. In the event we exercise our co-promotion option with respect to licensed products in one or more of the territories eligible for co-promotion, we would assume a portion of the co-promotion effort in the United Kingdom, Germany, France, Italy, Spain, the Netherlands, Belgium, and/or Luxembourg and share equally in the net profit and net losses in these territories instead of receiving royalties in those territories during the period of co-promotion.

The collaboration is managed by a set of joint committees comprised of equal numbers of representatives from each of us and Gilead. The joint steering committee monitors and provides strategic oversight of the activities under the collaboration and facilitates communications between the parties. The joint development committee oversees and coordinates the development of the licensed products. The joint commercialization committee will oversee commercialization of licensed products and co-promoted licensed products in co-promotion territories if we elect to exercise our co-promotion option, as described below.

Under the terms of the collaboration, Gilead is primarily responsible for development and for seeking regulatory approval of the licensed product. We are required to use commercially reasonable efforts as requested by Gilead to assist Gilead with certain development activities.

The collaboration agreement will expire (a) on a country-by-country basis at the end of the royalty term in such country and (b) at such time as a generic product is first sold in a co-promotion country in the event we exercise our co-promotion option with respect to licensed products in The United Kingdom, Germany, France, Italy, Spain, The Netherlands, Belgium, and/or Luxembourg. Upon expiration of the collaboration agreement, the licenses will become fully-paid, perpetual and irrevocable. Either we or Gilead may terminate the collaboration agreement for the other party’s uncured material breach. Either we or Gilead may terminate the collaboration agreement in the event of specified insolvency events involving the other party. Gilead may also terminate the collaboration agreement in its entirety for convenience following a certain period upon prior written notice.

If the collaboration agreement terminates in its entirety for any reason, all rights and licenses granted by either party will terminate, and we will obtain an exclusive, perpetual, irrevocable, royalty-bearing license from Gilead under certain intellectual property rights to exploit the licensed product that is the subject of development or commercialization at the time of termination. If the collaboration agreement is terminated in a specific territory, all rights and licenses granted by us will be deemed to be amended not to include such territory, and we will have a corresponding license with respect to such terminated country. The collaboration agreement also contains other termination rights specified therein.

Either party may, without the consent of the other party, assign the collaboration agreement to an affiliate or successor. Any other assignment requires written consent of the other party. However, with respect to an assignment to an affiliate, the assigning party will remain bound by the terms of the collaboration agreement. If we undergo a change in control, Gilead has the right to terminate the co-promotion option or, if the option has already been exercised, our right to co-promote, and disband all joint committees and undertake exclusive control of their activities; provided, that Gilead has no right to exercise such rights if we undergo a change in control with a drug company that has a market capitalization less than a certain percentage of our market capitalization.

Seasonality

Our business is currently not materially affected by seasonality.

 

68


Table of Contents

Manufacturing and Supply

We currently do not own or operate manufacturing facilities for the production of product candidates for pre-clinical, clinical or commercial use. We currently outsource to a limited number of external service providers the production of all drug substances and drug products, and we expect to continue to do so to meet the pre-clinical and clinical requirements of our product candidates. We do not have long-term agreements with these third parties. We have framework agreements with most of our external service providers, under which they generally provide services to us on a short-term, project-by-project basis.

Currently, our drug raw materials which support our clinical studies are manufactured by multiple suppliers. We have agreements for the supply of such drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, it would materially harm our business. We typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements. To date, the prices of our principal raw materials have not been volatile.

Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. The contract manufacturing organizations we use to manufacture our product candidates operate under current good manufacturing practice, or cGMP, conditions. cGMPs are regulatory requirements for the production of pharmaceuticals that will be used in humans. For most of our manufacturing processes a back-up GMP manufacturer is in place or can easily be identified.

Competition

Our industry is highly competitive and subject to rapid and significant change. While we believe that our development and commercialization experience, scientific knowledge and industry relationships provide us with competitive advantages, we face competition from pharmaceutical, medical device and biotechnology companies, including specialty pharmaceutical companies, and generic drug companies, academic institutions, government agencies and research institutions.

In the field of RA, therapeutic approaches have traditionally relied on DMARDS such as MTX and sulphasalazine as first-line therapy. These oral drugs work primarily to suppress the immune system and, while effective in this regard, the suppression of the immune system leads to an increased risk of infections and other side effects. Accordingly, in addition to DMARDS, monoclonal antibodies targeting TNF, like AbbVie’s Humira, or IL-6 like Roche’s Actemra, have been developed. These biologics, which must be delivered via injection, are currently the standard of care as first- and second-line therapies for RA patients who have an inadequate response to DMARDS. In November 2012, Xeljanz, marketed by Pfizer, was approved by the FDA as an oral treatment of adult patients with RA who have had an inadequate response to, or who are intolerant of, MTX. Xeljanz is the first JAK inhibitor for RA approved for commercial sale in the United States. We are aware of other JAK inhibitors in development for patients with RA, including a once- daily JAK1/2 inhibitor called baricitinib being developed by Lilly which is approved by the EMA for RA and is expected to be approved by the FDA as early as March 2017, a JAK3/2/1 inhibitor called ASP015k which is being developed in Japan by Astellas, and a JAK inhibitor called ABT-494 which is being developed by AbbVie. Filgotinib, which is a selective JAK1 inhibitor currently in three Phase 3 studies, is being developed in collaboration with Gilead.

We expect that filgotinib, for which we have completed a Phase 2 program in patients with moderate to severe RA who have an inadequate response to MTX, will compete with all of these therapies when marketed. If generic or biosimilar versions of these therapies are approved we would also expect to compete against these versions of the therapies.

In the field of IBD, first line therapies are oral (or local) treatments with several low-cost generic compounds such as mesalazine, more effective in UC, and azathioprine, more effective in CD. Steroids such as

 

69


Table of Contents

budesonide are used in both UC and CD. Companies such as Santarus have developed controlled-release oral formulation with the aim to have local intestinal delivery of budesonide thereby limiting systemic side effects. For more advanced therapy, monoclonal antibodies with various targets such as TNF and more recently, integrins by vedoluzimab (Entyvio) are approved. We are also aware of other biologics in clinical development for these indications, such as: ustekinumab, developed by Johnson & Johnson, which is in Phase 3 clinical trials. Celgene has two new oral therapies in development: ozanimod, currently in Phase 3 in UC and Phase 2 in CD, and mongersen in a Phase 3 study in CD and Phase 2 study in UC. Pfizer’s Xeljanz showed activity in Phase 3 and has been filed for approval in UC. The large number of treatments for UC, and somewhat less for CD, presents a substantial level of competition for any new treatment entering the IBD market.

In the field of CF, the approved therapies to treat CF patients have mostly been designed to treat the symptoms of the disease rather than its cause. Kalydeco and more recently Orkambi, both from Vertex, are currently the only two FDA-approved therapies to address the cause of Class III and Class II mutation CF, respectively. Kalydeco, also approved in Europe, is a CFTR potentiator to treat CF in patients with a Class III (G551D) mutation of the CFTR gene. Vertex also developed lumacaftor, a corrector molecule to address a broader patient population, including patients with a Class II (F508del) mutation of the CFTR gene. Vertex obtained approval in July 2015 in the United States for Orkambi, a combination product (Kalydeco + lumacaftor) and obtained approval in November 2015 in Europe. We are also aware of other companies, including Novartis, Nivalis, Pfizer, Proteostasis, and ProQR, and not-for-profit organizations like Flatley Discovery Lab, which are actively developing product candidates for the treatment of CF. These typically target the CFTR protein as potentiators, correctors or other modulators of its activity.

In the field of IPF, there are two approved disease modifying drugs, pirfenidone, marketed by Roche, and nintenanib, marketed by Boehringer Ingelheim. These drugs are not well tolerated by patients and prolong life for IPF patients by a matter of months, leaving an unmet medical need for those developing disease-modifying drugs in this field.

In the field of OA, there are currently no disease-modifying drugs approved. Current treatment involves weight loss, physical therapy, prednisolone, non-steroidal anti-inflammatory drugs, and pain management.

In the field of AtD, immunomodulators such as cyclosporine and mycophenolate mofetil and topical calcineurin inhibitors tacrolimus, marketed by Astellas, and pimecrolimus, marketed by Meda, currently dominate treatment share, according to a GlobalData 2015 report. Key opinion leaders interviewed by GlobalData for that same report indicated that a high unmet need remains for a better treatment armamentarium for severe, recalcitrant patients. This patient segment remains underserved as physicians have few to no pharmacological options following treatment failure with or intolerability to cyclosporine, and as a result physicians often resort to prescribing off-label therapies. Further compounding this issue is the fact that although cyclosporine is indicated for the short-term treatment of AtD in some European countries, leading dermatologists believe that no true systemic drug for the disease exists, and this remains the most pressing unmet need for developers to address.

Many of our competitors have significantly greater financial, technical and human resources than we have. Mergers and acquisitions in the pharmaceutical, medical device and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future product candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates. Our success will be based in part on our ability to identify, develop and manage a portfolio of product candidates that are safer and more effective than competing products.

 

70


Table of Contents

Government Regulation

Government Regulation and Product Approval

Government authorities in the United States at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing.

U.S. Regulation

U.S. Drug Development Process

The process of obtaining regulatory approvals and compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA’s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, voluntary product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following:

 

    completion of pre-clinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices regulations;

 

    submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;

 

    performance of adequate and well-controlled human clinical trials according to good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug for its intended use;

 

    preparation and submission to the FDA of a new drug application, or NDA;

 

    satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP;

 

    potential FDA audit of the clinical trial sites that generated the data in support of the NDA; and

 

    FDA review and approval of the NDA.

The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.

Once a pharmaceutical product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part of the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the initial clinical trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical trial lends itself to an efficacy evaluation. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance, and may be imposed on all drug products within a certain class of drugs. The FDA also can impose partial clinical holds, for example, prohibiting the initiation of clinical trials of a certain duration or for a certain dose.

 

71


Table of Contents

All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include the requirement that all research subjects provide informed consent in writing before their participation in any clinical trial. Further, an institutional review board, or IRB, must review and approve the plan for any clinical trial before it commences at any institution, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB considers, among other things, whether the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Each new clinical protocol and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

 

    Phase 1. The product is initially introduced into a small number of healthy human subjects or patients and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life- threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted in patients.

 

    Phase 2. Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.

 

    Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit relationship of the product and provide an adequate basis for physician labeling.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk to humans, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

A drug being studied in clinical trials may be made available to individual patients in certain circumstances. Pursuant to the 21st Century Cures Act, or Cures Act, which was signed into law in December 2016, the manufacturer of an investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational drug. This requirement applies on the later of 60 calendar days after the date of enactment of the Cures Act or the first initiation of a Phase 2 or Phase 3 trial of the investigational drug.

 

72


Table of Contents

U.S. Review and Approval Processes

The results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the drug, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA for a new drug, requesting approval to market the product. The submission of an NDA is subject to the payment of a substantial user fee; although a waiver of such fee may be obtained under certain limited circumstances. For example, the agency will waive the application fee for the first human drug application that a small business or its affiliate submits for review. The sponsor of an approved NDA is also subject to annual product and establishment user fees.

The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be re-submitted with the additional information. The re-submitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure the product’s identity, strength, quality and purity. Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. An advisory committee is a panel of experts, including clinicians and other scientific experts, who provide advice and recommendations when requested by the FDA. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making decisions.

The approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA in its present form. The complete response letter usually describes all of the specific deficiencies that the FDA identified in the NDA that must be satisfactorily addressed before it can be approved. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing.

If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, including Phase 4 clinical trials, to further assess a drug’s safety and effectiveness after NDA approval and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. As part of the NDA, the FDA also may require the submission of a risk evaluation and mitigation strategy, or REMS, to ensure that the benefits of the drug outweigh the risks of the drug. The REMS plan could include medication guides, physician communication plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. An assessment of the REMS must be conducted at set intervals. Following product approval, a REMS also may be required by the FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the drug outweigh the risks of the drug.

 

73


Table of Contents

Expedited Programs

Fast Track Designation

The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug may request the FDA to designate the drug as a Fast Track product concurrently with, or at any time after, submission of an IND, and the FDA must determine if the product candidate qualifies for fast track designation within 60 days of receipt of the sponsor’s request.

In addition to other benefits, such as the ability to engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug’s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of each portion of the NDA and the applicant pays applicable user fees. However, the FDA’s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

Accelerated Approval

Under FDA’s accelerated approval regulations, the FDA may approve a drug product for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a marker, such as a measurement of laboratory or clinical signs of a disease or condition that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of post-approval clinical trials sometimes referred to as Phase 4 trials to confirm the effect on the clinical endpoint. Failure to conduct required post- approval studies, or to confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.

Breakthrough Designation

The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require the FDA to expedite the development and review of a breakthrough therapy. A drug product can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug product be designated as a breakthrough therapy concurrently with, or at any time after, the submission of an IND, and the FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor’s request. If so designated, the FDA shall act to expedite the development and review of the product’s marketing application, including by meeting with the sponsor throughout the product’s development, providing timely advice to the sponsor to ensure that the development program to gather pre-clinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable.

 

74


Table of Contents

Priority Review

Priority review is granted where there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If a product that contains a new molecular entity is granted priority review, the FDA aims to review the application six months after it accepts the application for filing. If criteria are not met for priority review, the application is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/ medical standard for approval or the quality of evidence necessary to support approval.

Post-Approval Requirements

Any products for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.

Manufacturers and other entities involved in the manufacturing and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the product. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release. We rely, and expect to continue to rely, on third parties for the production of clinical quantities of our product candidates. Future FDA and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution or may require substantial resources to correct.

The FDA may withdraw a product approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, untitled or warning letters, holds on clinical trials, voluntary product recalls, product seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.

From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidances, and policies are often revised or reinterpreted by the agency in ways that may significantly affect our business and our product candidates. It is impossible to predict whether further legislative or FDA regulation or policy changes will be enacted or implemented and what the impact of such changes, if any, may be.

 

75


Table of Contents

Patent Term Restoration and Marketing Exclusivity

Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application, less any time the applicant did not act with due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration dates, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA; however, there can be no assurance that any such extension will be granted to us.

Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of exclusivity in the United States. Pediatric exclusivity, if granted, provides an additional six months to an existing exclusivity or statutory delay in approval resulting from a patent certification. This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric clinical trial in accordance with an FDA-issued “Written Request” for such a clinical trial.

Orphan Drugs

Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition—generally a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that costs of research and development of the drug for the indication can be recovered by sales of the drug in the United States. Orphan drug designation must be requested before submitting an NDA.

After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the

 

76


Table of Contents

duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease or condition with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.

During the exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease or condition, except in limited circumstances, such as if the second applicant demonstrates the clinical superiority of its product to the product with orphan drug exclusivity through a demonstration of superior safety, superior efficacy, or a major contribution to patient care. “Same drug” means, a drug that contains the same identity of the active moiety if it is a drug composed of small molecules, or of the principal molecular structural features if it is composed of macromolecules and is intended for the same use as a previously approved drug, except that if the subsequent drug can be shown to be clinically superior to the first drug, it will not be considered to be the same drug. Drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.

Pediatric Information

Under the Pediatric Research Equity Act of 2003, or PREA, NDAs or supplements to NDAs must contain data adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDASIA amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-phase 2 meeting or as may be agreed between the sponsor and the FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of data or full or partial waivers. The FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early phase clinical trials, and/or other clinical development programs. At this time, the requirements of PREA do not apply to an application to market a drug for an orphan-designated indication.

Disclosure of Clinical Trial Information

Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.

Pharmaceutical Coverage, Pricing and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a

 

77


Table of Contents

drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

Third-party payors are increasingly challenging the price and examining the medical necessity and cost- effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.

The U.S. government and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies’ share of sales to federal health care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals.

The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Other Healthcare Laws and Compliance Requirements

If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The U.S. laws that may affect our ability to operate include:

 

    the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;

 

    federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money to the federal government;

 

78


Table of Contents
    the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

 

    the federal transparency laws, including the provision of the Affordable Care Act commonly referred to as the federal Physician Payment Sunshine Act, that requires applicable manufacturers of covered drugs to disclose payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests;

 

    HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and

 

    state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

The Affordable Care Act broadened the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. § 1320a-7b. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute.

The U.S. federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent. Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to “cause” the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their off-label promotion of drugs. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $10,781 and $21,563 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act.

Patient Protection and Affordable Care Act

In March 2010, the Affordable Care Act was enacted, which includes measures that have or will significantly change the way health care is financed by both U.S. governmental and private insurers. Among the provisions of the Affordable Care Act of greatest importance to the pharmaceutical industry are the following:

 

   

The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer’s outpatient drugs furnished to Medicaid patients. The Affordable Care Act made several changes to the Medicaid Drug

 

79


Table of Contents
 

Rebate Program, including increasing pharmaceutical manufacturers’ rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of average manufacturer price, or AMP, and adding a new rebate calculation for “line extensions” (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The Affordable Care Act also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by expanding the population potentially eligible for Medicaid drug benefits. In addition, the Affordable Care Act provides for the public availability of retail survey prices and certain weighted average AMPs under the Medicaid program.

 

    In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. The Affordable Care Act expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children’s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs when used for the orphan indication. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.

 

    The Affordable Care Act imposed a requirement on manufacturers of branded drugs to provide a 50% discount off the negotiated price of branded drugs dispensed to Medicare Part D patients in the coverage gap.

 

    The Affordable Care Act imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications.

 

    The Affordable Care Act requires pharmaceutical manufacturers to track certain financial arrangements with physicians and teaching hospitals, including any “transfer of value” made or distributed to such entities, as well as any ownership and investment interests held by physicians and their immediate family members. Manufacturers annually report this information to CMS and the information is publicly available in a searchable format on a CMS website.

 

    A new Patient-Centered Outcomes Research Institute was established pursuant to the Affordable Care Act to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient- Centered Outcomes Research Institute may affect the market for certain pharmaceutical products.

 

    The Affordable Care Act created the Independent Payment Advisory Board which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription drugs. Under certain circumstances, these recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings.

 

    The Affordable Care Act established the Center for Medicare and Medicaid Innovation within CMS potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.

Some of the provisions of the Affordable Care Act have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, that while not a law, is widely viewed as the first step toward the passage

 

80


Table of Contents

of legislation that would repeal certain aspects of the Affordable Care Act. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of the Affordable Care Act that are repealed. Thus, the full impact of the Affordable Care Act, any law replacing elements of it, or the political uncertainty surrounding its repeal or replacement on our business remains unclear.

European Union Regulation

European Union Drug Review and Approval

In the EEA (which is comprised of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations: the Community MA, which is issued by the European Commission through the Centralized Procedure based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, a body of the European Medicines Agency, or EMA, and which is valid throughout the entire territory of the EEA; and the National MA, which is issued by the competent authorities of the Member States of the EEA and only authorizes marketing in that Member State’s national territory and not the EEA as a whole.

The Centralized Procedure is compulsory for human medicines for the treatment of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS), cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases; for veterinary medicines for use as growth or yield enhancers; for medicines derived from biotechnology processes, such as genetic engineering; for advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue- engineered medicines; and for officially designated “orphan medicines” (medicines used for rare human diseases). The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or for products which are in the interest of public health in the European Union. The National MA is for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. If the RMS proposes to authorize the product, and the other Member States do not raise objections, the product is granted a national MA in all the Member States where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

Regulation in the European Union

Product development, the regulatory approval process, and safety monitoring of medicinal products and their manufacturers in the European Union proceed in much the same manner as they do in the United States. Therefore, many of the issues discussed above apply similarly in the context of the European Union. In addition, drugs are subject to the extensive price and reimbursement regulations of the various European Union Member States.

 

81


Table of Contents

Clinical Trials

As is the case in the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls. The Clinical Trials Directive 2001/20/EC, as amended, (and which will be replaced by Regulation (EU) No 536/2014, currently expected to be in October 2018) provides a system for the approval of clinical trials in the European Union via implementation through national legislation of the Member States. Under this system, approval must be obtained from the competent national authorities of the European Union Member States in which the clinical trial is to be conducted. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application, which must be supported by an investigational medicinal product dossier with supporting information prescribed by the Clinical Trials Directive and corresponding national laws of the Member States and further detailed in applicable guidance documents. A clinical trial may only be undertaken if provision has been made for insurance or indemnity to cover the liability of the investigator or sponsor. In certain countries, the sponsor of a clinical trial has a strict (faultless) liability for any (direct or indirect) damage suffered by trial subjects. The sponsor of a clinical trial, or its legal representative, must be based in the European Economic Area. European regulators and ethics committees also require the submission of adverse event reports during a study and a copy of the final study report.

Marketing Approval

Marketing approvals under the European Union regulatory system may be obtained through a centralized or decentralized procedure. The centralized procedure results in the grant of a single marketing authorization that is valid for all (currently 28) European Union Member States and three European Free Trade Association members (Norway, Iceland, Liechtenstein).

Pursuant to Regulation (EC) No. 726/2004, as amended, the centralized procedure is mandatory for drugs developed by means of specified biotechnological processes, advanced therapy medicinal products, drugs for human use containing a new active substance for which the therapeutic indication is the treatment of specified diseases, including but not limited to acquired immune deficiency syndrome, neurodegenerative disorders, auto- immune diseases and other immune dysfunctions, as well as drugs designated as orphan drugs. The CHMP also has the discretion to permit other products to use the centralized procedure if it considers them sufficiently innovative or they contain a new active substance or they may be of benefit to public health at the Community level.

In the marketing authorization application, or MAA, the applicant has to properly and sufficiently demonstrate the quality, safety and efficacy of the drug. Under the centralized approval procedure, the CHMP, possibly in conjunction with other committees, is responsible for drawing up the opinion of the EMA on any matter concerning the admissibility of the files submitted in accordance with the centralized procedure, such as an opinion on the granting, variation, suspension or revocation of a marketing authorization, and pharmacovigilance.

The CHMP and other committees are also responsible for providing guidelines and have published numerous guidelines that may apply to our product candidates. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of drug products and may include, among other things, the pre-clinical studies required in specific cases; and the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long-term efficacy and potential adverse reactions. Although these guidelines are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any of our product candidates.

Following Article 6(3), first subparagraph, of Regulation (EC) No. 726/2004, the maximum timeframe for the evaluation of an MAA by the CHMP under the centralized procedure is 210 days after receipt of a valid application. This period will be suspended until such time as the supplementary information requested by the CHMP, has been provided by the applicant. Likewise, this time-limit will be suspended for the time allowed for

 

82


Table of Contents

the applicant to prepare oral or written explanations. When an application is submitted for a marketing authorization in respect of a drug which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced to 150 days, according to Article 14(9) of Regulation (EC) No. 726/2004, but it is possible that the CHMP can revert to the standard time-limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.

If the CHMP concludes that the quality, safety and efficacy of the product are sufficiently proven, it adopts a positive opinion. This is sent to the European Commission which drafts a decision. After consulting with the Member States, the European Commission adopts a decision and grants a marketing authorization, which is valid for the whole of the European Economic Area, or EEA. The marketing authorization may be subject to certain conditions, which may include, without limitation, the performance of post-authorization safety and/or efficacy studies. Pursuant to Regulation (EC) No. 726/2004, a new marketing authorization is valid for five years and may be renewed for an unlimited period on the basis of a re-evaluation of the risk-benefit balance after submission of a consolidated version of the initial marketing authorization application in addition to the pharmacovigilance data reported and all variations introduced since granting of the marketing authorization. The marketing authorization shall cease to be valid if any marketing authorization granted is not followed by the actual launch of the product on the market within three years or, if the product is no longer available on the market for three consecutive years.

European Union legislation also provides for a system of regulatory data and market exclusivity. According to Article 14(11) of Regulation (EC) No. 726/2004, as amended, and Article 10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved on the basis of a complete independent data package benefit from eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator’s data to assess a generic (abbreviated) application. During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator’s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the innovator is able to gain the period of data exclusivity, another company nevertheless could also market another version of the drug if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical test, pre-clinical tests and clinical trials. However, products designated as orphan medicinal products enjoy, upon receiving marketing authorization, a period of 10 years of orphan market exclusivity limited to the therapeutic indication for which orphan designation has been obtained—see also “—Orphan Drug Regulation.” Depending upon the timing and duration of the EU marketing authorization process, products may be eligible for up to five years’ supplementary protection certification, or SPC, pursuant to Regulation (EC) No. 469/2009. Such SPCs extend the rights under the basic patent for the drug.

Additional rules apply to medicinal products for pediatric use under Regulation (EC) No. 1901/2006. Potential incentives include a six-month extension of any supplementary protection certificate granted pursuant to Regulation (EC) No. 469/2009, however not in cases in which the relevant product is designated as orphan medicinal products pursuant to Regulation (EC) No. 141/2000, as amended. Instead, medicinal products designated as orphan medicinal product may enjoy an extension of the ten-year market exclusivity period granted under Regulation (EC) No. 141/2000 to twelve years subject to the conditions applicable to orphan drugs.

 

83


Table of Contents

Orphan Drug Regulation

In the European Union, Regulation (EC) No. 141/2000, as amended, states that a drug will be designated as an orphan drug if its sponsor can establish:

 

    that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the Community when the application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment; and

 

    that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, that the drug will be of significant benefit to those affected by that condition.

Regulation (EC) No. 847/2000 sets out further provisions for implementation of the criteria for designation of a drug as an orphan drug. An application for the designation of a drug as an orphan drug must be submitted at any stage of development of the drug before filing of a marketing authorization application.

If a European Union-wide community marketing authorization in respect of an orphan drug is granted or if all the European Union Member States have granted marketing authorizations in accordance with the procedures for mutual recognition, the European Union and the Member States will not, for a period of 10 years, accept another application for a marketing authorization, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication, in respect of a similar drug. This period may however be reduced to six years if, at the end of the fifth year, it is established, with respect to the drug concerned, that the criteria for orphan drug designation are no longer met, in other words, when it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity (cfr. Article 8(s) of Regulation (EC) No. 141/200). Notwithstanding the foregoing, Regulation (EC) No. 141/2000 states that a marketing authorization may be granted, for the same therapeutic indication, to a similar drug if:

 

    the holder of the marketing authorization for the original orphan drug has given its consent to the second applicant;

 

    the holder of the marketing authorization for the original orphan drug is unable to supply sufficient quantities of the drug; or

 

    the second applicant can establish in the application that the second drug, although similar to the orphan drug already authorized, is safer, more effective or otherwise clinically superior.

Other incentives available to orphan drugs in the European Union include financial incentives such as a reduction of fees or fee waivers and protocol assistance. Orphan drug designation does not shorten the duration of the regulatory review and approval process.

Pediatric Investigation Plan

An application for marketing authorization of a medicinal product for human use which is not yet authorized in the European Union shall be considered valid only if it includes a Pediatric Investigational Plan, or PIP, according to Regulation (EC) No. 1901/2006. The PIP or the application for waiver shall be submitted with a request for agreement, except in duly justified cases, early during the product development phase and not later than upon completion of the human pharmacokinetic studies in healthy subjects. The end of Phase 1 pharmacokinetic studies can coincide with the initial tolerability studies, or the initiation of the adult Phase 2 studies (proof-of-concept studies); in any case, submission of the PIP cannot be after initiation of pivotal trials or confirmatory (Phase 3) trials.

 

84


Table of Contents

The Pediatric Committee, a scientific committee established at Community level, shall assess the content of any PIP, waivers and deferrals for a medicinal product submitted to it in accordance with the regulation on medicinal products for pediatric use and formulate an opinion thereon.

Manufacturing and Manufacturers’ License

Pursuant to Directive 2003/94/EC, as transposed into the national laws of the Member States, the manufacturing of investigational medicinal products and approved drugs is subject to a separate manufacturer’s license and must be conducted in strict compliance with cGMP requirements, which mandate the methods, facilities, and controls used in manufacturing, processing, and packing of drugs to assure their safety and identity. Manufacturers must have at least one qualified person permanently and continuously at their disposal. The qualified person is ultimately responsible for certifying that each batch of finished product released onto the market has been manufactured in accordance with cGMP and the specifications set out in the marketing authorization or investigational medicinal product dossier. cGMP requirements are enforced through mandatory registration of facilities and inspections of those facilities. Failure to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost revenues, and subject the applicant to potential legal or regulatory action, including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.

Wholesale Distribution and License

Pursuant to Directive 2001/83/EC, the wholesale distribution of medicinal products is subject to the possession of an authorization to engage in activity as a wholesaler in medicinal products. Possession of a manufacturing authorization includes authorization to distribute by wholesale the medicinal products covered by that authorization. The distribution of medicinal products must comply with the principles and guidelines of good distribution practices, or GDP.

Advertising

In the European Union, the promotion of prescription medicines is subject to intense regulation and control, including EU and national legislation as well as self-regulatory codes (industry codes). Advertising legislation inter alia includes a prohibition on direct-to-consumer advertising. All prescription medicines advertising must be consistent with the product’s approved summary of products characteristics, and must be factual, accurate, balanced and not misleading. Advertising of prescription medicines pre-approval or off-label is not allowed.

Some jurisdictions require that all promotional materials for prescription medicines be subjected to either prior internal review and approval or regulatory review and approval.

Other Regulatory Requirements

A marketing authorization holder, or MAH, for a medicinal product is legally obliged to fulfill a number of obligations by virtue of its status as an MAH. The MAH can delegate the performance of related tasks to third parties, such as distributors or marketing partners, provided that this delegation is appropriately documented and the MAH maintains legal responsibility and liability.

The obligations of an MAH include:

Manufacturing and batch release. MAHs should guarantee that all manufacturing operations comply with relevant laws and regulations, applicable good manufacturing practices, with the product specifications and manufacturing conditions set out in the marketing authorization and that each batch of product is subject to appropriate release formalities.

 

85


Table of Contents

Availability and continuous supply. Pursuant to Directive 2001/83/EC, as transposed into the national laws of the Member States, the MAH for a medicinal product and the distributors of the said medicinal product actually placed on the market in a Member State shall, within the limits of their responsibilities, ensure appropriate and continued supplies of that medicinal product to pharmacies and persons authorized to supply medicinal products so that the needs of patients in the Member State in question are covered.

Pharmacovigilance. MAHs are obliged to establish and maintain a pharmacovigilance system, including a qualified person responsible for oversight, submit safety reports to the regulators and comply with the good pharmacovigilance practice guidelines adopted by the EMA.

Advertising and promotion. MAHs remain responsible for all advertising and promotion of its products, including promotional activities by other companies or individuals on their behalf and in some cases must conduct internal or regulatory pre-approval of promotional materials. Regulation in this area also covers interactions with healthcare practitioners and/or patient groups, and in some jurisdictions legal or self-regulatory obligations to disclose such interactions exist.

Medical affairs/scientific service. MAHs are required to disseminate scientific and medical information on its medicinal products to healthcare professionals, regulators and patients. Legal representation and distributor issues. MAHs are responsible for regulatory actions or inactions of their distributors and agents.

Preparation, filing and maintenance of the application and subsequent marketing authorization. MAHs must maintain appropriate records, comply with the marketing authorization’s terms and conditions, fulfill reporting obligations to regulators, submit renewal applications and pay all appropriate fees to the authorities. We may hold any future marketing authorizations granted for our product candidates in our own name, or appoint an affiliate or a collaboration partner to hold marketing authorizations on our behalf. Any failure by an MAH to comply with these obligations may result in regulatory action against an MAH and ultimately threaten our ability to commercialize our products.

Price and Reimbursement

In the European Union, the pricing and reimbursement mechanisms by private and public health insurers vary largely by country and even within countries. The public systems reimbursement for standard drugs is determined by guidelines established by the legislator or responsible national authority. The approach taken varies by Member State. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits and may limit or restrict reimbursement. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products and some of EU countries require the completion of studies that compare the cost-effectiveness of a particular product candidate to currently available therapies in order to obtain reimbursement or pricing approval. Special pricing and reimbursement rules may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition, results based rules of reimbursement may apply.

Legal Proceedings

From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

86


Table of Contents

Glossary of Terms

Glossary of terms, to be read only in conjunction with this annual report.

 

100 points clinical response

Percentage of patients achieving a 100-point decrease in CDAI score during a clinical trial in Crohn’s disease patients

 

ACR

American College of Rheumatology

 

ACR20 (ACR 20/50/70)

American College of Rheumatology 20% response rate signifies a 20% or greater improvement in the number of swollen and tender joints as well as a 20% or greater improvement in three out of five other disease-activity measures. ACR50 and ACR70 reflect the same, for 50% and 70% response rates, respectively

 

ADR

American Depositary Receipt; Galapagos has a Level 3 ADR listed on NASDAQ with ticker symbol GLPG and CUSIP number 36315X101. One ADR is equivalent to one ordinary share in Galapagos NV

 

AFM

Dutch Authority for the Financial Markets

 

Anemia

Condition in which the patient has an inadequate number of red blood cells to carry oxygen to the body’s tissues

 

Atherogenic index

Total cholesterol over HDL ratio. Improvement of the atherogenic index may be a forecast of cardiovascular health

 

Atopic dermatitis

Also known as atopic eczema, atopic dermatitis is a common pruritis inflammatory condition affecting the skin, which most frequently starts in childhood

 

Attrition rate

The historical success rate for drug discovery and development, based on publicly known development paths. Statistically seen, investment in at least 12 target-based programs is required to ensure that at least one of these will reach a Phase 3 study. Most new drug R&D programs are discontinued before reaching Phase 3 because they are not successful enough to be approved

 

Autotaxin (ATX)

An enzyme important for generating the signaling molecule lypophosphatidic acid (LPA). GLPG1690 targets autotaxin for IPF

 

BID dosing

Twice daily dosing (bis in die)

 

Bioavailability

Assessment of the amount of product candidate that reaches a body’s systemic circulation after (oral) administration

 

Biomarker

Substance used as an indicator of a biological process, particularly to determine whether a product candidate has a biological effect

 

Black & Scholes model

A mathematical description of financial markets and derivative investment instruments that is widely used in the pricing of European options and warrants

 

87


Table of Contents

Bleomycin model

A pre-clinical model involving use of bleomycin (a cancer medication) to induce IPF symptoms

 

CDAI

Crohn’s Disease Activity Index, evaluating patients on 8 different factors, each of which has a pre-defined weight as a way to quantify the impact of Crohn’s disease

 

CFTR

Cystic Fibrosis Transmembrane conductance Regulator protein. CFTR is an ion channel that transports chloride and thiocyanate ions across epithelial cell membranes. Mutations in the CFTR gene, that codes for the CFTR protein, cause cystic fibrosis

 

CIR

Crédit d’Impôt Recherche, or research credit. Under the CIR, the French government refunds up to 30% of the annual investment in French R&D operations, over a period of three years. Galapagos benefits from the CIR through its operations in Romainville, just outside Paris

 

Class II mutation

A genetic mutation in cystic fibrosis resulting in errors in CFTR folding, transport of functional CFTR to the cell membrane, and CFTR channel opening, whereby chloride ion flow at the cell surface in the membrane of affected organs is impacted negatively. More than 90% of cystic fibrosis patients are carriers of the Class II mutation. It is believed that a potentiator and multiple correctors will be needed to address the CFTR malfunction of Class II mutation patients. Orkambi is the only approved disease-modifying therapy for Class II mutation patients today

 

Class III mutation

A genetic mutation in cystic fibrosis resulting in errors in CFTR channel opening, whereby chloride ion flow at the cell surface in the membrane of affected organs is impacted negatively. Approximately 4% of cystic fibrosis patients are carriers of the Class III mutation. It is believed that a potentiator is needed to address the malfunction of Class III mutation patients. Kalydeco is the only approved disease-modifying therapy for Class III mutation patients today

 

Clinical Proof of Concept (PoC)

Point in the drug development process where the product candidate shows efficacy in a therapeutic setting

 

Compound

A chemical substance, often a small molecule with drug-like properties

 

Contract research organization

Organization which provides drug discovery and development services

 

Corrector drug

Drug that restores the correct protein formation in cystic fibrosis patients. In most CF patients, a potentiator and corrector drug are needed in combination to restore the channel function of the CFTR. Galapagos and AbbVie are planning to combine a potentiator with two correctors to be investigated in CF patients with the most prevalent mutation of CFTR

 

88


Table of Contents

Crohn’s disease (CD)

An inflammatory bowel disease involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel

 

CRP

C-reactive protein is a protein found in the blood, the levels of which rise in response to inflammation

 

Cystic fibrosis (CF)

A life-threatening genetic disease that affects approximately 80,000 people worldwide. Although the disease affects the entire body, difficulty breathing is the most serious symptom as a result of clogging of the airways due to mucus build-up and frequent lung infections

 

Cytokine

A category of small proteins which play important roles in signaling in processes in the body

 

DARWIN

Phase 2 program for filgotinib in rheumatoid arthritis; completed and reported in 2015 (except for the currently still ongoing DARWIN 3 study). DARWIN 1 explored three doses, in BID and QD administration, for up to 24 weeks in RA patients with insufficient response to methotrexate (MTX) and who remained on their stable background treatment with MTX. DARWIN 2 explored three QD doses for up to 24 weeks in RA patients with insufficient response to methotrexate (MTX) and who washed out of their treatment with MTX. DARWIN 1 and 2 were double-blind, placebo-controlled trials which recruited approximately 900 patients globally. DARWIN 3 is a long term extension trial currently ongoing; all patients are on 200 mg filgotinib, except for U.S. males who are on 100 mg.

 

DAS28(CRP)

DAS28 is an RA Disease Activity Score based on a calculation that uses tender and swollen joint counts of 28 defined joints, the physician’s global health assessment and a serum marker for inflammation, such as C-reactive protein. DAS28(CRP) includes c-reactive protein the score calculation: scores range from 2.0 to 10.0, with scores below 2.6 being considered remission.

 

Development

All activities required to bring a new drug to the market. This includes pre-clinical and clinical development research, chemical and pharmaceutical development and regulatory filings of product candidates

 

Discovery

Process by which new medicines are discovered and/or designed. At Galapagos, this is the department that oversees target and drug discovery research through to nomination of pre-clinical candidates

 

Disease-modifying

Addresses the cause of disease and modifying the disease progression, not just the symptoms of the disease

 

DIVERSITY

Phase 3 program evaluating filgotinib in Crohn’s disease

 

Dose-range finding study

Phase 2 clinical study exploring the balance between efficacy and safety among various doses of treatment in patients. Results are used to determine doses for later studies

 

89


Table of Contents

Double-blind

Term to characterize a clinical trial in which neither the physician nor the patient knows if the patient is taking placebo or the treatment being evaluated

 

Drug development

See: Development

 

Drug discovery

See: Discovery

 

Efficacy

Effectiveness for intended use

 

EMA

European Medicines Agency, in charge of European market authorization of new medications

 

Endoscopy

A non-surgical procedure involving use of an endoscope to examine a person’s digestive tract

 

Esbriet

An approved drug (pirfenidone) for IPF, marketed by Roche

 

FDA

The U.S. Food and Drug Administration is an agency responsible for protecting and promoting public health and in charge of American market approval of new medications

 

Fee-for-service

Payment system where the service provider is paid a specific amount for each procedure or service performed

 

Fibrotic score

The Ashcroft fibrotic score involves measuring pulmonary fibrosis through examination of histopathology tissue

 

FIH

First-in-human clinical trial, usually conducted in healthy volunteers with the aim to assess the safety, tolerability and pharmacokinetics of the product candidate

 

Filgotinib

Formerly known as GLPG0634. Small molecule selective JAK1 inhibitor which showed activity and favorable safety in rheumatoid arthritis and Crohn’s disease patients in Phase 2 trials. Filgotinib is partnered with Gilead. Galapagos and Gilead are running Phase 3 trials with filgotinib in RA, Crohn’s, and ulcerative colitis and expect to initiate Phase 2 trials with filgotinib in new indications in the course of 2017. Filgotinib is an investigational drug and its efficacy and safety have not been established.

 

FINCH

Phase 3 program evaluating filgotinib in rheumatoid arthritis

 

Fistulizing CD

Fistulae are inflammatory tracts that most often occur between the distal colon and the perianal region. Fistulae are one of the most severe sequelae of luminal CD and the lifetime risk of occurrence is close to 50% of those with active CD.

 

FITZROY

A double-blind, placebo controlled Phase 2 trial with filgotinib in 177 Crohn’s disease patients for up to 20 weeks; full results were published in The Lancet in 2016

 

90


Table of Contents

FLORA

A double-blind, placebo-controlled exploratory Phase 2a trial with GLPG1690 in up to 24 idiopathic pulmonary fibrosis patients; topline results are expected in the second half of 2017

 

FSMA

The Belgian market authority: Financial Services and Markets Authority, or Autoriteit voor Financiële Diensten en Markten

 

FTE

Full-time equivalent; a way to measure a worker’s involvement in a project. For example, an FTE of 1.0 means that the equivalent work of one full-time worker was used on the project

 

GLPG0634

Molecule number currently known as filgotinib

 

GLPG1690

A novel drug targeting autotaxin, with potential application in idiopathic pulmonary fibrosis. Fully proprietary to Galapagos. Testing in Phase 2 proof-of-concept FLORA study in IPF underway, with topline results expected in the second half of 2017

 

GLPG1837

A potentiator product candidate which showed activity and favorable safety in the Phase 2 SAPHIRA 1 and 2 trials in Class III cystic fibrosis mutation patients

 

GLPG1972

A novel mode-of-action product candidate that is part of the osteoarthritis alliance with Servier. GLPG1972 was in a Phase 1 trial with healthy volunteers. Galapagos expects to initiate a Phase 1b trial with GLPG1972 in osteoarthritis patients in the U.S. in 2017

 

GLPG2222

A C1 (early) corrector drug candidate which showed favorable safety in Phase 1 and is currently being tested in the ALBATROSS Phase 2 study in combination with Kalydeco in Class III mutation patients. In February 2017 Galapagos announced first dosing of GLPG2222 with GLPG2451 in healthy volunteers

 

GLPG2451

A potentiator drug candidate currently undergoing a Phase 1 safety trial. In February 2017 Galapagos announced first dosing of GLPG2222 with GLPG2451 in healthy volunteers

 

GLPG2534

A pre-clinical candidate with novel mode of action with potential application in atopic dermatitis. GLPG2534 is expected to enter Phase 1 trials in 2017

 

GLPG2737

A C2 (late) corrector drug candidate currently in a Phase 1 safety trial

 

GLPG2851

A C1 (early) corrector drug candidate currently at the pre-clinical stage. GLPG2851 is expected to enter Phase 1 trials in 2017

 

GLPG2938

A pre-clinical candidate with novel mode of action with potential application in IPF. GLPG 2938 is expected to enter Phase 1 trials in 2017

 

91


Table of Contents

GLPG3067

A potentiator drug candidate. GLPG3067 started a Phase 1 trial in March 2017

 

GLPG3221

A C2 (late) corrector drug candidate currently at the pre-clinical stage. GLPG3221 is expected to enter Phase 1 trials in 2017

 

HDL

High-density lipoprotein. HDL scavenges and reduces low-density lipoprotein (LDL) which contributes to heart disease at high levels. High levels of HDL reduce the risk for heart disease, while low levels of HDL increase the risk of heart disease

 

Hemoglobin

A protein inside red blood cells that carries oxygen from the lungs to tissues and organs in the body and carries carbon dioxide back to the lungs

 

Heterozygous

Genetic term meaning a cell containing different alleles for a gene

 

Histopathology

Microscopic examination of tissues for manifestations of a disease

 

Homozygous

Genetic term meaning identical alleles of the gene are present on both homologous chromosomes

 

IBD

Inflammatory Bowel Disease. This is a general term for an autoimmune disease affecting the bowel, including Crohn’s disease and ulcerative colitis. Crohn’s disease affects the small and large intestine, while ulcerative colitis affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel

 

IL-17C

IL-17C has been shown to be distinct from other members of the IL-17 family of cytokines. IL-17C has been shown to be an important mediator in inflammatory skin diseases, and is the target of MOR106

 

IPF

Idiopathic pulmonary fibrosis. A chronic and ultimately fatal disease characterized by a progressive decline in lung function. Pulmonary fibrosis involves scarring of lung tissue and is the cause of shortness of breath. Fibrosis is usually associated with a poor prognosis. The term “idiopathic” is used because the cause of pulmonary fibrosis is still unknown

 

Inflammatory diseases

A large, unrelated group of disorders associated with abnormalities in inflammation

 

In-/out-licensing

Receiving/granting permission from/to another company or institution to use a brand name, patent, or other proprietary right, in exchange for a fee and/or royalty

 

Intellectual property

Creations of the mind that have commercial value and are protected, including by patents, trademarks or copyrights

 

Intersegment

Occurring between the different operations of a company

 

92


Table of Contents

Investigational New Drug (IND) application

United States Federal law requires a pharmaceutical company to obtain an exemption to ship an experimental drug across state lines, usually to clinical investigators, before a marketing application for the drug has been approved. The IND is the means by which the sponsor obtains this exemption, allowing them to perform clinical studies

 

In vitro

Studies performed with cells outside their natural context, for example in a laboratory

 

JAK

Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in rheumatoid arthritis. Filgotinib is a selective JAK1 inhibitor

 

Kalydeco

A potentiator drug marketed by Vertex Pharmaceuticals

 

LDL

Low-density lipoprotein. LDL contributes to heart disease at high levels

 

Liver enzymes

Inflamed or injured liver cells secrete higher than normal amounts of certain chemicals, including liver enzymes, into the bloodstream

 

Lymphocyte

Type of white blood cell that is part of the immune system.

 

LPA

Lysophosphatidic acid, or LPA, is a signaling molecule involved in fibrosis

 

Milestone

Major achievement in a project or program; in our alliances, this is usually associated with a payment

 

MTX

Methotrexate; a first-line therapy for inflammatory diseases

 

Molecule collections

Chemical libraries, usually consisting of drug-like small molecules that are designed to interact with specific target classes. These collections can be screened against a target to generate initial “hits” in a drug discovery program

 

MOR106

A novel mode-of-action antibody product candidate currently being evaluated in atopic dermatitis patients in a Phase 1b trial. MOR106 acts on IL-17C, a novel antibody target discovered by Galapagos. MOR106 is part of the alliance with MorphoSys

 

NDA

New Drug Application

 

Neutrophil

Type of immune system cell which is one of the first cell types to travel to the site of an infection in the body. Neutrophils are another type of white blood cell which fight infection by ingesting and killing microorganisms

 

NK cells

Natural killer cells, type of white blood cell with granules of enzymes which can attack tumors or viruses

 

93


Table of Contents

Ofev

An approved drug (nintedanib) for IPF, marketed by Boehringer Ingelheim

 

Oral dosing

Administration of medicine by the mouth, either as a solution or solid (capsule, pill) form

 

Organoids

Miniature organ produced from cells from a donor; organoids have all the phenotypic characteristics of the patient donor, making them useful tools for in vitro drug research

 

Orkambi

A combination potentiator-corrector therapy marketed by Vertex Pharmaceuticals

 

Osteoarthritis

The most common form of arthritis, usually occurring after middle age, marked by chronic breakdown of cartilage in the joints leading to pain, stiffness, and swelling

 

Outsourcing

Contracting work to a third party

 

Pharmacokinetics (PK)

Study of what a body does to a drug; the fate of a substance delivered to a body. This includes absorption, distribution to the tissues, metabolism and excretion. These processes determine the blood concentration of the drug and its metabolite(s) as a function of time from dosing

 

Phase 1

First stage of clinical testing of an investigational drug designed to assess the safety and tolerability, pharmacokinetics of a drug, usually performed in a small number of healthy human volunteers

 

Phase 2

Second stage of clinical testing, usually performed in no more than several hundred patients, in order to determine efficacy, tolerability and the dose to use

 

Phase 3

Large clinical trials, usually conducted in several hundred to several thousand patients to gain a definitive understanding of the efficacy and tolerability of the candidate treatment; serves as the principal basis for regulatory approval

 

Placebo-controlled

A substance having no pharmacological effect but administered as a control in testing a biologically active preparation

 

Potentiator drug

Drug that restores the CFTR ion channel opening in cystic fibrosis patients. In most CF patients, a potentiator and corrector drug are needed in combination to restore the genetic defect causing CF. Galapagos and AbbVie are planning to combine a potentiator with two correctors to investigate in CF patients with the most prevalent mutation of CFTR

 

Pre-clinical

Stage of drug research development, undertaken prior to the administration of the drug to humans. Consists of in vitro and in vivo screening, pharmacokinetics, toxicology, and chemical upscaling

 

94


Table of Contents

Pre-clinical candidate (PCC)

A new molecule and potential drug that meets chemical and biological criteria to begin the development process

 

Product candidate

Substance that has satisfied the requirements of early pre-clinical testing and has been selected for development, starting with formal pre-clinical safety evaluation followed by clinical testing for the treatment of a certain disorder in humans

 

Proof of Concept study

Phase 2 patient study in which activity as well as safety in patients is evaluated, usually for a new mechanism of action

 

Pruritis

Extreme itching, as observed in atopic dermatitis patients

 

QD dosing

Once daily dosing (qd from the Latin quaque die)

 

Rheumatoid arthritis (RA)

A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability

 

R&D operations

Research and development operations; unit responsible for discovery and developing new product candidates for internal pipeline or as part of risk/reward sharing alliances with partners

 

SAPHIRA

A Phase 2 trial of potentiator GLPG1837 in cystic fibrosis patients carrying a Class III mutation. Results were reported in 2016, showing activity and favorable safety in two Class III mutations.

 

Screening

Method usually applied at the beginning of a drug discovery campaign, where a target is tested in a biochemical assay against a series of small molecules or antibodies to obtain an initial set of “hits” that show activity against the target. These hits are then further tested or optimized

 

SELECTION

Phase 2/3 program evaluating filgotinib in ulcerative colitis patients. Galapagos expects an interim readout for the Phase 2 portion of the program in late 2017

 

Service operations

Business unit primarily focused on delivering products and conducting fee-for-service work for clients. Our service operations included the BioFocus and Argenta business units, which were both sold in April 2014 to Charles River Laboratories

 

SES-CD scores

Simple endoscopic score for Crohn’s disease, involving review of 5 pre-defined bowel segments, assigning values from 0 (unaffected) to 3 (highly affected)

 

Small bowel CD (SBCD)

CD causes chronic inflammation and erosion of the intestines. It can affect different regions of gastrointestinal tract including the stomach and small and large intestines. While isolated SBCD is an uncommon presentation of CD, involvement of some portion of the small bowel, particularly the ileum, is common

 

95


Table of Contents

Target

Protein that has been shown to be involved in a disease process and forms the basis of therapeutic intervention or drug discovery

 

Target discovery

Identification and validation of proteins that have been shown to play a role in a disease process

 

Technology access fee

License payment made in return for access to specific technology (e.g. compound or virus collections)

 

(anti-)TNF

Tumor necrosis factor. An anti-TNF drug acts by modulation of TNF

 

Ulcerative colitis (UC)

UC is an inflammatory bowel disease (IBD) causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract)

 

C. Organizational Structure.

As of December 31, 2016, we had eight subsidiaries. The following table sets out for each of our principal subsidiaries, the country of incorporation, and percentage ownership and voting interest held by us (directly or indirectly through subsidiaries).

 

Company   Country of incorporation  

Percentage ownership and

voting interest

Galapagos B.V.   The Netherlands   100.0%
BioFocus DPI AG   Switzerland   100.0%
Inpharmatica Ltd   United Kingdom   100.0%
Galapagos SASU   France   100.0%
Fidelta d.o.o.   Croatia   100.0%
Discovery Partners International GmbH   Germany   100.0%
BioFocus, Inc.   United States   100.0%
Xenometrix, Inc.   United States   100.0%

 

D. Property, Plants and Equipment.

We have our principal executive, operational offices and laboratory space located in Mechelen, Belgium. We believe our current facility is sufficient to meet our current needs, but we intend to expand our facilities in Belgium by 2019 at the earliest in order to meet our future needs. We had a total of four facilities worldwide owned or leased as of December 31, 2016, as set forth in the following table:

 

Facility location    Use    Approx. size (m2)   Lease expiry

Mechelen, Belgium (leased)

   Headquarters, R&D, Operations    6,800 (1)   May 31, 2024

Romainville, France (leased)

   R&D    6,000   February 28, 2027

Zagreb, Croatia (leased)

   Research Services    6,000   May 4, 2018(2)

Leiden, the Netherlands (leased)

   R&D    3,000   September 1, 2025

 

(1) 6,800 m2 per December 31, 2016, which was increased to 7,200 m2 on January 1, 2017.
(2) With the exception of approximately 545 m² of laboratory and office space, for which the lease expires on January 1, 2021

 

96


Table of Contents

Environmental Issues

For more information on environmental issues that may affect our utilization of our facilities, please see the section of this annual report titled “Item 3.D.—Risk Factors—Risks Related to Our Organization, Structure and Operation—We could be subject to liabilities under environmental, health and safety laws or regulations, or fines, penalties or other sanctions, if we fail to comply with such laws or regulations or otherwise incur costs that could have a material adverse effect on the success of our business.”

 

Item 4B Unresolved Staff Comments.

Not applicable.

 

Item 5 Operating and Financial Review and Prospects.

Overview

We are a clinical-stage biotechnology company specialized in the discovery and development of medicines with novel modes of action, addressing disease areas of high unmet medical need. Our pipeline comprises programs ranging from discovery to Phase 3 clinical trials in inflammation, cystic fibrosis, fibrosis, osteoarthritis and other indications. Our highly flexible platform is applicable across many therapeutic areas. Our clinical stage programs include: filgotinib, which is currently in Phase 3 trials in rheumatoid arthritis (RA), Crohn’s disease (CD), and ulcerative colitis (UC); our cystic fibrosis (CF) portfolio of drugs aimed at a triple combination therapy for 90% of CF patients, for which we plan to initiate patient clinical trials by mid-2017; GLPG1690, our fully proprietary autotaxin inhibitor, which is currently in a Phase 2a trial for idiopathic pulmonary fibrosis (IPF); GLPG1972 for osteoarthritis (OA), which is expected to be dosed in a Phase 1b trial in U.S. patients in 2017; and MOR106, which is currently being dosed in atopic dermatitis (AtD) patients in a Phase 1b trial. Except for our CF program, these programs are derived from our proprietary target discovery platform. We have collaborations with Gilead for filgotinib, with AbbVie for CF, with Servier for GLPG1972, and with MorphoSys for MOR106.

We devote substantially all of our resources to our drug discovery efforts from target discovery through to clinical development. To date, we do not have any products approved for sale and have not generated any revenue from product sales. We sold our service division to Charles River Laboratories International, Inc., or Charles River, on April 1, 2014. As a result, the service division has been reported under discontinued operations, although certain entities of the service division were not sold and are therefore still reported under continuing operations.

To date, we funded our operations through public and private placements of equity securities, upfront and milestone payments received from pharmaceutical partners under our collaboration and alliance agreements, payments under our fee-for-service contracts, funding from governmental bodies, interest income as well as the net proceeds from the sale of our service division. From January 1, 2014 until December 31, 2016, we raised net proceeds of €651.2 million from a global offering of ordinary shares in May 2015 and from an equity investment by Gilead in January 2016, and we also received €395.6 million in payments through our collaboration and alliance agreements. These are non-recurring items which have a significant impact upon the profitability or cash flow of our business in each year in which they are received and earned. Fee-for-service payments and payments from governmental bodies contributed €18.3 million and €41.4 million, respectively. Over the same period, we also received €3.1 million in interest payments. In April 2014, the sale of our service division generated net proceeds of €130.8 million. As of December 31, 2016, we had cash and cash equivalents of €973.2 million.

Due to the sale of the service division, we realized a net income of €33.2 million for the year ended December 31, 2014. For the year ended December 31, 2015, we incurred a net loss of €118.4 million. Due to a

 

97


Table of Contents

non-cash adjustment on a short term financial asset, as described below, with regard to the share subscription agreement with Gilead on January 19, 2016, we realized a net income of €54.0 million for the year ended December 31, 2016. Excluding the impact of possible upfront and in-licensing payments we may receive from our collaborations, we forecast to continue incurring losses as we continue to invest in our clinical and pre-clinical development programs and our discovery platform.

In 2015, we recognized a short term financial asset worth €39 million and an offsetting deferred income of €39 million upon signing of the share subscription agreement with Gilead, as required under IAS 39. This financial asset initially reflected the share premium that Gilead committed to pay above the closing stock price of our ordinary shares on the day of signing of the subscription agreement. Under IAS 39, the fair value of the financial asset was re-measured at year end and again upon entering into force of the subscription agreement on January 19, 2016, when the financial asset expired. Variations in fair value of the financial asset were recorded in the income statement. The decrease in the fair value of the financial asset resulting from the increase in our share price between signing of the subscription agreement and December 31, 2015, resulted in a negative, non-cash fair value charge of €30.6 million in the 2015 financial results. The subsequent increase in the fair value of the financial asset resulting from the decrease in our share price between January 1, 2016 and January 19, 2016 resulted in a positive non-cash gain of €57.5 million in the financial result of 2016. The €65.9 million current financial asset from the share subscription agreement reflected the premium that Gilead paid compared to the closing price of our shares on the day of the capital increase. This financial asset expired on January 19, 2016, the effective date of the share subscription agreement and was derecognized through the share premium account.

Collaboration and Alliance Agreements

Our main collaborations and alliance agreements are summarized below. All U.S. dollar payment amounts which have been received in cash regarding our AbbVie collaboration in this Item 5 are converted into euros as per historical exchange rates (i.e., the spot rate at the moment of the transaction).

Amended AbbVie Collaboration Agreement for CF

In September 2013, we entered into a global collaboration agreement with AbbVie focused on the discovery and worldwide development and commercialization of potentiator and corrector molecules for the treatment of CF. On April 28, 2016, we and AbbVie entered into the amended and restated agreement, which expanded the parties’ CF collaboration by amending and restating the collaboration agreement to, among other things, increase the remaining total milestones under the amended and restated agreement up to approximately $600 million from $350 million. As amended, the collaboration will provide for the potential development and commercialization of triple combination products consisting of a potentiator molecule, a corrector 1 molecule and a corrector 2 molecule to treat specified populations of patients with CF. A detailed summary of this collaboration agreement is set forth in the section of this annual report titled “Item 4.B.—Business Overview—Collaborations—Amended and Restated Collaboration with AbbVie for CFTR Modulators (CF).”

Upon execution of the collaboration agreement, we received a one-time non-refundable, non-creditable upfront payment of $45.0 million (€34.0 million), which has been fully recognized as of June 2015. In December 2014, we initiated a Phase 1 trial for GLPG1837 for which we received a milestone payment of $10.0 million (€8.0 million). In November 2015, we initiated a Phase 1 trial for GLPG2222, for which we received a $10.0 million (€8.8 million) payment from AbbVie in January 2016. In April 2016, we initiated a Phase 1 trial for GLPG2451, for which we received a $10.0 million (€8.8 million) payment. In November 2016, we initiated a Phase 1 trial for GLPG2737, for which we received a $10.0 million (€9.1 million) payment. In January 2017, we received IND acceptance in U.S. from FDA for GLPG2222, for which we received a $10.0 million (€9.5 million) payment. In March 2017, we initiated a Phase 1 trial for GLPG3067, for which we will receive a $7.5 million (€7.1 million) payment. All payments by AbbVie to us are made in U.S. dollars.

Under the agreement, we are still eligible to receive up to $567.5 million in total additional developmental, regulatory, and sales-based milestones. In March 2017, we achieved a $7.5 million milestone, for which the

 

98


Table of Contents

payment is not yet received to date. In addition, we will be eligible to receive tiered royalty percentages ranging from the mid-teens to 20% on net sales of licensed products payable on a product-by-product basis. In the event we exercise our co-promotion option with respect to a licensed product, we would assume a portion of the co-promotion effort in the Netherlands, Belgium, and Luxembourg and share in the net profit and net losses in these territories instead of receiving royalties in those territories during the period of co-promotion.

Gilead Collaboration Agreement for Filgotinib

In December 2015, we entered into a global collaboration agreement with Gilead to develop and commercialize filgotinib for the treatment of inflammatory indications. A detailed summary of this collaboration agreement is set forth in the section of this annual report titled “Item 4.B.—Business Overview—Collaborations—Exclusive Collaboration Agreement with Gilead for Filgotinib.”

In connection with our entry into the collaboration agreement, we received in January 2016 an upfront payment of $725 million consisting of a one-time, non-refundable, non-creditable license fee in the amount of $300 million and a $425 million equity investment. In November 2016, Gilead initiated a Phase 3 trial in CD, for which we received a $50.0 million (€45.7 million) payment. In December 2016, Gilead initiated a Phase 2 trial in UC for which we received a $10.0 million (€9.4 million) payment. All payments by Gilead to us are made in U.S. dollars. In addition, we will be eligible to receive development and regulatory milestone-based payments of up to $695 million and sales-based milestone payments of up to $600 million. We will be eligible to receive tiered royalty percentages starting at 20% on global net sales of licensed products. The royalties payable to us under the collaboration agreement may be reduced under certain circumstances. Our right to receive royalties under the collaboration agreement continues, on a country-by-country basis, until the later to occur of certain specified events. In the event we exercise our co-promotion option with respect to licensed products in one or more of the territories eligible for co-promotion, we would assume a portion of the co-promotion effort in the United Kingdom, Germany, France, Italy, Spain, the Netherlands, Belgium, and/or Luxembourg and share equally in the net profit and net losses in these territories instead of receiving royalties in those territories during the period of co-promotion.

Financial Operations Overview

Revenue

Our revenues in our continuing operations to date have consisted principally of milestones, reimbursement income, license fees, and upfront payments received in connection with our collaboration and alliance agreements. Additionally, we have generated revenue from our fee-for-service activities and various R&D incentives and grants.

Collaboration and alliance agreements with our commercial partners for R&D activities generally include non-refundable, upfront fees; milestone payments, the receipt of which is dependent upon the achievement of certain clinical, regulatory or commercial milestones; license fees; and royalties on sales.

Our revenue recognition policies are as follows:

Upfront Payments

Non-refundable, upfront payments received in connection with R&D collaboration agreements are deferred and recognized over the relevant period of our involvement. At inception, management estimates the period of our involvement as well as the cost involved in the project. Upfront payments are recognized over the estimated period of involvement, either on a straight line basis or based on the cost incurred under the project if such cost can be reliably estimated. Periodically, we reassess the estimated time and cost to complete the project phase and adjust the time period over which the revenue is deferred accordingly.

 

99


Table of Contents

Milestone Payments

Research milestone payments are recognized as revenues when milestones are achieved. In addition, the payments have to be acquired irrevocably and the milestone payment amount needs to be substantive and commensurate with the magnitude of the related achievement. Milestone payments that are not substantive, not commensurate, or that are not irrevocable are recorded as deferred revenue. Revenue from these activities can vary significantly from period to period due to the timing of milestones.

Reimbursement Income

Cost reimbursements resulting from license and collaboration agreements with our commercial partners are recognized as reimbursement income in revenue as the related costs are incurred and upon agreement by the parties involved. The corresponding expenses are included in research and development expenditure.

Cost reimbursements from collaboration in which we share equally in the risks and benefits associated with development of a specific drug with a collaboration partner are recognized as decrease of the related incurred research and development expenditure.

License Fees

Revenues from term licenses are spread over the period to which the licenses relate, reflecting the obligation over the term, to update content and provide ongoing maintenance. Revenues from perpetual licenses are recognized immediately upon sale to the extent that there are no further obligations.

Royalties

Royalty revenues are recognized when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the period in which our licensees are reporting the royalties to us through royalty reports, that is, royalty revenues are generally recognized in arrears, i.e., after the period in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.

Grants and R&D Incentives

We benefit from various grants and R&D incentives from certain governmental agencies. These grants and R&D incentives generally aim to partly reimburse approved expenditures incurred in our R&D efforts and are credited to the income statement, under other income, when the relevant expenditure has been incurred and there is reasonable assurance that the grant or R&D incentive is receivable. The main grants and R&D incentives are as follows:

 

    Companies in Belgium are eligible to receive R&D incentives linked to R&D investments (cash rebates equaling 33.99% of 13.5% of the investment value in 2016, 33.99% of 13.5% of the investment value in 2015, or 33.99% of 13.5% of the investment value in 2014). This R&D tax credit results in a cash inflow to us from the tax authorities five years after the investment was made and capitalized in our standalone financial statements under Belgian GAAP for the portion that has not been used to offset the payment of corporate tax or is paid to us for the portion that remains unused. We also received several grants from an agency of the Flemish government to support various research programs focused on technological innovation in Flanders. These grants carry clauses which require us to maintain a presence in the Flemish region for a number of years and invest according to pre-agreed budgets. Finally, we also benefit from certain rebates on payroll withholding taxes for scientific personnel.

 

   

In France, we benefit from R&D incentives from the French Government for R&D activities whereby 30% of qualifying R&D expenses can be recuperated. This research tax credit (crédit d’impôt

 

100


Table of Contents
 

recherche), results in a cash inflow to us from the tax authorities after three years, i.e., it is used to offset the payment of corporate tax or is paid to us for the portion that remains unused. Qualifying expenditures largely comprise employment costs for research staff, consumables, and certain overhead costs as well as capped outsourcing costs incurred as part of R&D projects.

R&D Expenditure

Expenses on R&D activities are recognized as an expense in the period in which the expense is incurred.

An internally-generated intangible asset arising from our R&D activities would be recognized only when an asset is created that can be identified, it is probable that the asset created will generate future economic benefits, and the development cost of the asset can be measured reliably.

Our Funded R&D Expenditure

Our funded R&D expenditure consists of costs associated with our R&D activities such as:

 

    personnel costs associated with employing our team of R&D staff, including salaries, social security costs, and share-based compensation expenses;

 

    disposables and lab consumables used in the conduct of our in-house research programs;

 

    payments for research work conducted by sub-contractors and sponsorship of work by our network of academic collaborative research scientists;

 

    subcontracting costs paid to contracted research organizations, or CROs, for our pre-clinical studies or clinical trials, as well as costs associated with safety studies;

 

    premises costs associated with our laboratory and office space to accommodate our teams;

 

    depreciation of fixed assets used to develop our product candidates; and

 

    other operating expenses, namely software and licenses, maintenance costs for equipment, travel costs, and office expenses.

We expect to increase our investment in our funded R&D in the future as we seek to advance our most promising pipeline product candidates through further clinical development.

Alliance R&D Expenditure

R&D expenditure under alliance represent costs incurred by us in conducting R&D plans under our collaborations and alliance agreements. Our expenses primarily relate to the following key programs:

 

    Development costs for the development of filgotinib in RA and IBD (currently in collaboration with Gilead, previously with AbbVie) : these costs relate to the Phase 2 and Phase 3 trials and mainly consist of costs recharged by our collaboration partner as we are co-funding 20% of the global development activities, as well as costs paid to CROs in conjunction with clinical trials, costs for production of the compound for clinical testing, and, to a smaller extent, personnel costs and consultancy costs.

 

    Costs for the CF collaboration with AbbVie: these costs are primarily composed of (1) personnel costs, (2) internal laboratory costs, and (3) costs incurred in carrying out our pre-clinical toxicology, pharmacology, and both in vitro and in vivo pre-clinical models in the fields of CF.

 

    Other R&D programs: these expenses primarily consist of personnel costs, costs for production of the pre-clinical compounds, and costs paid to CROs in conjunction with pre-clinical studies and clinical trials.

 

101


Table of Contents

Our R&D expenses under alliance are expected to increase as we advance our filgotinib program, our CF program and any other alliance product candidate into clinical trials.

Since 2014, we cumulatively have spent approximately €380.4 million on R&D activities which can be split as follows between the key programs:

 

     Year ended December 31,              
     2016     2015     2014              
     (Euro, in thousands)     cumulative        

Filgotinib program (partnered)

   (22,376     (35,404   (33,843   (91,622     24

CF program (partnered)

     (31,203     (25,634     (14,894     (71,731     19

IPF program on GLPG1690 (proprietary)

     (7,129     (4,612     (4,592     (16,333     4

OA program on GLPG1972 (partnered)

     (6,538     (5,832     (801     (13,171     3

AtD program on MOR106 (partnered)

     (3,491     (4,651     (894     (9,036     2

Other

     (68,836     (53,582     (56,086     (178,504     47
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total R&D expenditure

   (139,573   (129,714   (111,110   (380,397     100
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

As illustrated above the R&D expenditures have shown a growth trend over the three years from €111.1 million for the year ended December 31, 2014 to €139.6 million for the year ended December 31, 2016. The increase is driven by the maturing pipeline of our R&D projects. As progressively product candidate compounds have been entering the clinic, costs for development of these molecules increased as well, specifically with regard to third-party CRO costs for conducting these clinical trials. Our program filgotinib accounts for 24% of the cumulative spend over the last three years with a total cost of €91.6 million. Costs reported under other programs relate to investments in own funded discovery and development projects, and in our discovery platform, as well as costs related to other collaborations and alliance contracts.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and benefits related to our executive, finance, business development, legal, intellectual property, and information technology support functions. Professional fees reported under general and administrative expenses mainly include legal fees, accounting fees, audit fees, and fees for taxation advisory. Other general and administrative operating expenses primarily encompass software and license costs, equipment maintenance and leasing costs, consultancy costs, insurance costs, office expenses, and travel costs.

We expect our general and administrative expenses to increase as we continue to support our growth and as we operate as a U.S.-listed company. Such costs include increases in our finance and legal personnel, additional external legal and audit fees, and expenses and costs associated with compliance with the regulations governing public companies. We also expect to incur increased costs for directors’ and officers’ liability insurance and an enhanced investor relations function.

Sales and Marketing Expenses

Sales and marketing expenses include costs associated with managing our commercial activities and the costs of compliance with the day-to-day requirements of being a listed public company in Belgium and the United States, such as:

 

    Headquarters costs related to investor relations and corporate communications in Belgium and the Netherlands.

 

    Sales and marketing department in Croatia as from 2013.

 

102


Table of Contents

Interest Expense and Interest Income

Interest expense consists primarily of interest expense incurred on finance leases.

Interest income consists primarily of interest earned by investing our cash reserves in short-term, interest-bearing deposit accounts.

Taxation

We have a history of losses. Excluding the impact of possible upfront or milestone payments we may receive from our collaborations, we forecast to continue incurring losses as we continue to invest in our clinical and pre-clinical development programs and our discovery platform. Consequently, we do not have any deferred tax asset on the balance sheet as at December 31, 2016, except for two subsidiaries operating on a cost plus basis for the company a deferred tax asset was set up for an amount of €2.0 million as of December 31, 2016.

As a company active in research and development in Belgium, we also expect to benefit in the future from the “patent income deduction” or the replacing “innovation deduction” in Belgium. The patent income deduction regime allows, in the case of taxable income, gross profits attributable to revenue from patented products to be taxed at a lower rate than other revenues, i.e., 6.8%. The innovative deduction regime allows net profits attributable to revenue from among others patented products (or products for which the patent application is pending) to be taxed at a lower rate than other revenues, i.e., 5.1%. When taken in combination with tax losses carried forward and research and development incentives mentioned above, we expect that this will result in a long-term low rate of corporation tax for us. The innovation deduction applies as of July 1, 2016, although subject to various conditions, the patent income deduction can continue to apply until June 30, 2021 at the latest.

Operating Segments

Following the sale of the service division on April 1, 2014, the continuing operations related primarily to R&D activities. Consequently, in 2014, we only had one reportable segment.

In 2015, the IFRS8 threshold of 10% of the combined revenues, external and inter-segment, of all segments was met by the external and internal revenues reported by our fee-for-service business located in Croatia. Consequently, there are two reportable segments in 2015 and 2016, R&D and fee-for-service business.

Financial information related to our two reportable segments and geographic information is contained in “Note 3—Segment information” in our consolidated financial statements appended to this annual report.

Risks

For further information regarding governmental economic, fiscal, monetary or political policies or factors that have materially affected, or could materially affect, directly or indirectly, our operations, please see the section of this annual report titled “Item 3.D.—Risk Factors.”

Critical Accounting Policies and Estimates

In the application of our accounting policies, we are required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Our estimates and assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revisions and future periods if the revision affects both current and future periods.

 

103


Table of Contents

Drafting financial statements in accordance with IFRS requires management to make judgments and estimates and to use assumptions that influence the reported amounts of assets and liabilities, the notes on contingent assets and liabilities on the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results may differ from these estimates.

The following are our critical judgments and estimates that we have made in the process of applying our accounting policies and that have the most significant effect on the amounts recognized in our consolidated financial statements presented elsewhere in this annual report.

Critical Judgments in Applying Accounting Policies

Share Subscription Agreement with Gilead: Classification as Derivative Financial Asset or Equity Instrument

As described in the section of this annual report titled “Item 5.A.—Operating Results—Comparison of Years Ended December 31, 2016 and 2015—Fair Value Re-measurement of Share Subscription Agreement,” as well as “Item 5.A.—Operating Results—Comparison of Years Ended December 31, 2015 and 2014—Fair Value Re-measurement of Share Subscription Agreement,” Gilead committed itself on December 16, 2015 to make a $425 million equity investment in our company by subscribing to new shares at a fixed price of €58 per share, including issuance premium upon completion of the license and collaboration agreement with us that took place on January 19, 2016.

Significant judgment had to be applied in assessing whether this forward subscription commitment of Gilead over the shares of our company shall be classified as an equity instrument or as a derivative financial asset of our company. IAS 32 requires that for a derivative to meet the definition of equity it must be settled only by the issuer exchanging a “fixed amount of cash or another financial asset for a fixed number of its own equity instruments.” Because the above-mentioned commitment by Gilead was made in U.S. dollars, the actual number of shares finally issued by us varied with the fluctuation in the $/€ exchange rate until the settlement date on January 19, 2016.

Despite the fact that this foreign currency exchange exposure was limited, management judged that this variability prevents the instrument from being classified as equity under IAS 32 and was therefore treated as a derivative at fair value through profit and loss.

Revenue Recognition

Evaluating the criteria for revenue recognition with respect to our R&D and collaboration agreements requires management’s judgment to ensure that all criteria have been fulfilled prior to recognizing any amount of revenue. In particular, such judgments are made with respect to determination of the nature of transactions, whether simultaneous transactions shall be considered as one or more revenue-generating transactions, allocation of the contractual price (upfront and milestone payments in connection with a collaboration agreement) to several elements included in an agreement, and the determination of whether the significant risks and rewards have been transferred to the buyer. Collaboration agreements are reviewed carefully to understand the nature of risks and rewards of the arrangement. All of our revenue-generating transactions have been subject to such evaluation by management.

 

104


Table of Contents

Critical Accounting Estimates

Fair Value Re-measurement of Our Share Subscription Agreement with Gilead (Derivative Financial Asset Instrument)

 

Current financial asset from share subscription agreement:

 

     (Euro, in thousands)  

Fair value at inception

     39,003  

Movement of 2015 ( recognized in the income statement)

     (30,632
  

 

 

 

Fair value per December 31, 2015

     8,371  
  

 

 

 

Movement of period January–19, 2016 (recognized in the income statement)

     57,479  
  

 

 

 

Fair value per January 19, 2016

     65,850  
  

 

 

 

Derecognition of the financial asset through the share premium account

     (65,850
  

 

 

 

Fair value per December 31, 2016

     —    
  

 

 

 

The fair value measurement of this derivative financial asset was categorized as a level 3 in the fair value hierarchy of the IFRS 13 Fair Value Measurement.

Its measurement was based on computing the difference between the strike price (€58 per share) and our anticipated forward price, discounted to the valuation date. The notional was converted from U.S. dollars to euros by the currency exchange forward rate, and the number of shares was computed by dividing the euro notional by the strike price.

Input data were taken from Bloomberg as of December 16, 2015 and December 31, 2015, including:

 

    Euro overnight index swap discount rates (curve 133);

 

    Implied forward rate of the GLPG shares at January 31, 2016; and

 

    Implied currency exchange forward rate at January 31, 2016.

This computation was based on the following unobservable assumptions:

 

  (1) Between the date that the deal was signed (December 16, 2015) until the date that the deal was complete, the two counterparties could not back off from the deal, and it was 100% certain that the regulator would give the green light.

 

  (2) At the two valuation dates, it was assumed that the date when the deal will be complete would be January 31, 2016. This was the forward date from where all the market data was taken from.

 

  (3) The effect of the correlation between our share price and the $/€ currency exchange rate was negligible. This was reasonable given the very short maturity of the deal.

Relationship of unobservable inputs to the fair value measurement:

 

    If one would have assumed that the closing date of the deal was January 19, 2016 (the actual closing date), the fair value of the derivative financial asset at December 31, 2015 would have been €8,367 thousand.

On January 19, 2016, the value of the financial asset at maturity amounted to €65.9 million, reflecting the share premium that Gilead paid above our closing share price on the day of the capital increase. This financial asset expired on the effective date of the share subscription agreement and was derecognized through the share premium account.

 

105


Table of Contents

Share-based Payments Plans

We determine the costs of the share-based payments plans (i.e., our warrant plans) on the basis of the fair value of the equity instrument at grant date. Determining the fair value assumes choosing the most suitable valuation model for these equity instruments, by which the characteristics of the grant have a decisive influence. This assumes also the input into the valuation model of some relevant judgments, like the estimated useful life of the warrant and the volatility.

Pension Obligations

The cost of a defined pension arrangement is determined based on actuarial valuations. An actuarial valuation assumes the estimation of discount rates, estimated returns on assets, future salary increases, mortality figures and future pension increases. Because of the long-term nature of these pension plans, the valuation of these is subject to important uncertainties.

Corporate Income Taxes

Significant judgment is required in determining the use of tax loss carry forwards. We recognize deferred tax assets arising from unused tax losses or tax credits only to the extent that we have sufficient taxable temporary differences or there is convincing evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilized by us. Management’s judgment is that such convincing evidence is currently not sufficiently available and a deferred tax asset is therefore not yet recognized, except for two subsidiaries operating on a cost plus basis for the company a deferred tax asset was set up for an amount of €2.0 million as of December 31, 2016.

As of December 31, 2016, we had a total of approximately €311 million of statutory tax losses carried forward which may be partially offset by future statutory taxable profits for an indefinite period, except for an amount of approximately €18 million in Switzerland, Croatia, the United States and the Netherlands with expiry dates between 2018 and 2030. As of December 31, 2016, the available tax losses carried forward in Belgium amounted to €231 million.

Long-term Management Bonus Provision

Our executive committee members, together with other senior managers, are eligible to receive bonuses under the Senior Management Bonus Scheme established in 2006. Pursuant to the rules of the Senior Management Bonus Scheme, 50% of the bonus is paid immediately around year-end and the payment of the remaining 50% is deferred for three years. The deferred 50% component is dependent on our share price change relative to the Next Biotech Index (which tracks our peers). Our share price and the Next Biotech Index at the start and end of the three-year period is calculated by the average price over the preceding and last month of the three-year period, respectively.

 

    If our share price change is better than or equal to the change in the Next Biotech Index, the deferred bonus will be adjusted by the share price increase/decrease and paid out.

 

    If our share price change is up to 10% worse than the change in the Next Biotech Index, 50% of the deferred bonus will be adjusted by the share price increase/decrease and paid out, and the remainder will be forfeited.

 

    If our share price change is more than 10% worse than the change in the Next Biotech Index, the deferred bonus will be forfeited.

Since the bonus is calculated by reference to our share price, it is accounted for as a cash-settled share-based payment under IFRS 2. The liability incurred is measured at the fair value of the liability. Until the liability is settled, the fair value of the liability is re-measured at the end of each reporting period and at the date of settlement, with any changes in fair value recognized in profit or loss for the period. Management judgment is required in determining the fair value.

 

106


Table of Contents
A. Operating Results

Comparison of Years Ended December 31, 2016 and 2015

The following table summarizes the results of our operations for the years ended December 31, 2016 and 2015, together with the changes to those items.

 

     Year ended December 31,        
         2016             2015         % Change  
     (Euro, in thousands,
except share and per share data)
       

Revenues

   129,519     39,563       227

Other income

     22,093       21,017       5
  

 

 

   

 

 

   

 

 

 

Total revenues and other income

     151,612       60,579       150
  

 

 

   

 

 

   

 

 

 

Research and development expenditure

     (139,573     (129,714     8

General and administrative expenses

     (21,744     (19,127     14

Sales and marketing expenses

     (1,785     (1,182     51
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     (163,103     (150,023     9
  

 

 

   

 

 

   

 

 

 

Operating loss

     (11,491     (89,444     (87 %) 
  

 

 

   

 

 

   

 

 

 

Fair value re-measurement of share subscription agreement

     57,479       (30,632     (288 %) 

Other financial income

     9,950       1,987       401

Other financial expenses

     (1,692     (1,539     10
  

 

 

   

 

 

   

 

 

 

Loss before tax

     54,246       (119,627     (145 %) 
  

 

 

   

 

 

   

 

 

 

Income taxes

     (235     1,218       (119 %) 
  

 

 

   

 

 

   

 

 

 

Net income / loss (-) from continuing operations

     54,012       (118,410     (146 %) 
  

 

 

   

 

 

   

 

 

 

Net income from discontinued operations

     —         —      
  

 

 

   

 

 

   

Net income / loss (-)

   54,012     (118,410  
  

 

 

   

 

 

   

Net income / loss (-) attributable to:

      

Owners of the parent

     54,012       (118,410  
  

 

 

   

 

 

   

Basic income / loss (-) per share

   1.18     (3.32  
  

 

 

   

 

 

   

Diluted income / loss (-) per share

   1.14     (3.32  
  

 

 

   

 

 

   

Basic income/ loss (-) per share from continuing operations

   1.18     (3.32  
  

 

 

   

 

 

   

Diluted income/ loss (-) per share from continuing operations

   1.14     (3.32  
  

 

 

   

 

 

   

Weighted average number of shares - Basic (in ‘000 shares)

     45,696       35,700    

Weighted average number of shares - Diluted (in ‘000 shares)

     47,308       35,700    

Revenues

 

     Year ended December 31,         
         2016              2015          % Change  
     (Euro, in thousands)         

Recognition of non-refundable upfront payments

   30,257      26,419        15

Milestone payments

     81,784        3,835        2033

Reimbursement income

     9,699        3,807        155

Other revenues

     7,777        5,501        41
  

 

 

    

 

 

    

 

 

 

Total revenues

   129,519      39,563        227
  

 

 

    

 

 

    

 

 

 

 

107


Table of Contents

Total revenues increased by €90.0 million, or 227%, to €129.5 million for the year ended December 31, 2016, from €39.6 million for the year ended December 31, 2015. This increase was mainly driven by a substantial increase in milestone payments, as explained below.

Revenue recognized in 2015 from upfront non-refundable payments related to the CF collaboration agreement with AbbVie signed in September 2013 and the contract signed with AbbVie in February 2012 for our filgotinib program (including the extension signed in March 2013). Those upfront payments were fully recognized into revenues by the end of August 2015.

In September 2015 AbbVie decided not to opt in, which ended the collaboration agreement regarding our filgotinib program and consequently the period of our involvement. There are no outstanding commitments for us regarding this terminated collaboration for our filgotinib program.

On December 16, 2015, we entered into a global collaboration with Gilead Sciences, Inc. for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory indications. On January 19, 2016, we completed the closing of the global collaboration agreement with Gilead, in the framework of which Gilead made a $425 million (or €392 million) equity investment in Galapagos NV by subscribing to new shares at a price of €58 per share, including issuance premium. This resulted in Gilead owning 6,760,701 ordinary shares of Galapagos NV, representing 14.75% percent of the then-outstanding share capital of Galapagos. We also received a license fee of $300 million. In addition, we are eligible for payments of up to $755 million in development and regulatory milestones and $600 million in sales milestones, with tiered royalties starting at 20% and a profit split in co-promotion territories. Finally, we agreed on a 20-80 cost split for development costs of the licensed product, i.e. we will support 20% of all development costs. As we do not expect to have a statutory taxable base in the foreseeable future, we did not recognize any additional deferred tax asset following the signing of this new collaboration.

The global collaboration with Gilead foresees continuous involvement from us, since we will perform certain R&D activities in the development phase of the filgotinib program; therefore, management assessed that the upfront payment of $300 million (or €275.6 million) received in January 2016 from Gilead should be spread as a function of the costs incurred for this program, applying the percentage of completion method. In the year ended December 31, 2016, €25.6 million revenues were recognized regarding this upfront payment.

In connection with the agreement with Gilead, we recognized a deferred income and an offsetting short-term financial asset (derivative) of €39 million upon signing of the share subscription agreement with Gilead, as required under IAS 39. The deferred income will be recognized in function of the costs incurred for this program, applying the percentage of completion method, along with the upfront payment. In the year ended December 31, 2016, €3.6 million revenues were recognized in the income statement.

In 2016, Galapagos signed a license agreement with ThromboGenics for an integrin antagonist (formerly GLPG0187), for which an upfront payment of €1 million was invoiced and fully recognized, as Galapagos has no further involvement or obligation in the contract.

 

108


Table of Contents

The following table summarizes the upfront payments recognition for years ended December 31, 2016 and 2015.

 

Agreement

  Upfront
received
    Upfront
received
    Date of
receipt
    Revenue
recognized, year
ended

December 31, 2016
    Revenue
recognized, year
ended December 31,
2015
    Outstanding
balance in deferred
income as at
December 31, 2016
 
    (USD,
in thousands)
    (Euro,
in thousands)
          (Euro, in thousands)  

AbbVie collaboration agreement for CF

 

    $45,000       €34,001       September 2013         €11,401    

AbbVie collaboration agreement for RA and CD (filgotinib)

 

    $150,000       €111,582       February 2012         €12,045    

First amendment to AbbVie collaboration agreement for RA and CD (filgotinib)

 

    $20,000       €15,619       March 2013         €2,973    

Gilead collaboration agreement for filgotinib

 

    $300,000       €275,558       January 2016       €25,621         €249,937  

Gilead collaboration agreement for filgotinib

 

    N.A.       €39,003 (*)       January 2016       €3,626         €35,376  

ThromboGenics license agreement for integrin antagonists

 

    N.A.       €1,000       April 2016       €1,000      

Sirion Biotech license agreement for RNA interference (RNAi) technologies

 

    N.A.       €10       June 2016       €10      
       

 

 

   

 

 

   

 

 

 

Total recognition of non-refundable upfront payments

 

    €30,257       €26,419       €285,314  
       

 

 

   

 

 

   

 

 

 

 

(*) deferred income of €39 million booked upon signing of the share subscription agreement with Gilead as required under IAS 39

Milestone revenues increased substantially by €77.9 million, to €81.8 million for the year ended December 31, 2016 compared to €3.8 million for the year ended December 31, 2015. Milestones in 2016 related to the filgotinib program with Gilead in CD and UC, and the CF program in with AbbVie. Milestones in 2015 related to our OA program with Servier.

Reimbursement income increased by €5.9 million or 155%, to €9.7 million for the year ended December 31, 2016 compared to €3.8 million for the year ended December 31, 2015, due to higher reimbursements in relation with the CF program with AbbVie and the filgotinib program with Gilead (which was partnered with AbbVie in 2015). The reimbursement of certain research and development costs related to the development work under our collaboration agreements amounted to €5.9 million for our CF program with AbbVie and €3.5 million for our filgotinib program with Gilead for the year ended December 31, 2016. For the year ended December 31, 2015, €2.2 million and €1.2 million of costs were reimbursed in relation with the CF and filgotinib collaboration agreements with AbbVie, respectively,

Other revenues increased by €2.3 million, or 41%, to €7.8 million for the year ended December 31, 2016 compared to €5.5 million for the year ended December 31, 2015, principally due to higher revenues from fee-for-service activities.

 

109


Table of Contents

Other Income

The following table summarizes our other income for the years ended December 31, 2016 and 2015, together with the changes to those items.

 

     Year ended December 31,         
         2016              2015          % Change  
     (Euro, in thousands)         

Grant income

   2,329      3,095        (25 %) 

Other income

     19,764        17,922        10
  

 

 

    

 

 

    

 

 

 

Total other income

   22,093      21,017        5
  

 

 

    

 

 

    

 

 

 

Total other income was composed of grant income and other income and increased by €1.1 million, or 5%, from €21.0 million for the year ended December 31, 2015 to €22.1 million for the year ended December 31, 2016.

Grant income decreased by €0.8 million, or 25%, from €3.1 million for the year ended December 31, 2015 to €2.3 million for the year ended December 31, 2016. The majority of this grant income is related to grants from a Flemish agency, representing approximately 88% of all reported grant income in 2016 (2015: 94%). In many cases these carry clauses which require us to maintain a presence in the same region for a number of years and invest according to pre-agreed budgets.

The decrease in grant income was more than offset by an increase in other income of €1.8 million, or 10%, from €17.9 million for the year ended December 31, 2015 to €19.8 million for the year ended December 31, 2016. Other income was primarily composed of:

 

    Income from an innovation incentive system of the French government, which represented €9.5 million of other income for the year ended December 31, 2016 compared to €8.7 million for the year ended December 31, 2015

 

    Income from Belgian R&D incentives with regard to incurred R&D expenses, which represented €5.8 million of other income for the year ended December 31, 2016 compared to €5.3 million for the year ended December 31, 2015

 

    Tax rebates on payroll withholding taxes of R&D personnel in Belgium and the Netherlands, representing €3.8 million of other income for the year ended December 31, 2016 compared to €3.0 million for the year ended December 31, 2015

R&D Expenditure

The following table summarizes our R&D expenditure for the years ended December 31, 2016 and 2015, together with the changes to those items.

 

     Year ended December 31,         
     2016      2015      % Change  
     (Euro, in thousands)         

Personnel costs

   (42,315    (35,875      18

Subcontracting

     (65,649      (65,883      (0 %) 

Disposables and lab fees and premises costs

     (20,414      (18,696      9

Other operating expenses

     (11,196      (9,260      21
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (139,573    (129,714      8
  

 

 

    

 

 

    

 

 

 

 

110


Table of Contents

R&D expenditure increased by €9.9 million, or 8%, to €139.6 million for the year ended December 31, 2016, from €129.7 million for the year ended December 31, 2015. This increase was principally due to:

 

    Increased R&D personnel costs of €6.4 million, or 18%, from €35.9 million for the year ended December 31, 2015 to €42.3 million for the year ended December 31, 2016, which was explained by an enlarged workforce, higher warrant costs and a higher liability for short term and long term management bonus, mainly as a result of the increase of our share price change relative to the Next Biotech Index on Euronext.

 

    Subcontracting costs were relatively stable and decreased slightly by €0.2 million, or 0.4%, from €65.9 million for the year ended December 31, 2015 to €65.6 million for the year ended December 31, 2016.

 

    Intensified use of lab consumables was the main driver of the increase in disposables, lab fees and premises costs of €1.7 million, or 9%, from €18.7 million for the year ended December 31, 2015 to €20.4 million for the year ended December 31, 2016.

 

    Other operating expenses increased by €1.9 million, or 21%, from €9.3 million for the year ended December 31, 2015 to €11.2 million for the year ended December 31, 2016, primarily due to an increase in depreciation of €1.0 million.

The table below summarizes our R&D expenditure for the years ended December 31, 2016 and 2015, broken down by R&D expenses under alliance and own funded R&D expenses. All filgotinib costs (both costs incurred in the period under alliance (with AbbVie) and costs incurred after AbbVie’s opt-out decision in September 2015) are presented as “R&D under alliance” or as “partnered” in the tables in this section for the year ended December 31, 2015, as a new alliance was signed in December 2015 with Gilead for this program.

 

     Year ended December 31,         
     2016      2015      % Change  
     (Euro, in thousands)         

R&D under alliance

   (71,980    (80,832      (11 %) 

Galapagos funded R&D

     (67,593      (48,882      38
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (139,573    (129,714      8
  

 

 

    

 

 

    

 

 

 

We track all R&D expenditures against detailed budgets and allocated them by individual project. The table below summarizes our R&D expenditure for the years ended December 31, 2016 and 2015, broken down by program.

     Year ended December 31,         
     2016      2015      % Change  
     (Euro, in thousands)         

Filgotinib program (partnered)

   (22,376    (35,404      (37 %) 

CF program (partnered)

     (31,203      (25,634      22

IPF program on GLPG1690 (proprietary)

     (7,129      (4,612      55

OA program on GLPG1972 (partnered)

     (6,538      (5,832      12

AtD program on MOR106 (partnered)

     (3,491      (4,651      (25 %) 

Other

     (68,836      (53,582      28
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (139,573    (129,714      8
  

 

 

    

 

 

    

 

 

 

R&D expenditure under alliance decreased by €8.9 million, or 11%, from €80.8 million for the year ended December 31, 2015 to €72.0 million for the year ended December 31, 2016, mainly due to our RA and IBD program on filgotinib (partnered with AbbVie in 2015 and partnered with Gilead in 2016), which has been

 

111


Table of Contents

partially offset by increased R&D spending on our CF program in collaboration with AbbVie. We increased our investments in our own funded portfolio by €18.7 million, or 38%, from €48.9 million for the year ended December 31, 2015 to €67.6 million for the year ended December 31, 2016, primarily because of intensified research investments in our proprietary programs on inflammation, HBV and fibrosis, as well as increased spending on our proprietary IPF program GLPG1690.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the years ended December 31, 2016 and 2015, together with the changes to those items.

 

     Year ended December 31,         
     2016      2015      % Change  
     (Euro, in thousands)         

Personnel costs and directors fees

   (15,160    (12,739      19

Other operating expenses

     (6,584      (6,388      3
  

 

 

    

 

 

    

 

 

 

Total general and administrative expenses

   (21,744    (19,127      14
  

 

 

    

 

 

    

 

 

 

General and administrative expenses amounted to €19.1 million for the year ended December 31, 2015 and increased by €2.6 million, or 14%, to €21.7 million for the year ended December 31, 2016. This increase was principally due to directors fees, which increased by €2.7 million, or 116%, from €2.4 million for the year ended December 31, 2015 to €5.1 million for the year ended December 31, 2016, resulting from various effects, such as increased costs of share-based payments plans (our warrant plans) and increased liability for short and long term management bonus, mainly as a result of the increase of our share price change relative to the Next Biotech Index on Euronext.

Sales and Marketing Expenses

The following table summarizes our sales and marketing expenses for the years ended December 31, 2016 and 2015, together with the changes to those items.

 

     Year ended December 31,         
         2016              2015          % Change  
     (Euro, in thousands)         

Personnel costs

   (1,167    (785      49

Other operating expenses

     (618      (397      56
  

 

 

    

 

 

    

 

 

 

Total sales and marketing expenses

   (1,785    (1,182      51
  

 

 

    

 

 

    

 

 

 

Sales and marketing expenses increased by €0.6 million, or 51%, from €1.2 million for the year ended December 31, 2015 to €1.8 million for the year ended December 31, 2016.

Fair Value Re-measurement of Share Subscription Agreement

On December 16, 2015, Gilead Sciences, Inc. and Galapagos NV entered into a global collaboration for the development and commercialization of filgotinib, in the framework of which Gilead committed to an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos NV by subscribing to new shares at a price of €58 per share, including issuance premium. This agreement was effectively completed and entered into force on January 19, 2016 and the full payment was received.

In connection with the agreement, we recognized a deferred income and an offsetting short term financial asset (derivative) of €39 million upon signing of the share subscription agreement with Gilead as required under IAS 39.

 

112


Table of Contents

This financial asset initially reflected the share premium that Gilead committed to pay above our closing share price on the day of entering into the subscription agreement. Under IAS 39 the fair value of the financial asset is re-measured at year-end and again upon entering into force of the share subscription agreement on January 19, 2016, when the financial asset expired. Variations in fair value of the financial asset are recorded in the income statement.

The decrease in the fair value of the financial asset resulting from the increase in the Galapagos share price between signing of the subscription agreement and December 31, 2015 resulted in a negative, non-cash fair value charge of €30.6 million in the financial results. The subsequent increase in the fair value of the financial asset resulting from the decrease in our share price between January 1, 2016 and January 19, 2016 resulted in a positive non-cash gain of €57.5 million in the financial result of 2016.

On January 19, 2016, the value of the financial asset at maturity amounted to €65.9 million, reflecting the share premium that Gilead paid above our closing share price on the day of the capital increase. This amount was composed of (1) the initial measurement on the day of entering into the share subscription agreement for an amount of €39 million which was reported in deferred income and (2) the subsequent re-measurements of the financial asset, reported as financial result under IAS 39: €30.6 million fair value loss reported in the year 2015 and €57.5 million fair value gain reported in the first quarter of 2016, together a net fair value gain of €26.8 million. This financial asset expired on the effective date of the share subscription agreement and was derecognized through the share premium account.

Other Financial Income and Expense

The following table summarizes other financial income and expense for the years ended December 31, 2016 and 2015.

 

    Year ended December 31,        
        2016             2015         % Change  
    (Euro, in thousands)        

Other financial income:

     

Interest on bank deposit

  1,614     1,246       29

Effect of discounting long term R&D incentives receivables

    99       99       —    

Currency exchange gain

    8,150       636       1182

Other finance income

    87       7       1142
 

 

 

   

 

 

   

 

 

 

Total other financial income

    9,950       1,987       401
 

 

 

   

 

 

   

 

 

 

Other financial expenses:

     

Interest expenses

    (47     (46     2

Currency exchange loss

    (1,453     (1,310     11
 

 

 

   

 

 

   

 

 

 

Other finance charges

    (191     (182     5
 

 

 

   

 

 

   

 

 

 

Total other financial expense

    (1,692     (1,539     10
 

 

 

   

 

 

   

 

 

 

Total other net financial income

  8,257     448       1742
 

 

 

   

 

 

   

 

 

 

Other financial income increased significantly by €8.0 million, or 401%, from €2.0 million for the year ended December 31, 2015 to €10.0 million for the year ended December 31, 2016. The increase relates to an exchange gain of €4.8 million on deposits held in U.S. dollar and exchange gains of €2.0 million realized on milestone payments from AbbVie and Gilead in U.S. dollar. For more information on currency exchange fluctuations on our business, please see the section of this annual report titled “Item 11—Quantitative and Qualitative Disclosures About Market Risk—Foreign Exchange Risk.”

Other financial expenses increased by €0.2 million, or 10% from €1.5 million for the year ended December 31, 2015 to €1.7 million for the year ended December 31, 2016. Net exchange profit amounts to €6.7 million for the year ended December 31, 2016, compared to a loss of €0.7 million for the year ended December 31, 2015. Interest expenses are related to interests paid on financial lease.

 

113


Table of Contents

Tax

The following table summarizes our tax result for the years ended December 31, 2016 and 2015.

 

     Year ended December 31,  
         2016              2015      
     (Euro, in thousands)  

Current tax

   (466    (215

Deferred tax

     231        1,433  
  

 

 

    

 

 

 

Total taxes

   (235    1,218  
  

 

 

    

 

 

 

Current tax representing €0.5 million for the year ended December 31, 2016 and €0.2 million for the year ended December 31, 2015 was related to taxes for subsidiaries operating on cost plus basis.

Deferred tax income of €0.2 million for the year ended December 31, 2016 and of €1.4 million for the year ended December 31, 2015 related to subsidiaries working on a cost plus basis.

Comparison of Years Ended December 31, 2015 and 2014

The following table summarizes the results of our operations for the years ended December 31, 2015 and 2014, together with the changes to those items

 

     Year ended December 31,        
     2015     2014     % Change  
     (Euro, in thousands, except
share and per share data)
       

Revenues

   39,563     69,368       (43 %) 

Other income

     21,017       20,653       2
  

 

 

   

 

 

   

 

 

 

Total revenues and other income

     60,579       90,021       (33 %) 
  

 

 

   

 

 

   

 

 

 

Research and development expenditure

     (129,714     (111,110     17

General and administrative expenses

     (19,127     (13,875     38

Sales and marketing expenses

     (1,182     (992     19

Restructuring and integration costs

     —         (669     (100 %) 
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     (150,023     (126,646     18
  

 

 

   

 

 

   

 

 

 

Operating loss

     (89,444     (36,624     144
  

 

 

   

 

 

   

 

 

 

Fair value re-measurement of share subscription agreement

     (30,632    

Other financial income

     1,987       2,291       (13 %) 

Other financial expenses

     (1,539     (867     78
  

 

 

   

 

 

   

 

 

 

Loss before tax

     (119,627     (35,201     240
  

 

 

   

 

 

   

 

 

 

Income taxes

     1,218       (2,103     (158 %) 
  

 

 

   

 

 

   

 

 

 

Net loss from continuing operations

     (118,410     (37,303     217
  

 

 

   

 

 

   

 

 

 

Net income from discontinued operations

     —         70,514    
  

 

 

   

 

 

   

Net income / loss (-)

   (118,410   33,211    
  

 

 

   

 

 

   

Net income / loss (-) attributable to:

      

Owners of the parent

     (118,410     33,211    
  

 

 

   

 

 

   

Basic and diluted income / loss (-) per share

   (3.32   1.10    
  

 

 

   

 

 

   

Basic and diluted loss per share from continuing operations

   (3.32   (1.24  

Weighted average number of shares (in ‘000 shares)

     35,700       30,108    

 

114


Table of Contents

Revenues

 

     Year ended December 31,         
         2015              2014          % Change  
     (Euro, in thousands)         

Recognition of non-refundable upfront payments

   26,419      45,838        (42 %) 

Milestone payments

     3,835        19,039        (80 %) 

Reimbursement income

     3,807        729        422

Other revenues

     5,501        3,762        46
  

 

 

    

 

 

    

 

 

 

Total revenues

   39,563      69,368        (43 %) 
  

 

 

    

 

 

    

 

 

 

Total revenues decreased by €29.8 million, or 43%, to €39.6 million for the year ended December 31, 2015, from €69.4 million for the year ended December 31, 2014. This decrease was mainly driven by lower recognition of non-refundable upfront payments and reduced milestone payments, as explained below.

Revenue from non-refundable upfront payments related to the deferred recognition of upfront payments received under the agreements with AbbVie, amounting to €111.6 million in 2012 and €49.6 million in 2013, which were amortized over a period ranging from 21 to 42 months, based on the estimated period of our involvement.

At inception and as of December 31, 2012, the period of involvement was estimated at 30 months starting in March 2012. As from April 2013 and as of December 31, 2013, we changed the estimate of our period of involvement to 34 months due to delays that occurred in clinical trials and changed our recognition of the remaining unrecognized upfront payments accordingly. As of June 30, 2014 and December 31, 2014, we changed the estimate of our period of involvement from 34 months to 39 months and 40 months, respectively, due to additional delays and changed our recognition of the remaining unrecognized upfront payments accordingly. As of June 30, 2015, we changed the estimate of our period of involvement from 40 months to 42 months, due to additional delays and changed our recognition of the remaining unrecognized upfront payments accordingly.

Milestone revenues and costs reimbursements decreased by €12.1 million, or 61%, to €7.6 million for the year ended December 31, 2015 compared to €19.8 million for the year ended December 31, 2014. This decrease was primarily related to fewer milestones achieved in 2015 compared to 2014 as a result of the increasing proprietary nature of our pipeline programs. For the year ended December 31, 2015, €2.2 million and €1.2 million of costs were reimbursed in relation with the CF and filgotinib collaboration agreements with AbbVie, respectively, and €3.8 million of milestones related to partnered programs with Servier were recognized. For the year ended December 31, 2014, €8.3 million of milestones were recognized in relation with the CF collaboration agreement with AbbVie and €11.5 million of milestones primarily related to partnered programs with Janssen Pharmaceutica, Servier and GSK.

Other revenues increased by €1.7 million, or 46%, to €5.5 million for the year ended December 31, 2015 compared to €3.8 million for the year ended December 31, 2014, principally due to higher revenues from fee-for-service activities.

Other Income

The following table summarizes our other income for the years ended December 31, 2015 and 2014, together with the changes to those items.

 

     Year ended December 31,         
         2015              2014          % Change  
     (Euro, in thousands)         

Grant income

   3,095      5,646        (45 %) 

Other income

     17,922        15,008        19
  

 

 

    

 

 

    

 

 

 

Total other income

   21,017      20,653        2
  

 

 

    

 

 

    

 

 

 

 

115


Table of Contents

Total other income was composed of grant income and other income and increased by €0.4 million, or 2%, from €20.7 million for the year ended December 31, 2014 to €21.0 million for the year ended December 31, 2015.

Grant income decreased by €2.6 million, or 45%, from €5.6 million for the year ended December 31, 2014 to €3.1 million for the year ended December 31, 2015. The majority of this grant income was related to grants from a Flemish agency, representing approximately 94% of all reported grant income in both years. In many cases these carry clauses require us to maintain a presence in the same region for a number of years and invest according to pre-agreed budgets.

The decrease in grant income was compensated by an increase in other income of €2.9 million, or 19%, from €15.0 million for the year ended December 31, 2014 to €17.9 million for the year ended December 31, 2015. Other income was primarily composed of:

 

    Income from an innovation incentive system of the French government, which represented €8.7 million of other income for the year ended December 31, 2015 compared to €7.8 million for the year ended December 31, 2014

 

    Income from Belgian R&D incentives with regard to incurred R&D expenses, which represented €5.3 million of other income for the year ended December 31, 2015 compared to €4.3 million for the year ended December 31, 2014

 

    Tax rebates on payroll withholding taxes of R&D personnel in Belgium and the Netherlands, representing €3.0 million of other income for the year ended December 31, 2015 compared to €2.4 million for the year ended December 31, 2014

R&D Expenditure

The following table summarizes our R&D expenditure for the years ended December 31, 2015 and 2014, together with the changes to those items.

 

     Year ended December 31,         
     2015      2014      % Change  
     (Euro, in thousands)         

Personnel costs

   (35,875    (31,038      16

Subcontracting

     (65,883      (54,293      21

Disposables and lab fees and premises costs

     (18,696      (16,830      11

Other operating expenses

     (9,260      (8,949      (3 %) 
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (129,714    (111,110      17
  

 

 

    

 

 

    

 

 

 

R&D expenditure increased by €18.6 million, or 17%, to €129.7 million for the year ended December 31 2015, from €111.1 million for the year ended December 31, 2014. This increase was principally due to:

 

    Increased R&D personnel costs of €4.8 million, or 16%, from €31.0 million for the year ended December 31, 2014 to €35.9 million for the year ended December 31, 2015, which was explained by an enlarged workforce, higher warrant costs and a higher liability for short-term and long-term management bonus, mainly as a result of the increase of our share price change relative to the Next Biotech Index on Euronext. Increased subcontracting costs of €11.6 million, or 21%, from €54.3 million for the year ended December 31, 2014 to €65.9 million for the year ended December 31, 2015. This cost increase was mainly driven by increased subcontracting costs of €8.4 million for the CF collaboration with AbbVie and to a lesser extent by the increase of €4.2 million in subcontracting costs for our other partnered and internal programs.

 

116


Table of Contents
    Intensified use of lab consumables was the main driver of the increase in disposables, lab fees and premises costs of €1.9 million, or 11%, from €16.8 million for the year ended December 31, 2014 to €18.7 million for the year ended December 31, 2015.

 

    Other operating expenses slightly increased by €0.3 million, or 3%, from €8.9 million for the year ended December 31, 2014 to €9.3 million for the year ended December 31, 2015.

The table below summarizes our R&D expenditure for the years ended December 31, 2015 and 2014, broken down by R&D expenses under alliance and own funded R&D expenses. All filgotinib costs (both costs incurred in the period under alliance (with AbbVie) and costs incurred after AbbVie’s opt-out decision in September 2015) are presented as “R&D under alliance” or as “partnered” in the tables in this section for the year ended December 31, 2015, as a new alliance was signed in December 2015 with Gilead for this program.

 

     Year ended December 31,         
     2015      2014      % Change  
     (Euro, in thousands)         

R&D under alliance

   (80,832    (76,297      6

Galapagos funded R&D

     (48,882      (34,813      40
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (129,714    (111,110      17
  

 

 

    

 

 

    

 

 

 

We track all R&D expenditures against detailed budgets and allocated them by individual project. The table below summarizes our R&D expenditure for the years ended December 31, 2015 and 2014, broken down by program.

 

     Year ended December 31,         
     2015      2014      % Change  
     (Euro, in thousands)         

RA program on filgotinib with AbbVie

   (30,998    (30,437      2

IBD program on filgotinib with AbbVie

     (4,406      (3,406      29

IBD program on GLPG1205

     (5,769      (6,020      (4 %) 

CF program with AbbVie

     (25,634      (14,894      72

Pulmonary program on GLPG1690

     (4,612      (4,592      0

Other

     (58,295      (51,762      (13 %) 
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (129,714    (111,110      17
  

 

 

    

 

 

    

 

 

 

R&D expenditure under alliance increased by €4.5 million, or 6%, from €76.3 million for year ended December 31, 2014 to €80.8 million for the year ended December 31, 2015, mainly due to our CF program in collaboration with AbbVie. We also increased our investments in our own funded portfolio by €14.1 million, or 40%, from €34.8 million for the year ended December 31, 2014 to €48.9 million for the year ended December 31, 2015, primarily because GLPG1205 and GLPG1690 programs became own funded.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the years ended December 31, 2015 and 2014, together with the changes to those items.

 

     Year ended December 31,         
     2015      2014      % Change  
     (Euro, in thousands)         

Personnel costs and directors fees

   (12,739    (8,087      58

Other operating expenses

     (6,388      (5,788      10
  

 

 

    

 

 

    

 

 

 

Total general and administrative expenses

   (19,127    (13,875      38
  

 

 

    

 

 

    

 

 

 

 

117


Table of Contents

General and administrative expenses amounted to €13.9 million for the year ended December 31, 2014 and increased by €5.2 million, or 38%, to €19.1 million for the year ended December 31, 2015. This increase was principally due to personnel costs and directors fees, which increased by €4.6 million, or 58%, from €8.1 million for the year ended December 31, 2014 to €12.7 million for the year ended December 31, 2015, resulting from various effects, such as increased costs of share-based payments plans (warrant plans) and increased liability for short- and long-term management bonus, mainly as a result of the increase of our share price change relative to the Next Biotech Index on Euronext. In addition, other operating expenses increased by €0.6 million, or 10%, from €5.8 million for the year ended December 31, 2014 to €6.4 million for the year ended December 31, 2015, mainly due to higher professional fees.

Sales and Marketing Expenses

The following table summarizes our sales and marketing expenses for the years ended December 31, 2015 and 2014, together with the changes to those items.

 

     Year ended December 31,         
         2015              2014          % Change  
     (Euro, in thousands)         

Personnel costs

   (785    (579      36

Other operating expenses

     (397      (412      (4 %) 
  

 

 

    

 

 

    

 

 

 

Total sales and marketing expenses

   (1,182    (992      19
  

 

 

    

 

 

    

 

 

 

Sales and marketing expenses increased by €0.2 million, or 19%, from €1.0 million for the year ended December 31, 2014 to €1.2 million for the year ended December 31, 2015.

Restructuring and Integration Costs

The restructuring and integration costs amounted to €0.7 million for the year ended December 31, 2014 and were entirely related to workforce reductions within certain of the R&D operations.

Fair Value Re-measurement of Share Subscription Agreement

On December 16, 2015, we entered into a global collaboration for the development and commercialization of filgotinib with Gilead, in the framework of which Gilead committed to an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in our company by subscribing to new shares at a price of €58 per share, including issuance premium. This agreement was effectively completed and entered into force on January 19, 2016 and the full payment was received.

In connection with the agreement, we recognized a deferred income and an offsetting short-term financial asset (derivative) of €39 million upon signing of the share subscription agreement with Gilead as required under IAS 39. This financial asset initially reflects the share premium that Gilead committed to pay above our closing share price on the day of entering into the subscription agreement. Under IAS 39 the fair value of the financial asset is re-measured at year-end and again upon entering into force of the share subscription agreement on January 19, 2016, when the financial asset expired. Variations in fair value of the financial asset are recorded in the income statement included in our consolidated financial statements appended to this annual report.

The decrease in the fair value of the financial asset resulting from the increase in our share price between signing of the subscription agreement and December 31, 2015 resulted in a negative, non-cash adjustment fair value charge of €30.6 million in the financial results. The subsequent increase in the fair value of the financial asset resulting from the decrease in our share price between January 1, 2016 and January 19, 2016 will result in a positive non-cash gain of €57.5 million in the financial result of the first quarter of 2016.

 

118


Table of Contents

Other Financial Income and Expense

The following table summarizes other financial income and expense for the years ended December 31, 2015 and 2014.

 

     Year ended December 31,         
         2015              2014          % Change  
     (Euro, in thousands)         

Other financial income:

        

Interest on bank deposit

   1,246      1,155        8

Effect of discounting long term R&D incentives receivables

     99        920        (89 %) 

Currency exchange gain

     636        198        221

Other finance income

     7        17        (59 %) 
  

 

 

    

 

 

    

 

 

 

Total other financial income

     1,987        2,291        (13 %) 
  

 

 

    

 

 

    

 

 

 

Other financial expenses:

        

Interest expenses

     (46      (110      (58 %) 

Currency exchange loss

     (1,310      (652      101

Other finance charges

     (182      (105      73
  

 

 

    

 

 

    

 

 

 

Total other financial expense

     (1,539      (867      77
  

 

 

    

 

 

    

 

 

 

Total other net financial income

   448      1,424        (69 %) 
  

 

 

    

 

 

    

 

 

 

Other financial income decreased slightly by €0.3 million, or 13%, from €2.3 million for the year ended December 31, 2014 to €2.0 million for the year ended December 31, 2015. The €0.8 million decrease in the effect of discounting long-term R&D incentives receivables was partly compensated by a €0.4 million increase in currency exchange gains. For more information on currency exchange fluctuations on our business, please see the section of this annual report titled “Item 11—Quantitative and Qualitative Disclosures About Market Risk—Foreign Exchange Risk.”

Other financial expense increased by €0.6 million, or 77%, from €0.9 million for the year ended December 31, 2014 to €1.5 million for the year ended December 31, 2015. Net exchange loss amounts to €0.7 million for the year ended December 31, 2015, as compared to €0.5 million for the year ended December 31, 2014. Interest expenses are related to interests paid on financial lease.

Tax

The following table summarizes our tax result for the years ended December 31, 2015 and 2014.

 

     Year ended December 31,  
         2015              2014      
     (Euro, in thousands)  

Current tax

   (215    (2,396

Deferred tax

     1,433        293  
  

 

 

    

 

 

 

Total taxes

   1,218      (2,103
  

 

 

    

 

 

 

Current tax representing €0.2 million for the year ended December 31, 2015 was related to taxes for subsidiaries operating on cost plus basis.

Current tax recorded in 2014 for an amount of €2.4 million related to a tax provision for subsidiaries operating under cost plus transfer pricing arrangements, triggered by a tax audit.

 

119


Table of Contents

Deferred tax income of €1.4 million for the year ended December 31, 2015 and €0.3 million for the year ended December 31, 2014 both related to subsidiaries working on a cost plus basis.

Results from Discontinued Operations

The following table summarizes the results from discontinued operations for the years ended December 31, 2015 and 2014.

 

     Year Ended December 31,  
             2015                      2014          
     (Euro, in thousands, except
share and per share data)
 

Service revenues

     —        17,502  

Other income

     —          669  
  

 

 

    

 

 

 

Total revenues and other income

     —          18,171  
  

 

 

    

 

 

 

Services cost of sales

     —          (11,283

General and administrative expenses

     —          (3,772

Sales and marketing expenses

     —          (255

Restructuring and integration costs

     —          (38

Loss on divestment

     —          —    

Gain on sale of service division

     —          67,508  
  

 

 

    

 

 

 

Operating income

     —          70,331  
  

 

 

    

 

 

 

Finance income / expense (-)

     —          417  
  

 

 

    

 

 

 

Income before tax

     —          70,748  
  

 

 

    

 

 

 

Income taxes

     —          (234
  

 

 

    

 

 

 

Net income from discontinued operations

     —        70,514  
  

 

 

    

 

 

 

Basic and diluted income per share from discontinued operations

     —        2.34  
  

 

 

    

 

 

 

Weighted average number of shares (in ‘000 shares)

     —          30,108  

The service division was sold on April 1, 2014. The above table illustrates the results of the discontinued operations included in the consolidated results of operations for the years ended December 31, 2015 and 2014. For the year ended December 31, 2014, results only relate to the period from January 1, 2014 through the disposal on April 1, 2014.

Net income amounting to €70.5 million in 2014 was mainly driven by the €67.5 million gain on disposal of the service division.

 

B. Liquidity and Capital Resources

To date, we have incurred significant operating losses. We have funded our operations through public and private placements of equity securities, upfront and milestone payments received from pharmaceutical partners under our collaboration and alliance agreements, payments under our fee-for-service contracts, funding from governmental bodies, interest income as well as the net proceeds from the sale of our service division. Our cash flows may fluctuate and are difficult to forecast and will depend on many factors. As at December 31, 2016, our cash and cash equivalents amounted to €973.2 million. For more information on our policies regarding financial instruments, please see “Note 2—Significant accounting policies—Financial instruments” included in our consolidated financial statements appended to this annual report.

 

120


Table of Contents

Cash Flows

Comparison for the Years Ended December 31, 2016 and 2015

The following table summarizes the results of our consolidated audited statement of cash flows for the years ended December 31, 2016 and 2015.

 

     2016     2015     Variance  
     (Euro, in thousands)        

Cash and cash equivalents at beginning of the period

   340,314     187,712     152,601  
  

 

 

   

 

 

   

 

 

 

Net cash flows generated / used (-) in operating activities

     239,403       (114,590     353,993  

Net cash flows used in investing activities

     (7,287     (4,297     (2,990

Net cash flows generated in financing activities

     395,996       271,370       124,626  

Effect of exchange rate differences on cash and cash equivalents

     4,816       118       4,697  
  

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of the period

   973,241     340,314     632,927  
  

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at December 31, 2016 amounted to €973.2 million.

Net cash outflow from operating activities decreased by €354.0 million to a €239.4 million inflow for the year ended December 31, 2016 compared to a €114.6 million outflow for the year ended December 31, 2015. This net cash inflow from operations recorded in 2016 was primarily due to the license fee of $300 million (€275.6 million) received from Gilead in relation with our collaboration agreement on filgotinib. In addition, milestone payments increased substantially in 2016 compared to 2015, which contributed significantly to the net cash inflow from operations in 2016.

The net cash outflow from investing activities increased by €3.0 million to €7.3 million net cash outflow for the year ended December 31, 2016 compared to €4.3 million net cash outflow for the year ended December 31, 2015, which was principally related to an acquisition of available-for-sale financial assets, as well as a lower decrease in restricted cash compared to previous year. Restricted cash amounted to €7.9 million for the year ended December 31, 2015, and decreased to €7.7 million for the year ended December 31, 2016. This decrease is related to a payment of a claim to Charles River by decrease of the escrow account for €0.3 million, which has been slightly offset by an increase in non-current restricted cash of €0.1 million related to an increase in the bank guarantee with regard to the rental of additional office space for the Belgian premises.

The net cash inflow from financing activities increased by €124.6 million, from €271.4 million net cash inflow for the year ended December 31, 2015 to €396.0 million net cash inflow for the year ended December 31, 2016. The net cash inflow in 2016 can mainly be attributed to the subscription on Galapagos shares by Gilead on January 19, 2016 for which the cash proceeds from capital and share premium increases amounted to €391.9 million, net of issue costs. The net cash inflow in 2015 can primarily be attributed to €259.4 million of net new funds from the global offering and concurrent listing on the NASDAQ Global Select Market on May 19, 2015. In addition, proceeds received on exercise of warrants contributed to cash generated by financing activities in 2016 for €4.3 million and to a greater extent for €12.0 million in 2015.

 

121


Table of Contents

Comparison of Years Ended December 31, 2015 and 2014

The following table summarizes the results of our consolidated statement of cash flows for the years ended December 31, 2015 and 2014.

 

     2015     2014     Variance  
     (Euro, in thousands)        

Cash and cash equivalents at beginning of the period

   187,712     138,175     49,538  
  

 

 

   

 

 

   

 

 

 

Net cash flows used in operating activities

     (114,590     (75,555     (39,035

Net cash flows generated / used (-) in investing activities

     (4,297     120,606       (124,904

Net cash flows generated in financing activities

     271,370       4,214       267,156  

Effect of exchange rate differences on cash and cash equivalents

     118       271       (153
  

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of the period

   340,314     187,712     152,601  
  

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at December 31, 2015 amounted to €340.3 million.

Net cash outflow from operating activities increased by €39.0 million to a €114.6 million outflow for the year ended December 31, 2015 compared to a €75.6 million outflow for the year ended December 31, 2014. The higher cash burn from operations recorded in 2015 was primarily explained by increased R&D investments, €15.9 million less cash received from milestones and costs reimbursement, of which mainly €5.9 million in alliance related receivables for which revenues were recorded in 2013 and for which payment came in the first half of 2014.

The net cash inflow from investing activities decreased by €124.9 million to €4.3 million net cash outflow for the year ended December 31, 2015 compared to €120.6 million net cash inflow for the year ended December 31, 2014, which reflected €130.8 million of net cash and cash equivalents proceeds from the sale of the service operations to Charles River on April 1, 2014 (€129 million headline consideration adjusted with agreed price adjustments and costs of the sale for a total amount of €1.9 million), decreased by €7.4 million held as escrow account and presented as restricted cash in our statement of financial position. Restricted cash amounted to €10.7 million for the year ended December 31, 2014, and decreased to €7.9 million for the year ended December 31, 2015. This decrease is related to (i) the release of the €3 million bank guarantee issued in 2013 for the rental of the new premises in France which expired on June 30, 2015 following the move to the new offices, (ii) the payment of a claim to Charles River by decrease of the escrow account, and (iii) a €0.7 million bank guarantee issued in September 2015 for the rental of new premises in the Netherlands (to replace the current premises) which will expire on October 1, 2025.

The net cash inflow from financing activities have increased by €267.2 million, from €4.2 million net cash inflow for the year ended December 31, 2014, to €271.4 million net cash inflow for the year ended December 31, 2015. The substantial net cash inflow in 2015 can primarily be attributed to €259.4 million of net new funds from the recent global offering and concurrent listing on the NASDAQ Global Select Market on May 19, 2015. In addition, proceeds received on exercise of warrants contributed to cash generated by financing activities in 2015 for €12.0 million and to a lesser extent for €4.4 million in 2014.

The consolidated cash flow table above included both continuing and discontinued operations. The table below summarizes our statement of cash flows from discontinued operations included in the table above for the years ended December 31, 2015 and 2014.

 

     Year ended December 31,        
         2015              2014         Variance  
     (Euro, in thousands)        

Net cash flows used in operating activities

   —        (1,722   1,722  

Net cash flows generated in investing activities

     —          122,580       (122,580

Net cash flows generated/ used (-) in financing activities

     —          —         —    
  

 

 

    

 

 

   

 

 

 

Net cash generated

   —        120,858     (120,858
  

 

 

    

 

 

   

 

 

 

 

122


Table of Contents

Cash and Funding Sources

The table below summarizes our sources of financing, excluding warrant exercises, for the years ended December 31, 2016, 2015 and 2014.

 

     Private placement  
     (Euro, in thousands)  

2014

   —    

2015

     259,343  

2016

     391,852  
  

 

 

 

Total sources of financing

   651,195  
  

 

 

 

On May 19, 2015, we completed a global offering of 7,532,499 ordinary shares, a concurrent public offering in the United States and private placement in Europe, in which framework we offered 5,746,000 ordinary shares through a public offering in the United States in the form of ADSs, at a price of $42.05 per ADS, before underwriting discounts and 1,786,499 ordinary shares through a European private placement at a price of €37.00 per share, before underwriting discounts. The ADSs were evidenced by American Depositary Receipts, and each ADS represents the right to receive one ordinary share. The ADSs are listed on the NASDAQ Global Select Market under the symbol “GLPG”. We received €278.7 million of gross proceeds from the global offering, decreased by €19.4 million of underwriter discounts and commission, and offering expenses, of which €19.3 million has been paid at December 31, 2015 and €0.1 million (remainder) has been settled at December 31, 2016. Total net cash proceeds from the global offering amounted to €259.3 million. On January 19, 2016, Gilead made a $425 million equity investment in Galapagos NV by subscribing to 6,760,701 new ordinary shares at a price of €58 per share, including issuance premium. Galapagos received €392.1 million of gross proceeds, decreased by €0.26 million of expenses, of which all has been paid at December 31, 2016. The total net cash proceeds from the share subscription by Gilead amounts to €391.9 million. The €65.9 million current financial asset from the share subscription agreement reflecting the premium that Gilead paid compared to the closing price of our shares on January 19, 2016 was derecognized through the share premium account.

As of December 31, 2016, we had no long-term debt, other than finance leases and advances from Oseo, a French public organization for innovation support, for €0.1 million.

Our ongoing financial commitments are listed in the section of this annual report titled “Item 5.F.—Tabular Disclosure of Contractual Obligations” and mainly consist of operating lease obligations and purchase commitments.

Payment of Dividends by Subsidiaries

The amount of dividends payable by our subsidiaries to us is subject to, among other restrictions, general limitations imposed by the corporate laws, capital transfer restrictions and exchange control restrictions of the respective jurisdictions where those subsidiaries are organized and operate.

Of our cash and cash equivalents held outside of Belgium as of December 31, 2016 and 2015, the amount of cash that would have been subject to withholding taxes if transferred to us by way of dividends and the amount of cash that could not have been transferred by law was in each case immaterial.

Funding Requirements

Based on conservative assumptions, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements at least through the next two to three years. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.

 

123


Table of Contents

Our present and future funding requirements will depend on many factors, including, among other things:

 

    the terms and timing of milestones, in-licensing payments and expense reimbursement payments, if any, from our collaboration and alliance agreements;

 

    the progress, timing, scope and costs of pre-clinical testing and clinical trials for any current or future compounds;

 

    the number and characteristics of potential new compounds we identify and decide to develop;

 

    our need to expand our development activities and, potentially, our research activities;

 

    the costs involved in filing patent applications and maintaining and enforcing patents;

 

    the cost, timing and outcomes of regulatory approvals;

 

    selling and marketing activities undertaken in connection with the anticipated commercialization of any of our current or future compounds; and

 

    the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our products.

We may raise additional capital through the sale of equity or convertible debt securities. In such an event, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of the ADSs or our ordinary shares.

For more information as to the risks associated with our future funding needs, see the section of this annual report titled “Item 3.D.—Risk Factors—Risks Related to Our Financial Position and Need for Additional Capital.”

Capital Expenditures

Our commitments for capital expenditures as of December 31, 2016 amount to €0.3 million.

Our capital expenditures amounted to €4.8 million, €6.7 million and €2.8 million for the years ended December 31, 2016, 2015 and 2014 respectively.

In 2016, our capital expenditures were primarily related to laboratory equipment for €3.3 million, €0.6 million for other tangible fixed assets and €0.3 million of intangible assets primarily related to software development.

In 2015, our capital expenditures were primarily related to laboratory equipment for €2.2 million, leasehold improvements mainly for our new building in Leiden (The Netherlands) for €2.2 million, €1.7 million for other tangible fixed assets and €0.6 million of intangible assets primarily related to software development.

In 2014, we invested €1.2 million in laboratory equipment, €0.9 million in other tangible assets and €0.7 million in intangible assets primarily related to software development.

 

C. Research and Development

For a discussion of our R&D activities, see “Item 4.B.—Business Overview” and “Item 5.A.—Operating Results.”

 

D. Trend Information

Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2016 to December 31, 2016 that are reasonably likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial conditions. For a discussion of trends, see “Item 4.B.—Business Overview,” “Item 5.A.—Operating Results,” and “Item 5.B.—Liquidity and Capital Resources.”

 

124


Table of Contents
E. Off-Balance Sheet Arrangements

During the periods presented, we did not and do not currently have any off-balance sheet arrangements as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.

Contingent Liabilities and Assets

On March 13, 2014, we announced the signing of a definitive agreement to sell the service division operations to Charles River Laboratories International, Inc., or CRL, for a total consideration of up to €134 million. CRL agreed to pay us an immediate cash consideration of €129 million. The potential earn-out of €5 million due upon achievement of a revenue target 12 months after transaction closing has not been obtained. Approximately 5% of the total consideration, including price adjustments, was being held on an escrow account. To date, four claims have been introduced by CRL, which have all been settled for a total amount of €1.3 million. On January 17, 2017 an amount of €4.1 million was released from the escrow account. The release of the remaining balance of the escrow account will be possible after final agreement between the parties on the amounts at stake.

Following the divestment, we remained guarantor until early February 2017 in respect of the lease obligations for certain U.K. premises amounting to £3 million future rent payments. CRL shall fully indemnify us against all liabilities arising in connection with the lease obligations. We evaluated the risk to be remote. Finally, following common practice, we have given customary representations and warranties which are capped and limited in time (since April 1, 2016, CRL can only introduce a claim covered by the Tax Deed (during a period of 5 years), other claims related to the sale cannot be submitted anymore).

In the course of 2008, a former director of one of the subsidiaries sued for wrongful termination and seeks damages of €1.5 million. We believe that the amount of damages claimed is unrealistically high. In 2014, the court requested an external advisor to evaluate the exact amount of damages. On January 29, 2016, the court made a 1st degree judgment, dismissing all claims in full. In appeal, the 2nd degree court instructed the 1st degree court to conduct a new trial, which is currently pending. So far, no hearings have been scheduled and no decisions have been made. Considering the defense elements provided, as well as the fact that so far the court has made no decision indicating that the claim would be sustained, our board and management evaluated the risk to be remote to possible, but not likely. Accordingly, it was decided not to record any provision in 2016 as the exposure was considered to be limited.

 

F. Tabular Disclosure of Contractual Obligations

We entered into lease agreements for office and laboratories which qualify as operating leases. We also have certain purchase commitments with contract research organization subcontractors principally. Future events could cause actual payments to differ from these estimates. On December 31, 2016, we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:

 

     Total      Less than
1 year
     1–3
years
     3–5
years
     More than 5
years
 
     (thousands of €)  

Operating lease obligations

   27,263      4,114      6,494      5,504      11,151  

Purchase commitments

     27,579        27,084        495        —          —    
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total contractual obligations & commitments

   54,842      31,198      6,989      5,504      11,151  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The table above does not include pension liabilities, non-current deferred income and other non-current liabilities.

We provide retirement benefit plans for all of our qualifying employees. We classify these benefits on the basis of the type of benefit provided and in particular as defined contribution plans, defined benefit obligations

 

125


Table of Contents

and other provisions for employees. At December 31, 2016 the liability for such obligations amounted to €3.5 million (€2.7 million at December 31, 2015). See note 29 to the consolidated financial statements.

Non-current deferred income amounted to €214.8 million at December 31, 2016 (nil at December 31, 2015) and related to the recognition of a deferred income upon signing of the share subscription agreement with Gilead, as well as an upfront payment from Gilead for an amount of $300 million that we received in January 2016. See note 24 to the consolidated financial statements.

Other non-current liabilities amounted to €2.5 million at December 31, 2016 (€2.3 million at December 31, 2015) and primarily related to deferred management bonuses. The executive committee members, together with other senior managers, are eligible to receive bonuses under the Senior Management Bonus Scheme. Pursuant to the rules of the Senior Management Bonus Scheme, 50% of the bonus is paid immediately around year-end and the payment of the remaining 50% is deferred for three years. The deferred 50% component is dependent on the Galapagos share price change relative to the Next Biotech Index (which tracks Euronext-listed biotech companies). See notes 2 and 24 to the consolidated financial statements.

 

G. Safe Harbor.

This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and as defined in the Private Securities Litigation Reform Act of 1995. See “Special Note Regarding Forward-Looking Statements” at the beginning of this annual report.

 

Item 6 Directors, Senior Management and Employees.

 

A. Directors and Senior Management.

Our Board of Directors

We currently have eight directors, less than a majority of whom are citizens or residents of the United States.

Under our articles of association, our board of directors must be composed of between five and nine members, of which at least three are independent directors as defined by the Belgian Companies Code. Half of the members of our board of directors must be non-executive directors. Within these limits, the number of directors is determined by our shareholders. Directors are elected, re-elected and may be removed at a shareholders’ general meeting with a simple majority vote of our shareholders. Pursuant to our articles of association, our directors serve four-year terms.

The following table sets forth certain information with respect to the current members of our board of directors, including their ages, as of December 31, 2016:

 

Name

   Age      Date service
began in
current term
     Date of
expiration of
current term (1)
    

Position(s)

Onno van de Stolpe

     57        2013        2017      Director and Chief Executive Officer

Rajesh Parekh, MA, DPhil(2)

     56        2013        2017      Chairman of the board of directors

Harrold van Barlingen, Ph.D.(3)

     51        2014        2018      Director

Werner Cautreels, Ph.D.(2)(3)

     64        2014        2018      Director

Howard Rowe, JD(3)

     47        2014        2018      Director

Katrine Bosley(2)

     48        2013        2017      Director

Christine Mummery, Ph.D.

     63        2015        2019      Director

Mary Kerr, Ph.D.

     56        2016        2020     

Director

 

(1) The term of the mandates of the directors will expire immediately after the annual shareholders’ meeting held in the year set forth next to the director’s name.
(2) Member of the nomination and remuneration committee.
(3) Member of the audit committee.

 

126


Table of Contents

The address for our directors is Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.

Our board of directors has determined that seven out of eight of the members of the board are independent under the NASDAQ Stock Market listing requirements and that five out of eight of the members of the board of directors are independent under Belgian law.

The following is the biographical information of the members of our board of directors:

Onno van de Stolpe founded our company in 1999 and has served as our Chief Executive Officer and a member of our board of directors from 1999 to the present. From 1998 to 1999, he was the Managing Director of Genomics at IntroGene B.V. (later Crucell N.V., which was acquired by Johnson & Johnson Services, Inc. in 2011). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe B.V. He established this European headquarters after joining Molecular Probes, Inc. in the United States. Previously, he worked for The Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotechnology and medical device companies to locate in the Netherlands. Mr. Van de Stolpe started his career as Manager of Business Development at MOGEN International N.V. in Leiden. He received an MSc degree from Wageningen University. Mr. Van de Stolpe currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V.

Rajesh Parekh, MA, DPhil has served as the Chairman of our board of directors since 2004. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2005. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc.; Avila Therapeutics, Inc.; EUSA Pharma (Europe) Limited; Thiakis Limited; Biocartis NV; and Amsterdam Molecular Therapeutics (AMT) Holding N.V. (now uniQure). Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners; Advent Life Sciences LLP; Aleta Inc.; Arrakis, Inc.; Aura Inc.; Artax Inc.; Capella BioSciences Ltd.; Cellnovo Limited; Itara Ltd.; Levicept Limited; PE Limited; and Project Paradise Limited. He is also a member of the Supervisory Board of the Novartis Venture Fund. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he has also been a Senior Research Fellow and Professor.

Harrold van Barlingen, Ph.D. has served as a member of our board of directors since 2005. Dr. Van Barlingen is the managing director and founder of Thuja Capital B.V., Thuja Capital Holding B.V. and Thuja Capital Management B.V. Prior to founding Thuja Capital, he headed the life sciences effort of AlpInvest Partners B.V. from 2001 to 2006, managing a portfolio of over 30 companies. Previously, he was at the Boston Consulting Group, or BCG, where he worked as a consultant in management and strategy from 1999 to 2002. Prior to BCG, Dr. Van Barlingen headed the continental activities of The Lewin Group (a Quintiles subsidiary), an internationally active firm specialized in the field of health economics. He holds an MSc in Medical Biology and a PhD in Medicine, both from Utrecht University. From 1991 to 1992 he was a visiting scientist at the University of Chicago. He is the author of a wide variety of peer-reviewed scientific and pharmaco-economics papers. He currently serves on the supervisory boards of Encare Biotech B.V., TheraSolve NV, Indigo Diabetes NV (chairman) (chairman), and Hemics B.V. (chairman). In addition, during the last five years he also served on the boards of Okapi Sciences NV and arGEN-X N.V.

Werner Cautreels, Ph.D. has served as a member of our board of directors since 2009. Dr. Cautreels is the President, Chief Executive Officer and member of the board of Selecta Biosciences, Inc. Previously, Dr. Cautreels joined Solvay Pharmaceuticals SA in 1998 where he was Global Head of R&D and later Global Chief Executive Officer from 2005 onwards, until it was acquired by Abbott Laboratories Inc. in February 2010. Prior to joining Solvay he was employed by Sanofi S.A., Sterling Winthrop, Inc. and Nycomed Amersham PLC in a variety of R&D management positions in Europe and in the United States from 1979 to 1998. Dr. Cautreels was a director of Innogenetics NV and ArQule, Inc. from 1999 until 2006 and of Seres Therapeutics Inc. from

 

127


Table of Contents

2012 until 2016. He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He graduated from the University of Antwerp, with a Doctorate in Chemistry, specializing in mass spectrometry. He received his management and financial education from the Harvard Business School.

Howard Rowe, JD has served as a member of our board of directors since 2010. Mr. Rowe is Managing Director at Hayfin Capital Management LLP. Prior to joining Hayfin Capital Management, Mr. Rowe was a Managing Director with The Goldman Sachs Group, Inc. where he had multiple healthcare responsibilities over his 12 years at the firm. His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. During that time he served on the boards of EUSA Pharma (Europe) Limited, Healthcare Brands International Limited, SmallBone Innovations, Inc., MedAvante, Inc. and Ikonisys, Inc. Prior to his investing activities, Mr. Rowe was a senior member of the European Healthcare Investment Banking team, where he advised numerous corporate clients on M&A and corporate finance activities. Before joining Goldman Sachs, he was a corporate lawyer with the law firm Sullivan & Cromwell LLP. Mr. Rowe received his Bachelor of Science in Psychobiology from the University of Southern California and his JD from Harvard Law School.

Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley has served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. since June 2014. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012, Ms. Bosley was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. Ms. Bosley served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, Ms. Bosley was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners, Inc. Ms. Bosley graduated from Cornell University with a B.A. in Biology. Ms. Bosley currently serves as chairman of the board of Genocea Biosciences, Inc. and as a director of Scholar Rock, LLC. She also serves on the board of directors of the Biotechnology Innovation Organization and is a review committee member of the Wellcome Trust.

Christine Mummery, Ph.D. has served as a member of our board of directors since September 30, 2015. Dr. Mummery has served as a Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Centre (LUMC) since 2008 and a Professor of Vascular Modelling at the Technical University of Twente in the Netherlands since September 2015. In 2007, she was a Radcliffe fellow at the Harvard Stem Cell Institute and Massachusetts General Hospital when human-induced pluripotent stem cells were being developed, and she was the first to derive these from patients in the Netherlands. In 2002, she became a Professor at the Utrecht University Medical Centre in the Netherlands. She was a postdoctoral fellow from 1981 to 1984 at the Hubrecht Institute in Utrecht, where she later also served as a staff scientist and group leader until 2008. Dr. Mummery obtained her B.S. in Physics, Electronics, and Mathematics at the University of Nottingham and her Ph.D. in BioPhysics at London University in the United Kingdom. Her primary research focus is currently the development and use of stem cells in cardiovascular development and disease. She served on the Ethical Councils of the Dutch Ministry of Health, is member of the Royal Netherlands Academy of Arts and Sciences (KNAW), editor-in-chief of the Cell Press journal Stem Cell Reports, former board member of the International Society for Stem Cell Research and past-president of the International Society of Differentiation. She was co-founder of Pluriomics B.V. In addition, she is on the board of ZonMw (Dutch Medical Research Council) and chairs the executive board of the Institute for human Organ and Disease Model Technologies (hDMT), a non-profit R&D institute of which we are a founding partner. She is a review committee member of the European Research Council, the Wellcome Trust ( ad hoc ) and the Heineken Jury Prize (KNAW).

Mary Kerr, Ph.D. has served as a member of our board of directors since July 26, 2016. Dr. Kerr, a UK national, is Chief Executive Officer and director at NeRRe Therapeutics. Prior to her appointment at NeRRe,

 

128


Table of Contents

Dr. Kerr held a range of senior leadership roles at GSK over more than 20 years, most recently as Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. Dr. Kerr was a founding member and on the Corporate Executive team of ViiV Healthcare where she led a turnaround in the performance of the HIV business in Europe. She has spent the majority of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. Dr. Kerr gained a Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit and has an MBA from the University of Kingston.

Executive Committee

Our board of directors has established an executive committee in accordance with article 524bis of the Belgian Companies Code. The following table sets forth certain information with respect to the members of our executive committee as of December 31, 2016:

 

Name

   Age     

Position(s)

Onno van de Stolpe

     57      Chief Executive Officer

Piet Wigerinck, Ph.D.

     52      Chief Scientific Officer

Bart Filius, MBA

     46      Chief Financial Officer

Andre Hoekema, Ph.D.

     59      Senior Vice President Corporate Development

The address for the members of our executive committee is Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.

There is no potential conflict of interest between the private interests or other duties of the members of the executive committee listed above and their duties to us.

Below are the biographies of those members of our executive committee who do not also serve on our board of directors:

Piet Wigerinck, Ph.D. joined our company in April 2008 from Tibotec-Virco Comm. VA (a subsidiary of Johnson & Johnson Services, Inc.) where he was the Vice President, Drug Discovery, Early Development and CM&C, and a member of the Management Board. He started his professional career as a medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec Group NV in 1998, where, under his leadership, TMC114 (Prezista™) and TMC435 (Olysio™) were selected and moved forward into clinical trials. Dr. Wigerinck played a key role in Tibotec’s expansion into novel diseases such as Hepatitis C and advanced several compounds into Phase 1 and Phase 2 clinical trials. He brings over 25 years of R&D experience from both large pharmaceutical companies and biotechnology companies to our company. Dr. Wigerinck holds a Ph.D. from the K.U. Leuven and is inventor on more than 25 patent applications.

Bart Filius, MBA has served as our Chief Financial Officer since December 2014. Prior to that, Mr. Filius worked over 13 years at Sanofi S.A., where he was the Chief Financial Officer of Sanofi Europe during the last three years. Earlier at Sanofi, Mr. Filius was the Country Manager and Chief Financial Officer of Sanofi in the Netherlands. Before that, he was Vice President for Mergers & Acquisitions, during which time Mr. Filius led and completed the divestiture of various franchises. Prior to joining Sanofi, Bart was a strategy consultant at Arthur D. Little. Mr. Filius has an MBA degree from INSEAD and a bachelor’s degree in business from Nyenrode Business University.

Andre Hoekema, Ph.D. is responsible for M&A, licensing and Intellectual Property at Galapagos. He had the lead in rolling out our pharmaceutical alliance strategy since its start in 2006, and is the architect of our collaboration with AbbVie in CF. Dr. Hoekema joined Galapagos in March 2005 from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe, overseeing licensing and M&A for Invitrogen Europe. He brings 30 years of biotech experience from positions at Molecular Probes Europe B.V. (Managing Director of the European office), Crucell N.V. (Director of Business Development and Intellectual

 

129


Table of Contents

Property), Koninklijke DSM N.V., MOGEN International N.V. (Research and Project Management), and Genentech, Inc. (postdoctoral researcher). Dr. Hoekema studied Chemistry and holds a Ph.D. from Leiden University. During his Ph.D. work, he invented the binary vector system for the genetic modification of plants, which he published in Nature in 1983; this has since then become the global standard in the field of agricultural biotech. He is the author of more than 30 peer-reviewed scientific papers, and an inventor of over 20 series of patent applications, resulting in 15 patents issued in the United States. Dr. Hoekema currently also serves as a member of the supervisory board of Mimetas B.V. and has previously served as a member of the supervisory board of VitalNext B.V.

On March 1, 2017, Dr. Walid Abi-Saab joined our company as Chief Medical Officer and member of the executive committee.

The executive committee exercises the powers delegated to it by the board of directors, such powers not being related to the general strategy of the company or to other actions which are reserved for the board of directors according to legal requirements, articles of association or the corporate governance charter of the company.

The tasks of the executive committee include the following matters: the research, identification and development of strategic possibilities and proposals which may contribute to our company’s development in general, the drafting and development of policy guidelines to be approved by our board of directors, our company’s management through, among other things, the implementation of policy guidelines, the supervision of the performance of the business in comparison with the strategic goals, plans and budgets, and the support of the chief executive officer with the day-to-day management of our company.

Notwithstanding the above, and according to its “evocation right,” our board of directors retains the right to deliberate and decide on matters which have in principle been delegated to our executive committee, but for which our board of directors is of the opinion that they require deliberation at the board of directors’ level.

Family Relationships

There are no family relationships among any of the members of our executive committee or directors.

 

B. Compensation.

The aggregate compensation paid and benefits in kind granted by us to our current members of the executive committee and directors, excluding share-based compensation, for the year ended December 31, 2016, was €3,455,648.97. For the year ended December 31, 2016, the total amounts set aside or accrued to provide pension, retirement or similar benefits to our executive committee amounted to €227,554.91.

For a discussion of our employment arrangements with the members of our executive committee and consulting arrangement with our directors, see the section of this annual report titled “Item 7.B.—Related Party Transactions—Agreements with Our Directors and Members of Executive Committee.” For more information regarding warrant grants, see “—Warrant Plans” below.

Compensation of Our Board of Directors

The remuneration of our directors (other than our chief executive officer) and the grant of warrants to our directors is submitted by our board of directors for approval to the shareholders’ meeting and is only implemented after such approval. The procedure for establishing the remuneration policy and setting remuneration for members of our board of directors is determined by our board of directors on the basis of proposals from the nomination and remuneration committee, taking into account relevant benchmarks from the biotechnology industry.

 

130


Table of Contents

The annual shareholders’ meeting of April 26, 2016 determined, upon recommendation of the nomination and remuneration committee, that the compensation (excluding expenses) of the non-executive directors for the exercise of their mandate during the financial year ending December 31, 2016 is as follows: (i) Chairman of the Board (i.e. Raj Parekh): €80,000; (ii) other non-executive board members (i.e., Werner Cautreels, Harrold van Barlingen, Howard Rowe, Katrine Bosley and Christine Mummery): €40,000 each; (iii) annual additional compensation for membership of a board committee (audit committee: Harrold van Barlingen and Howard Rowe; nomination and remuneration committee: Werner Cautreels and Katrine Bosley): €5,000; (iv) annual additional compensation for the chairmanship of a board committee (audit committee: Werner Cautreels; nomination and remuneration committee: Rajesh Parekh): €10,000. The same annual shareholders’ meeting granted a power of attorney to our board of directors to determine the total remuneration package of our managing director (CEO) for his management function in Galapagos. The special shareholders’ meeting of July 26, 2016, which resolved upon the appointment of Mary Kerr as a non-executive director of Galapagos NV determined that the remuneration principles for the financial year ending on December 31, 2016 approved by the annual shareholders’ meeting of April 26, 2016 shall apply to determine the compensation (excluding expenses) of Ms. Kerr, pro rata temporis, for the period starting on the date of her appointment and ending on December 31, 2016. Directors representing a shareholder on the board of directors would only receive reimbursement of the expenses incurred for participating in the board of directors (there were no such directors in 2016, nor are there currently).

The remuneration of the non-executive directors does not contain a variable part; hence no performance criteria apply to the remuneration of the non-executive directors.

The following table sets forth the fees (excluding expenses) received by our non-executive directors for the performance of their mandate as a board member, during the year ended December 31, 2016:

 

Name

   Fees earned
(€)
 

Rajesh Parekh(1)

     69,736.53  

Harrold van Barlingen

     45,000  

Werner Cautreels

     55,000  

Howard Rowe

     45,000  

Christine Mummery

     40,000  

Katrine Bosley

     45,000  

Mary Kerr(2)

     17,282.31  

Total

     317,018.84  

 

(1) During the first four months of 2016, Dr. Parekh did not receive remuneration for his director’s mandate, but was compensated through a consultancy agreement with Parekh Enterprises only (consultancy fee of €20,263 in 2016).
(2) Mary Kerr joined our board of directors effective July 26, 2016.

In addition to the benefits set forth above, our non-executive directors also received benefits consisting of tax advisory services in 2016 for an amount of €14,495.

Our executive director, Onno van de Stolpe, does not receive any specific or additional remuneration for his service on our board of directors, as this is included in his total remuneration package in his capacity as member of our executive committee. For more information regarding Mr. Van de Stolpe’s compensation, see “—Compensation of Members of the Executive Committee” below.

 

131


Table of Contents

The table below provides an overview as of December 31, 2016 of the warrants held by the non-executive directors.

 

     Warrant award  

Name

   Number of ordinary
shares underlying
warrants
     Warrant exercise
price (€)
     Warrant
expiration
date
 

Rajesh Parekh

     5,400        19.38        5/15/2021  
     5,400        14.54        7/24/2022  
     5,400        28.75        4/29/2023  
     15,000        49.00        12/21/2023  
     15,000        46.10        5/31/2024  
  

 

 

       

Total

     46,200        
  

 

 

       

Harrold van Barlingen

     2,520        14.19        9/2/2020  
     2,520        19.38        5/15/2021  
     2,520        14.54        7/24/2022  
     2,520        28.75        4/29/2023  
     7,500        49.00        12/21/2023  
     7,500        46.10        5/31/2024  
  

 

 

       

Total

     25,080        
  

 

 

       

Werner Cautreels

     3,780        19.38        5/15/2021  
     3,780        14.54        7/24/2022  
     3,780        28.75        4/29/2023  
     7,500        49.00        12/21/2023  
     7,500        46.10        5/31/2024  
  

 

 

       

Total

     26,340        
  

 

 

       

Howard Rowe

     2,520        14.19        9/2/2020  
     2,520        19.38        5/15/2021  
     2,520        14.54        7/24/2022  
     2,520        28.75        4/29/2023  
     7,500        49.00        12/21/2023  
     7,500        46.10        5/31/2024  
  

 

 

       

Total

     25,080        
  

 

 

       

Katrine Bosley

     7,500        19.38        5/15/2021  
     2,520        14.54        7/24/2022  
     2,520        28.75        4/29/2023  
     7,500        49.00        12/21/2023  
     7,500        46.10        5/31/2024  
  

 

 

       

Total

     27,540        
  

 

 

       

Christine Mummery

     7,500        49.00        12/21/2023  
     7,500        46.10        5/31/2024  
  

 

 

       

Total

     15,000        
  

 

 

       

Mary Kerr did not hold any warrants as of December 31, 2016.

No loans, quasi-loans or other guarantees were given to the non-executive directors during the year ended December 31, 2016.

 

132


Table of Contents

Compensation of Members of the Executive Committee

The compensation of the members of our executive committee is determined by our board of directors based on the recommendations by our nomination and remuneration committee.

The remuneration of the members of our executive committee consists of different components:

 

    Fixed remuneration: a basic fixed fee designed to fit responsibilities, relevant experience and competences, in line with market rates for equivalent positions. The amount of fixed remuneration is evaluated and determined by the board of directors every year, upon recommendation of the nomination and remuneration committee.

 

    Variable remuneration (short-term and long-term): members of the executive committee may be entitled to a bonus, depending on the level of achievement of the criteria from the Senior Management Bonus Scheme (i.e., corporate objective for that year). The maximum bonus of the chief executive officer is set at 100% of his yearly fixed salary. The actual bonus of the chief executive officer is determined by our board of directors, upon recommendation of the nomination and remuneration committee, and is based on the achievement of corporate and individual objectives. The maximum aggregate bonus pot for the other members of the executive committee is set at 75% of their combined salaries. The actual bonuses of these executive officers are determined by our board of directors, upon recommendation of the nomination and remuneration committee, and are based on the achievement of corporate and individual objectives. In addition, exceptional special bonuses, outside the scope of the regular bonus schemes, can be considered by the board of directors, upon recommendation of the nomination and remuneration committee, in the event of and for exceptional achievements. For each year, 50% of this variable remuneration is paid in early January of the following year, and the other 50% is deferred for three years and is adjusted in light of the change of the company’s share price relative to the Euronext Next Biotech Index.

 

    Incentive plan: warrants have been granted and may be granted in the future, to the members of the executive committee. For a description of the main characteristics of our warrant plans, see “—Warrant Plans” below.

 

    Other: our pension, company car, tax advisory services and payments for invalidity and healthcare cover and other fringe benefits of non-material value.

No loans, quasi-loans or other guarantees were given to members of our executive committee during the year ended December 31, 2016.

The following table sets forth information regarding compensation earned by Onno van de Stolpe, our chief executive officer, during the year ended December 31, 2016.

 

     Compensation
(€)
 

Fixed remuneration (gross)

     453,407.56  

Variable remuneration (short-term)(1)

     236,133.50  

Variable remuneration (long-term)(2)

     652,974.18  

Pension/life

     62,843.00  

Other benefits

     39,384.25  

Total

     1,444,742.49  

 

(1) 50% of the performance bonus for the year 2016, paid in January 2017. The remaining 50% is deferred for three years and is adjusted in light of the change of our company’s share price relative to the Euronext Next Biotech Index.
(2)

The value of the 50% deferred part of the bonus awarded over 2013 was established at the end of 2016 and resulted in a payment in early January 2017 of an amount of €652,974.18 (a multiple of 4.01 of the deferred

 

133


Table of Contents
  bonus, as a result of the share price performance over the period 2013–2016 as per the provisions of the Senior Management Bonus Scheme).

In addition, Mr. Van de Stolpe was granted (and accepted) 100,000 warrants under Warrant Plan 2016. The exercise price of these warrants is €46.10. These warrants are exercisable as from January 1, 2020.

The following table sets forth information concerning the aggregate compensation earned during the year ended December 31, 2016 by the other current members of our executive committee.

 

     Compensation
(€)
 

Fixed remuneration (gross)

     838,435.00  

Variable remuneration (short-term)(1)

     336,913.00  

Variable remuneration (long-term)(2)

     521,192.63  

Pension/life

     164,711.91  

Other benefits

     45,695.00  

Total

     1,906,947.54  

 

(1) 50% of the performance bonus for the year 2016, paid in January 2017. The remaining 50% is deferred for three years and is adjusted in light of the change of our company’s share price relative to the Euronext Next Biotech Index.
(2) The value of the 50% deferred part of the bonus awarded over 2013 was established at the end of 2016 and resulted in a payment in early January 2017 of an amount of €521,192.63 (a multiple of 4.01 of the deferred bonus, as a result of the share price performance over the period 2013–2016 as per the provisions of the Senior Management Bonus Scheme).

In addition, the other members of the executive committee were granted (and accepted) an aggregate amount of 175,000 warrants under Warrant Plan 2016, with an exercise price of €46.10.

 

134


Table of Contents

The table below provides an overview as of December 31, 2016 of the warrants held by the members of our executive committee.

 

     Warrant awards  

Name

   Number of
ordinary shares
underlying
warrants
     Warrant
exercise
price

(€)
     Warrant
expiration
date
 

Onno van de Stolpe

     90,000        6.91        7/3/2018  
     16,874        8.65        6/27/2020  
     100,000        14.19        9/2/2020  
     100,000        19.38        5/15/2021  
     100,000        14.54        7/24/2022  
     100,000        28.75        4/29/2023  
     100,000        49.00        12/21/2023  
     100,000        46.10        5/31/2024  
  

 

 

       

Total

     706,874        
  

 

 

       

Other officers

     25,000        6.76        2/1/2017  
     12,500        8.60        12/14/2018  
     30,000        8.65        6/27/2020  
     77,500        5.60        6/25/2021  
     35,000        11.55        4/26/2018  
     50,000        9.95        5/22/2019  
     70,000        14.19        9/2/2020  
     50,000        19.38        5/15/2021  
     80,000        14.54        7/24/2022  
     150,000        11.93        10/13/2022  
     75,000        28.75        4/29/2023  
     140,000        49.00        12/21/2023  
     175,000        46.10        5/31/2024  
  

 

 

       

Total

     970,000        
  

 

 

       

Limitations on Liability and Indemnification Matters

Under Belgian law, the directors of a company may be liable for damages to the company in case of improper performance of their duties. Our directors may be liable to our company and to third parties for infringement of our articles of association or Belgian company law. Under certain circumstances, directors may be criminally liable.

We maintain liability insurance for our directors and officers, including insurance against liability under the Securities Act.

Certain of our non-executive directors may, through their relationships with their employers or partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our board of directors.

In the underwriting agreement we entered into in connection with our May 2015 global offering, the underwriters agreed to indemnify, under certain conditions, us, the members of our board of directors and persons who control our company within the meaning of the Securities Act against certain liabilities, but only to the extent that such liabilities are caused by information relating to the underwriters furnished to us in writing expressly for use in our registration statement and certain other disclosure documents.

 

135


Table of Contents

Warrant Plans

We have established a number of warrant plans, under which we have granted warrants free of charge to the recipients, i.e., employees, directors and independent consultants of our company. For warrant plans issued prior to 2011, the warrants offered to the employees and independent consultants vest according to the following schedule: 10% of the warrants vest on the date of the grant; an additional 10% vest at the first anniversary of the grant; an additional 20% vest at the second anniversary of the grant; an additional 20% vest at the third anniversary of the grant; and an additional 40% vest at the end of the third calendar year following the grant. The warrants granted under warrant plans created from 2011 up to (and including) Warrant Plan 2016 and Warrant Plan 2016 RMV, with the exception of Warrant Plan 2015 (B) and Warrant Plan 2015 RMV, vest at the end of the third calendar year following the year of the grant, with no intermediate vesting. The warrants granted under Warrant Plan 2015 (B) and Warrant Plan 2015 RMV vest on the third anniversary of the notary deed enacting the acceptance of the warrants. The warrants offered to directors vest over a period of 36 months at a rate of 1/36th per month. Warrants cannot be exercised before the end of the third calendar year following the year of the grant, except for warrants granted under Warrant Plan 2015 (B) and Warrant Plan 2015 RMV, which become exercisable on the third anniversary of the notary deed enacting the acceptance of the warrants. Pursuant to a resolution adopted at the extraordinary general shareholders’ meeting held on May 23, 2011, a provision has been incorporated in the warrant plans, which provides that in the event of a change of control of our company, all outstanding warrants vest immediately and will be immediately exercisable.

After the reverse 4:1 share split approved by the shareholders’ meeting held on March 29, 2005, four warrants under Warrant Plan 2002 Belgium entitle the warrant holder to subscribe for one ordinary share. For the warrant plans created from 2005 onwards, one warrant entitles the warrant holder to subscribe for one ordinary share. In the summaries and tables below, the numbers of warrants issued under Warrant Plan 2002 Belgium are divided by four to avoid a mixture of rights.

Generally, unless our board of directors at the time of the grant of the warrant determines a higher exercise price, the exercise price of a warrant will at least be equal to:

 

    the last closing price of our ordinary shares on Euronext Amsterdam prior to the date on which the warrant is offered; or

 

    the average closing price of our ordinary shares on Euronext Amsterdam over the thirty-day period preceding the date on which the warrant is offered.

For beneficiaries of the warrant plan that are not employees of our company, the exercise price cannot be lower than the average closing price of our ordinary shares on Euronext Amsterdam over the thirty-day period preceding the date of the offer of the warrants.

However, for the warrants offered under Warrant Plan 2002 Belgium, since the ordinary shares of our company were not yet traded or listed on a stock exchange at the time of the relevant offers, the exercise price was to be determined by our board of directors at the time of the offer and had to be at least equal to the market value of the former Class D shares, as determined by the board of directors and as certified by the auditor of our company. In addition, the exercise price could not be lower than (1) the book value of the existing shares as appearing from the last approved annual accounts of the company at the date of the offer and (2) €1.

Since 2002 until December 31, 2016, an aggregate of 8,514,467 warrants were granted. Of these 8,514,467 warrants:

 

    147,112 warrants lapsed because they were not timely exercised by their beneficiaries;

 

    1,188,433 warrants lapsed due to their beneficiaries no longer being employed by the company or because another condition for vesting was not met; and

 

    3,712,515 warrants have been exercised.

 

136


Table of Contents

As a result, as of December 31, 2016, there were 3,466,407 warrants outstanding which represent approximately 7.5% of the total number of all our issued and outstanding voting financial instruments.

The table below sets forth the details of all warrants granted under the warrant plans in force as per December 31, 2016, including the plan under which the warrants were granted, the offer date, exercise price, expiry date, number of warrants exercised, number of warrants voided and number of warrants outstanding. Aside from the warrants set forth in the below table, there are currently no other stock options, options to purchase securities, convertible securities or other rights to subscribe for or purchase outstanding securities.

 

Warrant plan

  Offer date     Exercise
price (€)
    Number of
warrants
granted
    Number of
warrants
exercised
    Number of
warrants
voided
    Number of
warrants
still
outstanding
     Exercisable
from
    Expiry date  

2002 Belgium

    3/6/2002       4.00       553,705       423,698       130,007       —          1/1/2006       3/6/2010  
    9/2/2002       4.00       27,125       14,150       12,975       —          1/1/2006       9/2/2010  
    3/6/2003       4.00       5,250       1,287       3,963       —          1/1/2007       3/31/2007  
    4/1/2003       4.00       7,500       7,500       —         —          1/1/2007       4/1/2011  
    6/15/2004       4.00       2,000       2,000       —         —          1/1/2008       6/15/2012  
    7/9/2004       4.00       31,250       31,250       —         —          1/1/2008       2/1/2017  
    7/22/2004       4.00       7,500       —         7,500       —          1/1/2008       3/31/2008  
    1/31/2005       6.76       159,375       90,000       44,375       25,000        1/1/2009       2/1/2017  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        793,705       569,885       198,820       25,000       
     

 

 

   

 

 

   

 

 

   

 

 

      

2005

    7/4/2005       6.91       145,000       55,000       —         90,000        1/1/2009       7/3/2018  
    11/23/2005       8.35       125,000       75,000       50,000       —          1/1/2009       11/22/2018  
    12/15/2005       8.60       12,500       —         —         12,500        1/1/2009       12/14/2018  
    2/13/2006       8.61       40,000       8,000       32,000       —          1/1/2010       3/31/2010  
    2/13/2006       8.73       53,500       50,972       2,528       —          1/1/2010       3/31/2010  
    11/22/2006       8.65       82,600       61,285       21,315       —          1/1/2010       11/21/2019  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        458,600       250,257       105,843       102,500       
     

 

 

   

 

 

   

 

 

   

 

 

      

2006 BNL

    2/13/2006       8.61       112,953       100,662       12,291       —          1/1/2010       2/12/2019  
    11/22/2006       8.65       87,090       16,450       70,640       —          1/1/2010       11/21/2019  
    2/14/2007       9.57       102,900       9,170       93,730       —          1/1/2011       08/31/2011  
    5/4/2007       9.22       17,500       10,000       —         7,500        1/1/2011       5/3/2020  
    6/28/2007       8.65       735       —         —         735        1/1/2011       6/27/2020  
    12/21/2007       7.12       25,110       12,121       11,939       1,050        1/1/2011       12/20/2020  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        346,288       148,403       188,600       9,285       
     

 

 

   

 

 

   

 

 

   

 

 

      

2006 UK

    6/1/2006       8.70       302,191       230,963       71,228       —          1/1/2010       9/30/2014  
    11/22/2006       8.65       13,965       11,907       2,058       —          1/1/2010       11/21/2014  
    12/19/2006       9.18       77,700       31,885       45,815       —          1/1/2010       12/18/2014  
    6/28/2007       8.43       30,585       20,085       10,500       —          1/1/2011       6/27/2015  
    12/21/2007       7.25       945       945       —         —          1/1/2011       12/20/2015  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        425,386       295,785       129,601       —         
     

 

 

   

 

 

   

 

 

   

 

 

      

2007

    6/28/2007       8.65       108,126       108,126       —         —          1/1/2011       6/27/2015  
    6/28/2007       8.65       256,314       154,232       53,173       48,909        1/1/2011       6/27/2020  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        364,440       262,358       53,173       48,909       
     

 

 

   

 

 

   

 

 

   

 

 

      

2007 RMV

    10/25/2007       8.65       108,850       66,300       4,900       37,650        1/1/2011       10/24/2020  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        108,850       66,300       4,900       37,650       
     

 

 

   

 

 

   

 

 

   

 

 

      

2008

    6/26/2008       5.60       201,445       114,519       7,326       79,600        1/1/2012       6/25/2021  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        201,445       114,519       7,326       79,600       
     

 

 

   

 

 

   

 

 

   

 

 

      

 

137


Table of Contents

Warrant plan

  Offer date     Exercise
price (€)
    Number of
warrants
granted
    Number of
warrants
exercised
    Number of
warrants
voided
    Number of
warrants
still
outstanding
     Exercisable
from
    Expiry date  

2008 (B)

    6/26/2008       5.60       57,500       50,000       7,500       —          1/1/2012       6/25/2013  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        57,500       50,000       7,500       —         
     

 

 

   

 

 

   

 

 

   

 

 

      

2009

    4/1/2009       5.87       555,000       482,500       65,000       7,500        1/1/2013       3/31/2017  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        555,000       482,500       65,000       7,500       
     

 

 

   

 

 

   

 

 

   

 

 

      

2009 (B)

    6/2/2009       7.09       135,100       131,670       3,430       —          1/1/2013       6/1/2014  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        135,100       131,670       3,430       —         
     

 

 

   

 

 

   

 

 

   

 

 

      

2010

    4/27/2010       11.55       466,500       363,750       49,750       53,000        1/1/2014       4/26/2018  
    4/27/2010       11.55       40,000       40,000       —         —          4/27/2014       4/26/2018  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        506,500       403,750       49,750       53,000       
     

 

 

   

 

 

   

 

 

   

 

 

      

2010 (B)

    4/27/2010       11.55       195,040       190,108       4,932       —          1/1/2014       4/26/2015  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        195,040       190,108       4,932       —         
     

 

 

   

 

 

   

 

 

   

 

 

      

2010 (C)

    12/23/2010       11.74       75,000       75,000       —         —          1/1/2014       12/22/2018  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        75,000       75,000       —         —         
     

 

 

   

 

 

   

 

 

   

 

 

      

2011

    5/23/2011       9.95       561,500       375,000       129,000       57,500        1/1/2015       5/22/2019  
    5/23/2011       9.95       57,500       48,400       7,500       1,600        5/23/2015       5/22/2019  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        619,000       423,400       136,500       59,100       
     

 

 

   

 

 

   

 

 

   

 

 

      

2011 (B)

    5/23/2011       9.95       129,220       127,750       1,470       —          1/1/2015       5/22/2016  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        129,220       127,750       1,470       —         
     

 

 

   

 

 

   

 

 

   

 

 

      

2012

    9/3/2012       14.19       448,640       110,830       103,150       234,660        1/1/2016       9/2/2020  
    9/3/2012       14.19       32,500       10,000       10,000       12,500        9/3/2016       9/2/2020  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        481,140       120,830       113,150       247,160       
     

 

 

   

 

 

   

 

 

   

 

 

      

2013

    5/16/2013       19.38       602,790       —         170,550       432,240        1/1/2017       5/15/2021  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        602,790       —         170,550       432,240       
     

 

 

   

 

 

   

 

 

   

 

 

      

2013 (B)

    9/18/2013       15.18       75,000       —         45,000       30,000        1/1/2017       6/30/2017  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        75,000       —         45,000       30,000       
     

 

 

   

 

 

   

 

 

   

 

 

      

2014

    7/25/2014       14.54       571,660       —         35,000       536,660        1/1/2018       7/24/2022  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        571,660       —         35,000       536,660       
     

 

 

   

 

 

   

 

 

   

 

 

      

2014 (B)

    10/14/2014       11.93       150,000       —         —         150,000        1/1/2018       10/13/2022  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        150,000       —         —         150,000       
     

 

 

   

 

 

   

 

 

   

 

 

      

2015

    4/30/2015       28.75       532,053       —         15,000       517,053        1/1/2019       4/29/2023  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        532,053       —         15,000       517,053       
     

 

 

   

 

 

   

 

 

   

 

 

      

2015 (B)

    12/22/2015       49.00       399,000       —         —         399,000        03/02/2019       12/21/2023  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        399,000       —         —         399,000       
     

 

 

   

 

 

   

 

 

   

 

 

      

 

138


Table of Contents

Warrant plan

  Offer date     Exercise
price (€)
    Number of
warrants
granted
    Number of
warrants
exercised
    Number of
warrants
voided
    Number of
warrants
still
outstanding
     Exercisable
from
    Expiry date  

2015 RMV

    12/22/2015       49.00       97,500       —         —         97,500        03/02/2019       12/21/2023  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        97,500       —         —         97,500       
     

 

 

   

 

 

   

 

 

   

 

 

      

2016

    06/01/2016       46.1       514,250       —         —         514,250        01/01/2020       05/31/2024  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        514,250       —         —         514,250       
     

 

 

   

 

 

   

 

 

   

 

 

      

2016 RMV

    06/01/2016       46.1       120,000       —         —         120,000        01/01/2020       05/31/2024  
     

 

 

   

 

 

   

 

 

   

 

 

      

Total

        120,000       —         —         120,000       
     

 

 

   

 

 

   

 

 

   

 

 

      

Grand Total

        8,514,467       3,712,515       1,335,545       3,466,407       
     

 

 

   

 

 

   

 

 

   

 

 

      

 

C. Board Practices.

Our board of directors can set up specialized committees to analyze specific issues and advise the board of directors on those issues. Except for our executive committee, the committees are advisory bodies only and the decision-making remains within the collegial responsibility of the board of directors. The board of directors determines the terms of reference of each committee with respect to the organization, procedures, policies and activities of the committee.

Our board of directors has set up and appointed an executive committee, an audit committee and a nomination and remuneration committee. The composition and function of all of our committees will comply with all applicable requirements of the Belgian Companies Code, the Exchange Act, the exchanges on which the ordinary shares and ADSs are listed and SEC rules and regulations.

Except the arrangements described in the section of this annual report titled “Item 7.B.—Related-Party Transactions—Agreements with Our Directors and Members of Executive Committee,” there are no arrangements or understanding between us and any of the members of our executive committee or directors providing for benefits upon termination of their employment, other than as required by applicable law. For information regarding the expiration of our directors’ current terms of office and the period each director has served in that office, see “Item 6.A.—Directors and Senior Management—Our Board of Directors.”

Director Independence

As a foreign private issuer, under the listing requirements and rules of NASDAQ, we are not required to have independent directors on our board of directors, except that our audit committee is required to consist fully of independent directors, subject to certain phase-in schedules. However, our board of directors has determined that, under current listing requirements and rules of NASDAQ and taking into account any applicable committee independence standards, Rajesh Parekh, Harrold van Barlingen, Werner Cautreels, Howard Rowe, Katrine Bosley, Christine Mummery and Mary Kerr are “independent directors.” In making such determination, our board of directors considered the relationships that each non-executive director has with us and all other facts and circumstances our board of directors deemed relevant in determining the director’s independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities (if any).

The independence criteria under the applicable NASDAQ Stock Market Listing Rules differ from the independence criteria set forth in Article 526ter of the Belgian Companies Code. Under Article 526ter of the Belgian Companies Code, Werner Cautreels, Howard Rowe, Katrine Bosley, Christine Mummery and Mary Kerr are “independent directors.”

 

139


Table of Contents

Role of the Board in Risk Oversight

Our board of directors is responsible for the oversight of our risk management activities and has delegated to the audit committee the responsibility to assist our board in this task. While our board oversees our risk management, our management is responsible for day-to-day risk management processes. Our board of directors expects our management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face.

Corporate Governance Practices

Along with our articles of association, we adopted a corporate governance charter in accordance with the recommendations set out in the Belgian Corporate Governance Code issued on March 12, 2009 by the Belgian Corporate Governance Committee. The Belgian Corporate Governance Code is based on a “comply or explain” system: Belgian listed companies are expected to follow the Belgian Corporate Governance Code, but can deviate from specific provisions and guidelines (though not the principles) provided they disclose the justification for such deviations.

Our board of directors complies with the Belgian Corporate Governance Code, but believes that certain deviations from its provisions are justified in view of our particular situation. These deviations include the grant of warrants to non-executive directors. In this way, we have additional possibilities to attract competent non- executive directors and to offer them an attractive additional remuneration without the consequence that this additional remuneration weighs on our financial results. Furthermore, the grant of warrants is a commonly used method in the sector in which we operate. Without this possibility, we would be subject to a considerable disadvantage compared to competitors who do offer warrants to their non-executive directors. Our board of directors is of the opinion that the grant of warrants has no negative impact on the functioning of the non-executive directors.

Our board of directors reviews its corporate governance charter from time to time and makes such changes as it deems necessary and appropriate. Additionally, our board of directors adopted written terms of reference for each of the executive committee, the audit committee and the nomination and remuneration committee, which are part of the corporate governance charter.

Board Committees

The board of directors has established an audit committee and a nomination and remuneration committee, which operate pursuant to the written terms of reference for each of the audit committee and the nomination and remuneration committee that are part of the corporate governance charter adopted by our board of directors. The composition and functioning of all of our committees will comply with all applicable requirements of the Belgian Companies Code and the Belgian Corporate Governance Code, the Exchange Act, the exchange on which the ADSs are listed, and SEC rules and regulations, taking into account the differences set out below and the company’s status as a foreign private issuer.

The Listing Rules of the NASDAQ Stock Market include certain accommodations in the corporate governance requirements that allow foreign private issuers, to follow “home country” corporate governance practices in lieu of the otherwise applicable corporate governance standards of the NASDAQ Stock Market. The application of such exceptions requires that we disclose each of the NASDAQ Stock Market Listing Rules that we do not follow and describe the Belgian corporate governance practices we do follow in lieu of the relevant NASDAQ Stock Market corporate governance standard.

 

140


Table of Contents

We follow Belgian corporate governance practices in lieu of the corporate governance requirements of the NASDAQ Stock Market in respect of the following rules applicable to board committees:

 

    Compensation Committee. NASDAQ Stock Market Listing Rule 5605(d)(2) requires that compensation of officers must be determined by, or recommended to, the board of directors for determination, either by a majority of the independent directors, or a compensation committee comprised solely of independent directors. NASDAQ Stock Market Listing Rule 5605(e) requires that director nominees be selected, or recommended for selection, either by a majority of the independent directors or a nominations committee comprised solely of independent directors. Under Belgian law, we are not subject to such composition requirements. Pursuant to Article 526quater of the Belgian Companies Code and the principles and guidelines of the Belgian Corporate Governance Code, we are required to set up a remuneration committee within our board of directors. In addition, the Belgian Corporate Governance Code provides that the board of directors should set up a nomination committee, which can be combined with the remuneration committee. Our board of directors has set up and appointed a nomination and remuneration committee.

 

    Charters. NASDAQ Stock Market Listing Rules 5605(c)(1), (d)(1) and (e)(2) require that each committee of the board of directors must have a formal written charter. Pursuant to the Belgian Corporate Governance Code, our board of directors has drawn up a corporate governance charter including, amongst others, the internal rules of our committees.

Audit Committee

Our audit committee consists of three members: Werner Cautreels (Chairman), Harrold van Barlingen and Howard Rowe.

Our board of directors has determined that all members of our audit committee are independent under Rule 10A-3 of the Exchange Act and the applicable rules of the NASDAQ Stock Market and that Werner Cautreels qualifies as an “audit committee financial expert” as defined under the Exchange Act.

Our audit committee assists our board of directors in overseeing the accuracy and integrity of our accounting and financial reporting processes and audits of our consolidated financial statements, the implementation and effectiveness of an internal control system and our compliance with legal and regulatory requirements, the independent auditors’ qualifications and independence and the performance of the independent auditors.

Our audit committee’s duties and responsibilities to carry out its purposes include, among others:

 

    ensuring the integrity of our financial reporting, including review of period information before it is made public;

 

    evaluating our system of internal controls set up by our executive committee, including evaluation and approval of the explanatory notes on internal controls in our annual reports;

 

    reviewing the functions of our internal risk management system and the efficacy of these systems;

 

    assessing the necessity for setting up an internal audit function; and

 

    supervising our relationship with our external auditors during the external audit process, including evaluation of our auditors’ independence.

The committee reports regularly to our board of directors on the exercise of its functions. It informs our board of directors about all areas in which action or improvement is necessary in its opinion and produces recommendations concerning the necessary steps that need to be taken. The audit review and the reporting on that review cover us and our subsidiaries as a whole. The members of the audit committee are entitled to receive

 

141


Table of Contents

all information which they need for the performance of their function, from our board of directors, executive committee and employees. Every member of the audit committee shall exercise this right in consultation with the chairman of the audit committee.

Nomination and Remuneration Committee

Our nomination and remuneration committee consists of three members: Rajesh Parekh (Chairman), Katrine Bosley and Werner Cautreels.

Our board of directors has determined that all members of our nomination and remuneration committee are independent under the applicable rules of the NASDAQ Stock Market.

Concerning our company’s nomination policy, this committee’s duties and responsibilities to carry out its purposes include, among others:

 

    making and evaluating proposals to our board of directors with regard to the election and re-election of non-executive directors;

 

    advising on the size and composition of the board of directors periodically;

 

    making selection criteria and nomination procedures for members of the executive committee; and

 

    advising on proposals relating to the appointment or dismissal of the members of the executive committee.

Concerning our company’s remuneration policy, this committee’s duties and responsibilities to carry out its purposes include, among others:

 

    making and evaluating proposals to our board of directors with regard to the remuneration policy for non-executive directors and the proposals which have to be submitted to the shareholders;

 

    making and evaluating proposals to our board of directors relating to the remuneration policy for members of our executive committee;

 

    making proposals relating to individual remuneration, including bonuses; and

 

    discussing and evaluating the operations and performance of the executive committee at least once a year.

 

142


Table of Contents
D. Employees.

As of December 31, 2016, we had 508 employees. Our employees in France and Croatia are represented by a labor union and/or covered by a collective bargaining agreement. We have never experienced any employment related work stoppages, and we consider our relations with our employees to be good. We have also engaged and may continue to engage independent contractors to assist us with our clinical project activities. At each date shown, we had the following employees (excluding certain employees of our service division that was sold in April 2014), broken out by department and geography:

 

     December 31,  
             2014                      2015                      2016          

Function:

        

Executive officers

     4        4        4  

Research

     213        205        216  

Development

     38        53        88  

Research services

     102        102        116  

Corporate and support

     60        71        84  
  

 

 

    

 

 

    

 

 

 

Total

     417        435        508  

Geography:

        

Leiden, the Netherlands

     31        34        45  

Mechelen, Belgium

     138        151        189  

Romainville, France

     128        129        140  

Zagreb, Croatia

     120        121        134  
  

 

 

    

 

 

    

 

 

 

Total

     417        435        508  

 

E. Share Ownership.

For information regarding the share ownership of our directors and members of our executive committee, see “Item 6.B.—Compensation” and “Item 7.A.—Major Shareholders.”

 

Item 7 Major Shareholders and Related Party Transactions.

 

A. Major Shareholders.

The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March 15, 2017 for:

 

    each person who is known by us to own beneficially more than 5% of our outstanding ordinary shares;

 

    each member of our board of directors;

 

    our executive committee, excluding our chief executive officer, as a group; and

 

    all members of our board of directors and executive committee as a group.

Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares that can be acquired within 60 days of March 15, 2017. The percentage ownership information shown in the table is based upon 46,256,078 ordinary shares outstanding as of March 15, 2017.

Except as otherwise indicated, all of the shares reflected in the table are ordinary shares or ADSs, and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.

 

143


Table of Contents

In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, we deemed outstanding ordinary shares subject to warrants held by that person that are immediately exercisable or exercisable within 60 days of March 15, 2017. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the table below is based on information known to us or ascertained by us from public filings made by the shareholders. Except as otherwise indicated in the table below, addresses of the directors, members of our executive committee and named beneficial owners are in care of Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.

 

     Shares beneficially owned  

Name of beneficial owner

   Number     Percentage  

5% shareholders:

    

Gilead Sciences, Inc.

     6,760,701 (1)(2)      14.62

FMR LLC

     4,616,982 (1)(3)      9.98

Van Herk Investments B.V.

     3,943,150 (1)(4)      8.52

Directors and members of executive committee:

    

Rajesh Parekh, MA, DPhil

     36,650 (5)      *  

Onno van de Stolpe

     785,163 (6)      1.69

Werner Cautreels, Ph.D.

     6,300 (7)      *  

Harrold van Barlingen, Ph.D.

     20,660 (8)      *  

Howard Rowe, JD

     5,040 (9)      *  

Katrine Bosley

     7,500 (10)      —    

Christine Mummery, Ph.D.

     454 (11)      *  

Mary Kerr, Ph.D.

     —         —    

Executive committee excluding Onno van de Stolpe

     385,352 (12)      *  

All members of our board of directors and executive committee as a group (11 persons)

     1,247,119 (13)      2.66

 

(1) At the time of the most recent transparency notification or filing of a statement of beneficial ownership with the SEC.
(2) Consists of 6,760,701 shares held by Gilead Biopharmaceutics Ireland Unlimited Company, which is a direct subsidiary of Gilead Sciences, Inc., which has the sole voting and investment power with respect to these shares. The address of Gilead Sciences, Inc. is 1209 Orange Street, Wilmington, DE, 19801, United States of America.
(3) Consists of 4,616,982 shares held by FMR LLC, based on the transparency notification received on October 7, 2016. The address of FMR LLC is 1209 Orange Street, Wilmington, DE, 19801, United States of America.
(4) Consists of 3,943,150 shares held by Van Herk Investments B.V. Van Herk Private Equity Investments B.V. holds all shares in Van Herk Investments B.V. Adrianus van Herk holds all shares in Van Herk Private Equity Investments B.V. and has sole voting and investment power with respect to these shares. The address of Van Herk Investments B.V. is Lichtenauerlaan 30, 3062 ME Rotterdam, the Netherlands.
(5) Consists of (i) 31,250 shares and (ii) 5,400 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(6) Consists of (i) 478,289 shares and (ii) 306,874 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(7) Consists of (i) 2,520 shares and (ii) 3,780 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(8) Consists of (i) 15,620 shares and (ii) 5,040 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(9) Consists of 5,040 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(10) Consists of 7,500 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(11) Consists of 454 shares.

 

144


Table of Contents
(12) Consists of (i) 35,352 shares and (ii) 350,000 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.
(13) Includes 683,634 shares issuable upon the exercise of warrants that are immediately exercisable or exercisable within 60 days of March 15, 2017.

Each of our shareholders is entitled to one vote per ordinary share. None of the holders of our shares will have different voting rights from other holders of shares after the closing of this offering. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.

As of March 15, 2017, assuming that all of our ordinary shares represented by ADSs are held by residents of the United States, we estimate that approximately 36% of our outstanding ordinary shares were held in the United States by approximately 87 institutional holders of record, excluding Gilead Sciences, Inc., or Gilead. At such date, there were outstanding 9,686,518 ADSs, each representing one ordinary share, and in the aggregate representing 21% of our outstanding ordinary shares. The actual number of holders is greater than these numbers of record holders, and includes beneficial owners whose ADSs are held in street name by brokers and other nominees. This number of holders of record also does not include holders whose shares may be held in trust by other entities.

On January 28, 2016, we received a transparency notification from Wellington Management Group LLP, confirming that, as a result of the capital increase through which Gilead acquired 6,760,701 of our ordinary shares, its shareholding had passively decreased below the lowest 5% notification threshold of Galapagos NV’s voting rights. On March 1, 2016, we received a transparency notification from Johnson & Johnson, indicating that affiliates under its control sold 2,350,061 shares, as a result of which its shareholding decreased below the lowest 5% notification threshold of Galapagos NV’s voting rights. On July 20, 2016, we received a transparency notice from Federated Equity Management Company of Pennsylvania indicating that as a result of a sale of shares, its shareholding had decreased below the 5% notification threshold of Galapagos NV’s voting rights. On October 7, 2016, we received a transparency notice from FMR LLC indicating that, as a result of an acquisition of voting securities, affiliates under its control reached the 10% threshold of Galapagos NV’s voting rights. For information regarding the acquisition of 6,760,701 of our ordinary shares by Gilead in connection with its affiliate’s entry into an exclusive license and collaboration agreement relating to filgotinib, please see “Item 7.B.—Related Party Transactions” below.

 

B. Related Party Transactions.

Since January 1, 2016, we have engaged in the following transactions with our directors, members of our executive committee and holders of more than 10% of our outstanding voting securities and their affiliates.

Transaction with Major Shareholder

On December 16, 2015, we signed an exclusive license and collaboration agreement to develop and commercialize filgotinib in multiple indications with Gilead Biopharmaceutics Ireland Unlimited Company. Under the terms of the collaboration, Gilead is primarily responsible for development and for seeking regulatory approval of the licensed product. We are required to use commercially reasonable efforts as requested by Gilead to assist Gilead with certain development activities. In addition, we agreed on a 20-80 cost split for development costs of the licensed product, i.e. we will bear 20% of all development costs. In the framework of the closing of the transaction on January 19, 2016, Gilead Biopharmaceutics Ireland Unlimited Company paid a license fee of $300 million (or €275.6 million) and made a $425 million (or €392 million) equity investment in our share capital by subscribing to new ordinary shares at an issue price of €58.00 per share, including issuance premium. This resulted in Gilead owning 6,760,701 ordinary shares, representing 14.75% of our outstanding share capital as of the date of the capital increase. Moreover, under the subscription agreement relating hereto, the parties agreed to a lock-up and standstill arrangement. In the year ended December 31, 2016, we received $60.0 million (or €55.1 million) in milestone payments from Gilead under this exclusive license and collaboration agreement.

 

145


Table of Contents

We incurred €22.4 million in development costs for the development of filgotinib in collaboration with Gilead: these costs relate to the Phase 2b and Phase 3 trials and mainly consist of costs recharged by Gilead as we are co-funding 20% of the global development activities, as well as costs paid to CROs in conjunction with clinical trials, costs for production of the compound for clinical testing, and, to a smaller extent, personnel costs and consultancy costs. The reimbursement of research and development costs under the 20-80 cost split mechanism by Gilead to us amounted to €3.5 million for the year ended December 31, 2016. For further information on our exclusive license and collaboration agreement with Gilead, see the section of this annual report titled “Item 4.B.—Business Overview—Collaborations—Exclusive Collaboration Agreement with Gilead for Filgotinib.”

Transactions with Related Companies

From time to time, in the ordinary course of our business we may contract for services from companies in which certain of the members of our executive committee or directors may serve as director or advisor. The cost of these services is negotiated on an arm’s length basis and none of these arrangements is material to us.

Agreements with Our Directors and Members of Executive Committee

Employment and Management Arrangements

Onno van de Stolpe

On March 1, 2002, we entered into a management agreement with Onno van de Stolpe for the position of Managing Director and Chief Executive Officer for an indefinite period. Effective March 1, 2011, Mr. Van de Stolpe’s management agreement with Galapagos NV was reduced from a full-time basis to a part-time basis, for approximately 40% of his time, at which time he entered into (1) an employment agreement with Galapagos B.V. on a part-time basis, for approximately 35% of his time, and (2) a management agreement with Galapagos SASU for approximately 25% of his time. Mr. Van de Stolpe currently receives (1) a base remuneration from Galapagos NV of €188,907 (including €18,859.44 in the form of pension contributions), (2) a base salary from Galapagos B.V. of €165,294 (including an 8% holiday bonus) and (3) a base salary from Galapagos SASU of €118,067.

Bart Filius

On September 15, 2014, Galapagos B.V. entered into an employment agreement, subject to Dutch law, with Bart Filius for the position of Chief Financial Officer, starting December 1, 2014 for an indefinite period. Effective December 1, 2014, Mr. Filius’ employment agreement with Galapagos B.V. was reduced from a full-time basis to a part-time basis, for approximately 60% of his time, and he entered into a management agreement with Galapagos NV for approximately 40% of his time.

Andre Hoekema

On January 31, 2005, Galapagos B.V. entered into an employment agreement, subject to Dutch law, with Andre Hoekema for the position of Senior Vice President Corporate Development and member of the executive committee, for an indefinite period.

Piet Wigerinck

On February 28, 2008, we entered into a management agreement with Piet Wigerinck for the position of Senior Vice President Drug Development and member of the executive committee, for an indefinite period. Mr. Wigerinck was appointed Chief Scientific Officer effective March 1, 2012. The management agreement stipulates that Mr. Wigerinck shall perform his duties thereunder on an independent basis.

 

146


Table of Contents

Walid Abi-Saab

On October 26, 2016, Galapagos NV entered into a management agreement, subject to Belgian law, with Walid Abi-Saab for the position of Chief Medical Officer, starting March 1, 2017, for an indefinite period. Effective March 1, 2017, Mr. Abi-Saab’s management agreement with Galapagos NV was reduced from a full-time basis to a part-time basis, for approximately 95% of his time, and he entered into an employment agreement with Galapagos B.V. for approximately 5% of his time.

Severance Payments Upon Change of Control

The abovementioned agreements with the members of our executive committee do not provide for severance compensation. They do not contain notice periods that exceed six months. However, we entered into undertakings with the members of our executive committee providing that, in case their contract with us is terminated as a result of a change of control of our company, they would be entitled to a severance compensation of 12 months’ base salary for our chief executive officer and nine months’ base salary for the other executive committee members.

Consulting Arrangements

Parekh Enterprises Ltd

On August 1, 2005, we entered into a management agreement with Parekh Enterprises Ltd, duly represented by Rajesh Parekh, for the provision of consultancy services to the company consisting of the strategic positioning of our company, the evaluation of corporate transactions, the managing of relations with existing and potential investors and with stock markets and other matters of strategic importance for the company. This management agreement was terminated effective April 30, 2016. Parekh Enterprises Ltd received a fee of €20,263 for the provision of consultancy services during the first four months of 2016.

Director and Executive Committee Compensation

See the sections of this annual report in “Item 6.B.—Compensation” titled “—Compensation of Our Board of Directors” and “—Compensation of Members of the Executive Committee” for information regarding compensation of directors and members of our executive committee.

Equity Awards

Since January 1, 2016, we have granted warrants to certain of our directors and members of our executive committee.

See the section of this annual report titled “Item 7.A.—Major Shareholders” for information regarding equity awards to members of our executive committee.

Bonus Plans

See the section of this annual report titled “Item 6.B.—Compensation—Compensation of Members of the Executive Committee” for information regarding bonus plans for members of our executive committee.

Related-party Transactions Policy

Article 524 of the Belgian Companies Code provides for a special procedure that applies to intra-group or related party transactions with affiliates. The procedure applies to decisions or transactions between us and our affiliates that are not one of our subsidiaries. Prior to any such decision or transaction, our board of directors must appoint a special committee consisting of three independent directors, assisted by one or more independent

 

147


Table of Contents

experts. This committee must assess the business advantages and disadvantages of the decision or transaction, quantify its financial consequences and determine whether the decision or transaction causes a disadvantage to us that is manifestly illegitimate in view of our policy. If the committee determines that the decision or transaction is not illegitimate but will prejudice us, it must analyze the advantages and disadvantages of such decision or transaction and set out such considerations as part of its advice. Our board of directors must then make a decision, taking into account the opinion of the committee. Any deviation from the committee’s advice must be justified. Directors who have a conflict of interest are not entitled to participate in the deliberation and vote. The committee’s advice and the decision of the board of directors must be notified to our auditor, who must render a separate opinion. The conclusion of the committee, an excerpt from the minutes of the board of directors and the opinion by the auditor must be included in our annual report. This procedure does not apply to decisions or transactions in the ordinary course of business under customary market conditions and security documents, or to transactions or decisions with a value of less than 1% of our net assets as shown in our consolidated annual accounts.

In addition to this, our corporate governance charter provides for guidelines for transactions between our company and our directors or members of the executive committee. According to such guidelines:

 

    it is expected from all directors and members of the executive committee that they avoid all acts, standpoints or interests which are conflicting with, or which give the impression that they are conflicting with, the interests of our company;

 

    all transactions between our company and our directors, members of the executive committee or representatives need the approval of our board of directors. Such transactions could only be allowed at arm’s length (normal market conditions);

 

    our directors and members of the executive committee are, by way of example, not allowed, directly or indirectly, to enter into agreements with our company which relate to supply of materials or delivery of services (other than in the framework of their mandate for our company), except with the explicit approval of our board of directors;

 

    in the event our directors, members of the executive committee or their permanent representatives are confronted with a potential conflict of interest with regard to a decision or a transaction of our company, they shall immediately inform the chairman of the board of directors thereof. Conflict of interest means a conflict of proprietary interest, but also functional conflict of interest or conflicts of a family nature (up to second degree);

 

    in the event Article 523 of the Belgian Companies Code applies, our director or the member of the executive committee shall not participate in the deliberation on the subject matter; and

 

    in the event Article 523 of the Belgian Companies Code does not apply, the existence of the conflict of interest shall be written down in the minutes (but shall not be published) and the director or the member of the executive committee shall not vote.

We have adopted a related-party transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related-party transactions. For purposes of our policy only, a related-party transaction is a transaction in which we are a participant and a related party has a direct or indirect material interest. For purposes of this policy, a related party is any executive officer, director (or nominee for director) or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.

Under the policy, if a transaction has been identified as a related-party transaction, our audit committee will review and consider information regarding the related-party transaction. In reviewing any related-party transaction, the committee will take into account, among other factors it deems appropriate, (i) whether the transaction is on terms no less favorable to us than terms generally available in a transaction with an unaffiliated third party under the same or similar circumstances; and (ii) the extent of the related party’s interest in the

 

148


Table of Contents

related-party transaction. Additionally, we will provide the audit committee with all material information regarding the related-party transaction, the interest of the related party, and any potential disclosure obligations in connection therewith. In addition, under our Code of Business Conduct and Ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.

 

C. Interests of Experts and Counsel.

Not applicable.

 

Item 8 Financial Information

 

A. Consolidated Statements and Other Financial Information.

Consolidated Financial Statements

Our consolidated financial statements are appended at the end of this annual report, starting at page F-1, and incorporated herein by reference.

Legal Proceedings

From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Dividend Distribution Policy

We have never declared or paid any cash dividends on our ordinary shares. We do not anticipate paying cash dividends on our equity securities in the foreseeable future and intend for the foreseeable future to retain all available funds and any future earnings for use in the operation and expansion of our business. In general, distributions of dividends proposed by our board of directors require the approval of our shareholders at a shareholders’ meeting with a simple majority vote, although our board of directors may declare interim dividends without shareholder approval, subject to the terms and conditions of the Belgian Companies Code.

Pursuant to Belgian law, the calculation of amounts available for distribution to shareholders, as dividends or otherwise, must be determined on the basis of our non-consolidated statutory financial accounts. In addition, under the Belgian Companies Code, we may declare or pay dividends only if, following the declaration and issuance of the dividends, the amount of our net assets on the date of the closing of the last financial year according to our statutory annual accounts (i.e., the amount of the assets as shown in the balance sheet, decreased with provisions and liabilities, all as prepared in accordance with Belgian accounting rules), decreased with the non-amortized costs of incorporation and expansion and the non-amortized costs for research and development, does not fall below the amount of the paid-up capital (or, if higher, the called capital), increased with the amount of non-distributable reserves. Finally, prior to distributing dividends, we must allocate at least 5% of our annual net profits (under our non-consolidated statutory accounts prepared in accordance with Belgian accounting rules) to a legal reserve, until the reserve amounts to 10% of our share capital.

 

B. Significant Changes.

On January 20, 2017, our board of directors conditionally issued up to 150,000 warrants (subject to acceptance by the beneficiary) within the framework of the authorized capital for the benefit of our chief medical officer under a new warrant plan: Warrant Plan 2016 (B). The warrants to be issued under Warrant Plan 2016 (B) have a term of eight years and an exercise price of €62.50.

 

149


Table of Contents

On February 1, 2017, we announced the opening of an Investigational New Drug file with the U.S. Food and Drug Administration for GLPG2222, which triggered a $10 million milestone payment from our collaboration partner AbbVie.

On March 22, 2017, we announced the initiation of a Phase 1 trial with GLPG3067, triggering a $7.5 million milestone payment from AbbVie.

 

Item 9 The Offer and Listing.

 

A. Offer and Listing Details.

The ADSs have been listed on the NASDAQ Global Select Market, or NASDAQ, under the symbol “GLPG” since May 14, 2015. Prior to that date, there was no public trading market for the ADSs. Our ordinary shares have been trading on Euronext Amsterdam and Euronext Brussels under the symbol “GLPG” since May 6, 2005. Prior to that date, there was no public trading market for the ADSs or our ordinary shares. Our global offering in May 2015 was priced at $42.05 per ADS and €37.00 per ordinary share based on an exchange rate of $1.1365 per euro. The following tables set forth for the periods indicated the reported high and low sale prices per ADS on NASDAQ in U.S. dollars and per ordinary share on Euronext Amsterdam in euros.

NASDAQ

 

     Per ADS  

Period

   High      Low  

Annual:

     

2015 (beginning May 14)

   $ 65.54      $ 38.28  

2016

   $ 73.37      $ 37.03  

Quarterly:

     

Second Quarter 2015 (beginning May 14)

   $ 58.79      $ 44.36  

Third Quarter 2015

   $ 65.54      $ 38.28  

Fourth Quarter 2015

   $ 63.50      $ 39.03  

First Quarter 2016

   $ 61.69      $ 37.03  

Second Quarter 2016

   $ 61.02      $ 41.21  

Third Quarter 2016

   $ 73.37      $ 51.91  

Fourth Quarter 2016

   $ 67.56      $ 57.16  

First Quarter 2017 (through March 17)

   $ 82.14      $ 63.69  

Month Ended:

     

September 2016

   $ 73.37      $ 53.78  

October 2016

   $ 67.56      $ 59.93  

November 2016

   $ 62.65      $ 57.16  

December 2016

   $ 64.66      $ 57.86  

January 2017

   $ 70.10      $ 63.69  

February 2017

   $ 71.01      $ 65.78  

March 2017 (through March 17)

   $ 82.14      $ 70.51  

 

150


Table of Contents

Euronext Amsterdam

 

     Per Ordinary Share  

Period

   High      Low  

Annual:

     

2012

   17.95      9.75  

2013

   20.70      13.40  

2014

   18.42      10.00  

2015

   60.55      14.81  

2016

   66.19      32.50  

Quarterly:

     

First Quarter 2015

   24.68      14.81  

Second Quarter 2015

   55.40      22.00  

Third Quarter 2015

   59.00      31.15  

Fourth Quarter 2015

   60.55      34.54  

First Quarter 2016

   57.68      32.50  

Second Quarter 2016

   53.70      36.20  

Third Quarter 2016

   66.19      46.07  

Fourth Quarter 2016

   62.16      51.15  

First Quarter 2017 (through March 17)

   76.15      59.13  

Month Ended:

     

September 2016

   66.19      47.52  

October 2016

   62.16      54.84  

November 2016

   58.21      51.15  

December 2016

   61.94      53.84  

January 2017

   66.95      59.13  

February 2017

   67.90      60.41  

March 2017 (through March 17)

   76.15      65.00  

On March 17, 2017, the last reported sale price of the ADSs on NASDAQ was $81.86 per ADS, and the last reported sale price of the ordinary shares on Euronext Amsterdam was €76.15 per share.

 

B. Plan of Distribution.

Not applicable.

 

C. Markets.

The ADSs have been listed on NASDAQ under the symbol “GLPG” since May 14, 2015, and our ordinary shares have been listed on Euronext Amsterdam and Euronext Brussels under the symbol “GLPG” since May 6, 2005.

 

D. Selling Shareholders.

Not applicable.

 

E. Dilution.

Not applicable.

 

151


Table of Contents
F. Expenses of the Issue.

Not applicable.

 

Item 10 Additional Information.

 

A. Share Capital.

Not applicable.

 

B. Memorandum and Articles of Association.

The information set forth in our prospectus dated May 13, 2015, filed with the SEC pursuant to Rule 424(b), under the headings “Description of Share Capital—Articles of Association and Other Share Information,” “Description of Share Capital—Board of Directors,” “Description of Share Capital—Description of the Rights and Benefits Attached to Our Shares,” “Description of Share Capital—Belgian Legislation” and “Description of Share Capital—Limitations on the Right to Own Securities” is incorporated herein by reference.

 

C. Material Contracts.

We entered into an underwriting agreement among Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC, as representatives of the underwriters, on May 13, 2015, with respect to the ADSs and ordinary shares sold in our global offering. We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect of such liabilities. For additional information on our material contracts, please see the sections of this annual report titled “Item 4—Information on the Company” and “Item 7—Major Shareholders and Related Party Transactions.”

 

D. Exchange Controls.

There are no Belgian exchange control regulations that impose limitations on our ability to make, or the amount of, cash payments to residents of the United States.

We are in principle under an obligation to report to the National Bank of Belgium certain cross-border payments, transfers of funds, investments and other transactions in accordance with applicable balance-of-payments statistical reporting obligations. Where a cross-border transaction is carried out by a Belgian credit institution on our behalf, the credit institution will in certain circumstances be responsible for the reporting obligations.

 

E. Taxation.

Certain Material U.S. Federal Income Tax Considerations to U.S. Holders

The following is a summary of certain material U.S. federal income tax considerations relating to the ownership and disposition of ADSs by a U.S. holder (as defined below). This summary addresses only the U.S. federal income tax considerations for U.S. holders that hold such ADSs as capital assets for U.S. federal income tax purposes. This summary does not address all U.S. federal income tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations applicable to a holder of ADSs that may be subject to special tax rules including, without limitation, the following:

 

    banks, financial institutions or insurance companies;

 

    brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts;

 

    tax-exempt entities or organizations, including an “individual retirement account” or “Roth IRA” as defined in Section 408 or 408A of the Code (as defined below), respectively;

 

152


Table of Contents
    real estate investment trusts, regulated investment companies or grantor trusts;

 

    persons that hold the ADSs as part of a “hedging,” “integrated” or “conversion” transaction or as a position in a “straddle” for U.S. federal income tax purposes;

 

    partnerships (including entities classified as partnerships for U.S. federal income tax purposes) or other pass-through entities, or persons that will hold the ADSs through such an entity;

 

    certain former citizens or long-term residents of the United States;

 

    holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of the ADSs and shares; and

 

    holders that have a “functional currency” for U.S. federal income tax purposes other than the U.S. dollar.

Further, this summary does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local, or non-U.S. tax considerations of the ownership and disposition of the ADSs.

This description is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code; existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder, administrative and judicial interpretations thereof; and the income tax treaty between Belgium and the United States in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a contrary or different position concerning the tax consequences of the ownership and disposition of the ADSs or that such a position would not be sustained. Holders should consult their own tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning, and disposing of the ADSs in their particular circumstances.

For the purposes of this summary, a “U.S. holder” is a beneficial owner of ADSs that is (or is treated as), for U.S. federal income tax purposes:

 

    an individual who is a citizen or resident of the United States;

 

    a corporation, or other entity that is treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;

 

    an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or

 

    a trust, if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust or has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person.

If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds ADSs, the U.S. federal income tax consequences relating to an investment in the ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the U.S. federal income tax considerations of owning and disposing of the ADSs in its particular circumstances.

In general, a U.S. holder who owns ADSs will be treated as the beneficial owner of the underlying shares represented by those ADSs for U.S. federal income tax purposes. Accordingly, no gain or loss will generally be recognized if a U.S. holder exchanges ADSs for the underlying shares represented by those ADSs.

The U.S. Treasury has expressed concern that parties to whom ADSs are released before shares are delivered to the depositary (“pre-release”), or intermediaries in the chain of ownership between holders and the issuer of the

 

153


Table of Contents

security underlying the ADSs, may be taking actions that are inconsistent with the claiming of foreign tax credits by holders of ADSs. These actions would also be inconsistent with the claiming of the reduced rate of tax, described below, applicable to dividends received by certain non-corporate holders. Accordingly, the creditability of Belgian taxes, and the availability of the reduced tax rate for dividends received by certain non-corporate U.S. holders, each described below, could be affected by actions taken by such parties or intermediaries.

As indicated below, this discussion is subject to U.S. federal income tax rules applicable to a “passive foreign investment company,” or a PFIC.

Persons considering an investment in the ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the ownership and disposition of the ADSs, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.

Distributions. Although we do not currently plan to pay dividends, and subject to the discussion under “—Passive Foreign Investment Company Considerations” below, the gross amount of any distribution (before reduction for any amounts withheld in respect of Belgian withholding tax) actually or constructively received by a U.S. holder with respect to ADSs will be taxable to the U.S. holder as a dividend to the extent of the U.S. holder’s pro rata share of our current and accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of earnings and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce, the U.S. holder’s adjusted tax basis in the ADSs. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the U.S. holder as either long-term or short-term capital gain depending upon whether the U.S. holder has held the ADSs for more than one year as of the time such distribution is received. However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above. Non-corporate U.S. holders may qualify for the preferential rates of taxation with respect to dividends on ADSs applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) applicable to qualified dividend income (as discussed below) if we are a “qualified foreign corporation” and certain other requirements (discussed below) are met. A non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. The ADSs are listed on the NASDAQ Global Select Market, or NASDAQ, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on NASDAQ. However, there can be no assurance that the ADSs will be considered readily tradable on an established securities market in the United States in later years. The company, which is incorporated under the laws of Belgium, believes that it qualifies as a resident of Belgium for purposes of, and is eligible for the benefits of, The Convention between the Government of the United States of America and the Government of the Kingdom of Belgium for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, signed on November 27, 2006, or the U.S.-Belgium Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Belgium Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, subject to the discussion under “—Passive Foreign Investment Company Considerations” below, such dividends will generally be “qualified dividend income” in the hands of individual U.S. holders, provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. holders.

A U.S. holder generally may claim the amount of any Belgian withholding tax as either a deduction from gross income or a credit against U.S. federal income tax liability. However, the foreign tax credit is subject to

 

154


Table of Contents

numerous complex limitations that must be determined and applied on an individual basis. Generally, the credit cannot exceed the proportionate share of a U.S. holder’s U.S. federal income tax liability that such U.S. holder’s taxable income bears to such U.S. holder’s worldwide taxable income. In applying this limitation, a U.S. holder’s various items of income and deduction must be classified, under complex rules, as either “foreign source” or “U.S. source.” In addition, this limitation is calculated separately with respect to specific categories of income. The amount of a distribution with respect to the ADSs that is treated as a “dividend” may be lower for U.S. federal income tax purposes than it is for Belgian income tax purposes, potentially resulting in a reduced foreign tax credit for the U.S. holder. Each U.S. holder should consult its own tax advisors regarding the foreign tax credit rules.

In general, the amount of a distribution paid to a U.S. holder in a foreign currency will be the dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the U.S. holder receives the distribution, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend.

Sale, Exchange or Other Taxable Disposition of the ADSs. A U.S. holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or exchange and the U.S. holder’s tax basis for those ADSs. Subject to the discussion under “—Passive Foreign Investment Company Considerations” below, this gain or loss will generally be a capital gain or loss. The adjusted tax basis in the ADSs generally will be equal to the cost of such ADSs. Capital gain from the sale, exchange or other taxable disposition of ADSs of a non-corporate U.S. holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the non-corporate U.S. holder’s holding period determined at the time of such sale, exchange or other taxable disposition for such ADSs exceeds one year (i.e., such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations under the Code. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes.

Medicare Tax. Certain U.S. holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their “net investment income,” which may include all or a portion of their dividend income and net gains from the disposition of ADSs. Each U.S. holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in the ADSs.

Passive Foreign Investment Company Considerations. If we are classified as a PFIC in any taxable year, a U.S. holder would be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis.

A corporation organized outside the United States generally will be classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect to the income and assets of its subsidiaries, either: (i) at least 75% of its gross income is “passive income” or (ii) at least 50% of the average quarterly value of its total gross assets (which, assuming we are not a controlled foreign corporation for the year being tested, would be measured by the fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our ordinary shares, which are subject to change) is attributable to assets that produce “passive income” or are held for the production of “passive income.”

Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which

 

155


Table of Contents

produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of the ADSs. If a non-U.S. corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation’s income. If we are classified as a PFIC in any year with respect to which a U.S. holder owns the ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ADSs, regardless of whether we continue to meet the tests described above.

Whether we are a PFIC for any taxable year will depend on the composition of our income and the projected composition and estimated fair market values of our assets in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. The market value of our assets may be determined in large part by reference to the market price of the ADSs and our ordinary shares, which is likely to fluctuate after the offering. Based on the foregoing, with respect to the 2016 taxable year and foreseeable future tax years, we do not anticipate that we will be a PFIC based upon the expected value of our assets, including any goodwill, and the expected composition of our income and assets, however, as previously mentioned, we cannot provide any assurances regarding our PFIC status for the current, prior or future taxable years.

If we are a PFIC, and you are a U.S. holder, then unless you make one of the elections described below, a special tax regime will apply to both (a) any “excess distribution” by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or your holding period for the ADSs) and (b) any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder’s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under “—Distributions.”

Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market treatment) of the ADSs. If a U.S. holder makes the mark-to- market election, the U.S. holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. holder makes the election, the U.S. holder’s tax basis in the ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). The mark-to- market election is available only if we are a PFIC and the ADSs are “regularly traded” on a “qualified exchange.” The ADSs will be treated as “regularly traded” in any calendar year in which more than a de minimis quantity of the ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement as disregarded). NASDAQ is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the mark- to-market election will be available to a U.S. holder.

If we are a PFIC for any year during which a U.S. holder holds the ADSs, we must generally continue to be treated as a PFIC by that U.S. holder for all succeeding years during which the U.S. holder holds the ADSs, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a “deemed sale” election

 

156


Table of Contents

with respect to the ADSs. If such election is made, the U.S. holder will be deemed to have sold the ADSs it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject to the consequences described above. After the deemed sale election, the U.S. holder’s ADSs with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC.

The tax consequences that would apply if we were a PFIC would also be different from those described above if a U.S. holder were able to make a valid “qualified electing fund,” or QEF, election. However, we do not currently intend to provide the information necessary for U.S. holders to make a QEF election if we were treated as a PFIC for any taxable year and prospective investors should assume that a QEF election will not be available. U.S. holders should consult their tax advisors to determine whether any of these above elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.

If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect distributions and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs.

If a U.S. holder owns ADSs during any taxable year in which we are a PFIC, the U.S. holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. holder’s federal income tax return for that year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements.

The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisers with respect to the ownership and disposition of the ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect to the ownership and disposition of the ADSs.

Backup Withholding and Information Reporting. U.S. holders generally will be subject to information reporting requirements with respect to dividends on ADSs and on the proceeds from the sale, exchange or disposition of ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an “exempt recipient.” In addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S. holder provides a taxpayer identification number and a duly executed IRS Form W-9 or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.

Foreign Asset Reporting. Certain U.S. holders who are individuals are required to report information relating to an interest in the ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of the ADSs.

THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ADSS IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.

 

157


Table of Contents

Belgian Tax Consequences

The following paragraphs are a summary of material Belgian tax consequences of the ownership of ADSs by an investor. The summary is based on laws, treaties and regulatory interpretations in effect in Belgium on the date of this annual report, all of which are subject to change, including changes that could have retroactive effect.

The summary only discusses Belgian tax aspects which are relevant to U.S. holders of ADSs, or Holders. This summary does not address Belgian tax aspects which are relevant to persons who are fiscally resident in Belgium or who avail of a permanent establishment or a fixed base in Belgium to which the ADSs are effectively connected.

This summary does not purport to be a description of all of the tax consequences of the ownership of ADSs, and does not take into account the specific circumstances of any particular investor, some of which may be subject to special rules, or the tax laws of any country other than Belgium. This summary does not describe the tax treatment of investors that are subject to special rules, such as banks, insurance companies, collective investment undertakings, dealers in securities or currencies, persons that hold, or will hold, ADSs in a position in a straddle, share-repurchase transaction, conversion transactions, synthetic security or other integrated financial transactions. Investors should consult their own advisers regarding the tax consequences of an investment in ADSs in the light of their particular circumstances, including the effect of any state, local or other national laws.

In addition to the assumptions mentioned above, it is also assumed in this discussion that for purposes of the domestic Belgian tax legislation, the owners of ADSs will be treated as the owners of the ordinary shares represented by such ADSs. However, the assumption has not been confirmed by or verified with the Belgian Tax Authorities.

Dividend Withholding Tax

As a general rule, a withholding tax of 30% is levied on the gross amount of dividends paid on the ordinary shares represented by the ADSs, subject to such relief as may be available under applicable domestic or tax treaty provisions.

Dividends subject to the dividend withholding tax include all benefits attributed to the ordinary shares represented by the ADSs, irrespective of their form, as well as reimbursements of statutory share capital by us, except reimbursements of fiscal capital made in accordance with the Belgian Companies Code. In principle, fiscal capital includes paid-up statutory share capital, and subject to certain conditions, the paid-up issue premiums and the amounts subscribed to at the time of the issue of profit sharing certificates.

In case of a redemption by us of our own shares represented by ADSs, the redemption distribution (after deduction of the portion of fiscal capital represented by the redeemed shares) will be treated as a dividend which in principle is subject to the withholding tax of 30%, subject to such relief as may be available under applicable domestic or tax treaty provisions. In case of a liquidation of our company, any amounts distributed in excess of the fiscal capital will also be treated as a dividend, and will in principle be subject to a 30% withholding tax, subject to such relief as may be available under applicable domestic or tax treaty provisions.

For non-residents the dividend withholding tax, if any, will be the only tax on dividends in Belgium, unless the non-resident avails of a fixed base in Belgium or a Belgian permanent establishment to which the ADSs are effectively connected.

Relief of Belgian Dividend Withholding Tax

Under the U.S.-Belgium Tax Treaty, under which we are entitled to benefits accorded to residents of Belgium, there is a reduced Belgian withholding tax rate of 15% on dividends paid by us to a U.S. resident which beneficially owns the dividends and is entitled to claim the benefits of the U.S.-Belgium Tax Treaty under the limitation of benefits article included in the U.S.-Belgium Tax Treaty, or Qualifying Holders.

 

158


Table of Contents

If such Qualifying Holder is a company that owns directly at least 10% of our voting stock, the Belgian withholding tax rate is further reduced to 5%. No withholding tax is however applicable if the Qualifying Holder, is either of the following:

 

    a company that is a resident of the United States that has owned directly ADSs representing at least 10% of our capital for a twelve-month period ending on the date the dividend is declared, or

 

    a pension fund that is a resident of the United States, provided that such dividends are not derived from the carrying on of a business by the pension fund or through an associated enterprise.

Under the normal procedure, we or our paying agent must withhold the full Belgian withholding tax, without taking into account the reduced U.S.-Belgium Tax Treaty rate. Qualifying Holders may then make a claim for reimbursement for amounts withheld in excess of the rate defined by the U.S.-Belgium Tax Treaty. The reimbursement form (Form 276 Div-Aut.) can be obtained as follows:

 

    by letter from the Bureau Central de Taxation Bruxelles-Etranger, Boulevard du Jardin Botanique 50 boîte 3429, 1000 Brussels, Belgium;

 

    by fax at +32 (0) 257/968 42;

 

    via e-mail at ctk.db.brussel.buitenland@minfin.fed.be; or at

 

    http://financien.belgium.be/nl/ondernemingen/vennootschapsbelasting/voorheffingen/roerende_voorheffing/formulieren.

The reimbursement form is to be sent to the Bureau Central de Taxation Bruxelles-Etranger, Boulevard du Jardin Botanique 50 boîte 3429, 1000 Brussels, Belgium as soon as possible and in each case within a term of five years starting from the first of January of the year the withholding tax was withheld.

Qualifying Holders may also, subject to certain conditions, obtain the reduced U.S.-Belgium Tax Treaty rate at source. Qualifying Holders should deliver a duly completed Form 276 Div-Aut. no later than ten days after the date on which the dividend has been paid or attributed (whichever comes first).

Additionally, pursuant to Belgian domestic tax law, dividends distributed to corporate Holders that qualify as a parent company will be exempt from Belgian withholding tax provided that the ADSs held by the Holder, upon payment or attribution of the dividends, amount to at least 10% of our share capital and are held or will be held during an uninterrupted period of at least one year, and provided the anti-abuse provision does not apply. A Holder qualifies as a parent company if it has a legal form similar to the ones listed in the annex to the EU Parent-Subsidiary Directive of July 23, 1990 (90/435/EC), if it is considered to be a tax resident according to the laws of the United States of America and the U.S.-Belgium Tax Treaty, and if it is subject to a tax similar to the Belgian corporate income tax without benefiting from a tax regime that derogates from the ordinary tax regime.

In order to benefit from this exemption, the Holder must provide us or its paying agent with a certificate confirming its qualifying status and the fact that it satisfies the required conditions. If the Holder holds the ADSs for less than one year, at the time the dividends are paid on or attributed to the shares represented by the ADSs, we must deduct the withholding tax but we do not need to transfer it to the Belgian Treasury provided that the Holder certifies its qualifying status, the date from which the Holder has held the ADSs, and the Holder’s commitment to hold the shares for an uninterrupted period of at least one year. The Holder must also inform us or its paying agent when the one-year period has expired or if its shareholding drops below 10% of our share capital before the end of the one-year holding period. Upon satisfying the one-year shareholding requirement, the deducted dividend withholding tax will be paid to the Holder.

Dividends paid or attributable to a corporate Holder will under certain conditions be subject to a reduced 1.6995% withholding tax (5% of 33.99%), provided that the Holder has a legal form similar to the ones listed in Annex I, Part A to Council Directive 2011/96/EU of November 30, 2011 on the common system of taxation

 

159


Table of Contents

applicable in the case of parent companies and subsidiaries of different Member States, as amended by the Council Directive of July 8, 2014 (2014/86/EU) and holds a share participation in our share capital, upon payment or attribution of the dividends, of less than 10% but with an acquisition value of at least EUR 2,500,000 and has held this share participation in full legal ownership during an uninterrupted period of at least one year.

The reduced 1.6995% withholding tax is only applied to the extent that the Belgian withholding tax cannot be credited nor reimbursed at the level of the qualifying, dividend receiving, Holder. The Holder must provide us or its paying agent with a certificate confirming its qualifying status and the fact that it meets the required conditions.

Withholding tax is also not applicable, pursuant to Belgian domestic tax law, on dividends paid to a U.S. pension fund which satisfies the following conditions:

 

  (i) to be a legal entity with fiscal residence in the United States and without a permanent establishment or fixed base in Belgium,

 

  (ii) whose corporate purpose consists solely in managing and investing funds collected in order to pay legal or complementary pensions,

 

  (iii) whose activity is limited to the investment of funds collected in the exercise of its statutory mission, without any profit making aim and without operating a business in Belgium,

 

  (iv) which is exempt from income tax in the United States, and

 

  (v) provided that it (save in certain particular cases as described in Belgian law) is not contractually obligated to redistribute the dividends to any ultimate beneficiary of such dividends for whom it would manage the shares or ADSs, nor obligated to pay a manufactured dividend with respect to the shares or ADSs under a securities borrowing transaction. The exemption will only apply if the U.S. pension fund provides an affidavit confirming that it is the full legal owner or usufruct holder of the shares or ADSs and that the above conditions are satisfied. The organization must then forward that affidavit to us or our paying agent.

Prospective Holders are encouraged to consult their own tax advisers to determine whether they qualify for an exemption or a reduction of the withholding tax rate upon payment of dividends and, if so, the procedural requirements for obtaining such an exemption or a reduction upon the payment of dividends or making claims for reimbursement.

Capital Gains and Losses

Pursuant to the U.S.-Belgium Tax Treaty, capital gains and/or losses realized by a Qualifying Holder from the sale, exchange or other disposition of ADSs are exempt from tax in Belgium.

Capital gains realized on ADSs by a corporate Holder who is not a Qualifying Holder are generally not subject to taxation in Belgium unless such Holder is acting through a Belgian permanent establishment or a fixed place in Belgium to which the ADSs are effectively connected (in which case a 33.99%, 25.75%, 0.412% or 0% tax on the capital gain may apply, depending on the particular circumstances). Capital losses are generally not tax deductible.

Private individual Holders who are not Qualifying Holders and who are holding ADSs as a private investment will, as a rule, not be subject to tax in Belgium on any capital gains arising out of a disposal of ADSs. Losses will, as a rule, not be tax deductible.

Capital gains realized by a Holder upon the redemption of ADSs or upon our liquidation will generally be taxable as a dividend. See “—Dividend Withholding Tax” above.

 

160


Table of Contents

Estate and Gift Tax

There is no Belgium estate tax on the transfer of ADSs on the death of a Belgian non-resident. Donations of ADSs made in Belgium may or may not be subject to gift tax depending on the modalities under which the donation is carried out.

Belgian Tax on Stock Exchange Transactions

A stock market tax is normally levied on the purchase and the sale and on any other acquisition and transfer for consideration in Belgium of ADSs through a professional intermediary established in Belgium on the secondary market, so-called “secondary market transactions.” The tax is due from the transferor and the transferee separately. The applicable rate amounts to 0.27% with a cap of €1,600 per transaction and per party. Such tax is also due for transactions for which the order is directly or indirectly given by an individual with habitual abode in Belgium, or by a legal entity on account of its Belgian seat or establishment, to an intermediary established outside Belgium. In such case, this individual or legal entity should declare and pay the tax on stock exchange transactions due, unless if he can prove that it was already paid.

Belgian non-residents who purchase or otherwise acquire or transfer, for consideration, ADSs in Belgium for their own account through a professional intermediary may be exempt from the stock market tax if they deliver a sworn affidavit to the intermediary in Belgium confirming their non-resident status, except in case they would be considered to have their habitual abode or their seat or establishment in Belgium.

In addition to the above, no stock market tax is payable by: (i) professional intermediaries described in Article 2, 9 and 10 of the Law of August 2, 2002 acting for their own account, (ii) insurance companies described in Article 2, §1 of the Law of July 9, 1975 acting for their own account, (iii) professional retirement institutions referred to in Article 2, §1 of the Law of October 27, 2006 relating to the control of professional retirement institutions acting for their own account, (iv) collective investment institutions acting for their own account, (v) the aforementioned non-residents acting for their own account (upon delivery of a certificate of non-residency in Belgium), or (vi) regulated real estate companies acting for their own account.

No stock exchange tax will thus be due by Holders on the subscription, purchase or sale of ADSs, if the Holders are acting for their own account, except in case they would be considered to have their habitual abode or their seat or establishment in Belgium. In order to benefit from this exemption, the Holders must file with the professional intermediary in Belgium a sworn affidavit evidencing that they are non-residents for Belgian tax purposes.

Proposed Financial Transactions Tax

On February 14, 2013 the EU Commission adopted a Draft Directive on a common Financial Transaction Tax (the “FTT”). Earlier negotiations for a common transaction tax among all 28 EU Member States had failed. The current negotiations between Austria, Belgium, France, Germany, Greece, Italy, Portugal, Slovakia, Slovenia and Spain (the Participating Member States) are seeking a compromise under “enhanced cooperation” rules, which require consensus from at least nine nations. Earlier Estonia dropped out of the negotiations by declaring it would not introduce the FTT.

The Draft Directive currently stipulates that once the FTT enters into force, the Participating Member States shall not maintain or introduce taxes on financial transactions other than the FTT (or VAT as provided in the Council Directive 2006/112/EC of November 28, 2006 on the common system of value added tax). For Belgium, the tax on stock exchange transactions should thus be abolished once the FTT enters into force.

However, the Draft Directive on the FTT remains subject to negotiations between the Participating Member States. It may therefore be altered prior to any implementation, of which the eventual timing and outcome remains unclear. Additional EU Member States may decide to participate or drop out of the negotiations. If the number of Participating Member States would fall below nine, it would put an end to the legislative project.

 

161


Table of Contents

In June 2016, the Participating Member States declared that they would continue their efforts in the second half of the year but since then the negotiating parties have not been successful in reaching an agreement.

Prospective investors should consult their own professional advisors in relation to the FTT.

 

F. Dividends and Paying Agents.

Not applicable.

 

G. Statement by Experts.

Not applicable.

 

H. Documents on Display.

We are subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements will file reports with the SEC. Those reports may be inspected without charge at the locations described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. Nevertheless, we will file with the SEC an annual report containing financial statements that have been examined and reported on, with and opinion expressed by an independent registered public accounting firm.

We maintain a corporate website at www.glpg.com. We intend to post a link to our annual report on Form 20-F as filed with the SEC on our website promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this annual report. We have included our website address in this annual report solely as an inactive textual reference.

You may also review a copy of this annual report, including exhibits and any schedule filed herewith, and obtain copies of such materials at prescribed rates, at the SEC’s Public Reference Room in Room 1580, 100 F Street, NE, Washington, D.C. 20549-0102. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website ( www.sec.gov ) that contains reports, proxy and information statements and other information regarding registrants, such as Galapagos NV, that file electronically with the SEC.

With respect to references made in this annual report to any contract or other document of Galapagos NV, such references are not necessarily complete and you should refer to the exhibits attached or incorporated by reference to this annual report for copies of the actual contract or document.

 

I. Subsidiary Information.

Not applicable.

 

Item 11 Quantitative and Qualitative Disclosures About Market Risk.

Our financial risks are managed centrally. Our finance department coordinates the access to national and international financial markets and considers and manages continuously the financial risks concerning our activities. These relate to the financial markets risk, credit risk, liquidity risk and currency risk. There are no other important risks, such as interest rate risk, because we have nearly no financial debt and have a strong cash position. We do not buy or trade financial instruments for speculative purposes. For additional information on general risk factors, please see the section of this annual report titled “Item 3.D.—Risk Factors.”

 

162


Table of Contents

Liquidity Risk

Our consolidated balance sheet shows an amount of €112.3 million as incurred losses at the end of 2016. Management forecasts our liquidity requirements to ensure that there is sufficient cash to meet operational needs. We have no credit lines. Such forecasting is based on realistic assumptions with regards to milestone and upfront payments to be received, taking into account our past track record, including the assumption that not all new projects that are being planned will be realized.

Credit Risk

The term “credit risk” refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss.

Our trade receivables consist of a limited amount of creditworthy customers, many of which are large pharmaceutical companies, spread over different geographical areas. To limit the risk of financial losses, a policy of only dealing with creditworthy counterparties has been developed.

We grant credit to our clients in the framework of our normal business activities. Usually, we require no pledge or other collateral to cover the amounts due. Management continuously evaluates the client portfolio for creditworthiness. All receivables are considered collectable, except for these for which a provision for doubtful debtors has been established. The aging balance of receivables that are due, but that are still considered collectable is set forth in the table below:

 

     December 31,  
         2016              2015              2014      
     (Euro, in thousands)  

60–90 days

   170      86      17  

90–120 days

     —          —          —    

More than 120 days

   54      17      45  

Our cash and cash equivalents are invested primarily in savings and deposit accounts. Saving and deposit accounts generate a small amount of interest income. For banks and financial institutions, only independently rated parties with a minimum rating of ‘A’ are accepted at the beginning of the term.

Interest Rate Risk

The only variable interest-bearing financial asset is cash and cash equivalents.

Changes in interest rates may cause variations in interest income and expenses resulting from short term interest-bearing assets. Management does not expect the short term interest rates to decrease significantly in the immediate foreseeable future, which limits the interest exposure on our cash and cash equivalents.

Effect of Interest Rate Fluctuation

A 100 basis point increase in interest rates at balance sheet date would have increased profit and loss by approximately €10 million (2015: €3 million); a 100 basis point decrease in interest rates would have decreased profit and loss by approximately €10 million (2015: €3 million).

Foreign Exchange Risk

We are exposed to foreign exchange risk arising from various currency exposures. Our functional currency is euro, but we receive payments from our main business partners AbbVie and Gilead in U.S. dollars and acquire some consumables and materials in U.S. dollars, Swiss Francs, GB Pounds and Croatian Kuna.

 

163


Table of Contents

To limit this risk, we attempt to align incoming and outgoing cash flows in currencies other than the euro. In addition, contracts closed by our different entities are mainly in the functional currencies of that entity, except for the alliance agreements signed with AbbVie and Gilead for which payments are denominated in U.S. dollars.

In order to further reduce this risk, a netting system was implemented in the course of 2012, which restrains intra-group payments between entities with a different functional currency.

The exchange rate risk in case of a 10% change in the exchange rate amounts to:

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Net book value:

        

Increase in Euros - U.S. Dollars

   (16,863    506      589  

Increase in Euros - GB Pounds

     130        164        138  

Increase in Euros - CH Francs

     165        169        181  

Increase in Euros - HR Kunas

     (95      (50      215  

Increase in U.S. Dollars - GB Pounds

   (913    (907    (807

The exchange rate risk on the U.S. dollar is primarily related to our cash and cash equivalents held in U.S dollars.

Capital Risk Factors

We manage our capital to safeguard that we will be able to continue as a going concern. At the same time, we want to ensure the return to our shareholders through the results from our research and development activities.

Our capital structure consists of cash-at-bank and in-hand and cash equivalents, financial debt (which as of December 31, 2016, consists of finance leases and advances from Oseo, a French public organization for innovation support, for €0.1 million), and equity attributed to the holders of our equity instruments, such as capital, reserves and results carried forward, as mentioned in the consolidated statement of changes in equity.

We manage our capital structure and make the necessary adjustments in the light of changes of economic circumstances, the risk characteristics of underlying assets and the projected cash needs of the current research and development activities.

The adequacy of the capital structure will depend on many factors, including scientific progress in the research and development programs, the magnitude of those programs, the commitments to existing and new clinical contract research organizations, the ability to establish new alliance or collaboration agreements, the capital expenditures, market developments and any future acquisition.

Neither we nor any of our subsidiaries are subject to any externally imposed capital requirements, other than those imposed by generally applicable company law requirements.

 

Item 12 Description of Securities Other than Equity Securities.

 

A. Debt Securities.

Not applicable.

 

B. Warrants and Rights.

Not applicable.

 

164


Table of Contents
C. Other Securities.

Not applicable.

 

D. American Depositary Shares.

Citibank, N.A., as depositary, registers and delivers ADSs. Each ADS represents one ordinary share (or a right to receive one ordinary share) deposited with Citibank International Limited, located at EGSP 186, 1 North Wall Quay, Dublin 1 Ireland or any successor, as custodian for the depositary. Each ADS will also represent any other securities, cash or other property which may be held by the depositary in respect of the depositary facility. The depositary’s corporate trust office at which the ADSs are administered is located at 388 Greenwich Street, New York, New York 10013.

A deposit agreement among us, the depositary and the ADS holders sets out the ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. A copy of the deposit agreement is incorporated by reference as an exhibit to this annual report.

Fees and Charges

Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees:

 

Service    Fees

•      Issuance of ADSs

   Up to U.S. $0.05 per ADS issued

•      Cancellation of ADSs

   Up to U.S. $0.05 per ADS canceled

•      Distribution of cash dividends or other cash distributions

   Up to U.S. $0.05 per ADS held

•      Distribution of ADSs pursuant to stock dividends, free stock distributions or exercise of rights.

   Up to U.S. $0.05 per ADS held

•      Distribution of securities other than ADSs or rights to purchase additional ADSs

   Up to U.S. $0.05 per ADS held

•      ADS Services

   Up to U.S. $0.05 per ADS held on the applicable record date(s) established by the depositary

The holders of ADSs will also be responsible to pay certain fees and expenses incurred by the depositary and certain taxes and governmental charges such as:

 

    fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the ordinary shares in France (i.e., upon deposit and withdrawal of ordinary shares);

 

    expenses incurred for converting foreign currency into U.S. dollars;

 

    expenses for cable, telex and fax transmissions and for delivery of securities;

 

    taxes and duties upon the transfer of securities (i.e., when ordinary shares are deposited or withdrawn from deposit); and

 

    fees and expenses incurred in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs or American Depositary Receipts, or ADRs, or in connection with the delivery or servicing of ordinary shares on deposit.

Depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary by the brokers (on behalf of their clients) receiving the newly issued ADSs from the depositary and by the brokers

 

165


Table of Contents

(on behalf of their clients) delivering the ADSs to the depositary for cancellation. The brokers in turn charge these fees to their clients. Depositary fees payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary to the holders of record of ADSs as of the applicable ADS record date.

The depositary fees payable for cash distributions are generally deducted from the cash being distributed. In the case of distributions other than cash (i.e., stock dividend, rights), the depositary charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or uncertificated in direct registration), the depositary sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary generally collects its fees through the systems provided by DTC (whose nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients’ ADSs in DTC accounts in turn charge their clients’ accounts the amount of the fees paid to the depositary.

In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder.

Note that the fees and charges the holders of ADSs may be required to pay may vary over time and may be changed by us and by the depositary. The holders of ADSs will receive prior notice of such changes.

The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program established pursuant to the deposit agreement, by making available a portion of the depositary fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary may agree from time to time.

 

166


Table of Contents

PART II

 

Item 13 Defaults, Dividend Arrearages and Delinquencies.

Not applicable.

 

Item 14 Material Modifications to the Rights of Security Holders and Use of Proceeds.

Global Offering

In May 2015, we sold 5,746,000 ADSs, each representing one ordinary share, no nominal value, and 1,786,499 ordinary shares, in our global offering at a price of $42.05 per ADS and €37.00 per share, including the exercise in full by the underwriters of their option to purchase additional ADSs and ordinary shares, for aggregate gross proceeds to us of approximately €278.7 million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering expenses, were approximately €259.3 million. The offering commenced on May 6, 2015 and did not terminate before all of the securities registered in the registration statement were sold. The effective date of the registration statement, File No. 333-203435, for our global offering was May 13, 2015. Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC and Cowen and Company, LLC acted as joint book-running managers, and Nomura Securities International, Inc. and Bryan, Garnier & Co. acted as co-managers, of the global offering.

A portion of the net proceeds from our global offering was used to advance our CF program and our other discovery and development programs, as well as for general corporate and working capital purposes. The balance is held in cash and cash equivalents and is intended to be used to advance the discovery and development of our programs, mainly our CF and IPF programs, and for working capital and general corporate purposes. We currently expect that our cash needs for developing our filgotinib program with Gilead will be entirely financed by the equity investment and upfront payment which were received in January 2016.

None of the net proceeds of our global offering were paid directly or indirectly to any director, officer, general partner of ours or to their associates, persons owning 10% or more of any class of our equity securities, or to any of our affiliates.

 

Item 15 Controls and Procedures.

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b) as of December 31, 2016. While there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures, our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. Based upon our evaluation, as of December 31, 2016, the Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures, in accordance with Exchange Act Rule 13a-15(e), (i) are effective at that level of reasonable assurance in ensuring that information required to be disclosed in the reports that are filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, and (ii) are effective at that level of reasonable assurance in ensuring that information to be disclosed in the reports that are filed or submitted under the Exchange Act is accumulated and communicated to the management of our company, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed, under the supervision of the Chief

 

167


Table of Contents

Executive Officer and Chief Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with generally accepted accounting principles.

Our internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly, reflect transactions and dispositions of assets, provide reasonable assurance that transactions are recorded in the manner necessary to permit the preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are only carried out in accordance with the authorization of our management and directors, and provide reasonable assurance regarding the prevention or timely detection of any unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Moreover, projections of any evaluation of the effectiveness of internal control to future periods are subject to a risk that controls may become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.

Our management has assessed the effectiveness of internal control over financial reporting based on the Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on this assessment, our management has concluded that our internal control over financial reporting as of December 31, 2016 was effective.

The effectiveness of internal control over financial reporting as of December 31, 2016 has been audited by Deloitte Bedrijfsrevisoren BV o.v.v.e. CVBA, our independent registered public accounting firm. Their audit report, including their opinion on management’s assessment of internal control over financial reporting, is included in our audited consolidated financial statements included in this annual report.

Changes in Internal Control over Financial Reporting

During the period covered by this annual report, we have not made any change to our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 15T. Controls and Procedures.

Not applicable.

 

Item 16 Reserved.

Not applicable.

 

Item 16A Audit Committee Financial Expert.

Our board of directors has determined that Werner Cautreels is an audit committee financial expert as defined by SEC rules and has the requisite financial sophistication under the applicable rules and regulations of the NASDAQ Stock Market. Dr. Cautreels is independent as such term is defined in Rule 10A-3 under the Exchange Act and under the listing standards of the NASDAQ Stock Market.

 

Item 16B Code of Business Conduct and Ethics.

We have adopted a Code of Business Conduct and Ethics, or the Code of Conduct, that is applicable to all of our employees, members of our executive committee and directors. The Code of Conduct is available on our website at www.glpg.com . Our board of directors is responsible for administering the Code of Conduct and will

 

168


Table of Contents

be required to approve any waivers of the Code of Conduct for directors or members of our executive committee. Any waivers of the Code of Conduct for other employees may also be made by the compliance officer. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website.

 

Item 16C Principal Accountant Fees and Services.

Deloitte Bedrijfsrevisoren BV o.v.v.e. CVBA has served as our independent registered public accounting firm for 2015 and 2016. Our accountants billed the following fees to us for professional services in each of those fiscal years:

 

     Year ended December 31,  
         2016              2015      
     (Euro, in thousands)  

Audit fees

   515.0      280.0  

Audit-related fees

     186.0        538.4  

Tax fees

     —          7.9  

All other fees

     —          —    
  

 

 

    

 

 

 

Total

   701.0      826.3  
  

 

 

    

 

 

 

“Audit Fees” are the aggregate fees billed for the audit of our annual financial statements. This category also includes services that generally the independent accountant provides, such as consents and assistance with and review of documents filed with the SEC.

“Audit-Related Fees” are the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit and are not reported under Audit Fees. In 2015, “Audit Related Fees” also include fees billed for assurance and audit-related services regarding our global offering.

“Tax Fees” are the aggregate fees billed for professional services rendered by the principal accountant for tax compliance, tax advice and tax planning related services.

“All Other Fees” are any additional amounts billed for products and services provided by the principal accountant. No other fees were paid to Deloitte Bedrijfsrevisoren BV o.v.v.e. CVBA for the fiscal years ended December 31, 2016 and 2015 .

Audit and Non-Audit Services Pre-Approval Policy

The audit committee has responsibility for, among other things, appointing, setting compensation of and overseeing the work of our independent registered public accounting firm, or external auditor. In recognition of these responsibilities, the audit committee has adopted a policy governing the pre-approval of all audit and permitted non-audit services performed by our external auditor to ensure that the provision of such services does not impair the external auditor’s independence from us and our management. Unless a type of service to be provided by our external auditor has received general pre-approval from the audit committee, it requires specific pre-approval by the audit committee. The payment for any proposed services in excess of pre-approved cost levels requires specific pre-approval by the audit committee.

Pursuant to its pre-approval policy, the audit committee may delegate its authority to pre-approve services to the chairperson of the Audit Committee. The decisions of the chairperson to grant pre-approvals must be presented to the full audit committee at its next scheduled meeting. The audit committee may not delegate its responsibilities to pre-approve services to the management.

The audit committee has considered the non-audit services provided by Deloitte Bedrijfsrevisoren BV o.v.v.e. CVBA as described above and believes that they are compatible with maintaining Deloitte Bedrijfsrevisoren BV o.v.v.e. CVBA’s independence as our external auditor.

 

169


Table of Contents
Item 16D Exemptions from the Listing Standards for Audit Committees.

Not applicable.

 

Item 16E Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

Not applicable.

 

Item 16F Change in Registrant’s Certifying Accountant.

Not applicable.

 

Item 16G Corporate Governance.

As a Belgian naamloze vennootschap / société anonyme, we are subject to various corporate governance requirements under Belgian law. In addition, as a foreign private issuer listed on the NASDAQ Global Select Market, we will be subject to NASDAQ corporate governance listing standards. However, the NASDAQ Global Select Market’s listing standards provide that foreign private issuers are permitted to follow home country corporate governance practices in lieu of the NASDAQ rules, with certain exceptions. We intend to rely on the certain exemptions for foreign private issuers and follow Belgian corporate governance practices in lieu of the NASDAQ corporate governance rules.

Differences Between Our Corporate Governance Practices and the Listing Rules of the NASDAQ Stock Market

The following are the significant ways in which our corporate governance practices differ from those required for U.S. companies listed on NASDAQ:

 

    Quorum At Shareholder Meetings. NASDAQ Stock Market Listing Rule 5620(c) requires that for any shareholders’ meeting, the quorum must be no less than 33 1/3 % of the outstanding ordinary shares. There is no quorum requirement under Belgian law for our shareholders’ meetings, except as provided for by law in relation to decisions regarding certain matters.

 

    Committee. NASDAQ Stock Market Listing Rule 5605(d)(2) requires that compensation of officers must be determined by, or recommended to, the board of directors for determination, either by a majority of the independent directors, or a compensation committee comprised solely of independent directors. NASDAQ Stock Market Listing Rule 5605(e) requires that director nominees be selected, or recommended for selection, either by a majority of the independent directors or a nominations committee comprised solely of independent directors. Under Belgian law, we are not subject to such composition requirements. Pursuant to Article 526quater of the Belgian Companies Code and the principles and guidelines of the Belgian Corporate Governance Code, we are required to set up a remuneration committee within our board of directors. In addition, the Belgian Corporate Governance Code provides that the board of directors should set up a nomination committee, which can be combined with the remuneration committee. Our board of directors has set up and appointed a nomination and remuneration committee.

 

    Executive Session. NASDAQ Stock Market Listing Rule 5605(b)(2) requires that independent directors must have regularly scheduled meetings at which only independent directors are present. We do not intend to require our independent directors to meet separately from the full board of directors on a regular basis or at all, although the board of directors is supportive of its independent members voluntarily arranging to meet separately from the other members of our board of directors when and if they wish to do so.

 

    Charters. NASDAQ Stock Market Listing Rules 5605(c)(1), (d)(1) and (e)(2) require that each committee of the board of directors must have a formal written charter. Pursuant to the Belgian Corporate Governance Code, our board of directors has drawn up a corporate governance charter including, amongst others, the internal rules of our committees.

 

170


Table of Contents
    Shareholder Approval for Certain Issuances of Securities. NASDAQ Stock Market Listing Rule 5635 requires that a company obtains shareholder approval prior to making certain issuances of securities. Pursuant to the Belgian Companies Code and subject to the conditions set forth therein and in our articles of association, our board of directors is allowed to issue shares through the use of authorized capital limited to the maximum amount of our share capital. The authorized capital may however not be used for (i) capital increases by contribution in kind exclusively reserved for one of our shareholders holding shares to which more than 10% of the voting rights are attached, (ii) the issuance of shares at a price lower than the accounting par value (fractiewaarde/pair comptable) of the then outstanding shares of the same class, or (iii) the issuance of warrants intended mainly for one or more specified persons other than our or our subsidiaries’ employees. Restrictions on the use of the authorized capital also exist in case a public take-over bid on us has been announced.

 

Item 16H Mine Safety Disclosure.

Not applicable.

 

171


Table of Contents

PART III

 

Item 17 Financial Statements.

See pages F-1 through F-71 of this annual report.

 

Item 18 Financial Statements.

Not applicable.

 

Item 19 Exhibits.

The Exhibits listed in the Exhibit Index at the end of this annual report are filed as Exhibits to this annual report.

 

172


Table of Contents

Index to Financial Statements

FINANCIAL SECTION

Audited consolidated Financial Statements as of and for the years ended December 31, 2016, 2015 and 2014

Contents

 

Reports of Independent Registered Public Accounting Firm

     F-2  

Consolidated Statement of Financial Position

     F-4  

Consolidated Statement of Operations

     F-5  

Consolidated Statement of Comprehensive Income

     F-6  

Consolidated Statement of Changes in Equity

     F-7  

Consolidated Statement of Cash Flows

     F-8  

Notes to Consolidated Financial Statements

     F-9  

 

F-1


Table of Contents

REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

21 March 2017

To the board of directors and shareholders of Galapagos NV and subsidiaries

We have audited the accompanying consolidated statements of financial position of Galapagos NV and its subsidiaries (the “Company”) as of 31 December 2016, 2015 and 2014, and the related consolidated statements of operations, comprehensive income, changes in equity, and cash flows for each of the three years in the period ended 31 December 2016, 2015 and 2014. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such financial statements present fairly, in all material respects, the financial position of Galapagos NV and its subsidiaries as of 31 December 2016, 2015 and 2014, and the results of their operations, their comprehensive income, their changes in equity and their cash flows for each of the three years in the period ended 31 December 2016, 2015 and 2014, in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as of 31 December 2016, based on the criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated 21 March 2017 expressed an unqualified opinion on the Company’s internal control over financial reporting.

Zaventem, 21 March 2017

The statutory auditor

 

/s/ Gert Vanhees

DELOITTE Bedrijfsrevisoren / Reviseurs d’Entreprises

BV o.v.v.e. CVBA / SC s.f.d. SCRL
Represented by Gert Vanhees

 

F-2


Table of Contents

21 March 2017

To the board of directors and shareholders of Galapagos NV and subsidiaries

We have audited the internal control over financial reporting of Galapagos NV and its subsidiaries (the “Company”) as of 31 December 2016, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying consolidated statements of financial position. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of 31 December 2016, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated statements of financial position as of and for the year ended 31 December 2016 of the Company and our report dated 21 March 2017, expressed an unqualified opinion on those financial statements.

Zaventem, 21 March 2017

The statutory auditor

 

/s/ Gert Vanhees

DELOITTE Bedrijfsrevisoren / Reviseurs d’Entreprises
BV o.v.v.e. CVBA / SC s.f.d. SCRL
Represented by Gert Vanhees

 

F-3


Table of Contents

Consolidated Statement of Financial Position

 

     (Euro, in thousands)  
     December 31,        
     2016     2015     2014     Notes  

Assets

        

Intangible assets

   1,023     1,550     2,015       12  

Property, plant and equipment

     14,961       13,782       10,091       13  

Deferred tax assets

     1,957       1,726       293       22  

Non-current R&D incentives receivables

     54,188       49,384       43,944       15  

Non-current restricted cash

     1,098       1,046       306       16  

Other non-current assets

     2,880       557       215       14  
  

 

 

   

 

 

   

 

 

   

Non-currents assets

     76,107       68,044       56,864    
  

 

 

   

 

 

   

 

 

   

Inventories

     300       325       281    

Trade and other receivables

     9,728       3,931       3,211       17  

Current R&D incentives receivables

     10,154       9,161       7,351       15  

Cash and cash equivalents

     973,241       340,314       187,712       18  

Current restricted cash

     6,570       6,857       10,422       16  

Current financial asset from share subscription agreement

     —         8,371       —         7  

Other current assets

     7,239       5,512       4,625       17  
  

 

 

   

 

 

   

 

 

   

Current assets

     1,007,232       374,470       213,603    
  

 

 

   

 

 

   

 

 

   

Total assets

   1,083,338     442,514     270,467    
  

 

 

   

 

 

   

 

 

   

Equity and liabilities

        

Share capital

   223,928     185,399     157,274       19  

Share premium account

     649,135       357,402       114,182       19  

Other reserves

     (1,000     (18     (220     20  

Translation differences

     (1,090     (467     (1,157     21  

Accumulated losses

     (112,272     (177,317     (63,944  
  

 

 

   

 

 

   

 

 

   

Total equity

     758,701       364,999       206,135    
  

 

 

   

 

 

   

 

 

   

Pension liabilities

     3,520       2,693       2,865       29  

Provisions

     63       55       72       25  

Finance lease liabilities

     9       63       115       23  

Other non-current liabilities

     2,469       2,291       923       24  

Non-current deferred income

     214,785       —         —         24  
  

 

 

   

 

 

   

 

 

   

Non-current liabilities

     220,846       5,103       3,976    
  

 

 

   

 

 

   

 

 

   

Provisions

     —         —         105       25  

Finance lease liabilities

     54       52       52       23  

Trade and other payables

     31,269       29,482       30,007       24  

Current tax payable

     1,022       2,583       2,582       9  

Accrued charges

     619       490       585       24  

Deferred income

     70,827       39,806       27,026       24  
  

 

 

   

 

 

   

 

 

   

Current liabilities

     103,791       72,412       60,356    
  

 

 

   

 

 

   

 

 

   

Total liabilities

     324,637       77,515       64,332    
  

 

 

   

 

 

   

 

 

   

Total equity and liabilities

   1,083,338     442,514     270,467    
  

 

 

   

 

 

   

 

 

   

The accompanying notes form an integral part of these financial statements.

 

F-4


Table of Contents

Consolidated Statement of Operations

 

     (Euro, in thousands, except share and per share data)  
     Year Ended December 31,        
     2016     2015     2014     Notes  

Revenues

   129,519     39,563     69,368       4  

Other income

     22,093       21,017       20,653       4  
  

 

 

   

 

 

   

 

 

   

Total revenues and other income

     151,612       60,579       90,021    
  

 

 

   

 

 

   

 

 

   

Service cost of sales

        

Research and development expenditure

     (139,573     (129,714     (111,110     5  

General and administrative expenses

     (21,744     (19,127     (13,875     5  

Sales and marketing expenses

     (1,785     (1,182     (992     5  

Restructuring and integration costs

     —         —         (669     5  
  

 

 

   

 

 

   

 

 

   

Total operating expenses

     (163,103     (150,023     (126,646  
  

 

 

   

 

 

   

 

 

   

Operating loss

     (11,491     (89,444     (36,624  
  

 

 

   

 

 

   

 

 

   

Fair value re-measurement of share subscription agreement

     57,479       (30,632     —         7  

Other financial income

     9,950       1,987       2,291       8  

Other financial expenses

     (1,692     (1,539     (867     8  
  

 

 

   

 

 

   

 

 

   

Income / loss (-) before tax

     54,246       (119,627     (35,201  
  

 

 

   

 

 

   

 

 

   

Income taxes

     (235     1,218       (2,103     9  
  

 

 

   

 

 

   

 

 

   

Net income / loss (-) from continuing operations

     54,012       (118,410     (37,303  
  

 

 

   

 

 

   

 

 

   

Net income from discontinued operations

     —         —         70,514       10  
  

 

 

   

 

 

   

 

 

   

Net income / loss (-)

   54,012     (118,410   33,211       11  
  

 

 

   

 

 

   

 

 

   

Net income / loss (-) attributable to:

        

Owners of the parent

     54,012       (118,410     33,211    
  

 

 

   

 

 

   

 

 

   

Basic income / loss (-) per share

   1.18     (3.32   1.10       11  
  

 

 

   

 

 

   

 

 

   

Diluted income / loss (-) per share

   1.14     (3.32   1.10    
  

 

 

   

 

 

   

 

 

   

Basic income/ loss (-) per share from continuing operations

   1.18     (3.32   (1.24  
  

 

 

   

 

 

   

 

 

   

Diluted income/ loss (-) per share from continuing operations

   1.14     (3.32   (1.24  
  

 

 

   

 

 

   

 

 

   

Weighted average number of shares—Basic (in ‘000 shares)

     45,696       35,700       30,108       11  

Weighted average number of shares—Diluted (in ‘000 shares)

     47,308       35,700       30,108    

The accompanying notes form an integral part of these financial statements.

 

F-5


Table of Contents

Consolidated Statement of Comprehensive Income

 

     Year ended December 31,  
     2016     2015     2014  
     (Euro, in thousands)  

Net income / loss (-)

   54,012     (118,410   33,211  
  

 

 

   

 

 

   

 

 

 

Items that will not be reclassified subsequently to profit or loss:

      

Re-measurement of defined benefit obligation

     (583     202       (267

Items that may be reclassified subsequently to profit or loss:

      

Fair value adjustment of financial assets available for sale

     (399     —         —    

Translation differences, arisen from translating foreign activities

     (623     690       460  

Translation differences, arisen from the sale of service division

     —         —         (1,787
  

 

 

   

 

 

   

 

 

 

Other comprehensive income, net of income tax

     (1,605     892       (1,594
  

 

 

   

 

 

   

 

 

 

Total comprehensive income attributable to:

      

Owners of the parent

   52,406     (117,517   31,617  

The accompanying notes form an integral part of these financial statements.

 

F-6


Table of Contents

Consolidated Statement of Changes in Equity

 

     Share
capital
    Share
premium
account
     Translation
differences
    Other
reserves
    Accumul.
losses
    Total  

On January 1, 2014

   154,542     112,484      170     47     (100,107   167,137  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     —          —           —          —          33,211       33,211  

Other comprehensive income

     —          —           (1,327     (267     —          (1,594

Total comprehensive income

     —          —           (1,327     (267     33,211       31,617  

Share-based compensation

     —          —           —          —          2,952       2,952  

Exercise of warrants

     2,732       1,698        —          —          —          4,430  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2014

   157,274     114,182      (1,157   (220   (63,944   206,135  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     —          —           —          —          (118,410     (118,410

Other comprehensive income

     —          —           690       202       —          892  

Total comprehensive income

     —          —           690       202       (118,410     (117,517

Share-based compensation

     —          —           —          —          5,036       5,036  

Issue of new shares

     40,751       237,952        —          —          —          278,703  

Share issue costs

     (19,360     —           —          —          —          (19,360

Exercise of warrants

     6,734       5,269        —          —          —          12,002  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2015

   185,399     357,402      (467   (18   (177,317   364,999  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     —          —           —          —          54,012       54,012  

Other comprehensive income

     —          —           (623     (982     —          (1,605

Total comprehensive income

     —          —           (623     (982     54,012       52,406  

Share-based compensation

     —          —           —          —          11,034       11,034  

Issue of new shares

     36,575       289,696        —          —          —          326,271  

Share issue costs

     (269     —           —          —          —          (269

Exercise of warrants

     2,223       2,037        —          —          —          4,261  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2016

   223,928     649,135      (1,090   (1,000   (112,272   758,701  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes form an integral part of these financial statements.

 

F-7


Table of Contents

Consolidated Statement of Cash Flows

 

     (Euro, in thousands)        
     2016     2015     2014     Notes  

Cash and cash equivalents at beginning of year

   340,314     187,712     138,175       18  
  

 

 

   

 

 

   

 

 

   

Net income / loss (-)

     54,012       (118,410     33,211    

Adjustments for:

        

Tax income (-) /expenses

     235       (1,218     2,337       9  

Other net financial income

     (8,258     (448     (1,841     8  

Fair value re-measurement of share subscription agreement

     (57,479     30,632       —         7  

Depreciation of property, plant and equipment

     3,322       2,372       3,582       13  

Amortization of intangible fixed assets

     860       1,030       1,067       12  

Net realized gain / loss (-) on foreign exchange transactions

     1,229       (398     (261  

Share-based compensation

     11,034       5,036       2,952       30  

Increase / decrease (-) in provisions

     7       (125     27       25  

Increase in pension liabilities

     244       30       409       29  

Gain on disposal of fixed assets

     (14     (62     —      

Gain on sale of service division

     —         —         (67,508     33  
  

 

 

   

 

 

   

 

 

   

Operating cash flows before movements in working capital

     5,192       (81,560     (26,025  

Increase (-) / decrease in inventories

     25       (44     (32  

Increase in receivables

     (12,978     (7,220     (10,110     17  

Increase / decrease (-) in payables

     2,102       (39,508     11,642       24  

Increase / decrease (-) in deferred income

     245,806       12,780       (51,953     24  
  

 

 

   

 

 

   

 

 

   

Cash generated / used (-) from operations

     240,148       (115,553     (76,479  

Interest paid

     (47     (49     (113  

Interest received

     1,066       1,106       951    

Income taxes paid (-) / received

     (1,763     (94     86    
  

 

 

   

 

 

   

 

 

   

Net cash flows generated/used (-) in operating activities

     239,403       (114,590     (75,555  
  

 

 

   

 

 

   

 

 

   

Purchase of property, plant and equipment

     (4,458     (6,100     (2,061     13  

Purchase of and expenditure in intangible fixed assets

     (332     (565     (743     12  

Proceeds from disposal of intangible assets

     18       110       —         12  

Proceeds from disposal of property, plant and equipment

     —         —         45       13  

Disposals of subsidiaries, net of cash disposed

     —         —         130,787       33  

Increase (-) / decrease in restricted cash

     235       2,258       (7,422     16  

Acquisition of available-for-sale financial assets

     (2,750     —         —         14  
  

 

 

   

 

 

   

 

 

   

Net cash flows generated/used (-) in investing activities

     (7,287     (4,297     120,606    
  

 

 

   

 

 

   

 

 

   

Repayment of obligations under finance leases and other debts

     (49     (43     (216     23  

Proceeds from capital and share premium increases, net of issue costs

     391,784       259,410       —         19  

Proceeds from capital and share premium increases from exercise of warrants

     4,261       12,003       4,430       19  
  

 

 

   

 

 

   

 

 

   

Net cash flows generated in financing activities

     395,996       271,370       4,214    
  

 

 

   

 

 

   

 

 

   

Effect of exchange rate differences on cash and cash equivalents

     4,816       118       271    
  

 

 

   

 

 

   

 

 

   

Increase in cash and cash equivalents

     632,927       152,601       49,537    
  

 

 

   

 

 

   

 

 

   

Cash and cash equivalents at end of year

   973,241     340,314     187,712       18  
  

 

 

   

 

 

   

 

 

   

The accompanying notes form an integral part of these financial statements.

 

F-8


Table of Contents

Notes to Consolidated Financial Statements

1. General information

Galapagos NV is a limited liability company incorporated in Belgium and has its registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium. In the notes to the consolidated financial statements, references to “we,” “us,” “the group” or “Galapagos” include Galapagos NV together with its subsidiaries.

R&D

The R&D operations are specialized in the discovery and development of small molecules. Our ambition is to become a leading global biotechnology company focused on the development and commercialization of novel medicines. Our strategy is to leverage our unique and proprietary target discovery platform, which facilitates our discovery and development of therapies with novel modes of action.

The components of the operating result for continuing operations presented in the financial statements include the following companies: Galapagos NV (Mechelen, Belgium); Galapagos SASU (Romainville, France); Galapagos B.V. (Leiden, the Netherlands); Fidelta d.o.o. (Zagreb, Croatia); BioFocus, Inc. and its subsidiaries, BioFocus DPI LLC, and Xenometrix, Inc.; BioFocus DPI AG (Basel, Switzerland) and its subsidiary Discovery Partners International GmbH (Heidelberg, Germany); and Inpharmatica Ltd. (Saffron Walden, UK).

Our continuing operations have around 508 employees working in the operating facilities in Mechelen (the Belgian headquarters), the Netherlands, France, and Croatia.

SERVICES

We sold our service division to Charles River Laboratories International, Inc. on April 1, 2014.

The legal entities that were sold as part of this transaction were BioFocus DPI (Holdings) Ltd., BioFocus DPI Ltd., Argenta Discovery 2009 Ltd. and Cangenix Ltd. Galapagos B.V. was not sold; its service division operations were carved out by means of an asset deal.

As a result of this sale, the service division is reported as discontinued operations.

2. Significant accounting policies

Our principal accounting policies are summarized below.

BASIS OF PREPARATION AND GOING CONCERN ASSUMPTION

The consolidated financial statements are prepared in accordance with the International Financing Reporting Standards (IFRS), issued by the International Accounting Standard Board (IASB) and the interpretations issued by the IASB’s International Financial Reporting Interpretation Committee. The consolidated financial statements provide a general overview of our activities and the results achieved. They give a true and fair view of our financial position, our financial performance and cash flows, on a going concern basis.

NEW STANDARDS AND INTERPRETATIONS APPLICABLE FOR THE ANNUAL PERIOD BEGINNING ON JANUARY 1, 2016

 

    Amendments to IAS 1 Presentation of Financial Statements—Disclosure Initiative (applicable for annual periods beginning on or after 1 January 2016)

 

    Amendments to IAS 16 and IAS 38 Property, Plant and Equipment and Intangible Assets—Clarification of Acceptable Methods of Depreciation and Amortization (applicable for annual periods beginning on or after 1 January 2016)

 

    Amendments to IAS 19 Employee Benefits—Employee Contributions (applicable for annual periods beginning on or after 1 February 2015)

 

F-9


Table of Contents

STANDARDS AND INTERPRETATIONS PUBLISHED, BUT NOT YET APPLICABLE FOR THE ANNUAL PERIOD BEGINNING ON JANUARY 1, 2016

 

    IFRS 9 Financial Instruments and subsequent amendments (applicable for annual periods beginning on or after 1 January 2018)

 

    IFRS 15 Revenue from Contracts with Customers (applicable for annual periods beginning on or after 1 January 2018)

 

    IFRS 16 Leases (applicable for annual periods beginning on or after 1 January 2019, but not yet endorsed in the EU)

 

    Improvements to IFRS (2014-2016) (applicable for annual periods beginning on or after 1 January 2017 or 2018, but not yet endorsed in the EU)

 

    Amendments to IFRS 2 Classification and Measurement of Share-based Payment Transactions (applicable for annual periods beginning on or after 1 January 2018, but not yet endorsed in the EU)

 

    Amendments to IFRS 4 Insurance Contracts—Applying IFRS 9 Financial Instruments with IFRS 4 (applicable for annual periods beginning on or after 1 January 2018, but not yet endorsed in the EU)

 

    Amendments to IAS 7 Statement of Cash Flows—Disclosure Initiative (applicable for annual periods beginning on or after 1 January 2017, but not yet endorsed in the EU)

 

    Amendments to IAS 12 Income Taxes—Recognition of Deferred Tax Assets for Unrealized Losses (applicable for annual periods beginning on or after 1 January 2017, but not yet endorsed in the EU)

 

    IFRIC 22 Foreign Currency Transactions and Advance Consideration (applicable for annual periods beginning on or after 1 January 2018, but not yet endorsed in the EU)

The new standards applicable did not have any impact on our financials.

Assessment of the impact of IFRS 15 Revenue from Contracts with Customers (applicable for annual periods beginning on or after January 1, 2018) on the revenue recognition of our current material license and collaboration agreements.

The IASB has issued IFRS 15 Revenue from Contracts with Customers, with an effective date of January 1, 2018. It was endorsed by the EU in third quarter of 2016.

The IASB issued clarifications to IFRS 15 Amendments to IFRS 15 - Clarifications to IFRS 15 Revenue from Contracts with Customers, with an effective date of January 1, 2018, currently awaiting EU endorsement. The clarifications address how to identify the performance obligations in a contract, how to determine whether a party involved in a transaction is a principal or an agent, how to determine whether a license provides the customer with a right to access or a right to use the entity’s intellectual property, and added practical expedients to the transition requirements of IFRS 15.

Entities will apply a five step model to determine when, how and at what amount revenue is to be recognized depending on whether certain criteria are met.

The company is currently in process of reviewing all its research and development, license, and collaboration agreements to ascertain how IFRS 15 will impact the identification of performance obligations and the allocation of consideration to them. We performed preliminary qualitative assessments of the consequences of IFRS 15, which are however subject to change arising from a more detailed ongoing analysis.

 

1. Identify the contracts

The substance of our current arrangements is that Galapagos is licensing its IP or selling its compounds to collaborative partner entities and providing research and development (“R&D”) services. Such activities result in a good or service that is an output of Galapagos’ ordinary activities.

 

F-10


Table of Contents

We generate revenue through a number of these arrangements which include license fees, milestone payments, reimbursement income and future sales based milestones and sales based royalties.

Certain revenues from our current material licensing and collaboration agreements could be in the scope of IFRS 15.

 

2. Identify performance obligations

We assessed that there could be one single combined performance obligation for certain arrangements in our material ongoing license and collaboration arrangements under the new standards of IFRS 15; the transfer of a license combined with performance of R&D services. This is because we could consider that the license has no stand-alone value without Galapagos being further involved in the R&D collaboration and that there is interdependence between the license and the R&D services to be provided. For certain arrangements, we could consider that there is a transformational relationship between the license and the R&D services to be delivered. We could estimate that the Galapagos’ activities during the R&D collaboration are going to significantly add to Intellectual Property (IP) and thereby the value of the programs.

 

3. Determine the transaction price

We analyzed the transaction prices of our material ongoing license and collaboration agreements currently composed of upfront license fees, R&D milestones and cost reimbursements for R&D services being delivered. Sales based milestones and sales based royalties are part of certain of our arrangements but are not yet included in our revenues as our most advanced license and collaboration arrangement is entering into a late development phase. Transaction price must be re-assessed at each reporting periods under IFRS 15.

 

4. Allocate the transaction price

An entity shall allocate the transaction price to each performance obligation identified in the contract on a relative stand-alone selling price. The transaction price of certain of our arrangements could be allocated to a single combined performance obligation when the transfer of a license is considered to be combined with performance of R&D services. R&D milestone payment is variable consideration that could be entirely allocated to a specific performance obligation or to a distinct good or service that forms part of a single performance obligation if certain criteria under IFRS 15 are met.

 

5. Recognize revenue

Revenue from certain arrangements could be recognized as Galapagos satisfies a combined performance obligation.

Galapagos could recognize revenues allocated to a combined performance obligation over the estimated service period based on a pattern that reflects the transfer of the services. The revenues recognized would reflect the level of service each period. In this case, Galapagos would use an output model that considers estimates of the percentage of total R&D service costs that are completed each period compared to the total estimated services costs (% of completion method).

Milestone payments could be recognized in revenues entirely when achieved as we achieved a specific performance obligation or to a distinct good or service that forms part of a single performance obligation if certain criteria under IFRS 15 are met.

Costs reimbursements could be recognized in revenues when costs are incurred and agreed by the parties as Galapagos is acting as a principal in the scope of its stake of the R&D activities of its ongoing license and collaboration agreements.

 

F-11


Table of Contents

Assessment of the impact of IFRS 15

As the company’s assessment of all contracts, potential performance obligations, and potential allocation of the revenue is still ongoing, the company is not able at this stage to provide a final estimate of the impact of IFRS 15 on its consolidated financial statements. The company plans to adopt IFRS 15 on the effective date.

Assessment of the impact of the implementation of IFRS 9 Financial Instruments and subsequent amendments (applicable for annual periods beginning on or after January 1, 2018) on our consolidated financial statements.

The IASB has issued IFRS 9 Financial Instruments, with an effective date of January 1, 2018, endorsed by the EU in the fourth quarter of 2016. IFRS 9 addresses the classification, measurement and de-recognition of financial assets and financial liabilities and introduces new rules for hedge accounting. The new standard also introduces expanded disclosure requirements and changes in presentation.

We performed a preliminary assessment evaluating the guidance to determine the potential impact on the consolidated financial statements.

Financial assets and financial liabilities are recognized on our balance sheet when we become a party to the contractual provisions of the instrument. Hedging and derivatives have never been used: we do not actively use currency derivatives to hedge planned future cash flows, nor do we make use of forward foreign exchange contracts. However, at year-end 2015 and until 19 January 2016, an embedded derivative existed under the terms of the Gilead contract (see note 7).

As of December 31, 2016, some equity instruments held by the group were classified as “available-for-sale”. The group applies IAS 39 for its equity instruments.

We performed a preliminary assessment of the impact of the implementation of the new standards of IFRS 9 on our current accounting policies under IAS 39, and primarily on the current accounting treatment applied for our available-for-sale financial assets.

All equity investments in scope of IFRS 9 are to be measured at fair value in the statement of financial position, with value changes recognized in profit or loss, except for those equity investments for which the entity has elected to present value changes in ‘other comprehensive income’. There is no ‘cost exception’ for unquoted equities.

‘Other comprehensive income’ option under IFRS 9

If an equity investment is not held for trading, an entity can make an irrevocable election at initial recognition to measure it at fair value through other comprehensive income with only dividend income recognized in profit or loss.

Assessment of the impact of IFRS 9

Galapagos’ preliminary assessment is that the coming new standards IFRS 9 Financial Instruments and subsequent amendments (applicable for annual periods beginning on or after January 1, 2018) should not have a material impact on our consolidated financial statements. The company plans to adopt IFRS 9 on the effective date.

IFRS 16 Leases

The IASB has issued IFRS 16 Leases (applicable for annual periods beginning on or after January 1, 2019) currently awaiting EU endorsement. The standard requires that all leases be recognized in the balance sheet with

 

F-12


Table of Contents

a corresponding lease liability, except for short term assets and minor assets. IFRS 16 required leased assets to be amortized over the lease term, and payments will be allocated between instalments on the lease obligation and interest expense, classified as financial items. In addition, the nature of the expenses related to those leases will change as IFRS 16 replaces the straight-line operating lease expense with a depreciation charge for right of the use assets and interest expense on lease liabilities.

We know that this new coming standard will have an impact on our consolidated financial statements in 2019 and we are currently evaluating the guidance to determine this impact. We plan to adopt IFRS 16 on the effective date.

CONSOLIDATED REPORTING

The consolidated financial statements comprise the financial statements of Galapagos NV and entities controlled by Galapagos NV. Control is achieved where Galapagos NV has the power to govern the financial and operating policies of another entity so as to obtain benefits from its activities. The results of subsidiaries are included in the income statement and statement of comprehensive income from the effective date of acquisition up to the date when control ceases to exist. Where necessary, adjustments are made to the financial statements of subsidiaries to ensure consistency with our accounting policies. All intra-group transactions, balances, income and expenses are eliminated when preparing the consolidated financial statements.

BUSINESS COMBINATIONS

The acquisition of subsidiaries is accounted for using the acquisition method. The cost of the acquisition is measured as the aggregate of the fair values, at the date of exchange, of assets given, liabilities incurred or assumed, and equity instruments issued by us in exchange for control of the acquired entity.

The acquired entity’s identifiable assets, liabilities and contingent liabilities that meet the conditions for recognition under IFRS 3 are recognized at their fair value at the acquisition date.

Goodwill arising on business combinations is recognized as an asset and initially measured as excess of the cost of acquisition over our interest in the fair value of the identifiable assets, liabilities and contingent liabilities of the acquired subsidiary less the value of the non-controlling interests at date of the acquisition. Goodwill is not amortized but tested for impairment on an annual basis and whenever there is an indication that the cash generating unit to which goodwill has been allocated may be impaired. Goodwill is stated at cost less accumulated impairment losses. An impairment loss recognized for goodwill is not reversed in a subsequent period.

In cases in which the acquirer’s interest in the net fair value of the acquired entity’s identifiable assets, liabilities and contingent liabilities less the value of the non-controlling interests exceeds cost, all fair values and cost calculations are reassessed. In the event that an excess still exists, it is immediately recognized in the profit or loss statement.

INTANGIBLE ASSETS

Expenditure on research activities is recognized as an expense in the period in which it is incurred.

An internally generated intangible asset arising from our development activities is recognized only if all of the following conditions are met:

 

    Technically feasible to complete the intangible asset so that it will be available for use or sale

 

    We have the intention to complete the intangible assets and use or sell it

 

    We have the ability to use or sell the intangible assets

 

F-13


Table of Contents
    The intangible asset will generate probable future economic benefits, or indicate the existence of a market

 

    Adequate technical, financial and other resources to complete the development are available

 

    We are able to measure reliably the expenditure attributable to the intangible asset during its development.

The amount capitalized as internally generated intangible assets is the sum of the development costs incurred as of the date that the asset meets the conditions described above.

Internally generated intangible assets are amortized on a straight-line basis over their estimated useful lives. If the recognition criteria for accounting as an intangible asset are not met, development costs are recognized as an expense in the period in which they are incurred.

Intellectual property, which comprises patents, licenses and rights, is measured internally at purchase cost and is amortized on a straight-line basis over the estimated useful life on the following bases:

 

    Customer relationships: 1–10 years

 

    In process technology: 3–5 years

 

    Software & databases: 3–5 years

 

    Brands, licenses, patents & know how: 5–15 years

In the event an asset has an indefinite life, this fact is disclosed along with the reasons for being deemed to have an indefinite life.

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are recognized at cost less accumulated depreciation and any impairment loss. Depreciation is recognized so as to write off the cost or valuation of assets over their useful lives, using the straight-line method, on the following bases:

 

    Installation & machinery: 4–15 years

 

    Furniture, fixtures & vehicles: 4–10 years

Any gain or loss incurred at the disposal of an asset is determined as the difference between the sale proceeds and the carrying amount of the asset, and is recognized in profit or loss.

LEASEHOLD IMPROVEMENTS

Leasehold improvements are depreciated over the term of the lease, unless a shorter useful life is expected.

ASSETS HELD UNDER FINANCE LEASE

Assets held under finance leases are depreciated over their useful lives on the same bases as owned assets or, where shorter, over the term of the related lease agreement.

INVENTORIES

Inventories are valued at the lower of cost and net realizable value. The net realizable value represents the estimated sales price less all estimated costs for completion and costs for marketing, sales and logistics.

Cost of raw materials comprises mainly purchase costs. Raw materials are not ordinarily interchangeable, and they are as such accounted for using the specific identification of their individual cost.

 

F-14


Table of Contents

FINANCIAL INSTRUMENTS

Financial assets and financial liabilities are recognized on our balance sheet when we become a party to the contractual provisions of the instrument. Hedging and derivatives have never been used: we do not actively use currency derivatives to hedge planned future cash flows, nor do we make use of forward foreign exchange contracts. However, at year-end 2015 and until January 19, 2016 an embedded derivative existed under the terms of the Gilead contract (see note 7).

Available-for-sale financial assets

The group applies IAS 39 for its equity instruments. At the time of purchase, management determines the financial instrument’s classification and reviews this classification at each reporting date. The classification depends on the purpose of acquiring the financial instrument. As of December 31, 2016, some financial instruments held by the group were classified as “available-for-sale”. These financial instruments are recognized or derecognized as of the date of settlement. Following their initial recognition, available-for-sale financial assets are measured at fair value, and any resulting gain or loss is reported directly in the revaluation reserve within equity until the financial instruments are sold, redeemed, otherwise disposed of or considered impaired, at which time the accumulated gain or loss is reported in profit and loss. Initial recognition at fair value is defined as the fair value of the consideration provided net of transaction costs. However, when investments in equity instruments do not have a quoted market price in an active market and the fair value cannot be reliably measured; those equity instruments are measured at cost.

RESEARCH AND DEVELOPMENT INCENTIVES RECEIVABLES

The R&D incentives receivables relate to refunds resulting from R&D incentives on research and development expenses in France and Belgium. Non-current research and development incentives receivables are discounted over the period until maturity date according to the appropriate discount rates.

TRADE RECEIVABLES

Trade receivables do not carry any interest and are stated at their nominal value reduced by appropriate allowances for irrecoverable amounts.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents are measured at nominal value. For the purposes of the cash flow statements, cash and cash equivalents comprise cash on hand, deposits held on call with banks, other short-term deposits and highly liquid investments. Cash and cash equivalents exclude restricted cash which is presented separately in the statement of financial position.

TRADE PAYABLES

Trade payables bear no interest and are measured at their nominal value.

TAXATION

Income tax in the profit or loss accounts represents the sum of the current tax and deferred tax.

Current tax is the expected tax payable on the taxable profit of the year. The taxable profit of the year differs from the profit as reported in the financial statements as it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Our liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

F-15


Table of Contents

Deferred income tax is provided in full, using the liability-method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, the deferred income tax is not accounted for if it arises from the initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss.

Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. As such, a deferred tax asset for the carry forward of unused tax losses will be recognized to the extent that is probable that future taxable profits will be available.

FOREIGN CURRENCIES

 

    Functional and presentation currency

Items included in the financial statements of each of our entities are valued using the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros, which is our functional and presentation currency.

 

    Transactions and balances in foreign currency

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of transaction. We are using monthly transaction rates based on the closing exchange rates of the foreign currencies on the last business day of the month preceding the date of the transaction. Foreign currency gains and losses resulting from the settlement of such transactions and from the translation at closing rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.

Non-monetary assets and liabilities measured at historical cost that are denominated in foreign currencies are translated using the exchange rate at the date of the transaction.

 

    Financial statements of foreign group companies

The results and financial position of all our entities that have a functional currency different from Euro are translated as follows:

 

    Assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;

 

    Income and expenses for each income statement are translated at average exchange rates;

 

    All resulting cumulative exchange differences are recognized as a separate component of equity;

 

    Such cumulative exchange differences are recognized in profit or loss in the period in which the foreign operation is disposed of.

RECOGNITION OF EXPENSES LINKED TO CLINICAL TRIAL MILESTONES

We recognize expenses specifically linked to clinical trial milestones with regard to patient recruitment and patient treatment (i.e. completion), incurred in carrying out clinical trials, in line with actual patient recruitment or treatment at each period end, in reference to the milestone targets for patient recruitment or treatment.

This involves the calculation of clinical trial accruals at each period end, for which an estimation of the expected full clinical trial milestone cost is required, as well as the current stage of patient recruitment or treatment.

 

F-16


Table of Contents

Clinical trials usually take place over extended time periods and typically involve a set-up phase, a recruitment phase and a completion phase which ends upon the receipt of a final report containing full statistical analysis of trial results. Accruals for patient recruitment and patient completion are prepared separately for each clinical trial in progress and take into consideration the stage of completion of each trial including the number of patients that have entered the trial and the number of patients that have been treated in the trial. In all cases, the full cost of each trial is expensed by the time the final report is received.

REVENUE RECOGNITION

Revenues to date have consisted principally of milestones, license fees and upfront payments received in connection with collaboration and alliance agreements. We also generate revenue from our fee-for-service activities, and various research and development incentives and grants.

Collaboration and alliance agreements with our commercial partners for research and development activities generally include non-refundable upfront fees; costs reimbursements; milestone payments, the receipt of which is dependent upon the achievement of certain clinical, regulatory or commercial milestones; license fees and royalties on sales.

The revenue recognition policies can be summarized as follows:

Upfront payments

Non-refundable, upfront payments received in connection with research and development collaboration agreements are deferred and recognized over the relevant, required periods of our involvement. The payments and our involvement relate to a contractually defined phase of the project. At inception management estimates the period of our involvement as well as the cost involved in the project. Upfront payments are recognized over the estimated period of involvement, either on a straight line basis or based on the cost incurred under the project if such cost can be reliably estimated. Periodically we reassess the estimated time and cost to complete the project phase and adjust the time period over which the revenue is deferred accordingly.

Milestone payments

Research milestone payments are recognized as revenues when achieved. In addition, the payments have to be acquired irrevocably and the milestone payment amount needs to be substantive and commensurate with the magnitude of the related achievement. Milestone payments that are not substantive, not commensurate or that are not irrevocable are recorded as deferred revenue. Revenue from these activities can vary significantly from period to period due to the timing of milestones.

Reimbursement income

Cost reimbursements resulting from license and collaboration agreements with our commercial partners are recognized as reimbursement income in revenue as the related costs are incurred and upon agreement by the parties involved. The corresponding expenses are included in research and development expenditure.

Cost reimbursements from collaboration in which we share equally in the risks and benefits associated with development of a specific drug with a collaboration partner are recognized as decrease of the related incurred research and development expenditure.

Licenses

Revenues from term licenses are spread over the period to which the licenses relate, reflecting the obligation over the term, to update content and provide ongoing maintenance. Revenues from perpetual licenses are recognized immediately upon sale to the extent that there are no further obligations.

 

F-17


Table of Contents

Royalties

Royalty revenues are recognized when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the period in which the licensees are reporting the royalties to us through royalty reports, that is, royalty revenues are generally recognized in arrears, i.e. after the period in which sales by the licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.

Grants and R&D incentives

As we carry out extensive research and development activities, we benefit from various grants and R&D incentives from certain governmental agencies. These grants and R&D incentives generally aim to partly reimburse approved expenditures incurred in our research and development efforts and are credited to the income statement, under other income, when the relevant expenditure has been incurred and there is reasonable assurance that the grants or R&D incentives are receivable.

INTERESTS IN JOINT OPERATIONS

A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities, relating to the arrangement. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

When we undertake our activities under joint operations, we as a joint operator recognize in relation to our interest in a joint operation:

 

    Our assets, including our share of any assets held jointly

 

    Our liabilities, including our share of any liabilities incurred jointly

 

    Our revenue from the sale of our share of the output arising from the joint operation

 

    Our share of the revenue from the sale of the output by the joint operation

 

    Our expenses, including our share of any expenses incurred jointly

We account for the assets, liabilities, revenues and expenses relating to our interest in a joint operation in accordance with IFRSs applicable to the particular assets, liabilities, revenues and expenses.

When we transact with a joint operation in which we are a joint operator (such as sale or contribution of assets), we are considered to be concluding the transaction with the other parties to the joint operation, and gains and losses resulting from the transactions are recognized in our consolidated financial statements only to the extent of other parties’ interests in the joint operation.

When we transact with a joint operation in which we are a joint operator (such as purchase of assets), we do not recognize our share of the gains and losses until we resell those assets to a third party.

EQUITY INSTRUMENTS

Equity instruments issued by us are measured by the fair value of the proceeds received, net of direct issue costs.

EMPLOYEE BENEFITS

a/ Defined contribution plans

Contributions to defined contribution pension plans are recognized as an expense in the income statement as incurred.

 

F-18


Table of Contents

b/ Defined benefit plans

For defined retirement benefit plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding interest), is reflected immediately in the statement of financial position with a charge or credit recognized in other comprehensive income in the period in which they occur. Re-measurement recognized in other comprehensive income is reflected immediately in retained earnings and will not be reclassified to profit or loss. Past service cost is recognized in profit or loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. Defined benefit costs are categorized as follows:

 

    Service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements)

 

    Net interest expenses or income

 

    Re-measurement

The retirement benefit obligation recognized in the consolidated statement of financial position represents the actual deficit or surplus in the defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or a reduction in future contributions to the plans. A liability for a termination benefit is recognized at the earlier of when we can no longer withdraw the offer of the termination benefit and when we recognize any related restructuring costs.

c/ Staff bonus plan

We recognize an expense in the income statement for staff bonus plans.

d/ Management bonus plan

The executive committee members, together with other senior managers, are eligible to receive bonuses under the Senior Management Bonus Scheme established in 2006. Pursuant to the rules of the Senior Management Bonus Scheme, 50% of the bonus is paid immediately around year-end and the payment of the remaining 50% is deferred for three years. The deferred 50% component is dependent on the Galapagos share price change relative to the Next Biotech Index (which tracks Euronext-listed biotech companies). The Galapagos share price and the Next Biotech Index at the start and end of the 3-year period is calculated by the average price over the preceding and last month of the 3-year period, respectively.

 

    If the Galapagos share price change is better than or equal to the change in the Next Biotech Index, the deferred bonus will be adjusted by the share price increase/decrease and paid out

 

    If the Galapagos share price change is up to 10% worse than the change in the Next Biotech Index, 50% of the deferred bonus will be adjusted by the share price increase/decrease and paid out, and the remainder will be forfeited

 

    If the Galapagos share price change is more than 10% worse than the change in the Next Biotech Index the deferred bonus will be forfeited

The possible payment of the deferred component of the Senior Management Bonus Schemes within three years is recognized at the moment that the bonus amount is determined, based on the fair value of the liability at each reporting period. The fair value of the liability is measured by use of the Monte Carlo valuation model taking into consideration (a) the average reference price of the Galapagos share and Next Biotech Index, (b) the average price of the reporting period of the Galapagos share and the Next Biotech Index, (c) the simulation of the evolution of the Galapagos share price and the Next Biotech Index based on their volatility and correlation until

 

F-19


Table of Contents

maturity of the bonus, (d) the applicable discount rates at the end of the reporting period and (e) the probability of the number of beneficiaries assumed to stay with us until maturity of the bonus. The changes in fair value are recognized in profit or loss for the period.

SHARE-BASED PAYMENTS

We grant equity-settled incentives to certain employees, directors and consultants in the form of warrants. Equity-settled warrants are measured at fair value at the date of acceptance. The fair value determined at the acceptance date of the warrants is expensed over the vesting period, based on our estimate of warrants that are expected to be exercised. Fair value is measured by use of the Black & Scholes model. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.

PROVISIONS

Provisions are recognized on the balance sheet when we have a present obligation as a result of a past event; when it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations and a reliable estimate can be made of the amount of the obligations. The amount recognized as a provision is the best estimate of the expenditure required to settle the present obligation at the balance sheet date. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of the money and, when appropriate, the risk specified to the liability.

FINANCE AND OPERATING LEASES

Leases are classified as finance leases whenever the terms of the lease substantially transfer all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Assets held under finance leases are recognized as our assets at their fair value or, if lower, at the present value of the minimum lease payments, each determined at the inception of the lease. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation. The payments are divided proportionally between the financial costs and a diminution of the outstanding balance of the obligation, so that the periodic interest rate on the outstanding balance of the obligation would be constant. Interest is recognized in the income statement, unless it is directly attributable to the corresponding asset, in which case they are capitalized.

Rents paid on operating leases are charged to income on a straight-line basis over the term of the relevant lease. Benefits received and receivable as an incentive to enter into an operating lease are also spread on a straight-line basis over the lease term.

IMPAIRMENT OF TANGIBLE AND INTANGIBLE ASSETS

At each balance sheet date, we review the carrying amount of our tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, we estimate the recoverable amount of the cash-generating unit to which the asset belongs.

An intangible asset with an indefinite useful life is tested for impairment annually, and whenever there is an indication that the asset might be impaired. The recoverable amount is the higher of fair value less costs to sell and value in use.

If the recoverable amount of an asset or cash generating unit is estimated to be less than the carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognized as an expense immediately.

 

F-20


Table of Contents

When an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined, had no impairment loss been recognized for the asset in prior years. A reversal of an impairment loss resulting from a sale of a subsidiary is recognized as income. In other cases impairment losses of goodwill are never reversed.

NET INCOME / LOSS PER SHARE

Basic net income/loss per share is computed based on the weighted average number of shares outstanding during the period. Diluted net income per share is computed based on the weighted average number of shares outstanding including the dilutive effect of warrants, if any.

DISCONTINUED OPERATIONS

A discontinued operation is a component of us that either has been disposed of or is classified as held for sale and (a) represents a separate major line of business or geographical area of operations, (b) is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations, or (c) is a subsidiary acquired exclusively with a view to resale.

SEGMENT REPORTING

Segment results include revenue and expenses directly attributable to a segment and the relevant portion of revenue and expenses that can be allocated on a reasonable basis to a segment. Segment assets and liabilities comprise those operating assets and liabilities that are directly attributable to the segment or can be allocated to the segment on a reasonable basis; and do not include income tax items. We have only two segments.

3. Segment information

In 2015, the IFRS 8 threshold of 10% of the combined revenues, external and inter-segment, of all segments was met by the external and internal revenues reported by our fee-for-service business located in Croatia. Consequently, there were two reportable segments in 2015 and 2016, R&D and fee-for-service business.

In 2014, following the sale of the service division on April 1, 2014, the continuing operations related primarily to R&D activities. Consequently, there was one reportable segment as at December 31, 2014.

However, our fee-for-service business was presented separately for the year 2014 for comparison with the years 2015 and 2016.

Segment information for year 2016

(Euro, in thousands)

 

     R&D      Fee-for-services      Inter-segment
elimination
     Group  

External revenue

     121,616        7,903        —          129,519  

Internal revenue

     —          4,379        (4,379      —    

Other income

     21,922        171        —          22,093  
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues & other income

     143,538        12,453        (4,379      151,612  
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment result

     1,138        (1,787         (649
  

 

 

    

 

 

       

 

 

 

Unallocated expenses(1)

              (10,841
           

 

 

 

Operating loss

              (11,491
           

 

 

 

Financial income(2)

              65,737  
           

 

 

 

Result before tax

              54,246  
           

 

 

 

Incomes taxes(2)

              (235
           

 

 

 

Net profit

              54,012  
           

 

 

 

 

F-21


Table of Contents
(1) The unallocated expenses of €10,841 thousand were composed of (a) €11,034 thousand of warrant costs; and (b) €193 thousand of reduced cost from the IAS19R reclassification of actuarial losses on long term defined post-employment benefit obligations, from profit or loss accounts to other comprehensive income. The above listed items are not presented to management in our management reporting as segment results, and are, therefore, presented on the line “unallocated expenses” in our segment reporting.
(2) Cash and taxes are handled at group level and are therefore presented under unallocated (expenses) / income.

Segment information for year 2015

(Euro, in thousands)

 

     R&D      Fee-for-services      Inter-segment
elimination
     Group  

External revenue

     34,129        5,434        —          39,563  

Internal revenue

     —          5,459        (5,459   

Other income

     20,778        238        —          21,017  
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues & other income

     54,907        11,131        (5,459      60,579  
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment result

     (82,024      (2,690         (84,713
  

 

 

    

 

 

       

 

 

 

Unallocated expenses(1)

              (4,731
           

 

 

 

Operating loss

              (89,444
           

 

 

 

Financial (expenses)/income(2)

              (30,184
           

 

 

 

Result before tax

              (119,627
           

 

 

 

Incomes taxes(2)

              1,218  
           

 

 

 

Net loss

              (118,410
           

 

 

 

 

(1) The unallocated expenses of €4,731 thousand were composed of (a) €5,036 thousand of warrant costs; (b) €507 thousand of decrease in depreciation cost triggered by an IFRS adjustment on the depreciation charges reported by Fidelta (Croatia) reflecting the expected useful lifetime following the purchase accounting of the acquisition of the Zagreb Research operations of GSK in 2010; and (c) €202 thousand of cost from the IAS19R reclassification of actuarial gains on long term defined post-employment benefit obligations, from profit or loss accounts to other comprehensive income. The above listed items are not presented to management in our management reporting as segment results, and are, therefore, presented on the line “unallocated expenses” in our segment reporting.
(2) Cash and taxes are handled at group level and are therefore presented under unallocated (expenses) / income.

 

F-22


Table of Contents

Segment information for the year 2014

(Euro, in thousands)

 

     R&D      Fee-for-services      Inter-segment
elimination
     Group  

External revenue

     65,642        3,726        —          69,368  

Internal revenue

     —          4,083        (4,083      —    

Other income

     20,437        217        —          20,653  
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues & other income

     86,079        8,025        (4,083      90,021  
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment result

     (30,369      (4,704         (35,073
  

 

 

    

 

 

       

 

 

 

Unallocated expenses(1)

              (1,551
           

 

 

 

Operating loss

              (36,624
           

 

 

 

Financial (expenses)/income(2)

              1,424  
           

 

 

 

Result before tax

              (35,201
           

 

 

 

Incomes taxes(2)

              (2,103
           

 

 

 

Net loss from continuing operations

              (37,303
           

 

 

 

Net income from discontinued operations

              70,514  
           

 

 

 

Net income

              33,211  
           

 

 

 

 

(1) Unallocated expenses consisted mainly of expenses for warrant plans under IFRS 2.
(2) Cash and taxes are handled at group level and are therefore presented under unallocated (expenses)/income.

Segment assets and liabilities are not information being provided to the chief operating decision maker on a recurring basis. This information is therefore not disclosed in our segment information.

GEOGRAPHICAL INFORMATION

In 2014, 2015 and 2016, our operations were located in Belgium, Croatia, France and the Netherlands.

In 2016 our top 10 customers represented 98% of the revenues. In 2015 our top 10 customers represents 97% of the revenues. In 2014 the continuing operations top 10 customers represents 98% of the revenues. Our client base in 2016, 2015 and 2014 included six of the top 20 pharmaceutical companies in the world.

Following table summarizes the revenues by destination of customer:

 

     Year Ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

United States

   88,628      17,077      31,100  

Europe

     40,884        22,446        38,169  

Asia Pacific

     6        40        100  
  

 

 

    

 

 

    

 

 

 

Total

   129,519      39,563      69,368  
  

 

 

    

 

 

    

 

 

 

 

F-23


Table of Contents

Following table summarizes the revenues by major customers:

 

     Year ended December 31,  
Spilt up of revenues by major customers    2016     2015     2014  
     (Euro, in
thousands)
     %     (Euro, in
thousands)
     %     (Euro, in
thousands)
     %  

Gilead

     87,813        68     —          0     —          0

United States

     87,813        68     —          0     —          0

AbbVie

     32,596        25     29,870        75     54,092        78

Europe

     32,596        25     13,640        34     24,054        35

United States

     —          0     16,229        41     30,038        43

Janssen Pharmaceutica

     243        0     566        1     8,662        12

Europe

     156        0     112        0     8,662        12

United States

     87        0     454        1     —          0

Les Laboratoires Servier

     265        0     3,835        10     2,095        3

Europe

     265        0     3,835        10     2,095        3
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total revenues

     120,917        93     34,271        87     64,849        93
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Following table summarizes the revenues of the continuing operations by destination:

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Galapagos NV (Belgium)

   121,703      34,082      65,448  

Galapagos SASU (France)

     84        25        108  

Fidelta d.o.o. (Croatia)

     7,732        5,440        3,726  

Xenometrix, Inc. (United States)

     —          16        86  
  

 

 

    

 

 

    

 

 

 

Total revenues

   129,519      39,563      69,368  
  

 

 

    

 

 

    

 

 

 

In 2016, we held €76 million of non-current assets (€68 million in 2015; €57 million in 2014) distributed as follows:

 

    Belgium: €37 million (€30 million in 2015; €25 million in 2014)

 

    France: €31 million (€29 million in 2015; €26 million in 2014)

 

    Croatia: €4 million (€5 million in 2015; €4 million in 2014)

 

    The Netherlands: €4 million (€4 million in 2015; €1 million in 2014)

The increase in non-current assets 2016 vs 2015 was mainly explained by the increase in non-current R&D incentives receivables (see note 15).

4. Total revenues and other income

REVENUES

The following table summarizes the revenues for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Recognition of non-refundable upfront payments

   30,257      26,419      45,838  

Milestone payments

     81,784        3,835        19,039  

Reimbursement income

     9,699        3,807        729  

Other revenues

     7,777        5,501        3,762  
  

 

 

    

 

 

    

 

 

 

Total revenues

   129,519      39,563      69,368  
  

 

 

    

 

 

    

 

 

 

 

F-24


Table of Contents

Total revenues decreased by €29.8 million, or 43%, to €39.6 million for the year ended December 31, 2015, from €69.4 million for the year ended December 31, 2014. This decrease was mainly driven by lower recognition of non-refundable upfront payments and reduced milestone payments, as explained below.

 

    Revenue from non-refundable upfront payments related to the deferred recognition of upfront payments received under the agreements with AbbVie, amounting to €111.6 million in 2012 and €49.6 million in 2013, which were amortized over a period ranging from 21 to 42 months, based on the estimated period of the involvement.

 

    Milestone revenues and costs reimbursements decreased by €12.1 million, or 61%, to €7.6 million for the year ended December 31, 2015 compared to €19.8 million for the year ended December 31, 2014. This decrease was primarily related to fewer milestones achieved in 2015 compared to 2014 as a result of the increasing proprietary nature of the pipeline programs. For the year ended December 31, 2015 €2.2 million and €1.2 million of costs were reimbursed in relation with respectively the CF and Filgotinib collaboration agreements with AbbVie, and €3.8 million of milestones related to partnered programs with Servier were recognized.

 

    Other revenues increased by €1.7 million, or 46%, to €5.5 million for the year ended December 31, 2015 compared to €3.8 million for the year ended December 31, 2014, principally due to higher revenues from fee-for-service activities.

Total revenues increased by €90.0 million, or 227%, to €129.5 million for the year ended December 31, 2016, from €39.6 million for the year ended December 31, 2015. This increase was mainly driven by a substantial increase in milestone payments, as explained below.

Revenue recognized in 2015 from upfront non-refundable payments related to the CF collaboration agreement with AbbVie signed in September 2013 and the contract signed with AbbVie in February 2012 for our filgotinib program (including the extension signed in March 2013). Those upfront payments were fully recognized into revenues by the end of August 2015.

In September 2015 AbbVie decided not to opt in, which ended the collaboration agreement regarding our filgotinib program and consequently the period of our involvement. There are no outstanding commitments for us regarding this terminated collaboration for our filgotinib program.

On December 16, 2015, we entered into a global collaboration with Gilead Sciences, Inc. for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory indications. On January 19, 2016, we completed the closing of the global collaboration agreement with Gilead, in the framework of which Gilead made a $425 million (or €392 million) equity investment in Galapagos NV by subscribing to new shares at a price of €58 per share, including issuance premium. This resulted in Gilead owning 6,760,701 ordinary shares of Galapagos NV, representing 14.75% percent of the then-outstanding share capital of Galapagos. We also received a license fee of $300 million. In addition, we are eligible for payments of up to $695 million in additional development and regulatory milestones and $600 million in sales milestones, with tiered royalties starting at 20% and a profit split in co-promotion territories. In 2016, $60 million of development milestones was already achieved and paid by Gilead. Furthermore, development costs of the licensed product will be split 20-80. As such Galapagos will support 20% of all development costs. As we do not expect to have a statutory taxable base in the foreseeable future, we did not recognize any additional deferred tax asset following the signing of this new collaboration.

The global collaboration with Gilead foresees continuous involvement from us, since we will perform certain R&D activities in the development phase of the filgotinib program; therefore, management assessed that the upfront payment of $300 million (or €275.6 million) received in January 2016 from Gilead should be spread as a function of the costs incurred for this program, applying the percentage of completion method. In the year ended December 31, 2016, €25.6 million revenues were recognized regarding this upfront payment.

In connection with the agreement with Gilead, we recognized a deferred income and an offsetting short-term financial asset (derivative) of €39 million upon signing of the share subscription agreement with Gilead, as

 

F-25


Table of Contents

required under IAS 39. We refer to note 7 for further details. The deferred income will be recognized in function of the costs incurred for this program, applying the percentage of completion method, along with the upfront payment. In the year ended December 31, 2016, €3.6 million revenues were recognized in the income statement.

In 2016, Galapagos signed a license agreement with ThromboGenics for an integrin antagonist (formerly GLPG0187), for which an upfront payment of €1 million was invoiced and fully recognized, as Galapagos has no further involvement or obligation in the contract.

The following table summarizes the upfront payments recognition for years ended December 31, 2016 and 2015.

 

Agreement

  Upfront
received
    Upfront
received
    Date of
receipt
    Revenue
recognized, year
ended

December 31,
2016
    Revenue
recognized, year
ended

December 31,
2015
    Outstanding
balance in

deferred
income as at
December
31, 2016
 
    (USD,
in thousands)
    (Euro,
in thousands)
          (Euro, in thousands)  

AbbVie collaboration agreement for CF

  $ 45,000     34,001       September 2013       —       11,401       —    

AbbVie collaboration agreement for RA and CD (filgotinib)

  $ 150,000     111,582       February 2012       —       12,045       —    

First amendment to AbbVie collaboration agreement for RA and CD (filgotinib)

  $ 20,000     15,619       March 2013       —       2,973       —    

Gilead collaboration agreement for filgotinib

  $ 300,000     275,558       January 2016     25,621       —       249,937  

Gilead collaboration agreement for filgotinib

    N.A.     39,003  (*)      January 2016     3,626       —       35,376  

ThromboGenics license agreement for integrin antagonists

    N.A.     1,000       April 2016     1,000       —         —    

Sirion Biotech license agreement for RNA interference (RNAi) technologies

    N.A.     10       June 2016     10       —         —    
       

 

 

   

 

 

   

 

 

 

Total recognition of non-refundable
upfront payments

        30,257     26,419     285,314  
       

 

 

   

 

 

   

 

 

 

 

(*) deferred income of €39 million booked upon signing of the share subscription agreement with Gilead as required under IAS 39

Milestone revenues increased substantially by €77.9 million to €81.8 million for the year ended December 31, 2016 compared to €3.8 million for the year ended December 31, 2015. Milestones in 2016 related to the filgotinib program with Gilead in CD and UC, and the CF program with AbbVie.

Reimbursement income increased by €5.9 million or 155%, to €9.7 million for the year ended December 31, 2016 compared to €3.8 million for the year ended December 31, 2015, due to higher reimbursements in relation with the CF program with AbbVie and the filgotinib program with Gilead (which was partnered with AbbVie in 2015). The reimbursement of certain research and development costs related to the development work under the Galapagos’ collaboration agreements amounted to €5.9 million for our CF program with AbbVie and €3.5 million for our filgotinib program with Gilead for the year ended December 31, 2016.

Other revenues increased by €2.3 million, or 41%, to €7.8 million for the year ended December 31, 2016 compared to €5.5 million for the year ended December 31, 2015, principally due to higher revenues from fee-for-service activities.

 

F-26


Table of Contents

OTHER INCOME

The following table summarizes other income for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Grant income

   2,329      3,095      5,646  

Other income

     19,764        17,922        15,008  
  

 

 

    

 

 

    

 

 

 

Total other income

   22,093      21,017      20,653  
  

 

 

    

 

 

    

 

 

 

Total other income was composed of grant income and other income and increased by €0.4 million, or 2%, from €20.7 million for the year ended December 31, 2014 to €21.0 million for the year ended December 31, 2015. Grant income decreased by €2.6 million, or 45%, from €5.6 million for the year ended December 31, 2014 to €3.1 million for the year ended December 31, 2015. The majority of this grant income was related to grants from a Flemish agency, representing approximately 94% of all reported grant income in both years. In many cases these carry clauses which require us to maintain a presence in the same region for a number of years and invest according to pre-agreed budgets.

The decrease in grant income was compensated by an increase in other income of €2.9 million, or 19%, from €15.0 million for the year ended December 31, 2014 to €17.9 million for the year ended December 31, 2015. Other income was primarily composed of:

 

    Income from an innovation incentive system of the French government, which represented €8.7 million of other income for the year ended December 31, 2015 compared to €7.8 million for the year ended December 31, 2014

 

    Income from Belgian R&D incentives with regard to incurred R&D expenses, which represented €5.3 million of other income for the year ended December 31, 2015 compared to €4.3 million for the year ended December 31, 2014

 

    Tax rebates on payroll withholding taxes of R&D personnel in Belgium and the Netherlands, representing €3.0 million of other income for the year ended December 31, 2015 compared to €2.4 million for the year ended December 31, 2014.

Total other income was composed of grant income and other income and increased by €1.1 million, or 5%, from €21.0 million for the year ended December 31, 2015 to €22.1 million for the year ended December 31, 2016.

Grant income decreased by €0.8 million, or 25%, from €3.1 million for the year ended December 31, 2015 to €2.3 million for the year ended December 31, 2016. The majority of this grant income is related to grants from a Flemish agency, representing approximately 88% of all reported grant income in 2016 (2015: 94%). In many cases these carry clauses which require us to maintain a presence in the same region for a number of years and invest according to pre-agreed budgets.

The decrease in grant income was more than offset by an increase in other income of €1.8 million, or 10%, from €17.9 million for the year ended December 31, 2015 to €19.8 million for the year ended December 31, 2016. Other income was primarily composed of:

 

    Income from an innovation incentive system of the French government, which represented €9.5 million of other income for the year ended December 31, 2016 compared to €8.7 million for the year ended December 31, 2015

 

    Income from Belgian R&D incentives with regard to incurred R&D expenses, which represented €5.8 million of other income for the year ended December 31, 2016 compared to €5.3 million for the year ended December 31, 2015

 

F-27


Table of Contents
    Tax rebates on payroll withholding taxes of R&D personnel in Belgium and the Netherlands, representing €3.8 million of other income for the year ended December 31, 2016 compared to €3.0 million for the year ended December 31, 2015

5. Operating costs

Operating result has been calculated after charging (-) / crediting:

RESEARCH AND DEVELOPMENT EXPENDITURE

The following table summarizes research and development expenditure for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Personnel costs

   (42,315    (35,875    (31,038

Subcontracting

     (65,649      (65,883      (54,293

Disposables and lab fees and premises costs

     (20,414      (18,696      (16,830

Other operating expenses

     (11,196      (9,260      (8,949
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (139,573    (129,714    (111,110
  

 

 

    

 

 

    

 

 

 

R&D expenditure increased by €18.6 million, or 17%, to €129.7 million for the year ended December 31, 2015, from €111.1 million for the year ended December 31, 2014. This increase was principally due to:

 

    Increased R&D personnel costs of €4.8 million, or 16%, from €31.0 million for the year ended December 31, 2014 to €35.9 million for the year ended December 31, 2015, which was explained by an enlarged workforce, higher warrant costs and a higher payable for short-term and long-term management bonus, mainly as a result of the evolution of our share price change relative to the Next Biotech Index on Euronext.

 

    Increased subcontracting costs of €11.6 million, or 21%, from €54.3 million for the year ended December 31, 2014 to €65.9 million for the year ended December 31, 2015. This cost increase was mainly driven by increased subcontracting costs of €8.4 million for the CF collaboration with AbbVie and to a lesser extent by the increase of €4.2 million in subcontracting costs for our other partnered and internal programs.

 

    Intensified use of lab consumables was the main driver of the increase in disposables, lab fees and premises costs of €1.9 million, or 11%, from €16.8 million for the year ended December 31, 2014 to €18.7 million for the year ended December 31, 2015

 

    Other operating expenses slightly increased by €0.3 million, or 3%, from €8.9 million for the year ended December 31, 2014 to €9.3 million for the year ended December 31, 2015.

R&D expenditure increased by €9.9 million, or 8%, to €139.6 million for the year ended December 31, 2016, from €129.7 million for the year ended December 31, 2015. This increase was principally due to:

 

    Increased R&D personnel costs of €6.4 million, or 18%, from €35.9 million for the year ended December 31, 2015 to €42.3 million for the year ended December 31, 2016, which was explained by an enlarged workforce, higher warrant costs and a higher payable for short term and long term management bonus, mainly as a result of the increase of our share price change relative to the Next Biotech Index on Euronext

 

    Intensified use of lab consumables was the main driver of the increase in disposables, lab fees and premises costs of €1.7 million, or 9%, from €18.7 million for the year ended December 31, 2015 to €20.4 million for the year ended December 31, 2016

 

F-28


Table of Contents
    Other operating expenses increased by €1.9 million, or 21%, from €9.3 million for the year ended December 31, 2015 to €11.2 million for the year ended December 31, 2016, primarily due to an increase in depreciation of €1.0 million.

Subcontracting costs were relatively stable and decreased slightly by €0.2 million, or 0.4%, from €65.9 million for the year ended December 31, 2015 to €65.6 million for the year ended December 31, 2016.

The table below summarizes our research and development expenditure for the years ended December 31, 2016, 2015 and 2014, broken down by research and development expenses under alliance and own funded research and development expenses. All filgotinib costs (both costs incurred in the period under alliance (with AbbVie) and costs incurred after AbbVie’s opt-out decision in September 2015) are presented as “R&D under alliance” or as “partnered” in the tables in this section for the year ended December 31, 2015, as a new alliance was signed in December 2015 with Gilead for this program.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

R&D under alliance

   (71,980    (80,832    (76,297

Galapagos funded R&D

     (67,593      (48,882      (34,813
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (139,573    (129,714    (111,110
  

 

 

    

 

 

    

 

 

 

All research and development expenditures are tracked against detailed budgets and allocated by individual project. The table below summarizes our research and development expenditure for the years ended December 31, 2016, 2015 and 2014, broken down by program.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Filgotinib program (partnered)

   (22,376      (35,404    (33,843

CF program (partnered)

     (31,203      (25,634      (14,894

IPF program on GLPG1690 (proprietary)

     (7,129      (4,612      (4,592

OA program on GLPG1972 (partnered)

     (6,538      (5,832      (801

AtD program on MOR106 (partnered)

     (3,491      (4,651      (894

Other

     (68,836      (53,582      (56,086
  

 

 

    

 

 

    

 

 

 

Total R&D expenditure

   (139,573    (129,714    (111,110
  

 

 

    

 

 

    

 

 

 

Research and development expenditure under alliance increased by €4.5 million, or 6%, to €80.8 million for the year December 31, 2015, mainly due to our CF program in collaboration with AbbVie. We also increased our investments in our own funded portfolio by €14.1 million, or 40%, from €34.8 million for the year ended December 31, 2014 to €48.9 million for the year ended December 31, 2015, primarily because GLPG1205 and GLPG1690 programs became own funded.

R&D expenditure under alliance decreased by €8.9 million, or 11%, from €80.8 million for the year ended December 31, 2015 to €72.0 million for the year ended December 31, 2016, mainly due to decreased R&D spending in our RA and IBD program on filgotinib (partnered with AbbVie in 2015 and partnered with Gilead in 2016), which has been partially offset by increased R&D spending on our CF program in collaboration with AbbVie. We increased our investments in our own funded portfolio by €18.7 million, or 38%, from €48.9 million for the year ended December 31, 2015 to €67.6 million for the year ended December 31, 2016, primarily because of intensified research investments in our proprietary programs on inflammation, HBV and fibrosis, as well as increased spending on our proprietary IPF program GLPG1690.

 

F-29


Table of Contents

GENERAL AND ADMINISTRATIVE EXPENSES

The following table summarizes the general and administrative expenses for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Personnel costs and directors fees

   (15,160    (12,739    (8,087

Other operating expenses

     (6,584      (6,388      (5,788
  

 

 

    

 

 

    

 

 

 

Total general and administrative expenses

   (21,744    (19,127    (13,875
  

 

 

    

 

 

    

 

 

 

General and administrative expenses increased by €5.2 million, or 38%, to €19.1 million for the year ended December 31, 2015. This increase was principally due to personnel costs and directors fees, which increased by €4.6 million, or 58%, from €8.1 million for the year ended December 31, 2014 to €12.7 million for the year ended December 31, 2015, resulting from various effects, such as increased costs of share-based payments plans (warrant plans) and increased payables for short- and long-term management bonus, mainly as a result of the evolution of our share price change relative to the Next Biotech Index on Euronext. In addition, other operating expenses increased by €0.6 million, or 10%, from €5.8 million for the year ended December 31, 2014 to €6.4 million for the year ended December 31, 2015, mainly due to higher professional fees.

General and administrative expenses amounted to €19.1 million for the year ended December 31, 2015 and increased by €2.6 million, or 14%, to €21.7 million for the year ended December 31, 2016. This increase was principally due to directors fees, which increased by €2.7 million, or 116%, from €2.4 million for the year ended December 31, 2015 to €5.1 million for the year ended December 31, 2016, resulting from various effects, such as increased costs of share-based payments plans (our warrant plans) and increased payables for short and long term management bonus, mainly as a result of the increase of our share price change relative to the Next Biotech Index on Euronext.

SALES AND MARKETING EXPENSES

The following table summarizes the sales and marketing expenses for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Personnel costs

   (1,167    (785    (579

Other operating expenses

     (618      (397    (412
  

 

 

    

 

 

    

 

 

 

Total sales and marketing expenses

   (1,785    (1,182    (992
  

 

 

    

 

 

    

 

 

 

Sales and marketing expenses increased by €0.2 million, or 19%, from €1.0 million for the year ended December 31, 2014, to €1.2 million for the year ended December 31, 2015.

Sales and marketing expenses increased by €0.6 million, or 51%, from €1.2 million for the year ended December 31, 2015 to €1.8 million for the year ended December 31, 2016.

 

F-30


Table of Contents

RESTRUCTURING COSTS

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Restructuring costs

   —        —        (669
  

 

 

    

 

 

    

 

 

 

Total restructuring and integration costs

   —        —        (669
  

 

 

    

 

 

    

 

 

 

The restructuring and integration costs amounted to €0.7 million for the year ended December 31, 2014 and were entirely related to workforce reductions within certain of the R&D operations.

6. Staff costs

The following table illustrates the personnel costs of the continuing operations for the years 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Wages and salaries

   (34,857    (33,676    (26,891

Social security costs

     (7,328      (7,328      (7,468

Pension costs

     (1,728      (1,456      (1,454

Other personnel costs

     (9,617      (4,574      (2,635
  

 

 

    

 

 

    

 

 

 

Total personnel costs

   (53,530    (47,034    (38,447
  

 

 

    

 

 

    

 

 

 

The other personnel costs mainly related to costs for warrants granted of €6.6 million (2015: €2.9 million). For the costs of warrants granted, see note 30.

7. Fair value re-measurement of share subscription agreement

On December 16, 2015, Gilead Sciences, Inc. and Galapagos NV entered into a global collaboration for the development and commercialization of filgotinib, in the framework of which Gilead committed to an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos NV by subscribing to new shares at a price of €58 per share, including issuance premium. This agreement was effectively completed and entered into force January 19, 2016 and full payment was received.

In connection with the agreement, we recognized a deferred income and an offsetting short-term financial asset (derivative) of €39 million upon signing of the share subscription agreement with Gilead as required under IAS 39. This financial asset initially reflects the share premium that Gilead committed to pay above the closing stock price of Galapagos on the day of entering into the subscription agreement. Under IAS 39 the fair value of the financial asset is re-measured at year-end and again upon entering into force of the subscription agreement on January 19, 2016, when the financial asset expired. Variations in fair value of the financial asset are recorded in the income statement.

The decrease in the fair value of the financial asset resulting from the increase in the Galapagos share price between signing of the subscription agreement and December 31, 2015 resulted in a negative, non-cash fair value charge of €30.6 million in the financial results. The subsequent increase in the fair value of the financial asset resulting from the decrease in our share price between January 1st, 2016 and January 19, 2016 resulted in a positive non-cash gain of €57.5 million in the financial result of 2016.

On January 19, 2016, the value of the financial asset at maturity amounted to €65.9 million, reflecting the share premium that Gilead paid above our closing share price on the day of the capital increase. This amount was

 

F-31


Table of Contents

composed of (1) the initial measurement on the day of entering into the share subscription agreement for an amount of €39 million which was reported in deferred income and (2) the subsequent re-measurements of the financial asset, reported as financial result under IAS 39: €30.6 million fair value loss reported in the year 2015 and €57.5 million fair value gain reported in the year 2016, together a net fair value gain of €26.8 million. This financial asset expired on the effective date of the share subscription agreement and was derecognized through the share premium account.

8. Other financial income / expenses

The following table summarizes other financial income and expense for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Other financial income:

        

Interest on bank deposit

   1,614      1,246      1,155  

Effect of discounting long term R&D incentives receivables

     99        99        920  

Currency exchange gain

     8,150        636        198  

Other finance income

     87        7        17  
  

 

 

    

 

 

    

 

 

 

Total other financial income

     9,950        1,987        2,291  
  

 

 

    

 

 

    

 

 

 

Other financial expenses:

        

Interest expenses

     (47      (46      (110

Currency exchange loss

     (1,453      (1,310      (652

Other finance charges

     (191      (182      (105
  

 

 

    

 

 

    

 

 

 

Total other financial expense

     (1,692      (1,539      (867
  

 

 

    

 

 

    

 

 

 

Total other net financial income

   8,257      448      1,424  
  

 

 

    

 

 

    

 

 

 

Other finance income decreased slightly by €0.3 million, or 13%, to €2.0 million for the year ended December 31, 2015. The decrease in the effect of discounting long-term R&D incentives receivables (-€0.8 million) was partly compensated by an increase in currency exchange gains (+ €0.4 million).

Other financial income increased significantly by €8.0 million, or 401%, from €2.0 million for the year ended December 31, 2015 to €10.0 million for the year ended December 31, 2016. The increase primarily related to an exchange gain of €4.8 million on deposits held in U.S. dollar and exchange gains of €2.0 million realized on milestone payments from AbbVie and Gilead in U.S. dollar.

Other finance expense increased by €0.6 million, or 77% to €1.5 million for the year ended December 31, 2015. Net exchange loss amounted to €0.7 million for the year ended December 31, 2015, as compared to €0.5 million for the year ended December 31, 2014.

Other financial expenses increased by €0.2 million, or 10% from €1.5 million for the year ended December 31, 2015 to €1.7 million for the year ended December 31, 2016. Net exchange profit amounts to €6.7 million for the year ended December 31, 2016, compared to a net exchange loss of €0.7 million for the year ended December 31, 2015.

Interest expenses were related to interests paid on financial lease.

 

F-32


Table of Contents

9. Taxes

INCOME TAXES RELATING TO CONTINUING OPERATIONS

The following table summarizes the income tax recognized in profit or loss for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
Taxes recognized in profit or loss    2016      2015      2014  
     (Euro, in thousands)  

Continuing operations:

        

Current tax

   (466    (215    (2,396

Deferred tax

     231        1,433        293  
  

 

 

    

 

 

    

 

 

 

Total continuing operations

     (235      1,218        (2,103
  

 

 

    

 

 

    

 

 

 

Discontinued operations:

        

Current tax

     —          —        (437

Deferred tax

     —          —          203  
  

 

 

    

 

 

    

 

 

 

Total discontinued operations

     —          —          (234
  

 

 

    

 

 

    

 

 

 

Total taxes

   (235    1,218      (2,337
  

 

 

    

 

 

    

 

 

 

Current tax amounted to €0.5 million for the year ended December 31, 2016 and €0.2 million for the year ended December 31, 2015 and was related to taxes for subsidiaries operating on cost plus basis. Current tax recorded in 2014 for an amount of €2.4 million related to a tax provision for subsidiaries operating under cost plus transfer pricing arrangements, triggered by a tax audit.

Deferred tax income of €0.2 million for the year ended December 31, 2016, €1.4 million for the year ended December 31, 2015 and €0.3 million for the year ended December 31, 2014 related to subsidiaries working on a cost plus basis.

TAX LIABILITIES

The below table illustrates the tax liabilities related captions in the balance sheet on December 31, 2016, 2015 and 2014.

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Current tax payable

   1,022      2,583      2,582  
  

 

 

    

 

 

    

 

 

 

Total tax liabilities

   1,022      2,583      2,582  
  

 

 

    

 

 

    

 

 

 

On December 31, 2015 and 2014, tax liabilities included €2.6 million primarily related to the recognition of tax liabilities for two subsidiaries operating on a cost plus basis. This amount was partly due to a tax audit on the years 2008 to 2011 and underlying proposed tax adjustment amounting to €1.9 million in cash and decrease of our tax losses carried forward for €19.5 million. A liability was recognized in 2014 considering this claim and the potential risk, partly under current tax liability for €1.3 million and partly as a decrease of the R&D incentives receivables for €0.6 million. The tax adjustment was settled in cash in the fourth quarter of 2016. However, discussions are still ongoing with regard to this claim.

 

F-33


Table of Contents

In addition, taxes on gain on the sale of the service division in 2014 were included in the tax liabilities on December 31, 2015 for €0.4 million and were paid in 2016.

On December 31, 2016, €1.0 million of tax liabilities were primarily related to two of our subsidiaries operating on a cost plus basis.

Corporation tax was calculated at 34% (2015 and 2014: 34%)—which is the tax rate applied in Belgium—on the estimated assessable profit for the year. The applied tax rate for other territorial jurisdictions was the tax rate that is applicable in these respective territorial jurisdictions on the estimated taxable result of the accounting year.

 

     Year ended December 31,  
     2016            2015            2014  
     (Euro, in thousands)  

The tax of the year can be reconciled to the accounting result as follows:

            

Income / loss (-) before tax from continuing operations

   54,246        (119,627      (35,201

Income before tax from discontinued operations

     —         %          %        70,748  
  

 

 

      

 

 

      

 

 

 

Income/ loss (-) before tax

     54,246       34        (119,627     34        35,548  
  

 

 

      

 

 

      

 

 

 

Income tax debit / credit (-), calculated using the Belgian statutory tax rate on the accounting income / loss (-) before tax (theoretical)

     18,438          (40,661        12,083  
  

 

 

      

 

 

      

 

 

 

Tax expenses / income (-) in income statement (effective) from continuing operations

     235          (1,218        2,103  

Tax expenses in income statement (effective) from discontinued operations

     —            —            234  
  

 

 

      

 

 

      

 

 

 

Tax expenses / income (-) in income statement (effective)

     235          (1,218        2,337  
  

 

 

      

 

 

      

 

 

 

Difference in tax expense / income to explain

   (18,203      39,444        (9,746
  

 

 

      

 

 

      

 

 

 

Effect of tax rates in other jurisdictions

   163        328        6  

Effect of non taxable revenues

     (27,399        (5,934        (41,249

Effect of consolidation entry without tax impact

     2          57          12,786  

Effect of non tax deductible expenses

     4,387          12,378          1,459  

Effect of recognition of previously non recognized deferred tax assets

     (421        (1,307        (293

Effect of change in tax rates

     —            —            (165

Effect of tax losses (utilized) reversed

     (655        (597        (1,549

Effect from under or over provisions in prior periods

     —            58          2,144  

Effect of non recognition of deferred tax assets

     5,720          34,783          17,688  

Effect of R&D tax credit claims

     —            (322        (572
  

 

 

      

 

 

      

 

 

 

Total explanations

   (18,203      39,444        (9,746
  

 

 

      

 

 

      

 

 

 

The main difference between the theoretical tax and the effective tax for the years 2016 and 2015 was primarily explained by the unrecognized deferred tax assets on tax losses carried forward for which we conservatively assess that it is not likely that these will be realized in the foreseeable future

The main difference between the theoretical tax and the effective tax for the year 2014 was primarily explained by low capital gain tax (less than 1%) under Belgian tax law, on the gain on sale of the service division (see line non-taxable revenues and effect of consolidation entries), and by the unrecognized deferred tax assets on tax losses carried forward.

Non-taxable revenues for the years ended December 31, 2014, 2015 and 2016 related to non-taxable subsidies and tax credits. Non-taxable revenues in 2016 also included the financial profit related to the fair value re-measurement of the share subscription agreement.

 

F-34


Table of Contents

10. Discontinued operations

The following table summarizes the results from discontinued operations for the years ended December 31, 2016, 2015 and 2014.

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands, except share
and per share data)
 

Service revenues

         17,502  

Other income

           669  
        

 

 

 

Total revenues and other income

           18,171  
        

 

 

 

Services cost of sales

           (11,283

General and administrative expenses

           (3,772

Sales and marketing expenses

           (255

Restructuring and integration costs

           (38

Loss on divestment

           —    

Gain on sale of service division

           67,508  
        

 

 

 

Operating income

           70,331  
        

 

 

 

Finance income / expense (-)

           417  
        

 

 

 

Income before tax

           70,748  
        

 

 

 

Income taxes

           (234
        

 

 

 

Net income from discontinued operations

         70,514  
        

 

 

 

Basic and diluted income per share from discontinued operations

         2.34  
        

 

 

 

Weighted average number of shares (in ‘000 shares)

           30,108  

The service division was sold on April 1, 2014. The above table illustrates the results of the discontinued operations included in the consolidated results of operations for the years ended December 31, 2016, 2015 and 2014. For the year ended December 31, 2014, results only relate to the period from January 1, 2014 through the disposal on April 1, 2014.

Net income amounting to €70.5 million in 2014 was mainly driven by the €67.5 million gain on disposal of the service division.

Cash flows from discontinued operations can be summarized as follows:

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Net cash flows used in operating activities

     —          —        (1,722

Net cash flows generated in investing activities

     —          —          122,580  

Net cash flows generated/ used (-) in financing activities

     —          —          —    
  

 

 

    

 

 

    

 

 

 

Net cash generated

   —        —        120,858  
  

 

 

    

 

 

    

 

 

 

 

F-35


Table of Contents

11. Result per share

Basic result per share is calculated by dividing the net result attributable to shareholders by the weighted average number of ordinary shares issued during the year.

Diluted result per share is calculated based on the weighted average number of shares (diluted) also considering outstanding warrants, for which our average share price of the year was higher than the exercise price.

Income / loss per share

 

     Year ended December 31,  
     2016      2015     2014  

Income/ loss per share:

     

Result for the purpose of basic income / loss (-) per share (thousands €)

   54,012      (118,410   33,211  

Number of shares (thousands)

       

Weighted average number of shares for the purpose of basic income / loss per share

     45,696        35,700       30,108  
  

 

 

    

 

 

   

 

 

 

Basic income / loss (-) per share (Euros)

   1.18      (3.32   1.10  
  

 

 

    

 

 

   

 

 

 

Result for the purpose of diluted income/ loss (-) per share
(thousands €)

   54,012      (118,410   33,211  

Number of shares (thousands)

       

Weighted average number of shares for the purpose of diluted income / loss per share

     45,696        35,700       30,108  

Number of dilutive potential ordinary shares

     1,612        —         —    
  

 

 

    

 

 

   

 

 

 

Diluted income / loss (-) per share (Euros)

   1.14      (3.32   1.10  
  

 

 

    

 

 

   

 

 

 

As our continuing operations report a net loss in 2014 and 2015, the outstanding warrants (specified in note 30) have an anti-dilutive effect rather than a dilutive effect. Consequently, basic and diluted loss per share are the same for 2014 and 2015.

Basic income per share of €1.18 and diluted income per share of €1.14 in 2016 are based on a net income for 2016 which was strongly influenced by the non-cash gain from the fair value re-measurement of the share subscription agreement with Gilead amounting to €57.5 million.

 

F-36


Table of Contents

12. Intangible assets

 

     Customer
relationships
    In process
technology
     Software &
databases
    Brands,
licenses,
patents &
know-how
    Total  
     (Euro, in thousands)  

Acquisition value:

           

On January 1, 2014

   2,055     5,561      7,681     17,698     32,993  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Additions

     —         —          728       15       743  

Sales and disposals

     —         —          (503     —         (503

Sale of the service division

     (2,055     —          —         (16,227     (18,282

Translation differences

     —         —          183       26       209  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2014

     —         5,561        8,088       1,512       15,161  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Additions

     —         —          565       —         565  

Sales and disposals

     —         —          (1,512     —         (1,512

Reclassifications

     —         —          —         —         —    

Translation differences

     —         —          177       —         177  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2015

     —         5,561        7,318       1,512       14,392  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Additions

     —         —          317       15       332  

Sales and disposals

     —         —          (508     (4     (512

Reclassifications

     —         —          —         —         —    

Translation differences

     —         —          58       0       58  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2016

     —         5,561        7,185       1,523       14,269  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Amortization and impairment:

           
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On January 1, 2014

     912       5,561        6,321       12,366       25,161  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Amortization

     25       —          748       294       1,067  

Sales and disposals

     —         —          (500     —         (500

Sale of the service division

     (937     —          —         (11,853     (12,790

Reclassifications

     —         —          (666     666       —    

Translation differences

     —         —          184       24       208  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2014

     —         5,561        6,087       1,497       13,147  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Amortization

     —         —          1,026       4       1,030  

Sales and disposals

     —         —          (1,512     —         (1,512

Reclassifications

     —         —          —         —         —    

Translation differences

     —         —          177       —         177  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2015

     —         5,561        5,777       1,501       12,841  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Amortization

     —         —          856       4       860  

Sales and disposals

     —         —          (509     (5     (514

Reclassifications

     —         —          —         —         —    

Translation differences

     —         —          57       —         57  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2016

     —         5,561        6,182       1,501       13,246  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Carrying amount:

           

On December 31, 2014

     —         —          2,000       15       2,015  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2015

     —         —          1,540       11       1,550  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2016

   —       —        1,003     22     1,023  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

The intangible assets decreased by €0.5 million from €2 million at December 31, 2014, to €1.5 million at December 31, 2015. The amortization of €1.0 million was partly compensated by new additions for €0.5 million.

 

F-37


Table of Contents

The intangible assets decreased by €0.5 million from €1.5 million as at December 31, 2015, to €1.0 million as at December 31, 2016. The amortization of €0.9 million was partly compensated by new additions for €0.3 million.

13. Property, plant and equipment

 

     Land &
building
improvements
    Installation &
machinery
    Furniture,
fixtures &
vehicles
    Other
tangible
assets
    Total  
     (Euro, in thousands)  

Acquisition value:

          

On January 1, 2014

   13,898     52,251     4,455     3,565     74,169  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additions

     117       1,155       104       685       2,061  

Sales and disposals

     (1,733     (4,549     (73     —         (6,355

Sale of the service division

     (4,022     (23,677     (1,919     (370     (29,988

Reclassifications

     —         3,543       16       (3,559     —    

Translation differences

     26       97       11       —         134  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2014

     8,286       28,820       2,594       321       40,021  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additions

     2,158       2,250       285       1,407       6,100  

Sales and disposals

     (6,395     (5,041     (188     (11     (11,635

Reclassifications

     —         540       3       (543     —    

Translation differences

     —         19       1       (1     20  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2015

     4,049       26,588       2,695       1,174       34,506  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additions

     296       3,325       210       627       4,458  

Sales and disposals

     —         (1,315     (105     (0     (1,420

Reclassifications

     67       1,064       167       (1,299     (1

Translation differences

     —         70       6       4       81  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2016

     4,412       29,733       2,973       505       37,624  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Depreciations and impairment:

          
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On January 1, 2014

     12,715       36,720       3,086       2,123       54,644  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Depreciation

     639       2,531       243       168       3,581  

Sales and disposals

     (1,700     (4,011     (42     —         (5,753

Sale of the service division

     (3,694     (17,404     (1,247     (299     (22,644

Reclassifications

     —         1,884       —         (1,884     —    

Translation differences

     24       70       6       2       102  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2014

     7,984       19,790       2,046       110       29,930  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Amortization

     164       1,873       272       63       2,372  

Sales and disposals

     (6,395     (4,996     (188     (7     (11,587

Reclassifications

     —         44       —         (44     —    

Translation differences

     —         8       —         —         8  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2015

     1,753       16,718       2,130       122       20,724  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Amortization

     272       2,752       243       55       3,322  

Sales and disposals

     —         (1,315     (100     —         (1,415

Reclassifications

     —         67       (93     26       —    

Translation differences

     —         29       5       —         34  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2016

     2,025       18,252       2,184       203       22,663  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Carrying amount:

          

On December 31, 2014

     302       9,031       547       210       10,091  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2015

     2,296       9,870       565       1,051       13,782  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2016

   2,387     11,481     789     302     14,961  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

F-38


Table of Contents

The property, plant and equipment increased from €10.1 million at December 31, 2014 to €13.8 million at December 31, 2015. This increase was mainly the result of new additions of €6.1 million, partly compensated by a depreciation charge of €2.4 million. The sales and disposals in 2015 related to the move to new premises in France and the Netherlands.

The property, plant and equipment increased from €13.8 million as at December 31, 2015 to €15.0 million as at December 31, 2016. This increase was mainly the result of new additions of €4.5 million, partly compensated by a depreciation charge of €3.3 million. There are no pledged items of property, plant and equipment. There are also no restrictions in use on any items of property, plant and equipment.

14. Other non-current assets

On July 15, 2016, we invested €2.75 million in Pharnext, a French advanced clinical stage biopharmaceutical company developing new therapeutics for severe orphan and common neurological diseases, listed on Euronext. Galapagos has no restrictions on the sale of this equity investment and the asset is not pledged under any Galapagos’ liabilities. This investment is classified as available-for-sale equity investment which qualifies for level 1 fair value measurement based upon the closing price of the PXT securities on Euronext at each reporting date. Fair value changes on available-for-sale financial assets are recognized directly in equity, through the statement of changes in equity.

As of December 31, 2016, other non-current assets mainly consisted of available-for-sale equity investments in Pharnext re-measured at fair value for €2.4 million as follows.

 

     Fair value of
available-for-sale
financial assets
 
     (thousands of €)  

Costs at January 1, 2016

     —    

Additions of the year

     2,750  
  

 

 

 

Costs at December 31, 2016

     2,750  
  

 

 

 

Fair value adjustment of the year

     (399
  

 

 

 

Fair value adjustment at December 31, 2016

     (399
  

 

 

 

Net book value at December 31, 2016

     2,351  
  

 

 

 

The unrealized loss of €399 thousand as of December 31, 2016, based on unadjusted quoted market price, was recorded as a separate item within equity (revaluation reserve) in the line “other reserves”.

15. Research and Development incentives receivables

The table below illustrates the R&D incentives receivables related captions in the balance sheet at December 31, 2016, 2015 and 2014:

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Non-current R&D incentives receivables

   54,188      49,384      43,944  

Current R&D incentives receivables

     10,154        9,161        7,351  
  

 

 

    

 

 

    

 

 

 

Total R&D incentives receivables

   64,342      58,545      51,296  
  

 

 

    

 

 

    

 

 

 

Total R&D incentives receivables increased by €7.2 million for the year ended December 31, 2015 compared to December 31, 2014. This increase was explained by new R&D incentives reported in 2015 for €14.0 million

 

F-39


Table of Contents

(€8.7 million related to French R&D incentives and €5.3 million related to Belgian R&D incentives) less the payment received related to French R&D incentives amounting to €6.7 million.

Total R&D incentives receivables increased by €5.8 million for the year ended December 31, 2016, compared to December 31, 2015. This increase is explained by new R&D incentives reported in 2016 for €15.3 million (€9.5 million related to French R&D incentives and €5.8 million related to Belgian R&D incentives) less the payments received related to French R&D incentives amounting to €8.7 million and to Belgian R&D incentives amounting to €0.8 million. The R&D incentives receivables relate to future refunds resulting from R&D incentives on research expenses in France and Belgium. Non-current R&D incentives receivables are discounted over the period until maturity date.

The table below provides detailed information on the maturity of the non-current R&D incentives receivables reported in the balance sheet at December 31, 2016.

Non-current R&D incentives receivables

 

    December 31, 2016 maturity date        
    2018     2019     2020     2021     2022–2026     Total  
    (Euro, in thousands)        

French non-current R&D incentives receivables—nominal value

  8,214     8,621     9,168       —         —       26,003  

French non-current R&D incentives receivables—discounted value

    8,214       8,621       9,168       —         —         26,003  

Belgian non-current R&D incentives receivables—nominal value

    2,074       2,966       3,831     4,188     15,235       28,294  

Belgian non-current R&D incentives receivables—discounted value

    2,074       2,966       3,831       4,188       15,126       28,185  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total non-current R&D incentives receivables—nominal value

  10,288     11,587     12,999     4,188     15,235     54,297  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total non-current R&D incentives receivables—discounted value

  10,288     11,587     12,999     4,188     15,126     54,188  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

16. Restricted cash

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Non-current restricted cash

   1,098      1,046      306  

Current restricted cash

     6,570        6,857        10,422  
  

 

 

    

 

 

    

 

 

 

Total restricted cash

   7,668      7,903      10,728  
  

 

 

    

 

 

    

 

 

 

Restricted cash amounted to €10.7 million on December 31, 2014, and decreased to €7.9 million on December 31, 2015. This decrease was related to (a) the release of the €3 million bank guarantee issued in 2013 for the rental of the new premises in France which expired on June 30, 2015 following the move to the new offices, (b) the payment of a claim to Charles River by decrease of the escrow account, and (c) a €0.7 million bank guarantee issued in September 2015 for the rental of new premises in the Netherlands (to replace the current premises) which will expire on October 1, 2025. Restricted cash on December 31, 2015 was related to €0.3 million and €0.7 million bank guarantees on real estate lease obligations in Belgium and in the Netherlands respectively, and to €6.9 million escrow account containing part of the proceeds from the sale of the service division in 2014.

 

F-40


Table of Contents

Restricted cash amounted to €7.9 million on December 31, 2015, and decreased to €7.7 million on December 31, 2016. This decrease is related to the payment of a claim to Charles River by decrease of the escrow account for €0.3 million, which has been slightly offset by an increase in non-current restricted cash of €0.1 million related to an increase in the bank guarantee with regard to the rental of additional office space for the Belgian premises. Restricted cash on December 31, 2016 is related to €0.4 million and €0.7 million of bank guarantees on real estate lease obligations in Belgium and in the Netherlands respectively, and to €6.6 million escrow account containing part of the proceeds from the sale of the service division in 2014 for which the release will be possible after final agreement between the parties.

17. Trade and other receivables and other current assets

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Trade receivables

   6,629      1,494      1,340  

Prepayments

     21        11        9  

Other receivables

     3,078        2,426        1,862  
  

 

 

    

 

 

    

 

 

 

Trade and other receivables

     9,728        3,931        3,211  
  

 

 

    

 

 

    

 

 

 

Accrued income

     3,617        2,976        3,242  

Deferred charges

     3,621        2,536        1,384  
  

 

 

    

 

 

    

 

 

 

Other current assets

     7,239        5,512        4,625  
  

 

 

    

 

 

    

 

 

 

Total trade and other receivables & other current assets

   16,966      9,443      7,836  
  

 

 

    

 

 

    

 

 

 

The carrying amount of trade and other receivables approximates their fair value. Other current assets mainly included accrued income from subsidy projects and deferred charges.

On December 31, 2016, we did not have any bad debt allowance.

18. Cash and cash equivalents

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Cash at banks

   357,630      240,292        137,711  

Term deposits

     515,632        100,000        50,000  

Money market funds

     99,977        —          —    

Cash on hand

     2        22        1  
  

 

 

    

 

 

    

 

 

 

Total cash and cash equivalents

     973,241        340,314        187,712  
  

 

 

    

 

 

    

 

 

 

We reported a cash position of €187.7 million at the end of December 2014 compared to €138.2 million at year-end 2013. The operating activities reported use of €75.6 million of cash in 2014 while the investing activities brought €120.6 million of cash in-flow mainly due the proceeds from the sale of the service division (€130.8 million) and €4.2 million from the financing activities.

We reported a cash position of €340.3 million at the end of December 2015. The operating and investing activities reported use of respectively €114.6 million and €4.3 million of cash in 2015 while the financing activities brought €271.4 million of cash in-flow mainly due to the proceeds of a recent global offering and concurrent listing on NASDAQ (€259.4 million) and due to warrant exercises (€12 million).

 

F-41


Table of Contents

We reported a cash position of €973.2 million at the end of December 2016 compared to €340.3 million at year-end 2015. Net cash inflow from operating activities amounted to €239.4 million for the year ended December 31, 2016. This net cash inflow from operations recorded in 2016 was primarily due to the license fee of $300 million (€275.6 million) received from Gilead in relation with our collaboration agreement on filgotinib. In addition, milestone payments increased substantially in 2016 (compared to 2015), which contributed significantly to the net cash inflow from operations in 2016. The net cash outflow from investing activities amounted to €7.3 million for the year ended December 31, 2016, which included an acquisition of available-for-sale equity investment (see note 14). The net cash inflow from financing activities amounted to €396.0 million for the year ended December 31, 2016, which can mainly be attributed to the subscription of Galapagos shares by Gilead on January 19, 2016 for which the cash proceeds from capital and share premium increases amounted to €391.9 million, net of issue costs. In addition, proceeds received on exercise of warrants contributed to cash generated by financing activities in 2016 in the amount of €4.3 million.

Cash and cash equivalents comprise cash at banks, short term bank deposits and money market funds that are readily convertible to cash and are subject to an insignificant risk of changes in value. Our cash management strategy monitors and optimizes our liquidity position. Our cash management strategy may allow short term deposits with an original maturity exceeding 3 months while monitoring all liquidity aspects. Cash and cash equivalents comprise €515.6 million of term deposits of which €458.7 million had an original maturity longer than 3 months. All cash and cash equivalents are available upon maximum one month notice period. Cash at banks were mainly composed of savings accounts and current accounts. We maintain our bank deposits in highly rated financial institutions to reduce credit risk. Cash invested in highly liquid money market funds represented €100.0 million and was aimed at meeting short-term cash commitments, while reducing the counterparty risk of investment.

19. Share capital

The share capital of Galapagos NV, as set forth in the articles of association, reconciles to ‘share capital’ on the balance sheet as follows:

 

     2016      2015      2014  
     (Euro, in thousands)  

On January 1

   185,399      157,274      154,542  
  

 

 

    

 

 

    

 

 

 

Share capital increase

     38,798        47,485        2,732  

Costs of capital increase

     (269      (19,360      —    
  

 

 

    

 

 

    

 

 

 

Share capital on December 31

   223,928      185,399      157,274  
  

 

 

    

 

 

    

 

 

 

Aggregate share capital

   250,187      211,389      163,904  

Costs of capital increase (accumulated)

     (26,259      (25,990      (6,629
  

 

 

    

 

 

    

 

 

 

Share capital on December 31

   223,928      185,399      157,274  
  

 

 

    

 

 

    

 

 

 

Costs of capital increases are netted against the proceeds of capital increases, in accordance with IAS 32 Financial instruments: disclosure and presentation.

 

F-42


Table of Contents

HISTORY OF SHARE CAPITAL

The history of the share capital of Galapagos NV between January 1, 2014 and December 31, 2016 is as follows:

 

Date

   Share capital
increase

new shares
(in thousands €)
     Share capital
increase
warrants

(in thousands €)
     Number of
shares issued
(in thousands
of shares)
     Aggregate
number of
shares after
transaction
(in thousands
of shares)
     Aggregate
share capital
after
transaction
(in thousands €)
 

January 1, 2014

              29,794      161,171  
           

 

 

    

 

 

 

April 10, 2014

      1,649        305        

July 4, 2014

        982        182        

September 25, 2014

        66        12        

December 9, 2014

        35        7        
           

 

 

    

 

 

 

December 31, 2014

              30,299        163,904  
           

 

 

    

 

 

 

March 26, 2015

        3,092        571        

May 19, 2015

   40,751           7,532        

June 19, 2015

        2,659        491        

September 25, 2015

        640        118        

December 4, 2015

        344        64        
           

 

 

    

 

 

 

December 31, 2015

              39,075        211,390  
           

 

 

    

 

 

 

January 19, 2016

     36,575           6,761        

April 1, 2016

        668        132        

May 19, 2016

        762        141        

September 19, 2016

        326        60        

November 28, 2016

        467        86        
           

 

 

    

 

 

 

December 31, 2016

              46,256      250,187  
           

 

 

    

 

 

 

On January 1, 2014, Galapagos NV’s share capital amounted to €161,171.6 thousand, represented by 29,794,046 shares. All shares were issued, fully paid up and of the same class.

On April 10, 2014, warrants were exercised at various exercise prices (with an average exercise price of €7.81 per warrant) resulting in a share capital increase (including issuance premium) of €2,381.2 thousand and the issuance of 304,791 new ordinary shares. The closing price of the Galapagos share at this date was €16.80.

On July 4, 2014, warrants were exercised at various exercise prices (with an average exercise price of €10.26 per warrant), resulting in a share capital increase (including issuance premium) of €1,862.3 thousand and the issuance of 181,507 new ordinary shares. The closing price of the Galapagos share on July 4, 2014, was €15.13.

On September 25, 2014, warrants were exercised at various exercise prices (with an average exercise price of €10.60 per warrant), resulting in a share capital increase (including issuance premium) of €130.0 thousand and the issuance of 12,260 new ordinary shares. The closing price of the Galapagos share at this date was €12.19.

On December 9, 2014, warrants were exercised at various exercise prices (with an average exercise price of €8.61 per warrant), resulting in a share capital increase (including issuance premium) of €56.2 thousand and the issuance of 6,525 new ordinary shares. The closing price of the Galapagos share on December 9, 2014, was €14.77.

On December 31, 2014, Galapagos NV’s share capital amounted to €163,904.1 thousand, represented by 30,299,129 shares. All shares were issued, fully paid up and of the same class.

 

F-43


Table of Contents

On March 26, 2015, warrants were exercised at various exercise prices (with an average exercise price of €10.18 per warrant), resulting in a share capital increase (including issuance premium) of €5,819 thousand and the issuance of 571,548 new ordinary shares. The closing price of the Galapagos share at this date was €21.26.

On May 19, 2015, Galapagos completed a global offering of 7,532,499 ordinary shares consisting of a concurrent public offering in the United States and private placement in Europe and countries other than the United States and Canada. Galapagos offered 5,746,000 ordinary shares through a public offering in the United States in the form of American Depositary Shares, or ADSs, at a price of $42.05 per ADS, before underwriting discounts. The ADSs are evidenced by American Depositary Receipts, or ADRs, and each ADS represents the right to receive one ordinary share. The ADSs are listed on the NASDAQ Global Select Market under the symbol “GLPG.” Galapagos offered 1,786,499 ordinary shares through a private placement in Europe and countries other than the United States and Canada at a price of €37.00 per share, before underwriting discounts.

Galapagos received €278.7 million of gross proceeds from the global offering, decreased by €19.4 million of underwriter discounts and commission, and offering expenses, of which €19.3 million has been paid at December 31, 2015 and €0.1 million has been paid in 2016. The total net cash proceeds from the global offering after remaining settlements will amount to €259.3 million.

On June 19, 2015, warrants were exercised at various exercise prices (with an average exercise price of €8.94 per warrant), resulting in a share capital increase (including issuance premium) of €4,395 thousand and the issuance of 491,406 new ordinary shares. The closing price of the Galapagos share on June 19, 2015, was €46.73.

On September 25, 2015, warrants were exercised at various exercise prices (with an average exercise price of €10.13 per warrant), resulting in a share capital increase (including issuance premium) of €1,198 thousand and the issuance of 118,260 new ordinary shares. The closing price of the Galapagos share at this date was €44.75.

On December 4, 2015, warrants were exercised at various exercise prices (with an average exercise price of €9.30 per warrant), resulting in a share capital increase (including issuance premium) of €590.8 thousand and the issuance of 63,500 new ordinary shares. The closing price of the Galapagos share on December 4, 2015, was €44.78.

On December 31, 2015, Galapagos NV’s share capital amounted to €211,388.9 thousand, represented by 39,076,342 shares. All shares were issued, fully paid up and of the same class.

On January 19, 2016, Gilead made a $425 million equity investment in Galapagos NV by subscribing to 6,760,701 new ordinary shares at a price of €58 per share, including issuance premium. Galapagos received €392.1 million of gross proceeds, decreased by €0.26 million of expenses, which were all paid at December 31, 2016. The total net cash proceeds from the share subscription by Gilead amounts to €391.9 million. The closing price of the Galapagos share on January 19, 2016 was €48.26.

On April 1, 2016, warrants were exercised at various exercise prices (with an average exercise price of €10.70 per warrant) resulting in a share capital increase (including issuance premium) of €1,409.3 thousand and the issuance of 131,695 new shares. The closing price of the Galapagos share on this date was €36.64.

On May 19, 2016, warrants were exercised at various exercise prices (with an average exercise price of €10.49 per warrant) resulting in a share capital increase (including issuance premium) of €1,476.4 thousand and the issuance of 140,770 new shares. The closing price of the Galapagos share on this date was €45.41.

On September 19, 2016, warrants were exercised at various exercise prices (with an average exercise price of €10.00 per warrant) resulting in a share capital increase (including issuance premium) of €603.3 thousand and the issuance of 60,320 new shares. The closing price of the Galapagos share on this date was €58.62.

 

F-44


Table of Contents

On November 28, 2016, warrants were exercised at various exercise prices (with an average exercise price of €8.94 per warrant) resulting in a share capital increase (including issuance premium) of €771.3 thousand and the issuance of 86,250 new shares. The closing price of the Galapagos share on this date was €55.73.

On December 31, 2016, Galapagos NV’s share capital amounted to €250,187 thousand, represented by 46,256,078 shares. All shares were issued, fully paid up and of the same class.

All of the share issuances listed above were for cash consideration.

The below table summarizes the capital increases for the years 2014, 2015 and 2016.

 

(thousands of €, except share data)    Number of shares      Share
capital
    Share
premium
    Share capital
and share
premium
 

On January 1, 2014

     29,794,046        154,542       112,484       267,026  
  

 

 

    

 

 

   

 

 

   

 

 

 

April 10, 2014 : exercise of warrants

     304,791        1,649       732       2,381  
  

 

 

    

 

 

   

 

 

   

 

 

 

July 4, 2014 : exercise of warrants

     181,507        982       880       1,862  
  

 

 

    

 

 

   

 

 

   

 

 

 

September 25, 2014 : exercise of warrants

     12,260        66       64       130  
  

 

 

    

 

 

   

 

 

   

 

 

 

December 9, 2014 : exercise of warrants

     6,525        35       21       56  
  

 

 

    

 

 

   

 

 

   

 

 

 

On January 1, 2015

     30,299,129        157,274       114,182       271,456  
  

 

 

    

 

 

   

 

 

   

 

 

 

March 26, 2015: exercise of warrants

     571,548        3,092       2,727       5,819  
  

 

 

    

 

 

   

 

 

   

 

 

 

May 19, 2015: global offering

         

Ordinary shares (fully paid)

     1,786,499        9,665       56,436       66,100  

ADSs (fully paid)

     5,746,000        31,086       181,516       212,602  

Underwriter discounts and offering expenses (fully paid)

     —          (19,360     —         (19,293

Total global offering

     7,532,499        21,391       237,952       259,343  
  

 

 

    

 

 

   

 

 

   

 

 

 

June 19, 2015: exercise of warrants

     491,406        2,659       1,737       4,395  
  

 

 

    

 

 

   

 

 

   

 

 

 

September 25, 2015: exercise of warrants

     118,260        640       558       1,198  
  

 

 

    

 

 

   

 

 

   

 

 

 

December 4, 2015: exercise of warrants

     63,500        344       247       591  
  

 

 

    

 

 

   

 

 

   

 

 

 

On January 1, 2016

     39,076,342        185,399       357,402       542,803  
  

 

 

    

 

 

   

 

 

   

 

 

 

January 19, 2016 : share subscription from Gilead

         

Ordinary shares (fully paid)

     6,760,701        36,575       355,546       392,121  

Derecognition of financial asset from share subscription agreement

     —          —         (65,850     (65,850

Capital increase expenses (fully paid)

     —          (269     —         (269

Total share subscription by Gilead

     6,760,701        36,306       289,696       326,002  
  

 

 

    

 

 

   

 

 

   

 

 

 

April 1, 2016 : exercise of warrants

     131,695        668       741       1,409  
  

 

 

    

 

 

   

 

 

   

 

 

 

May 19, 2016 : exercise of warrants

     140,770        762       715       1,476  
  

 

 

    

 

 

   

 

 

   

 

 

 

September 19, 2016 : exercise of warrants

     60,320        326       277       603  
  

 

 

    

 

 

   

 

 

   

 

 

 

November 28, 2016 : exercise of warrants

     86,250        467       305       772  
  

 

 

    

 

 

   

 

 

   

 

 

 

On December 31, 2016

     46,256,078        223,928       649,135       873,063  
  

 

 

    

 

 

   

 

 

   

 

 

 

Other information

 

     Ordinary shares      Total  

Par value of shares (€)

     5.41        5.41  

 

F-45


Table of Contents

The board of directors is authorized for a period of five years starting from the date of the publication in the Annexes to the Belgian State Gazette of the shareholders’ resolution that granted the renewed authorization, being June 3, 2016, to increase the share capital of Galapagos NV within the framework of the authorized capital through contributions in kind or in cash, with limitation or cancellation of the shareholders’ preferential subscription rights. Said authorization can be renewed. The board of directors is currently not authorized to increase the share capital after notification by the FSMA (Financial Services and Markets Authority) of a public takeover bid on Galapagos NV’s shares.

The authorized capital as approved by the extraordinary shareholders’ meeting of April 26, 2016 amounted to €49,726.5 thousand. As of December 31, 2016, €3,431.3 thousand of the authorized capital was used, so that an amount of €46,295.2 thousand still remained available.

20. Other reserves

Actuarial and other gains or losses recognized through other comprehensive income

 

    2016      2015      2014  
    (Euro, in thousands)  

On January 1

  (18    (220    47  
 

 

 

    

 

 

    

 

 

 

Gain or loss (-) on defined benefit obligation recognized through OCI

    (583      202        (267

Loss on financial asset available-for-sale recognized through OCI

    (399      —          —    
 

 

 

    

 

 

    

 

 

 

Other reserves on December 31

  (1,000    (18    (220
 

 

 

    

 

 

    

 

 

 

The other reserves amounted to a negative of €18 thousand on December 31, 2015 (2014: €220 thousand; 2013; positive of €47 thousand) and related to the re-measurement of defined benefit obligations recognized through OCI in line with IAS19R.

Other reserves on December 31, 2016 consisted of (1) a negative of €601 thousand, compared to a negative of €18 thousand in 2015 (2014: €220 thousand), which was related to the re-measurement of defined benefit obligations recognized through OCI in line with IAS19R, and (2) a negative of €399 thousand, compared to nil in 2015 and 2014, related to the fair value adjustment on the available-for-sale equity investment in 2016 (see note 14).

DERIVATIVE FINANCIAL INSTRUMENTS: CURRENCY DERIVATIVES

We do not actively use currency derivatives to hedge planned future cash flows. On the balance sheet date, total notional amount of outstanding forward foreign exchange contracts that we have committed were nil (2015: nil, 2014: nil).

On December 31, 2016 the fair value of our currency derivatives was nil (2015: nil, 2014: nil). We do not designate our foreign currency denominated debt as a hedge instrument for the purpose of hedging the translation of our foreign operations.

See note 35 for further information on how we manage financial risks.

21. Translation differences

 

     2016     2015     2014  
     (Euro, in thousands)  

On January 1

   (467   (1,157   170  
  

 

 

   

 

 

   

 

 

 

Translation differences, arisen from translating foreign activities

     (623     690       460  

Translation differences, arisen from the sale of the service division

     —         —         (1,787
  

 

 

   

 

 

   

 

 

 

Translation differences on December 31

   (1,090   (467   (1,157
  

 

 

   

 

 

   

 

 

 

 

F-46


Table of Contents

Translation differences decreased to a negative of €1.2 million at the end of December 2014 mainly due to the sale of the service division which reported positive translation differences of €2.0 million at the end of December 2013.

Translation differences increased from a negative €1.2 million at the end of December 2014 to a negative of €0.5 million at the end of December 2015 mainly due to the increase of the GB pounds and U.S. dollar exchange rates.

Translation differences decreased from a negative €0.5 million at the end of December 2015 to a negative of €1.1 million at the end of December 2016 mainly due to fluctuations of the GB pounds and the U.S. dollar exchange rates.

22. Deferred tax

 

     December 31,  
     2016     2015      2014  
     (Euro, in thousands)  

Recognized deferred tax assets and liabilities:

       

Assets

   1,957     1,726      293  

Liabilities

   —       —        —    

Continuing operations

       

Assets

     1,957       1,726        293  

Liabilities

     —         —          —    

Deferred tax assets unrecognized

   128,377     145,513      104,484  
  

 

 

   

 

 

    

 

 

 

Deferred taxes in the consolidated statement of operations

   231     1,433      496  
  

 

 

   

 

 

    

 

 

 

Continuing operations

     231       1,433        293  
  

 

 

   

 

 

    

 

 

 

Tax benefit arising from previously unrecognized tax assets used to reduce deferred tax expense (+)

     421       1,433        293  

Deferred tax expenses relating to use of previously recognized deferred tax assets

     (190     —          —    
  

 

 

   

 

 

    

 

 

 

Discontinued operations

          203  
  

 

 

   

 

 

    

 

 

 

Deferred tax expenses net relating to origination and reversal of temporary differences

     —         —          203  

Tax benefit arising from previously unrecognized tax assets used to reduce deferred tax expense (+)

     —         —          —    

Deferred tax expenses relating to write down of previously recognized deferred tax assets

     —         —          —    

The notional interest deduction for an amount of €2.6 million (2015 and 2014: €2.6 million) and the investment deduction of €1 million (2015 and 2014: €1 million) could give rise to deferred tax assets. The amount of notional interest deduction that has been accumulated in the past can be carried forward for maximum seven years, the notional interest deduction of 2012 and following years will not be carried forward according to a change in the Belgian tax legislation. There is no limit in time for the investment deduction.

The consolidated unused tax losses carried forward at December 31, 2016 amounted to €385 million (2015: €434 million; 2014: €315 million), €17 million were related to unrecognized tax losses with expiry date between 2018 and 2030.

The available statutory tax losses carried forward that can be offset against future statutory taxable profits amounted to €311.1 million on December 31, 2016. These statutory tax losses can be compensated with future statutory profits for an indefinite period except for an amount of €18 million in Switzerland, Croatia, the United States and the Netherlands with expiry date between 2018 and 2030. On December 31, 2016, the available tax losses carried forward in Galapagos NV (Belgium) amounted to €230.9 million.

 

F-47


Table of Contents

We have a history of losses. Excluding the impact of possible upfront or milestone payments to be received from collaborations, we forecast to continue incurring taxable losses in the foreseeable future as we continue to invest in clinical and pre-clinical development programs and discovery platforms. Consequently, no deferred tax asset was set up as at December 31, 2016, except for two subsidiaries operating on a cost plus basis for which deferred tax assets were recognized for €2.0 million (2015: €1.7 million; 2014: €0.3 million).

23. Finance lease liabilities

 

     December 31,      December 31,  
     2016      2015      2014      2016      2015      2014  
     (Euro, in thousands)  
     Minimum lease
payments
     Present value of
    minimum lease payments    
 

Amounts payable under finance lease:

                 

Within one year

   56      56      58      54      52      52  

In the second to fifth years inclusive

     9        65        121        9        63        115  

After five years

     —          —          —          —          —          —    
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   65      121      179      63      115      167  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Less future finance charges

     2        6        12           
  

 

 

    

 

 

    

 

 

          

Present value of lease obligation

   63      115      167           
  

 

 

    

 

 

    

 

 

          

Less amount due for settlement within 12 months

              54        52        52  
           

 

 

    

 

 

    

 

 

 

Amount due for settlement after 12 months

            9      63      115  
        

 

 

    

 

 

    

 

 

 
     December 31,      December 31,  
     2016      2015      2014      2016      2015      2014  
     (Euro, in thousands)  
     Net book value      Acquisition cost  

Leased assets:

                 

Installation & machinery

   58      109      161      251      251      295  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total leased assets

   58      109      161      251      251      295  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

We lease certain of our installation and machinery under finance leases. For the year ended December 31, 2016, the average borrowing rate was 4.34% (2015: 4.3%; 2014: 6.27%). The interest rates were fixed at the date of the contracts. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.

The fair value of our lease obligations approximates their carrying value.

 

F-48


Table of Contents

24. Trade and other liabilities

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Trade and other payables

   31,209      29,113      29,344  

Other current liabilities

     60        369        663  

Other non-current liabilities

     2,469        2,291        923  

Accrued charges

     619        490        585  

Deferred income

     285,612        39,806        27,026  
  

 

 

    

 

 

    

 

 

 

Total trade and other liabilities

   319,969      72,068      58,541  
  

 

 

    

 

 

    

 

 

 

Included in current liabilities

     102,715        69,777        57,618  

Included in non-current liabilities

     217,254        2,291        923  
  

 

 

    

 

 

    

 

 

 

Total trade and other liabilities

   319,969      72,068      58,541  
  

 

 

    

 

 

    

 

 

 

The trade and other liabilities, amounting to €72.1 million as of December 31, 2015, increased by €13.5 million compared to the €58.5 million reported as of December 31, 2014.

 

    The trade and other payables amounting to €29.1 million as of December 31, 2015 remained stable compared to the €29.3 million as of December 31, 2014. Nevertheless, trade payables decreased by €2.7 million compared to the same period last year which fully compensated the increase in other payables by €2.5 million as a result of higher bonus payables.

 

    Deferred income amounted to €39.8 million at December 31, 2015 and increased by €12.8 million compared to December 31, 2014. On the one hand there was an increase of €39 million due to the recognition of a deferred income upon signing of the share subscription agreement with Gilead (see note 7). On the other hand there was a substantial decrease of €26.4 million, which was mainly explained by revenues from non-refundable upfront payments recognized in the income statement. For the year ended December 31, 2014, €15.0 million revenue was deferred for the filgotinib program for rheumatoid arthritis and Crohn’s disease with AbbVie, and €11.4 million was deferred for the CF program with AbbVie.

 

    The outstanding deferred income balance at December 31, 2015 included €39.0 million deferred income related to the Gilead share subscription agreement and €0.8 million primarily related to deferred revenues from grants.

Our trade and other liabilities, amounting to €320.0 million as of December 31, 2016, increased by €247.9 million compared to the €72.1 million reported as of December 31, 2015.

The trade and other payables, amounting to €31.2 million as of December 31, 2016, increased slightly compared to the €29.1 million reported as of December 31, 2015. This increase is mainly due to higher trade payables.

Deferred income (long term and short term) amounted to €285.6 million at December 31, 2016 and increased by €245.8 million compared to €39.8 million as at December 31, 2015. On the one hand we had per December 31, 2015 a deferred income of €39 million due to recognition of a deferred income upon signing of the share subscription agreement with Gilead (see note 7). On the other hand we received in January 2016 an upfront payment from Gilead for an amount of $300 million (or €276 million). The global collaboration with Gilead foresees continuous involvement from us, since we will perform certain R&D activities in the development phase of the filgotinib program; therefore, management assessed that both items of the deferred income should be spread in function of the costs incurred for the filgotinib program, applying the percentage of completion method. For the year ended December 31, 2016, €29.2 million were recognized in revenue, of which €3.6 million were related to the deferred income from the share subscription agreement and €25.6 million were related to the upfront payment.

 

F-49


Table of Contents

The outstanding deferred income balance at December 31, 2016 included €285.3 million deferred income related to filgotinib (€214.8 million classified as non-current deferred income)—of which €35.4 million deferred income related to the Gilead share subscription agreement, remaining €249.9 million deferred income related to the $300 million upfront payment—and €0.3 million deferred grant income.

25. Provisions

 

     Post-
employment
benefits
(non-current)
    Other
provisions
(non-current)
    Restructuring
provision
(current)
    Other
provisions
(current)
    Total  
     (Euro, in thousands)        

On January 1, 2014

   7     660     81     —       747  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additional provisions

     7       —         —         73       80  

Provisions utilized amounts

     —         (3     (50     —         (53

Sale of the service division

     —         (604     —         —         (604

Translation differences

     —         4       1       —         5  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2014

     14       57       32       73       176  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additional provisions

     —         —         —         —         —    

Provisions utilized amounts

     (7     (10     (35     (73     (125

Translation differences

     —         —         4       —         4  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2015

     8       47       0       0       55  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Additional provisions

     —         10       —         —         10  

Provisions utilized amounts

     (2     —         —         —         (2

Translation differences

     0       0       —         —         1  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On December 31, 2016

   6     57     —       —       63  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The decrease in provisions in 2014 is mainly due to the sale of the service division (€0.6 million).

The decrease in provisions in 2015 is mainly due to the use of the provision for decontamination of the building in France (€0.1 million).

The provisions remained stable at €0.1 million in 2016.

26. Operating lease obligations

We entered into lease agreements for office and laboratories which qualify as operating leases.

Minimum lease payments under operating leases recognized in the income statement for the year

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Continuing operations

   4,302      4,020      3,676  

Discontinued operations

     —          —          643  
  

 

 

    

 

 

    

 

 

 

Total minimum lease payments under operating leases

   4,302      4,020      4,319  
  

 

 

    

 

 

    

 

 

 

Regarding outstanding commitments for future minimum lease payments under operating leases, see off-balance sheet arrangements as explained in note 27 below.

 

F-50


Table of Contents

27. Off-balance sheet arrangements

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

We entered into lease agreements for office and laboratories which qualify as operating leases. We also have certain purchase commitments with CRO subcontractors principally.

On December 31, 2016, we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:

 

     Total      Less than
1 year
     1–3
years
     3–5
years
     More than
5 years
 
            (thousands
of €)
        

Operating lease obligations

   27,263      4,114      6,494      5,504      11,151  

Purchase commitments

     27,579        27,084        495        —          —    
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total contractual obligations & commitments

   54,842      31,198      6,989      5,504      11,151  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

28. Contingent assets and liabilities

On March 13, 2014, we announced the signing of a definitive agreement to sell the service division operations to Charles River Laboratories International, Inc. or CRL for a total consideration of up to €134 million. CRL agreed to pay us an immediate cash consideration of €129 million. The potential earn-out of €5 million due upon achievement of a revenue target 12 months after transaction closing has not been obtained. Approximately 5% of the total consideration, including price adjustments, was being held on an escrow account. To date, four claims have been introduced by CRL, of which all have been settled for a total amount of €1.3 million. On January 17, 2017 an amount of €4.1 million was released from the escrow account. The release of the remaining balance of the escrow account will be possible after final agreement between the parties on the amounts at stake.

Following the divestment, we remained guarantor until early February 2017 in respect of the lease obligations for certain U.K. premises amounting to £3 million future rent payments. CRL shall fully indemnify us against all liabilities arising in connection with the lease obligations. We evaluated the risk to be remote. Finally, following common practice, we have given customary representations and warranties which are capped and limited in time (since April 1, 2016, CRL can only introduce a claim covered by the Tax Deed (during a period of 5 years), other claims related to the sale cannot be submitted anymore).

In the course of 2008, a former director of one of the subsidiaries sued for wrongful termination and seeks damages of €1.5 million. We believe that the amount of damages claimed is unrealistically high. In 2014, the court requested an external advisor to evaluate the exact amount of damages. On January 29, 2016, the court made a 1st degree judgment, dismissing all claims in full. In appeal, the 2nd degree court instructed the 1st degree court to conduct a new trial, which is currently pending. So far, no hearings have been scheduled and no decisions have been made. Considering the defense elements provided, as well as the fact that so far the court has made no decision indicating that the claim would be sustained, our board and management evaluated the risk to be remote to possible, but not likely. Accordingly, it was decided not to record any provision in 2016 as the exposure is considered to be limited.

29. Retirement benefit plans

DEFINED CONTRIBUTION PLANS

We operate defined contribution systems for all of our qualifying employees. The assets of the schemes are held separately from ours in designated pension plans. For defined contribution systems, we pay contributions to publicly or privately administered pension or insurance funds. Once the contribution is paid, we do not have any remaining obligation.

 

F-51


Table of Contents

DEFINED BENEFIT PLANS IN BELGIUM

Our personnel in Belgium participated in a defined contribution plan (extra-legal pension). The Belgian defined contribution pension plans were by law subject to minimum guaranteed rates of return, 3.25% on employer contributions and 3.75% on employee contributions. These rates, which apply as an average over the entire career, may be modified by Royal Decree. Therefore, those plans were basically accounted for as defined contribution plans.

As a consequence of the law of December 18, 2015, minimum returns were guaranteed by the employer as follows: (a) for the contributions paid as from January 1, 2016, a new variable minimum return based on OLO rates, with a minimum of 1.75% and a maximum of 3.75%. In review of the low rates of the OLO in the last years, the return has been initially set to 1.75%; (b) for the contributions paid until end of December 2015, the previously applied legal returns as mentioned above, continue to apply until the leaving of the employees.

In view of the minimum returns guarantees, the Belgian defined contribution plans classify as defined benefit plans as from end December 2015.

As at December 31, 2015 no net liability was recognized (2014: nil) in the balance sheet as the minimum rates of return to be guaranteed by the employer are closely matched by the rates of return guaranteed by the insurer. As at December 31, 2016 however a net liability of €386.6 thousand was recorded.

The contributions for those plans that were due by the employer for 2016, 2015 and 2014 amounted to respectively €528.0 thousand, €476.3 thousand and €465.6 thousand, of which €42.5 thousand was paid after December 31, 2016 (2015: €35.9 thousand; 2014: €32.9 thousand). No contributions were made by the employees.

The plan assets as at December 31, 2016 consisted of €1,788.7 thousand (2015: 1,063.7 thousand) individual insurance reserves, which benefit from a weighted average guaranteed interest rate of 2.82% (2015 : 3.0%).

DEFINED BENEFIT PLANS IN FRANCE

We use two defined benefit plans for the employees of our French entity. The defined benefit plans are not supported by funds.

The chemical and pharmaceutical industry’s collective bargaining agreements require that the French entity pays a retirement allowance depending on the seniority of the employees at the moment they retire. The benefit obligations for these retirement allowances amounted to €1,808.5 thousand for 2016 (2015: €1,520.9 thousand; 2014: €1,622.3 thousand). The decrease in 2015 compared to 2014 is mainly due to changed actuarial assumptions (increase of discount rate from 1.75% to 2%). The increase in 2016 is mainly due to changed actuarial assumptions (decrease of discount rate from 2% to 1.44%).

Additionally, there are also seniority premiums paid in France. The provisions for these premiums amounted to €1,324.9 thousand in 2016 (2015: €1,172.0 thousand; 2014: €1,242.9 thousand).

Total obligation included in the balance sheet related to the defined benefit plans amounts to €3,133.4 thousand for the year ended December 31, 2016 (2015: €2,692.9 thousand; 2014: €2,865.2 thousand).

Actuarial gains and losses are recognized immediately on the balance sheet, with a charge or credit to other comprehensive income (OCI), in accordance with IAS 19R. They are not recycled subsequently. Actuarial losses of €193.2 thousand have been booked through other comprehensive income (OCI) at the end of 2016 (2015: €201.5 thousand of actuarial gains, 2014: €266.6 thousand of actuarial losses).

Total amounts due by all entities to these pension plans in 2016 were €1.7 million in total (2015: €1.5 million, 2014: €1.5 million).

 

F-52


Table of Contents

Obligations included in the balance sheet

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Present value of funded defined benefit obligation

   2,175        —          —    

Plan assets

   (1,789    (1,064      —    

Deficit/ surplus

     387        (1,064      —    

Present value of unfunded defined benefit obligation

     3,133        2,693      2,865  

Reclassification—Belgian contribution plans

     —          1,064        —    
  

 

 

    

 

 

    

 

 

 

Liability included in the balance sheet

   3,520      2,693      2,865  
  

 

 

    

 

 

    

 

 

 

The present value of the gross obligation developed as follows:

 

     2016     2015     2014  
     (Euro, in thousands)  

Opening balance

   3,757     2,865     2,189  

Current service cost

     649       194       228  

Actual taxes on contributions paid

     (48     —         —    

Interest cost

     82       50       65  

Benefits paid

     (119     (44     (48

Reclassification—Belgian contribution plans

     —         1,064       —    

Actuarial gains (-) or losses due to experience adjustments

     500       (27     82  

Actuarial losses due to experience adjustments related to new financial assumptions

     432       (99     347  

Actuarial gains (-) or losses due to experience adjustments related to new demographic assumptions

     56       (247     3  
  

 

 

   

 

 

   

 

 

 

Closing balance

   5,308     3,757     2,865  
  

 

 

   

 

 

   

 

 

 

The fair value of the plan assets developed as follows:

 

     2016      2015      2014  
     (Euro, in thousands)  

Opening balance

   (1,064      —          —    

Interest income on plan assets

     (32      —          —    

Actual administration costs

     2        —          —    

Contributions from employer

     (411      —          —    

Actual taxes on contributions paid

     48        —          —    

Plan assets gain during the period

     (332      —          —    

Reclassification—Belgian contribution plans

     —          (1,064      —    
  

 

 

    

 

 

    

 

 

 

Closing balance

   (1,788    (1,064    —    
  

 

 

    

 

 

    

 

 

 

The expected rate of return on the plan assets is 2%.

The fair value of the plan assets is the fair market value of the plan assets. The fair value of the plan assets was calculated as the reduced lump sums (received from the plan administrators) actualized with the assumptions set (discount rate and mortality tables). The total plan assets are equal to the fair value of the plan assets increased with the financing fund.

 

F-53


Table of Contents

Amounts recognized in profit or loss for defined benefit plans are as follows:

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Current service cost

   649      194      228  

Interest cost

     82        50        65  

Interest income

     (32      —          —    

Administration expenses

     2        —          —    

Revaluations of net liability / net asset

     73        (171      165  
  

 

 

    

 

 

    

 

 

 

Total expense

   773      73      457  
  

 

 

    

 

 

    

 

 

 

Obligation included in the balance sheet reconciles as follows:

 

     2016      2015      2014  
     (Euro, in thousands)  

Opening balance

   2,693      2,865      2,189  

Real employer contributions

     (411      —          —    

Total expense recognized in the income statement

     773        73        457  

Re-measurement on the net defined benefit liability

     583        (202      267  

Benefits paid

     (119      (44      (48
  

 

 

    

 

 

    

 

 

 

Closing balance

   3,520      2,693      2,865  
  

 

 

    

 

 

    

 

 

 

The main actuarial assumptions were:

 

     December 31,  
     2016     2015     2014  
     (%)  

Discount rate

     1.60     2.00     1.75

Expected salary increase

     2.50     2.25     2.25

Inflation rate

     1.75     1.75     1.75

The discount rate was based on the Merrill Lynch yields for AA rated Eurozone corporate bonds (bonds with maturity dates which correspond with the commitments).

Breakdown of defined benefit obligation by type of plan participants:

 

     December 31,  
     2016      2015      2014  
     (number of participants)  

Active plan participants

     267        254        125  

Breakdown of defined benefit obligation by type of benefits:

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Retirement and death benefits

   3,983        2,585        1,622  

Other post-employment benefits

     1,325        1,172        1,243  

 

F-54


Table of Contents

Major categories of plan assets: fair value plan of assets:

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Equity

   89      74     

Debt

     1,698        979     

Cash

        11     

Sensitivity analysis on discount rate: effect on obligation:

 

           December 31,  
           2016  
           Obligation
(Euro, in
thousands)
 

Discount rate

     1.10   3,792  

Discount rate

     1.35     3,661  

Discount rate

     1.60     3,520  

Discount rate

     1.85     3,419  

Discount rate

     2.10   3,312  

 

           December 31,  
           2015  
           Obligation
(Euro, in
thousands)
 

Discount rate

     1.50   2,868  

Discount rate

     1.75     2,779  

Discount rate

     2.00     2,693  

Discount rate

     2.25     2,612  

Discount rate

     2.50   2,534  

 

           December 31,  
           2014  
           Obligation
(Euro, in
thousands)
 

Discount rate

     1.25   3,068  

Discount rate

     1.50     2,964  

Discount rate

     1.75     2,865  

Discount rate

     2.00     2,772  

Discount rate

     2.25   2,682  

30. Warrant plans

Presented below is a summary of warrant plans activities for the reported periods. Various warrant plans were approved for the benefit of our employees, and for directors and independent consultants of Galapagos NV. For warrant plans issued prior to 2011, the warrants offered to the employees and independent consultants vest according to the following schedule: 10% of the warrants vest on the date of the grant; an additional 10% vest at the first anniversary of the grant; an additional 20% vest at the second anniversary of the grant; an additional 20% vest at the third anniversary of the grant; and an additional 40% vest at the end of the third calendar year following the grant. The warrants granted under warrant plans created from 2011 up to (and including) Warrant Plan 2015 vest at the end of the third calendar year following the year of the grant, with no intermediate vesting. The warrants granted under Warrant Plan 2015 (B) and Warrant Plan 2015 RMV vest on the third anniversary of the notary deed enacting the acceptance of the warrants. The warrants granted under Warrant plan 2016 and

 

F-55


Table of Contents

Warrant Plan 2016 RMV vest at the end of the third calendar year following the year of the grant, with no intermediate vesting.

The warrants offered to directors vest over a period of 36 months at a rate of 1/36th per month. Warrants cannot be exercised before the end of the third calendar year following the year of the grant, except for warrants granted under Warrant Plan 2015 (B) and Warrant Plan 2015 RMV, which become exercisable on the third anniversary of the notary deed enacting the acceptance of the warrants. In the event of a change of control over Galapagos NV, all outstanding warrants vest immediately and will be immediately exercisable.

After the reverse 4:1 share split approved by the extraordinary shareholders’ meeting of March 29, 2005, four warrants under Warrant Plan 2002 Belgium entitle the warrant holder to subscribe for one ordinary share. For the warrant plans created from 2005 onwards, one warrant entitles the warrant holder to subscribe for one ordinary share. In the summaries and tables below, the numbers of warrants issued under Warrant Plan 2002 Belgium are divided by four to avoid confusion in entitlements and rights.

The table below sets forth a summary of warrants outstanding and exercisable at December 31, 2016, per warrant plan:

 

Warrantplan

  Allocation
date
    Expiry
date
    Exercise
price (€)
    Outstanding
per
January 1,
2016
    Granted
during
the year
    Exercised
during
the year
    Forfeited
during
the year
    Expired
during the
year
    Outstanding
per
December 31,
2016
    Exercisable
per
December 31,
2016
 

2002 B

    7/9/2004       7/8/2017       4       31,250         (31,250         0       0  

2002 B

    1/31/2005       1/30/2017       6.76       30,000         (5,000         25,000       25,000  

2005

    7/4/2005       7/3/2018       6.91       120,000         (30,000         90,000       90,000  

2005

    12/15/2005       12/14/2018       8.6       12,500               12,500       12,500  

2006 BNL

    5/4/2007       5/3/2020       9.22       7,500               7,500       7,500  

2006 BNL

    6/28/2007       6/27/2020       8.65       735               735       735  

2006 BNL

    12/21/2007       12/20/2020       7.12       1,575         (525         1,050       1,050  

2007

    6/28/2007       6/27/2020       8.65       48,909               48,909       48,909  

2007 RMV

    10/25/2007       10/24/2020       8.65       44,125         (6,475         37,650       37,650  

2008

    6/26/2008       6/25/2021       5.6       89,915         (10,315         79,600       79,600  

2009

    4/1/2009       3/31/2017       5.87       42,500         (35,000         7,500       7,500  

2010

    4/27/2010       4/26/2018       11.55       96,300         (43,300         53,000       53,000  

2011

    5/23/2011       5/22/2019       9.95       77,500         (18,400         59,100       59,100  

2011 (B)

    5/23/2011       5/22/2016       9.95       117,940         (117,940         0       0  

2012

    9/3/2012       9/2/2020       14.19       370,490         (120,830       (2,500     247,160       247,160  

2013

    5/16/2013       5/15/2021       19.38       445,740           (13,500       432,240    

2013 (B)

    9/18/2013       9/17/2021       15.18       30,000               30,000    

2014

    7/25/2014       7/24/2022       14.54       556,660           (20,000       536,660    

2014 (B)

    10/14/2014       10/13/2022       11.93       150,000               150,000    

2015

    4/30/2015       4/29/2023       28.75       532,053           (15,000       517,053    

2015 (B)

    12/22/2015       12/21/2023       49         399,000             399,000    

2015 RMV

    12/22/2015       12/21/2023       49         97,500             97,500    

2016

    6/1/2016       5/31/2024       46.1         514,250             514,250    

2016 RMV

    6/1/2016       5/31/2024       46.1         120,000             120,000    
       

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

          2,805,692       1,130,750       (419,035     (48,500     (2,500     3,466,407       669,704  
       

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

F-56


Table of Contents
     Warrants      Weighted
average
exercise
price (€)
 
     

Outstanding on January 1, 2014

     3,627,076      11.50  
  

 

 

    

 

 

 

Exercisable on December 31, 2013

     1,138,438     

Granted during the period

     721,660     

Forfeited during the year

     (252,800   

Exercised during the period

     (505,083   

Expired during the year

     —       
  

 

 

    

 

 

 

Outstanding on December 31, 2014

     3,590,853      12.06  
  

 

 

    

 

 

 

Exercisable on December 31, 2014

     1,355,213     

Granted during the period

     532,053     

Forfeited during the year

     (72,500   

Exercised during the period

     (1,244,714   

Expired during the year

     —       
  

 

 

    

 

 

 

Outstanding on December 31, 2015

     2,805,692      16.22  
  

 

 

    

 

 

 

Exercisable on December 31, 2015

     720,749     

Granted during the period

     1,130,750     

Forfeited during the year

     (48,500   

Exercised during the period

     (419,035   

Expired during the year

     (2,500   
  

 

 

    

 

 

 

Outstanding on December 31, 2016

     3,466,407      27.06  
  

 

 

    

 

 

 

Exercisable on December 31, 2016

     669,704     

The table below sets forth the inputs into the valuation of the warrants.

 

    2016     2016 RMV     2015 (B)     2015 RMV     2015     2014     2014  
      June 1         June 1     December 22     December 22     April 30     Oct 14     Jul 25  

Exercise Price

  46.10     46.10     49.00     49.00     28.75     11.93     14.54  

Share price at acceptance date

  48.71     47.63     39.85     39.78     46.09     10.95     14.38  

Fair value on the acceptance date

  21.95     21.16     15.41     15.39     26.05     4.35     6.14  

Estimated volatility (%)

    40.69       40.69       41.1       41.08       39.2       38.03       38.76  

Time to expiration (years)

    8       8       8       8       8       8       8  

Risk free rate (%)

    0       0       0.24       0.28       0.39       0.58       0.58  

Expected dividends

    None       None       None       None       None       None       None  

Warrant Plans

The exercise price of the warrants is determined pursuant to the applicable provisions of the Belgian Companies Code.

The estimated volatility is calculated on the basis of the historical volatility of the share price over the expected life of the warrants, validated by reference to the volatility of a representative biotech index.

The time to expiration of the warrant is calculated as the estimated duration until exercise, taking into account the specific features of the plans.

The warrants were accounted for in accordance with International Financial Reporting Standard 2 on Share Based Payments. IFRS 2 takes effect for all warrants offered after November 7, 2002.

 

F-57


Table of Contents

Our warrants expense in 2016 amounted to €11,034 thousand (2015: 5,036 thousand; 2014: €2,952 thousand).

The following table provides an overview of the outstanding warrants per category of warrant holders at December 31, 2016, 2015 and 2014.

Category

 

     December 31,  
     2016      2015      2014  
     (in number of warrants)  

Non-executive directors

     165,240        115,730        199,070  

Executive team

     1,676,874        1,376,874        1,520,000  

Other

     1,624,293        1,313,088        1,871,783  
  

 

 

    

 

 

    

 

 

 

Total warrants outstanding

     3,466,407        2,805,692        3,590,853  
  

 

 

    

 

 

    

 

 

 

The outstanding warrants at the end of the accounting period have an average exercise price of €27.06 (2015: €16.22; 2014: €12.06) and a weighted average remaining expected life of 1,482 days (2015: 1,469 days; 2014: 1,639 days).

31. Related parties

Relationship and transactions with entities with (joint) control of, or significant influence over, Galapagos

There are no shareholders or other entities who, solely or jointly, control Galapagos or exercise significant influence over Galapagos.

Relationship and transactions with subsidiaries

Please see Note 32 for an overview of the consolidated companies of the group, which are all wholly-owned subsidiaries of Galapagos NV.

Intercompany transactions between Galapagos NV and its subsidiaries, and amongst the subsidiaries, have been eliminated in the consolidation and are not disclosed in this note.

Relationship and transactions with key management personnel

Our key management personnel consists of the members of our executive committee and the members of our board of directors. All amounts mentioned in this section are based on expenses recognized in the financial statements for the relevant financial year.

Remuneration of key management personnel

On December 31, 2016, our executive committee had four members: Mr. Onno van de Stolpe, Mr. Bart Filius, Dr. Piet Wigerinck and Dr. Andre Hoekema. On December 31, 2016, our board of directors consisted of eight members: Mr. Onno van de Stolpe, Dr. Raj Parekh, Dr. Werner Cautreels, Dr. Harrold van Barlingen, Mr. Howard Rowe, Ms. Katrine Bosley, Dr. Christine Mummery and Dr. Mary Kerr.

Only the CEO is a member of both the executive committee and the board of directors. Our CEO does not receive any special remuneration for his board membership, as this is part of his total remuneration package in his capacity as member of the executive committee.

 

F-58


Table of Contents

Historically, the chairman of the board of directors, Dr. Parekh, did not receive remuneration like the other directors. Between August 1, 2005 and April 30, 2016, Dr. Parekh received an annual consulting fee of £50,000 under a consultancy contract with his management company, Parekh Enterprises Ltd. as compensation for his specific assignment to assist the group in strategic positioning, financing and acquisitions. Since May 1, 2016, Dr. Parekh receives remuneration for his director’s mandate in the same way as the other directors.

The remuneration package of the members of key management personnel comprises:

 

     Year ended December 31,  
     2016      2015      2014  
     (Euro, in thousands, except for the
number of warrants)
 

Remuneration of key management personnel:

        

Short-term employee benefits (*)

        

Executive committee members as a group

   3,124      2,937      1,506  

Raj Parekh (^)

     73        —          —    

Harrold van Barlingen

     47        40        20  

Howard Rowe

     50        40        20  

Werner Cautreels

     56        45        45  

Katrine Bosley

     45        40        40  

Christine Mummery (#)

     43        10        —    

Mary Kerr (##)

     18        —          —    

Vicki Sato (###)

     —          —          40  

Post-employment benefits(°)

     228        215        184  
  

 

 

    

 

 

    

 

 

 

Total benefits excluding warrants

   3,683      3,327      1,855  
  

 

 

    

 

 

    

 

 

 

Number of warrants granted in the year

        

Executive committee members as a group

     515,000        175,000        330,000  

Raj Parekh (^)

     30,000        5,400        5,400  

Harrold van Barlingen

     15,000        2,520        2,520  

Howard Rowe

     15,000        2,520        2,520  

Werner Cautreels

     15,000        3,780        3,780  

Katrine Bosley

     15,000        2,520        2,520  

Christine Mummery (#)

     15,000        —          —    

Mary Kerr (##)

     —          —          —    

Vicki Sato (###)

     —          —          2,520  
  

 

 

    

 

 

    

 

 

 

Total number of warrants granted in the year

     620,000        191,740        349,260  
  

 

 

    

 

 

    

 

 

 

 

(*) Includes for executive committee members: salaries, employer social security contributions, other short-term benefits; includes for board members: board fees, other short-term benefits.
(^) During the first four months of 2016, Dr. Parekh did not receive remuneration for his director’s mandate, but was compensated through a consultancy agreement only (consultancy fee of €20 thousand in 2016).
(°) Only executive committee members are granted post-employment benefits.
(#) Dr. Mummery joined the board on September 30, 2015.
(##) Dr. Kerr joined the board on July 26, 2016.
(###) Dr. Sato resigned from the board on December 31, 2014.

SHORT-TERM EMPLOYEE BENEFITS AND BOARD FEES

 

The members of the executive committee provide their services to us on a full-time basis.

 

F-59


Table of Contents

The four members of the executive committee (including the CEO) who were in function in the course of 2016 were paid an aggregate amount of €1,291.84 in remuneration and received an aggregate amount of €1,747.21 in bonuses (2015: €1,245.5 thousand in remuneration and €1,629.5 thousand in bonuses; 2014, for the six members of the executive committee who were in function in the course of 2014: €1,151.6 thousand in remuneration and €268.6 thousand in bonuses). The aggregate bonus amount for 2016 was composed of two parts: (i) an aggregate bonus of €573.05 thousand, being 50% of the bonus for performance over 2016 (paid in early January 2017), with the other 50% being deferred for 3 years, (ii) an aggregate amount of €1,174.17 thousand as deferred part of the bonus for performance over 2013 (paid in early January 2017). The aggregate bonus amount for 2015 was composed of 3 parts: (i) an aggregate bonus of €488.5 thousand, being 50% of the bonus for performance over 2015 (paid in early January 2016), with the other 50% being deferred for 3 years, (ii) an aggregate amount of €628.5 thousand as deferred part of the bonus for performance over 2012 (paid in early January 2016) and (iii) an aggregate amount of €512.5 thousand, being 50% of the exceptional special bonus awarded for the success of the NASDAQ listing (paid in June 2015), with the other 50% being deferred for 3 years. The aggregate bonus amount for 2014 was composed of 2 parts: (a) an aggregate bonus of €234 thousand, being 50% of the bonus for performance over 2014 (paid in early January 2015), with the other 50% being deferred for 3 years, (b) an aggregate amount of €34.6 thousand as an exceptional special bonus granted to former executive committee member Mr. Smith in connection with his instrumental role in the divestment of the group’s services division. No performance bonus was awarded for the year 2011, as three out of five of the corporate objectives for 2011 were not achieved. Therefore, no deferred part of the bonus for the year 2011 was paid out in 2014.

Other components of the remuneration of the executive committee members included contributions to health insurance schemes, company cars, tax advisory services and certain fringe benefits of non-material value.

Pursuant to the decision of the annual shareholders’ meeting of April 26, 2016, Dr. Parekh received €70 thousand (or, taking into account €20 thousand received in consultancy fees for the first four months of 2016, an aggregate of €90 thousand: €80 thousand as chairman of the board, and €10 thousand as chairman of the nomination and remuneration committee), Dr. Cautreels received €55 thousand (€40 thousand as non-executive director, €10 thousand as chairman of the audit committee and €5 thousand as member of the nomination and remuneration committee), Ms. Bosley, Mr. Rowe and Dr. Van Barlingen each received €45 thousand (€40 thousand as non-executive director and €5 thousand as member of the nomination and remuneration committee or audit committee) and Dr. Mummery received €40 thousand as non-executive director. Dr. Kerr, being appointed as non-executive director as from July 26, 2016, received €17 thousand as remuneration for the performance of her mandate during the remainder of 2016 pursuant to the decision of the special shareholders’ meeting of July 26, 2016. Pursuant to a power of attorney granted by the annual shareholders’ meeting of April 28, 2015, the board determined, after discussion within the nomination and remuneration committee, to allocate the aggregate annual remuneration for directors for 2015 as follows: (a) annual remuneration for each non-executive director (Dr. Cautreels, Dr. Van Barlingen, Mr. Rowe and Ms. Bosley): €40 thousand; and (b) additional remuneration for the chairman of the audit committee (Dr. Cautreels): €5 thousand. Dr. Mummery, being appointed as non-executive director as from September 30, 2015, received €10 thousand as remuneration for the performance of her mandate during the last quarter of 2015. Pursuant to a power of attorney granted by the annual shareholders’ meeting of April 29, 2014, the board determined, after discussion within the nomination and remuneration committee, to allocate the aggregate annual remuneration for directors for 2014 as follows: (a) remuneration for non-executive directors who do not represent a shareholder (Dr. Van Barlingen and Mr. Rowe): €20 thousand; (b) remuneration for non-EU-based directors (who do not represent a shareholder) and/or for directors who actively and on a regular basis provide independent clinical, scientific and/or transactional advice to the board of directors (Dr. Cautreels, Dr. Sato and Ms. Bosley): €40 thousand; (c) additional remuneration for the chairman of the audit committee (Dr. Cautreels): €5 thousand.

The increase in board fees is due to the increased number of directors and the decision of the annual shareholders’ meeting of April 26, 2016 to increase the amount of remuneration paid to the directors, also taking into account their positions as board chairman, committee chairman and committee member. In addition, Dr. Parekh did not receive remuneration for his director’s mandate in 2014, 2015 and the first four months of

 

F-60


Table of Contents

2016, but was instead compensated only through a consultancy agreement until April 30, 2016. Finally, in 2016, a total amount of €14.5 thousand was paid as other short-term benefit for the non-executive directors (2015: €4.95 thousand). These benefits related to the payment of tax advisory services.

POST-EMPLOYMENT BENEFITS

The post-employment benefits to the members of the executive committee are granted under separate retirement benefit schemes, including pension schemes, post-employment life insurance and additional individual pension contributions.

SEVERANCE PAYMENTS

The employment and management agreements of the members of the executive committee do not provide for severance compensation. They do not contain notice periods that exceed six months. However, Galapagos entered into undertakings with the members of the executive committee providing that, in case their contract with the group is terminated as a result of a change of control of Galapagos NV, they would be entitled to a severance compensation of 12 months’ base salary for the Chief Executive Officer and nine months’ base salary for the other executive committee members.

WARRANTS GRANTED IN 2016

In 2016, 60,000 warrants were granted to independent directors (2015: 8,820; 2014: 11,340) and 45,000 warrants were granted to the other non-executive directors (2015: 7,920; 2014: 7,920). The increase can be explained by the fact that the final acceptance and issuance of the warrants under Warrant Plan 2015 (B) took place in 2016, and are counted as warrants granted in 2016 along with the warrants granted under Warrant Plan 2016. The special shareholders’ meeting of December 22, 2015, upon the proposal of our nomination and remuneration committee, offered additional warrants to our directors under Warrant Plan 2015 (B) in light of an independent benchmarking exercise and recommendation by an external advisor, following the growth of the company and the U.S. listing on Nasdaq in 2015.

OTHER

No loans, quasi-loans or other guarantees were given by Galapagos NV or any of its subsidiaries to members of the board and of the executive committee. We have not entered into transactions with our key management personnel, other than as described above with respect to remuneration arrangements relating to the exercise of their mandates as members of the executive committee and the board of directors.

 

F-61


Table of Contents

32. Consolidated companies as of December 31, 2016

 

        Year ended December 31,  
      2016     2015     2014  

Name of the subsidiary

 

Country

  % voting right
Galapagos NV
(directly or
indirectly
through
subsidiaries)
    Change in %
voting right
previous
period (2016
vs 2015)
    % voting right
Galapagos NV
(directly or
indirectly
through
subsidiaries)
    % voting right
Galapagos NV
(directly or
indirectly
through
subsidiaries)
 

Continuing operations:

         

BioFocus DPI AG

  Switzerland     100%         100%       100%  

BioFocus DPI LLC

  United States     0%       (100 %)      100%       100%  

BioFocus, Inc.

  United States     100%         100%       100%  

Discovery Partners International GmbH

  Germany     100%         100%       100%  

Galapagos B.V.

  The Netherlands     100%         100%       100%  

Galapagos NV

  Belgium     parent company         parent company       parent company  

Fidelta d.o.o.

  Croatia     100%         100%       100%  

Galapagos SASU

  France     100%         100%       100%  

Inpharmatica Ltd.

  United Kingdom     100%         100%       100%  

Xenometrix, Inc.

  United States     100%         100%       100%  

Discontinued operations: *

         

Argenta Discovery 2009 Ltd.

  United Kingdom     0%       —         0%       0%  

BioFocus DPI (Holdings) Ltd.

  United Kingdom     0%       —         0%       0%  

BioFocus DPI Ltd.

  United Kingdom     0%       —         0%       0%  

Cangenix Ltd.

  United Kingdom     0%       —         0%       0%  

 

* On April 1, 2014 these entities were sold to Charles River.

BioFocus DPI LLC was voluntarily cancelled in 2016.

There are no significant restrictions on the ability to access or use assets and settle liabilities.

There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities of one of the group’s subsidiaries.

 

F-62


Table of Contents

33. Company acquisitions and disposals

COMPANY DISPOSALS: SALE OF SERVICE DIVISION

On April 1, 2014, we sold our service division, comprising all service operations of BioFocus and Argenta in the UK and the Netherlands, to Charles River Laboratories International, Inc. In particular, we disposed of following companies which were previously fully consolidated: BioFocus DPI (Holdings) Ltd. and BioFocus DPI Ltd. (Saffron Walden, UK), Argenta Discovery 2009 Ltd. (Harlow, UK) and its subsidiary Cangenix Ltd. (Canterbury, UK). In addition, also certain assets from Galapagos B.V. (Leiden, the Netherlands) have been acquired by Charles River Laboratories International, Inc.

 

     April 1, 2014  
     (Euro, in thousands)  

Consideration received in cash and cash equivalents

   137,760  

Correction on consideration still to settle

     (650
  

 

 

 

Total consideration

   137,111  
  

 

 

 

 

     April 1, 2014  
     (Euro, in thousands)  

Cash

   6,115  

Trade and other receivables

     18,165  
  

 

 

 

Current assets

     24,280  
  

 

 

 

Goodwill

     39,246  

Fixed assets

     13,397  

Deferred tax assets

     4,588  
  

 

 

 

Non-current assets

     57,231  
  

 

 

 

Trade payables

     (2,569

Other payables

     (5,263
  

 

 

 

Current liabilities

     (7,831
  

 

 

 

Provisions

     (604

Deferred tax liabilities

     (1,996

Other non-current liabilities

     (549
  

 

 

 

Non-current liabilities

     (3,149
  

 

 

 

Net assets disposed of

   70,531  
  

 

 

 

 

     April 1, 2014  
     (Euro, in thousands)  

Total consideration

   137,111  

Net assets disposed of

     (70,531

Effect from Cumulative Translation Adjustments reclassified from equity

     1,787  

Costs associated to sale

     (858
  

 

 

 

Gain on disposal

   67,508  
  

 

 

 

 

F-63


Table of Contents

The gain on the sale is included in the income from discontinued operations for the year ended December 31, 2014.

 

     April 1, 2014  
     (Euro, in thousands)  

Consideration received in cash and cash equivalents

   137,760  

Less: cash and cash equivalent balances disposed

     (6,115
  

 

 

 

Total consideration received

     131,645  
  

 

 

 

Costs associated to sale

     (858
  

 

 

 

Cash in from disposal of subsidiaries, net of cash disposed

   130,787  
  

 

 

 

34. Critical accounting estimates and judgments

In the application of the accounting policies, we are required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Our estimates and assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revisions and future periods if the revision affects both current and future periods.

Drafting financial statements in accordance with IFRS requires management to make judgments and estimates and to use assumptions that influence the reported amounts of assets and liabilities, the notes on contingent assets and liabilities on the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results may differ from these estimates.

The following are the critical judgments and estimates that we have made in the process of applying the accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements presented elsewhere in this annual report.

Critical judgments in applying accounting policies

Share subscription agreement with Gilead- classification as derivative financial asset or equity instrument

As described in note 7, Gilead Sciences, Inc. (“Gilead”) committed itself on December 16, 2015 to make a $425 million equity investment in Galapagos by subscribing to new shares at a fixed price of €58 per share, including issuance premium upon completion of the license and collaboration agreement with Galapagos that took place on January 19, 2016.

Significant judgment had to be applied in assessing whether this forward subscription commitment of Gilead over the own shares of Galapagos shall be classified as an own equity instrument of Galapagos or as a derivative financial asset. IAS 32 requires that for a derivative to meet the definition of equity it must be settled only by the issuer (Galapagos) exchanging a “fixed amount of cash or another financial asset for a fixed number of its own equity instruments.” Because the above mentioned commitment of Gilead was made in $, the actual number of shares finally issued by Galapagos varied with the fluctuation in the $/€ exchange rate until the settlement date on January 19, 2016.

Despite the fact that this foreign exchange exposure was limited, management judged that this variability prevents the instrument from being classified as equity under IAS 32 and was therefore treated as a derivative at fair value through profit and loss.

 

F-64


Table of Contents

Revenue recognition

Evaluating the criteria for revenue recognition with respect to our research and development and collaboration agreements requires management’s judgment to ensure that all criteria have been fulfilled prior to recognizing any amount of revenue. In particular, such judgments are made with respect to determination of the nature of transactions, whether simultaneous transactions shall be considered as one or more revenue-generating transactions, allocation of the contractual price (upfront and milestone payments in connection with a collaboration agreement) to several elements included in an agreement, and the determination of whether the significant risks and rewards have been transferred to the buyer. Collaboration agreements are reviewed carefully to understand the nature of risks and rewards of the arrangement. All of our revenue-generating transactions have been subject to such evaluation by management.

Critical accounting estimates

Fair value re-measurement of the Gilead share subscription agreement (derivative financial asset instrument)

 

     (Euro, in thousands)  

Fair value at inception

     39,003  

Movement of 2015 ( recognized in the income statement)

     (30,632
  

 

 

 

Fair value per December 31, 2015

     8,371  
  

 

 

 

Movement of period January 1-19, 2016 ( recognized in the income statement)

     57,479  
  

 

 

 

Fair value per January 19, 2016

     65,850  
  

 

 

 

Derecognition of the financial asset through the share premium account

     (65,850
  

 

 

 

Fair value per December 31, 2016

     —    
  

 

 

 

The fair value measurement of this derivative financial asset was categorized as a level 3 in the fair value hierarchy of IFRS 13 Fair Value Measurement.

Its measurement was based on computing the difference between the strike price (58 EUR / share) and the anticipated Galapagos forward price, discounted to the valuation date. The notional was converted from USD to EUR by the FX forward rate and the number of shares was computed by dividing the EUR notional by the strike.

Input data were taken from Bloomberg as of December 16, 2015 and December 31, 2015, including:

 

    EUR OIS Discount rates (curve 133)

 

    Implied forward rate of the GLPG share at January 31, 2016

 

    Implied FX Forward rate at January 31, 2016.

This computation was based on the following unobservable assumptions:

 

  1) Between the date that the deal was signed (December 16, 2015) till the date the deal was complete, the two counterparties could not back off from the deal and it was 100% certain that the regulator would give the green light.

 

  2) At the two valuation dates, it was assumed that the date when the deal will be complete would be January 31, 2016. This was the forward date where all the market data was taken from.

 

  3) It was assumed that the effect of the correlation between the Galapagos share price and the €/$ FX rate was negligible. This was reasonable given the very short maturity of the deal.

 

F-65


Table of Contents

Relationship of unobservable inputs to the fair value measurement:

 

    If one would have assumed that the closing date of the deal was January 19, 2016 (the actual closing date) the fair value of the derivative financial asset at December 31, 2015 would have been €8,367 thousands.

On January 19, 2016, the value of the financial asset at maturity amounted to €65.9 million, reflecting the share premium that Gilead paid above our closing share price on the day of the capital increase. This financial asset expired on the effective date of the share subscription agreement and was derecognized through the share premium account.

Share-based payments plans

We determine the costs of the share-based payments plans (our warrant plans) on the basis of the fair value of the equity instrument at grant date. Determining the fair value assumes choosing the most suitable valuation model for these equity instruments, by which the characteristics of the grant have a decisive influence. This assumes also the input into the valuation model of some relevant judgments, like the estimated expected life of the warrant and the volatility. The judgments made and the model used are further specified in note 30.

Pension obligations

The cost of a defined pension arrangement is determined based on actuarial valuations. An actuarial valuation assumes the estimation of discount rates, estimated returns on assets, future salary increases, mortality figures and future pension increases. Because of the long-term nature of these pension plans, the valuation of these is subject to important uncertainties. See note 29 for additional details.

Corporate income taxes

Significant judgment is required in determining the use of tax loss carry forwards. Deferred tax assets arising from unused tax losses or tax credits are only recognized to the extent that there are sufficient taxable temporary differences or there is convincing evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilized. Management’s judgment is that such convincing evidence is currently not sufficiently available except for two subsidiaries operating intercompany on a cost plus basis and as such a deferred tax asset is therefore recognized. As of December 31, 2016, we had a total of approximately €311.1 million of statutory tax losses carried forward which can be compensated with future taxable statutory profits for an indefinite period except for an amount of €18 million in Switzerland, Croatia, the United States and the Netherlands with expiry date between 2018 and 2030. As of December 31, 2016, the available tax losses carried forward in Belgium amounted to €230.9 million.

As from July 1, 2016, the existing Belgian patent income deduction (‘PID’) regime has been abolished and replaced by the innovation income deduction (‘IID’) regime (adopted by the Belgian Chamber of Representatives on February 2, 2017 and published in the official Belgian gazette on February 20, 2017).

Taxpayers benefitting from the previous PID regime will be able to still choose for the old PID regime (instead of the new IID regime) for five years (grandfathering until June 30, 2021).

The choice for the PID regime is however irrevocable. An assessment is currently ongoing to determine which regime is the most favorable for Galapagos. Given this ongoing assessment, the company has taken the position to make abstract of the new IID regime when estimating the tax provision in respect of assessment year 2017. In case the newly IID regime would be applied, it is possible that an additional carried-forward tax asset could be recognized (however subject to further analysis).

 

F-66


Table of Contents

35. Financial risk management

See “Risk Factors” for additional details on general risk factors.

Financial risk factors

Our financial risks are managed centrally. Our finance department coordinates the access to national and international financial markets and considers and manages continuously the financial risks concerning our activities. These relate to the financial markets risk, credit risk, liquidity risk and currency risk. There are no other important risks, such as interest rate risk, because we have nearly no financial debt and have a strong cash position. We do not buy or trade financial instruments for speculative purposes.

Categories of material financial assets and liabilities:

 

     December 31,  
     2016      2015      2014  
     (Euro, in thousands)  

Financial assets:

        

Cash and cash equivalents

   973,241      340,314      187,712  

Restricted cash (current and non-current)

     7,668        7,903        10,728  

Trade receivables

     6,629        1,494        1,340  

R&D incentives receivables (current and non-current)

     64,342        58,545        51,296  

Current financial asset from share subscription agreement

     —          8,371        —    

Available-for-sale financial assets

     2,351        —          —    

Other amounts receivable

     3,078        2,426        1,862  
  

 

 

    

 

 

    

 

 

 

Total financial assets

   1,057,309      419,052      252,937  
  

 

 

    

 

 

    

 

 

 

Financial liabilities:

        

Trade & other payables

   31,269      29,482      30,007  

Other non-current liabilities

     2,469        2,291        923  

Leasing debts

     63        115        167  

Tax payable

     1,022        2,583        2,582  
  

 

 

    

 

 

    

 

 

 

Total financial liabilities

   34,823      34,471      33,679  
  

 

 

    

 

 

    

 

 

 

Share subscription agreement with Gilead

We have been temporarily exposed to financial market and currency risk though our share subscription agreement with Gilead.

On December 16, 2015, Gilead Sciences, Inc. and Galapagos NV entered into a global collaboration for the development and commercialization of filgotinib, in the framework of which Gilead committed to an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos NV by subscribing to new shares at a price of €58 per share, including issuance premium. This agreement was effectively completed and entered into force January 19, 2016 and full payment was received.

In connection with the agreement, we recognized a deferred income and an offsetting short-term financial asset (derivative) of €39 million upon signing of the share subscription agreement with Gilead as required under IAS 39. This financial asset initially reflected the share premium that Gilead committed to pay above the closing stock price of Galapagos on the day of entering into the subscription agreement. This amount also represented a deferred income that will be recognized in revenues at the same rhythm than the $300 million upfront payment for the license.

 

F-67


Table of Contents

The fair value of this derivative financial asset was initially measured on December 16, 2015, based on the implied value of the Galapagos share at the end of January 2016, the implied volatility of the €/$ currency exchange rates and applicable discount rates.

Under IAS 39 the fair value of the derivative financial asset is re-measured at year end and again upon execution of the subscription agreement on January 19, 2016, when the financial asset expired. Variations in fair value of the financial asset are recorded in the income statement.

The decrease in the fair value of the financial asset resulting from the increase in the Galapagos share price between signing of the subscription agreement and December 31, 2015 resulted in a non-cash, fair value re-measurement of €30.6 million in the financial results. On December 31, 2015, the fair value of the financial asset was re-measured based on the implied value of the Galapagos share at the end of January 2016, the implied volatility of the €/$ currency exchange rates and applicable discount rates.

On January 19, 2016, the transaction was officially completed materialized by the share subscription of Gilead Biopharmaceutics Ireland Unlimited Company, of 6,760,701 new ordinary shares of Galapagos NV at a price of €58.00 per share including share premium, amounting to $425 million converted to €392,120,658 at a €/$ exchange rate of 1.0839.

The increase in the fair value of the financial asset resulting from the decrease in the Galapagos share price between January 1, 2016 and January 19, 2016 resulted in a positive non-cash gain of €57.5 million in the financial result of 2016.

On January 19, 2016, the value of the financial asset at maturity amounted to €65.9 million, reflecting the share premium that Gilead paid above our closing share price on the day of the capital increase. This amount was composed of (1) the initial measurement on the day of entering into the share subscription agreement for an amount of €39 million which was reported in deferred income and (2) the subsequent re-measurements of the financial asset, reported as financial result under IAS 39: €30.6 million fair value loss reported in the year 2015 and €57.5 million fair value gain reported in the first quarter of 2016, together a net fair value gain of €26.8 million. This financial asset expired on the effective date of the share subscription agreement and was derecognized through the share premium account.

Available-for-sale financial assets

On July 15, 2016, we invested €2.75 million in Pharnext, a French advanced clinical stage biopharmaceutical company developing new therapeutics for severe orphan and common neurological diseases, listed on Euronext. Galapagos has no restrictions on the sale of this equity investment and the asset is not pledged under any Galapagos’ liabilities. This investment is classified as available-for-sale equity investment which qualifies for level 1 fair value measurement based upon the closing price of the PXT securities on Euronext at each reporting date.

The market price of the Pharnext shares might face fluctuations and might be affected by a variety of factors, such as the global economic situation, the business development of competitors, sector mergers and acquisitions; it is difficult to mitigate this risk.

Liquidity risk

Our consolidated balance sheet shows an amount of €112.3 million as incurred losses at the end of 2016. Management forecasts our liquidity requirements to ensure that there is sufficient cash to meet operational needs. We have no credit lines. Such forecasting is based on realistic assumptions with regards to milestone and upfront payments to be received, taking into account our past track record, including the assumption that not all new projects that are being planned will be realized.

 

F-68


Table of Contents

Credit risk

The term “credit risk” refers to the risk that counterparty will default on its contractual obligations resulting in financial loss.

The trade receivables consist of a limited amount of creditworthy customers, many of which are large pharmaceutical companies, spread over different geographical areas. To limit the risk of financial losses, a policy of only dealing with creditworthy counterparties has been developed.

We grant credit to our clients in the framework of our normal business activities. Usually, we require no pledge or other collateral to cover the amounts due. Management continuously evaluates the client portfolio for creditworthiness. All receivables are considered collectable, except for these for which a provision for doubtful debtors has been established.

Aging balance of receivables that are due, but that are still considered collectable:

 

     December 31,  
         2016              2015              2014      
     (Euro, in thousands)  

60–90 days

   170      86      17  

90–120 days

     —          —          —    

more than 120 days

   54      17      45  

Our cash and cash equivalents are invested primarily in saving and deposit accounts. Saving and deposit accounts generate a small amount of interest income. For banks and financial institutions, only independently rated parties with a minimum rating of ‘A’ are accepted at the beginning of the term.

Interest rate risk

The only variable interest-bearing financial asset is cash and cash equivalents.

Changes in interest rates may cause variations in interest income and expenses resulting from short term interest-bearing assets.

Management does not expect the short term interest rates to decrease significantly in the immediate foreseeable future, which limits the interest exposure on our cash and cash equivalents.

Effect of interest rate fluctuation

A 100 basis point increase in interest rates at balance sheet date would have increased profit and loss by approximately €10 million (2015: €3 million; 2014: €2 million); a 100 basis point decrease in interest rates would have decreased profit and loss by approximately €10 million (2015: €3 million; 2014 : €2 million).

Foreign exchange risk

We are exposed to foreign exchange risk arising from various currency exposures. Our functional currency is euro, but we receive payments from our main collaboration partners AbbVie and Gilead in U.S. dollar and acquire some consumables and materials in U.S. dollars, Swiss Francs, GB Pounds and Croatian Kuna.

To limit this risk, we attempt to align incoming and outgoing cash flows in currencies other than EUR. In addition, contracts closed by our different entities are mainly in the functional currencies of that entity, except for the alliance agreements signed with AbbVie and Gilead for which payments are denominated in U.S. dollars.

 

F-69


Table of Contents

In order to further reduce this risk, a netting system was implemented in the course of 2012, which restrains intra-group payments between entities with a different functional currency. The exchange rate risk in case of a 10% change in the exchange rate amounts to:

 

     Year ended December 31,  
       2016          2015          2014    
     (Euro, in thousands)  

Net book value:

        

Increase in Euros—U.S. Dollars

   (16,863    506      589  

Increase in Euros—GB Pounds

     130        164        138  

Increase in Euros—CH Francs

     165        169        181  

Increase in Euros—HR Kunas

     (95      (50      215  

Increase in U.S. Dollars—GB Pounds

   (913    (907    (807

The exchange rate risk on the U.S. dollar is primarily related to our cash and cash equivalents held in U.S dollars.

Capital risk factors

We manage our capital to safeguard that we will be able to continue as a going concern. At the same time, we want to ensure the return to our shareholders through the results from our research and development activities.

Our capital structure consists of cash at bank and in hand and cash equivalents, financial debt (which currently we barely have: as of December 31, 2016, we had no financial debt other than finance leases and advances from Oseo, a French public organization for innovation support, for €0.1 million), and equity attributed to the holders of our equity instruments, such as capital, reserves and results carried forward, as mentioned in the consolidated statement of changes in equity.

We manage our capital structure and make the necessary adjustments in the light of changes of economic circumstances, the risk characteristics of underlying assets and the projected cash needs of the current research and development activities.

The adequacy of the capital structure will depend on many factors, including scientific progress in the research and development programs, the magnitude of those programs, the commitments to existing and new clinical CROs, the ability to establish new alliance or collaboration agreements, the capital expenditures, market developments and any future acquisition.

Neither Galapagos NV nor any of its subsidiaries are subject to any externally imposed capital requirements, other than those imposed by generally applicable company law requirements.

36. Auditor’s remuneration

The statutory auditor’s fees for carrying out his mandate at group level amounted to €475.0 thousand in 2016 (2015: €235.0 thousand). The fees for audit-related services executed by the statutory auditor, in particular other assurance engagements primarily related to the performance of the audit or review of the company’s financial statements, amounted to €186.0 thousand in 2016 (2015: €538.4 thousand), of which €6.2 thousand related to legal assignments (2015: €33.0 thousand). Fees for persons related to the statutory auditor for carrying out an auditor’s mandate at group level amounted to €40.0 thousand in 2016 (2015: €45.0 thousand). The audit committee and the board of directors are of the opinion that these non-audit services do not affect the independence of the statutory auditor in the performance of his audit. The abovementioned additional fees were fully approved by the audit committee in accordance with article 133 §6 of the Belgian Companies Code.

 

F-70


Table of Contents

37. Events after balance sheet date

On January 17, 2017, we announced the appointment of Dr. Walid Abi-Saab as Chief Medical Officer and member of the executive committee, beginning on March 1, 2017.

On January 20, 2017, the board of directors conditionally issued 150,000 warrants within the framework of the authorized capital, for the benefit of Dr. Abi-Saab (“Warrant Plan 2016 (B)”). The issuance of the warrants is subject to acceptance by Dr. Abi-Saab. These warrants have a term of eight years and an exercise price of €62.50.

On February 1, 2017, we announced the dosing of the first patient with CF Class III (F508del and a gating mutation like G551D) with our novel CF corrector GLPG2222 as an add-on to Kalydeco® in a Phase 2a study. We also announced the opening of an Investigational New Drug file with the U.S. Food & Drug Administration for GLPG2222, which triggered a $10 million milestone payment from AbbVie to Galapagos.

On March 10, 2017, we announced the initiation of two additional Phase 2 studies with filgotinib: one in small bowel Crohn’s disease, and one in fistulizing Crohn’s disease.

On March 22, 2017, we announced the initiation of a Phase 1 trial with GLPG3067, triggering a $7.5 million milestone payment from our collaboration partner AbbVie.

 

F-71


Table of Contents

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

GALAPAGOS NV

/s/ Onno van de Stolpe

By:

  Onno van de Stolpe

Title:

  Chief Executive Officer (Principal Executive Officer)

Date: March 23, 2017


Table of Contents

EXHIBIT INDEX

 

          Incorporated by Reference  

Exhibit

  

Description

   Schedule/
Form
   File Number      Exhibit      File Date
(mm/dd/yyyy)
 
  1.1    Articles of Association (English translation), as amended    Form S-8      333-215783        4.1        01/27/2017  
  2.1    Form of Deposit Agreement    Form F-1/A      333-203435        4.1        04/30/2015  
  2.2    Form of American Depositary Receipt (included in Exhibit 2.1)    Form F-1/A      333-203435        4.2        04/30/2015  
  4.1    Lease dated June 30, 1999 between the registrant and Innotech N.V., as amended (English translation)    Form F-1      333-203435        10.1        04/15/2015  
  4.2†    Warrant Plans (English translation)    Form F-1/A      333-203435        10.3        05/11/2015  
  4.3**    Collaboration Agreement dated February 28, 2012 between the registrant and Abbot Hospitals Limited, as amended    Form F-1/A      333-203435        10.4        05/05/2015  
  4.4**    Collaboration Agreement dated September 23, 2013 between the registrant and AbbVie S.à.r.l.    Form F-1/A      333-203435        10.5        05/05/2015  
  4.5†    Employment and Management Agreements between Onno van de Stolpe and the registrant and its affiliates (English translation)    Form F-1      333-203435        10.6        04/15/2015  
  4.6##    Sale & Purchase Agreement dated March 13, 2014 between the registrant and Charles River Laboratories Holding Limited, as amended    Form F-1      333-203435        10.7        04/15/2015  
  4.7†    Warrant Plan 2015 (B) (English translation)    Form S-8      333-208697        99.1        12/22/2015  
  4.8**    License and Collaboration Agreement dated December 16, 2015 by and between the registrant and Gilead Biopharmaceutics Ireland Unlimited Company    Form 6-K      001-37384        10.1        01/19/2016  
  4.9**    Amended and Restated Collaboration Agreement dated April 28, 2016 by and between the registrant and AbbVie S.à.r.l.    Form 6-K      001-37384        10.1        06/01/2016  
  4.10†    Warrant Plan 2016 (English translation)    Form S-8      333-211834        99.1        06/03/2016  
  4.11†    Warrant Plan 2016 (B) (English translation)    Form S-8      333-215783        99.1        01/27/2017  
  4.12†#    Warrants Plans 2015 RMV and 2016 RMV (English translation)            
  4.13#    Lease Addendum dated April 28, 2016 between the registrant and Intervest Offices & Warehouses NV (English translation)            
  8.1#    List of subsidiaries of the registrant            
12.1#    Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            
12.2#    Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            


Table of Contents
          Incorporated by Reference  

Exhibit

  

Description

   Schedule/
Form
   File Number      Exhibit      File Date
(mm/dd/yyyy)
 
13.1*    Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            
13.2*    Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            
15.1#    Consent of Deloitte Bedrijfsrevisoren BV o.v.v.e. CVBA            

 

# Filed herewith.
* Furnished herewith.
Indicates a management contract or any compensatory plan, contract or arrangement.
## Certain exhibits and schedules to these agreements were omitted from the registration statement pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any of the exhibits and schedules to the U.S. Securities and Exchange Commission upon request.
** Confidential treatment status has been granted as to certain portions thereto, which portions are omitted and filed separately with the U.S. Securities and Exchange Commission.
EX-4.12 2 d333278dex412.htm EX-4.12 EX-4.12

Exhibit 4.12

Free translation for information purposes only

LOGO

WARRANT PLAN 2015 RMV

ON SHARES

GALAPAGOS NV

GENERAL RULES

 

 


Free translation for information purposes only

LOGO

 

Table of Contents

 

1      Basis and Purpose

     1  

2      Definitions

     1  

3      Warrants

     2  

    3.1     General

     2  

    3.2     Number per Beneficiary

     2  

    3.3     Transfer restrictions

     2  

    3.4     Exercise Price

     2  

    3.5     Administration of the Warrant Plan

     3  

4      Beneficiaries of the Plan

     3  

5      Acceptance or Refusal of the Offer

     3  

6      Exercise and Payment Conditions

     3  

    6.1     Exercise Term

     3  

    6.2     Vesting of Warrants

     4  

    6.3     Exercise Period

     4  

    6.4     Conditions of Exercise

     4  

    6.5     Exercise of the Warrants in accordance with the Belgian Companies Code

     4  

    6.6     Change in Control of the Company

     4  

7    Issuance of New Shares

     5  

8    Cessation of the Employment relationship

     5  

    8.1     Cessation of the employment relationship

     5  

    8.2     Decease

     5  

    8.3     Retirement

     6  

    8.4     Sickness or Disability

     6  

    8.5     Deviations

     6  

9       Amendments and Modifications

     7  

10      Dispute Resolution

     7  

11      Final Provisions

     7  

    11.1     Additional Information

     7  

    11.2     Taxes and Social Security Treatment

     7  

    11.3     Costs

     8  

    11.4     Relation to employment agreement

     8  

    11.5     Shareholders’ Meetings

     8  

    11.6     Communication with Warrant Holders

     8  

    11.7     Address Change

     8  

    11.8     Language

     8  

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 1 of 1


Free translation for information purposes only

LOGO

 

1 Basis and Purpose

The Board of Directors of Galapagos NV (hereinafter referred to as the “Company”) has approved the present Warrant Plan 2015 RMV by resolution of 1 December 2015 (and by notarial deed of 21 December 2015).

With the Plan set forth hereafter the Company wants to inform all Beneficiaries (see infra sub 2 (“Definitions: Beneficiary”) and sub 4 (“Beneficiaries of the Plan”)) of the conditions under which the Company is willing to offer Warrants. The Company thus wants to acknowledge the efforts made by the Beneficiaries to help to develop the Company to a successful enterprise.

 

2 Definitions

In this Plan the words and terms mentioned hereunder have the meanings given below:

Beneficiary: the Employees of the Company and its Subsidiaries whose name is mentioned in Annex A to this Warrant Plan 2015 RMV;

Board of Directors: the board of directors of the Company;

Cessation of the Employment agreement: the effective date of the cessation, for whatever reason, of the employment agreement between the relevant Warrant Holder-Employee and either the Company or a Subsidiary (including, for the avoidance of doubt, the relevant employing entity ceasing to be a Subsidiary of the Company), with the exception of a cessation accompanied by a simultaneous execution or continuation of (other) employment agreement, with the Company or a Subsidiary;

Company: the limited liability company Galapagos, having its registered office at Generaal De Wittelaan, L11 A3, 2800 Mechelen, Belgium;

Control: the power, de jure or de facto, to have a decisive influence on the appointment of the majority of the Directors or on the orientation of the management, as set forth in article 5 et seq. of the Belgian Companies Code. The terms “to Control” and “Controlled by” shall be construed accordingly;

Deed of Issuance: the notarial deed enacting (i) the acceptance or refusal of the Warrants and (ii) the unconditional issuance of the Warrants;

Employee: each employee of the Company or a Subsidiary with an employment contract;

Exercise Period: a period of two weeks within the Exercise Term, to be determined by the Board of Directors, during which Warrants can be Exercised;

Exercise Price: the pre-determined price at which a New Share can be acquired when Exercising a Warrant, during one of the Exercise Periods within the Exercise Term;

Exercise Term: the term during which the Warrant Holder can exercise his Warrants to acquire Shares of the Company, taking into account the specific Exercise Periods and the specific exercise conditions as set forth in chapter 6 of this Plan;

Exercise: to make use of the right attached to the Warrants that were acquired by accepting the Offer, to acquire New Shares at the Exercise Price;

New Shares: the Shares to be issued pursuant to the exercise of the Warrants under this Plan;

Notice of Acceptance: the form that the Beneficiary receives at the moment of the Offer and that the Beneficiary needs to return, duly executed, to the Company for the acceptance of the Offer;

Offer: the written and dated notification to the Beneficiaries of the Plan as to the opportunity for them to acquire Warrants in accordance with the provisions of this Plan;

Personal Representative(s): the heir(s) of a deceased Warrant Holder;

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 1 of 8


Free translation for information purposes only

LOGO

 

Plan: the present Warrant Plan 2015 RMV approved by the Board of Directors, as amended from time to time by the Board of Directors in accordance with the provisions of this Plan;

Retirement: any Cessation of the Employment agreement, on the initiative of the Employee or the Company or a Subsidiary, based on the age and the rights of the Warrant Holder to receive state pension entitlement;

Shares: the shares of the Company;

Subsidiary: a company under the Control of the Company, as further set forth in article 6 of the Belgian Companies Code and (in any case) in which the Company holds (directly or indirectly) at least 10% of the share capital and voting rights;

Warrant Agreement: the agreement that may be entered into between the Warrant Holder and the Company;

Warrant: the right to subscribe, within the framework of this Plan, to one New Share within the Exercise Term and the Exercise Period and at the Exercise Price;

Warrant Holder: each Beneficiary who has accepted the Offer and who owns one or more Warrants in accordance with this Plan.

Words and terms denoting the plural shall include the singular and vice versa.

 

3 Warrants

 

3.1 General

The number of Warrants issued in the framework of this Plan is maximum 97,500. These Warrants will be designated as “Warrants 2015 RMV”. The detail of the number of Warrants per Beneficiary, offered under this Plan, is set forth in Annex A to this Plan.

The Warrants are granted by the Company to the Beneficiaries for free.

Each Warrant entitles the Beneficiary to subscribe to one New Share in accordance with the terms and conditions of the Plan.

Offers under this Plan do not need to be the same for every Beneficiary.

 

3.2 Number per Beneficiary

The number of Warrants to be offered to the Beneficiaries is determined by the Board of Directors, and as regards any Employees who are also a member of the Board of Directors of the Company, in accordance with the authorization granted by the Shareholders’ Meeting of the Company. This number is set forth in Annex A.

 

3.3 Transfer restrictions

The Warrants received are registered in the name of the Warrant Holder and cannot be transferred inter vivos once granted to a Beneficiary.

The Warrant cannot be encumbered by any pledge or in any other manner.

Warrants that, in contravention with the foregoing, are transferred or encumbered shall automatically become null and void.

 

3.4 Exercise Price

The Board of Directors shall determine the Exercise Price per Warrant on the day when the Offer of Warrants to the Beneficiaries is made.

As the Shares of the Company are listed or traded on a regulated market at the date of the Offer, the Exercise Price of the Warrants shall be determined by the Board of Directors, and shall be at least equal to the higher of (a) 80% of the average of the closing price of the Share of the Company on Euronext

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 2 of 8


Free translation for information purposes only

LOGO

 

Amsterdam and Brussels during the last twenty (20) trading days preceding the Board of Director’s decision and (b) the average of the closing price of the Share of the Company on Euronext Amsterdam and Brussels during the last thirty (30) days preceding the date of the Offer.

Upon Exercise and subsequent capital increase the Exercise Price must be booked as capital for an amount equal to the accounting par value of the Shares at the moment of the establishment of the capital increase resulting from the Exercise. The part of the Exercise Price that exceeds the accounting par value must be booked as an issuance premium.

 

3.5 Administration of the Warrant Plan

The Company is responsible for the management and the administration of the Plan and ensures that all questions of Beneficiaries or Warrant Holders are answered accurately and rapidly.

 

4 Beneficiaries of the Plan

Beneficiaries are the individuals as indicated in section 2 (“Definitions - Beneficiary”).

Warrants shall not be granted to Employees holding more than 10% of the Company’s share capital.

 

5 Acceptance or Refusal of the Offer

The Beneficiaries have the possibility to accept the individual Offer in whole, in part or not at all. Each Beneficiary shall receive a Notice of Acceptance form wherein the Beneficiary mentions his/her decision regarding the Offer: (full or partial) Acceptance or Refusal. Acceptance of the Offer has to be formally established by ticking the relevant paragraph in the Notice of Acceptance.

The Notice of Acceptance needs to be returned prior to the ultimate date of response as set forth in the Notice of Acceptance, duly completed and signed, to the address mentioned in the Notice of Acceptance. Such ultimate date of response cannot be later than 75 calendar days after the date of the Offer.

In case the Beneficiary has not accepted the Offer in writing prior to the date mentioned in the Notice of Acceptance, he shall be deemed to have refused the Offer.

For the purposes of this Plan (including for Belgian fiscal reasons), the Warrants shall be deemed to be granted on the sixtieth day following the date of the Offer if the Offer is accepted within sixty days after the date of the Offer.

The Warrants are registered in the name of the Beneficiary. In case of acceptance, the Beneficiary will be recorded as a Warrant Holder in the register of warrant holders of the Company. This register is kept at the registered office of the Company, mentioning the identity of the Warrant Holders and previous warrant holders and the number of Warrants held by them. The Warrant Holder will receive a confirmation of the number of Warrants he has accepted.

The Nomination and Remuneration Committee may decide to replace or complete the Notice of Acceptance by or with a written Warrant Agreement to be signed by the Warrant Holder and the Company and which shall contain the conditions determined by the Nomination and Remuneration Committee, in accordance with this Plan.

The Beneficiary who has accepted the Offer will receive the Warrants as soon as these have been issued by the Deed of Issuance.

 

6 Exercise and Payment Conditions

 

6.1 Exercise Term

The Exercise Term is eight (8) years, starting from the date of the Offer.

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 3 of 8


Free translation for information purposes only

LOGO

 

6.2 Vesting of Warrants

Except to the extent expressly stated otherwise in this Plan or decided otherwise by the Board of Directors in accordance with section 8.5, all granted Warrants will fully vest on the third anniversary of the Deed of Issuance.

 

6.3 Exercise Period

Warrants may not be exercised prior to the third anniversary of the Deed of Issuance.

As of the third anniversary of the Deed of Issuance, all vested Warrants may be exercised, during an Exercise Period.

The Board of Directors will establish at least one Exercise Period of two weeks per semester. The Exercise Periods shall be notified by or on behalf of the Company to the Beneficiaries.

The Board of Directors shall decide, when required, in accordance with the applicable rules relating to abuse of insider information, to establish closed periods during which the Warrants cannot be exercised.

 

6.4 Conditions of Exercise

Individual Warrants can only be exercised as a whole.

In order to exercise a Warrant, the Warrant Holder needs to submit an appropriate declaration to that effect (the exercise form) to the Board of Directors or to an authorized person designated by the Board of Directors, and to pay the Exercise Price into a bank account designated by the Company and opened in the name of the Company.

On the exercise form, the Warrant Holder needs to mention the number of Warrants he desires to exercise.

In case the bank account is not or not sufficiently credited prior to the end of the Exercise Period, the Warrants will be deemed not to be exercised. The Company will inform the Warrant Holder thereof and will reimburse the amount that was deposited too late or was insufficient as soon as possible within the limits set by law. The Warrants will consequently not be lost and remain exercisable at a later stage insofar as the Exercise Term has not expired.

 

6.5 Exercise of the Warrants in accordance with the Belgian Companies Code

In case a Warrant, that is not exercisable or cannot be exercised in accordance with the issuance conditions (as specified in the Plan), becomes prematurely exercisable pursuant to article 501 of the Belgian Companies Code and is thus also prematurely exercised pursuant to article 501 of the Belgian Companies Code, the New Shares that the Warrant Holders receives as a result of such Exercise will not be transferable, except with the explicit prior consent of the Board of Directors, until such time as the Warrant would have become exercisable in accordance with the Plan.

 

6.6 Change in Control of the Company

Notwithstanding anything to the contrary in this Plan, in the event of a change in Control of the Company, all Warrants granted to a Warrant Holder whose relationship with the Company or with a Subsidiary has not ended prior to such change in Control, shall, in principle, immediately vest (to the extent they had not all vested yet) and become immediately exercisable during an Exercise Period determined by the Board of Directors, provided, however, that in compliance with applicable (tax) laws the Board of Directors is authorized to establish certain conditions for such vesting and/or exercising that will be applicable to some or all of the Warrant Holders involved, and provided further that, in the event a public takeover bid is made on the securities of the Company, the Warrants shall immediately become fully vested and exercisable as from the date of the announcement of such public takeover bid by the FSMA. The Board of Directors shall establish an Exercise Period as soon as practicable following the announcement of such public takeover bid.

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 4 of 8


Free translation for information purposes only

LOGO

 

7 Issuance of New Shares

The Company shall only be obliged to issue New Shares pursuant to the Exercise of Warrants if all exercise conditions set forth in chapter 6 have been complied with.

As soon as these exercise conditions are complied with, the New Shares will be issued, taking into account the time needed to fulfill the required administrative formalities. The Board of Directors shall to this effect timely at a date to be determined by the Board of Directors and at least once per semester have the capital increase established by notary deed.

New Shares participate in the profit of the financial year of the Company that started on the first of January of the year in which the relevant New Shares have been issued.

In view of a rapid delivery of the Shares resulting from the exercise of Warrants, the Company may propose to the Warrant Holders who have complied with the exercise conditions to receive existing Shares awaiting the issuance of New Shares by notary deed. In such case the Warrant Holders will receive an advance of existing Shares subject to the condition that they sign an authorization by which the New Shares will, upon issuance, immediately and directly be delivered to the Company or to any other party who advanced them the existing Shares.

The Board of Directors has granted power of attorney to any two (2) members of the Board of Directors acting jointly, as well as to the managing Director acting individually, with possibility of sub-delegation and the power of subrogation, to take care of the establishment by notary deed of the acceptance of the Warrants offered, the exercise of the Warrants, the issuance of the corresponding number of New Shares, the payment of the exercise price in cash, the corresponding realization of the capital increase, the allocation to the unavailable account “issuance premiums” of the difference between the subscription price for the Shares and the accounting par value, to bring the Articles of Association in accordance with the new situation of the registered capital, to sign and deliver the relevant Euroclear and bank documentation, and to sign and deliver all necessary documents in connection with the delivery of the Shares (acquired as a result of the exercise of the Warrants) to the Beneficiaries.

The Company will take the necessary actions to have the New Shares listed for trading on a regulated market as soon as they have been issued. The Company has not issued VVPR strips and has no intention to do so in the future.

 

8 Cessation of the Employment relationship

 

8.1 Cessation of the employment relationship

In case of Cessation of the Employment agreement after the third anniversary of the Deed of Issuance, the Warrant Holder will have time to exercise, during an Exercise Period, his non-exercised Warrants until the closing date of the second Exercise Period occurring after the date of the Cessation of the Employment Agreement, after which date all his remaining non-exercised Warrants shall become null and void.

If Cessation of the Employment agreement occurs prior to the third anniversary of the Deed of Issuance, all granted Warrants shall automatically become null and void. This principle does however not apply in the event of cessation resulting from decease, Retirement, or sickness or disability.

 

8.2 Decease

In case of decease of a Warrant Holder, all fully vested Warrants acquired by such Warrant Holder pass to his Personal Representative(s) and such Personal Representative(s) will be entitled to exercise such Warrants during a six-month period as from the date of the death of the Warrant Holder, after which period all remaining non-exercised Warrants will automatically become null and void.

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 5 of 8


Free translation for information purposes only

LOGO

 

In case of decease prior to the third anniversary of the Deed of Issuance, the number of vested Warrants shall be determined by multiplying the number of Warrants granted with the result of the following division:

number of days between the Deed of Issuance and the date of decease

 

 

1,095

The Personal Representative(s) will have time to exercise the vested Warrants that do not automatically become null and void pursuant to the abovementioned clause during a six-month period as from the date of the death of the Warrant Holder, after which period all remaining non-exercised Warrants shall become null and void.

 

8.3 Retirement

In case of Retirement of a Warrant Holder, the Warrant Holder will have time to exercise his fully vested Warrants, during an Exercise Period, until the closing date of the second Exercise Period occurring after the date of Retirement of the Warrant Holder, after which date all his remaining non-exercised Warrants will automatically become null and void.

In case of Retirement prior to the third anniversary of the Deed of Issuance, the number of vested Warrants shall be determined by multiplying the number of Warrants granted with the result of the following division:

number of days between the Deed of Issuance and the date of Retirement

 

 

1,095

The Warrant Holder will have time to exercise, during an Exercise Period, the vested Warrants that do not automatically become null and void pursuant to the abovementioned clause, as from the third anniversary of the Deed of Issuance until the closing date of the second Exercise Period occurring after the third anniversary of the Deed of Issuance, after which date all remaining non-exercised Warrants shall become null and void.

 

8.4 Sickness or Disability

In case of cessation of the employment agreement or of the management agreement as a result of long-term sickness requiring his definitive replacement or disability, the Warrant Holder will have time to exercise his fully vested Warrants, during an Exercise Period, until the closing date of the second Exercise Period occurring after such cessation, after which date all his remaining non-exercised Warrants will automatically become null and void.

In case of such cessation prior to the third anniversary of the Deed of Issuance, the number of vested Warrants shall be determined by multiplying the number of Warrants granted with the result of the following division:

number of days between the Deed of Issuance and the date of such cessation

 

 

1,095

The Warrant Holder will have time to exercise, during an Exercise Period, the vested Warrants that do not automatically become null and void pursuant to the abovementioned clause, as from the third anniversary of the Deed of Issuance until the closing date of the second Exercise Period occurring after the third anniversary of the Deed of Issuance, after which date all remaining non-exercised Warrants shall become null and void.

 

8.5 Deviations

The Board of Directors may at its discretion decide to deviate at any time from the provisions set forth in this chapter 8, provided that such provisions comply with compulsory statutory provisions (in particular with article L. 225-183 paragraph 3 of the French Commercial Code).

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 6 of 8


Free translation for information purposes only

LOGO

 

9 Amendments and Modifications

In case of share capital amortization, share capital decrease, change in the distribution of the profits, allocation of free Company’s shares, share capital increase through incorporation of reserves, profits or premiums, distribution of reserves, or any rights issue of shares or other securities in respect of which the existing shareholders are entitled to exercise preferential subscription rights, the Company shall take any necessary measure in order to protect the Beneficiaries’ interests in accordance with the applicable provisions of the French Commercial Code.

The Board of Directors is authorized to take appropriate measures to safeguard the interests of the Warrant Holders in case:

-            a fundamental change in the Control of the Company occurs;

-            a fundamental change in the applicable laws or regulations occurs; or

-            a serious and exceptional circumstance jeopardizing the rights of the Beneficiaries occurs.

In addition, the Board of Directors may amend the provisions of this Plan to the benefit of the Warrant Holders, to the extent that the contemplated amendments comply with all applicable laws.

This Plan may, if required by the circumstances, be amended by the Company. The Beneficiary shall be informed of such amendments and will be bound by them. The amendments may in no event affect the essential provisions of the Plan. The amendments may not harm the rights under this Plan of the existing Warrant Holders. In the event the rights of the existing Warrant Holders under this Plan would be harmed, the amendments may not be made without their agreement.

 

10 Dispute Resolution

All disputes relating to this Plan will be brought to the attention of the Board of Directors, who may propose an amicable settlement for a dispute, as the case may be. If required the dispute will be submitted to Courts and Tribunals competent for the judicial area of Antwerp, department of Mechelen (Belgium) whereby all parties involved shall make election of domicile at the seat of the Company. This Plan is governed by Belgian law.

 

11 Final Provisions

 

11.1 Additional Information

The Company will provide the Beneficiary at his request with a copy of the articles of association of the Company and any amendments thereto.

 

11.2 Taxes and Social Security Treatment

The Company or a Subsidiary shall be entitled, in accordance with the applicable law or customs, to apply a withholding on the cash salary or the compensation for the month in which the taxable moment occurs or on the cash salary or the compensation of any other following month, and/or the Beneficiary shall be obliged to pay to the Company or a Subsidiary (if so required by the Company or by a Subsidiary) the amount of any tax and/or social security contributions due or payable because of the fact of the grant, the acceptance, the fact that Warrants become susceptible of being exercised or of the exercise of the Warrants, or due or payable in respect of the delivery of the New Shares.

The Company or a Subsidiary shall be entitled, in accordance with the applicable law or customs, to prepare the required reports, necessary as a result of grant of the Warrants, the fact that Warrants become susceptible of being exercised, or the delivery of the Shares.

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 7 of 8


Free translation for information purposes only

LOGO

 

11.3 Costs

Stamp duties, stock exchange taxes and similar charges and taxes levied at the occasion of the exercise of the Warrants and/or the delivery of the New Shares or existing Shares shall be borne by the Warrant Holder.

Costs relating to the issue of the Warrants or to the issue of New Shares shall be borne by the Company.

 

11.4 Relation to employment agreement

No person has a right to participate in this Plan and a participation in this Plan does not give the Beneficiaries a right to future grants of additional Warrants. The grant of Warrants under this Plan does not contain a promise of a continuous employment by the Company or its Subsidiaries.

Notwithstanding any provision of the Plan, the rights and obligations of any individual or entity as determined in the provisions of his/her employment agreement concluded with the Company or a Subsidiary shall not be affected by his/her participation in the Plan or by any right that he/she may have to participate therein.

An individual to whom Warrants are granted in accordance with the Plan shall not be entitled to any damages or compensation as a result of the cessation of his mandate or employment agreement with the Company or a Subsidiary, based on any reason whatsoever (with the exception of abusive or unlawful dismissal in accordance with French case law), to the extent that these rights would arise or might arise based on the cessation of the rights he/she might have or the claims he/she could make concerning the exercise of Warrants pursuant to the Plan because of the cessation of such agreement or by reason of the loss or decrease in value of the rights or benefits.

 

11.5 Shareholders’ Meetings

Warrant Holders have the right to participate in the Shareholders’ Meetings of the Company, but without voting right and only with an advisory voice, subject to complying with the formalities set forth in the convocation for the Shareholders’ Meeting.

 

11.6 Communication with Warrant Holders

By accepting Warrants, the Warrant Holder agrees that documentation can be validly communicated by the Company by e-mail, including convocations for Shareholders’ Meetings and documentation pertaining to the exercise of Warrants.

 

11.7 Address Change

Warrant Holders are obliged to keep the Company informed of changes to their address and changes to their e-mail address. Communications sent by the Company to the last known address or e-mail address of the Warrant Holder are validly made.

 

11.8 Language

In case of discrepancies between the French, Dutch and English versions of the present Warrant Plan, the French language version of the Plan shall prevail.

***

 

 

Galapagos NV  |  Warrant Plan 2015 RMV    Page 8 of 8


Free translation for information purposes only

LOGO

 

WARRANT PLAN 2016 RMV

ON SHARES

GALAPAGOS NV

GENERAL RULES


Free translation for information purposes only

LOGO

 

Table of Contents

 

1     Basis and Purpose

     3  

2     Definitions

     3  

3     Warrants

     4  

    3.1     General

     4  

    3.2    Number per Beneficiary

     4  

    3.3    Transfer restrictions

     5  

    3.4    Exercise Price

     5  

    3.5    Administration of the Warrant Plan

     5  

4     Beneficiaries of the Plan

     5  

5     Acceptance or Refusal of the Offer

     5  

6     Exercise and Payment Conditions

     6  

    6.1    Exercise Term

     6  

    6.2    Vesting of Warrants

     6  

    6.3    Exercise Period

     6  

    6.4    Conditions of Exercise

     6  

    6.5    Exercise of the Warrants in accordance with the Belgian Companies Code

     6  

    6.6    Change in Control of the Company

     7  

7     Issuance of New Shares

     7  

8     Cessation of the Employment relationship

     7  

    8.1    Good Leaver Situations

     7  

    8.2    Bad Leaver Situation

     8  

        8.2.1    After the end of the third calendar year

     8  

        8.2.2    Before the end of the third calendar year

     8  

    8.3    Change of employment

     8  

    8.4    Deviations

     8  

9     Amendments and Modifications

     8  

10     Dispute Resolution

     9  

11     Final Provisions

     9  

    11.1    Additional Information

     9  

    11.2    Taxes and Social Security Treatment

     9  

    11.3    Costs

     9  

    11.4    Relation to employment agreement

     10  

    11.5    Shareholders’ Meetings

     10  

    11.6    Communication with Warrant Holders

     10  

    11.7    Address Change

     10  

    11.8    Language

     10  


Free translation for information purposes only

LOGO

 

1 Basis and Purpose

The Board of Directors of Galapagos NV (hereinafter referred to as the “Company”) has approved the present Warrant Plan 2016 RMV by resolution of 1 June 2016 (and by notarial deed of 1 June 2016).

With the Plan set forth hereafter the Company wants to inform all Beneficiaries (see infra sub 2 (“Definitions: Beneficiary”) and sub 4 (“Beneficiaries of the Plan”)) of the conditions under which the Company is willing to offer Warrants. The Company thus wants to acknowledge the efforts made by the Beneficiaries to help to develop the Company to a successful enterprise.

 

2 Definitions

In this Plan the words and terms mentioned hereunder have the meanings given below:

Bad Leaver Situation: the effective date on which one of the following situations occurs:

 

  (i) the unilateral termination by the Warrant Holder of his employment agreement with the Company or a Subsidiary, or

 

  (ii) the termination by the relevant Company or Subsidiary of the employment agreement of a Warrant Holder for breach or insufficiency by the Warrant Holder in the performance of the relevant agreement.

Beneficiary: the Employees of the Company and its Subsidiaries whose name is mentioned in Annex A to this Warrant Plan 2016 RMV;

Board of Directors: the board of directors of the Company;

Company: the limited liability company Galapagos, having its registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium;

Consultant: a natural person who provides services to the Company or a Subsidiary on a contractual basis, but who is not an Employee (irrespective of whether the contract was entered into directly with the relevant natural person or with a legal entity who has entrusted the performance of the services to such natural person);

Control: the power, de jure or de facto, to have a decisive influence on the appointment of the majority of the Directors or on the orientation of the management, as set forth in article 5 et seq. of the Belgian Companies Code. The terms “to Control” and “Controlled by” shall be construed accordingly;

Deed of Issuance: the notarial deed enacting (i) the acceptance or refusal of the Warrants and (ii) the unconditional issuance of the Warrants;

Director: a natural person or legal entity who at any moment during the existence of the Company exercises a director’s mandate in the Company to which they were appointed by either the Shareholders’ Meeting or the Board of Directors by way of cooptation;

Employee: each employee of the Company or a Subsidiary with an employment contract;

Exercise Period: a period of two weeks within the Exercise Term, to be determined by the Board of Directors, during which Warrants can be Exercised;

Exercise Price: the pre-determined price at which a New Share can be acquired when Exercising a Warrant, during one of the Exercise Periods within the Exercise Term;

Exercise Term: the term during which the Warrant Holder can exercise his Warrants to acquire Shares of the Company, taking into account the specific Exercise Periods and the specific exercise conditions as set forth in chapter 6 of this Plan;

Exercise: to make use of the right attached to the Warrants that were acquired by accepting the Offer, to acquire New Shares at the Exercise Price;

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 3 of 10


Free translation for information purposes only

LOGO

 

Good Leaver Situation: the effective date of the cessation, in other circumstances than those listed in the definition of Bad Leaver Situation, of the employment agreement of the relevant Warrant Holder with either the Company or a Subsidiary (including the relevant employing entity ceasing to be a Subsidiary of the Company), with the exception of a cessation accompanied by a simultaneous (other) employment or appointment of the relevant Warrant Holder (or a company Controlled by the Warrant Holder) as a Consultant, Employee or Director of the Company or a Subsidiary;

Grant: the moment on which the Beneficiary accepts the Warrants offered. For the purposes of this Plan (including for Belgian fiscal reasons), the Grant shall be deemed to take place on the sixtieth day following the date of the Offer if the Offer is accepted within sixty days after the date of the Offer;

New Shares: the Shares to be issued pursuant to the exercise of the Warrants under this Plan;

Notice of Acceptance: the form that the Beneficiary receives at the moment of the Offer and that the Beneficiary needs to return, duly executed, to the Company for the acceptance of the Offer;

Offer: the written and dated notification to the Beneficiaries of the Plan as to the opportunity for them to acquire Warrants in accordance with the provisions of this Plan;

Personal Representative(s): the heir(s) of a deceased Warrant Holder;

Plan: the present Warrant Plan 2016 RMV approved by the Board of Directors, as amended from time to time by the Board of Directors in accordance with the provisions of this Plan;

Shares: the shares of the Company;

Subsidiary: a company under the Control of the Company, as further set forth in article 6 of the Belgian Companies Code and (in any case) in which the Company holds (directly or indirectly) at least 10% of the share capital and voting rights;

Warrant Agreement: the agreement that may be entered into between the Warrant Holder and the Company;

Warrant: the right to subscribe, within the framework of this Plan, to one New Share within the Exercise Term and the Exercise Period and at the Exercise Price;

Warrant Holder: each Beneficiary who has accepted the Offer and who owns one or more Warrants in accordance with this Plan.

Words and terms denoting the plural shall include the singular and vice versa.

 

3 Warrants

 

3.1 General

The number of Warrants issued in the framework of this Plan is maximum 120,000. These Warrants will be designated as “Warrants 2016 RMV”. The detail of the number of Warrants per Beneficiary, offered under this Plan, is set forth in Annex A to this Plan.

The Warrants are granted by the Company to the Beneficiaries for free.

Each Warrant entitles the Beneficiary to subscribe to one New Share in accordance with the terms and conditions of the Plan.

Offers under this Plan do not need to be the same for every Beneficiary.

 

3.2 Number per Beneficiary

The number of Warrants to be offered to the Beneficiaries is determined by the Board of Directors, and as regards any Employees who are also a member of the Board of Directors of the Company, in accordance with the authorization granted by the Shareholders’ Meeting of the Company. This number is set forth in Annex A.

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 4 of 10


Free translation for information purposes only

LOGO

 

3.3 Transfer restrictions

The Warrants received are registered in the name of the Warrant Holder and cannot be transferred inter vivos once granted to a Beneficiary.

The Warrant cannot be encumbered by any pledge or in any other manner.

Warrants that, in contravention with the foregoing, are transferred or encumbered shall automatically become null and void.

 

3.4 Exercise Price

The Board of Directors shall determine the Exercise Price per Warrant on the day when the Offer of Warrants to the Beneficiaries is made.

As the Shares of the Company are listed or traded on a regulated market at the date of the Offer, the Exercise Price of the Warrants shall be determined by the Board of Directors, and shall be at least equal to the higher of (a) 80% of the average of the closing price of the Share of the Company on Euronext Amsterdam and Brussels during the last twenty (20) trading days preceding the Board of Director’s decision and (b) the average of the closing price of the Share of the Company on Euronext Amsterdam and Brussels during the last thirty (30) days preceding the date of the Offer.

Upon Exercise and subsequent capital increase the Exercise Price must be booked as capital for an amount equal to the accounting par value of the Shares at the moment of the establishment of the capital increase resulting from the Exercise. The part of the Exercise Price that exceeds the accounting par value must be booked as an issuance premium.

 

3.5 Administration of the Warrant Plan

The Company is responsible for the management and the administration of the Plan and ensures that all questions of Beneficiaries or Warrant Holders are answered accurately and rapidly.

 

4 Beneficiaries of the Plan

Beneficiaries are the individuals as indicated in section 2 (“Definitions - Beneficiary”).

Warrants shall not be granted to Employees holding more than 10% of the Company’s share capital.

 

5 Acceptance or Refusal of the Offer

The Beneficiaries have the possibility to accept the individual Offer in whole, in part or not at all. Each Beneficiary shall receive a Notice of Acceptance form wherein the Beneficiary mentions his/her decision regarding the Offer: (full or partial) Acceptance or Refusal. Acceptance of the Offer has to be formally established by ticking the relevant paragraph in the Notice of Acceptance.

The Notice of Acceptance needs to be returned prior to the ultimate date of response as set forth in the Notice of Acceptance, duly completed and signed, to the address mentioned in the Notice of Acceptance. Such ultimate date of response cannot be later than 75 calendar days after the date of the Offer.

In case the Beneficiary has not accepted the Offer in writing prior to the date mentioned in the Notice of Acceptance, he shall be deemed to have refused the Offer.

For the purposes of this Plan (including for Belgian fiscal reasons), the Warrants shall be deemed to be granted on the sixtieth day following the date of the Offer if the Offer is accepted within sixty days after the date of the Offer.

The Warrants are registered in the name of the Beneficiary. In case of acceptance, the Beneficiary will be recorded as a Warrant Holder in the register of warrant holders of the Company. This register is kept at the registered office of the Company, mentioning the identity of the Warrant Holders and previous warrant holders and the number of Warrants held by them. The Warrant Holder will receive a confirmation of the number of Warrants he has accepted.

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 5 of 10


Free translation for information purposes only

LOGO

 

The Nomination and Remuneration Committee may decide to replace or complete the Notice of Acceptance by or with a written Warrant Agreement to be signed by the Warrant Holder and the Company and which shall contain the conditions determined by the Nomination and Remuneration Committee, in accordance with this Plan.

The Beneficiary who has accepted the Offer will receive the Warrants as soon as these have been issued by the Deed of Issuance.

 

6 Exercise and Payment Conditions

 

6.1 Exercise Term

The Exercise Term is eight (8) years, starting from the date of the Offer.

 

6.2 Vesting of Warrants

Except to the extent expressly stated otherwise in this Plan or decided otherwise by the Board of Directors in accordance with section 8.4, all granted Warrants will fully vest on the first day of the fourth calendar year following the calendar year in which the Grant was made.

 

6.3 Exercise Period

Warrants may not be exercised until the end of the third calendar year following the calendar year in which the Grant was made.

As of the commencement of the fourth calendar year following the calendar year in which the Grant was made, all vested Warrants may be exercised, during an Exercise Period.

The Board of Directors will establish at least one Exercise Period of two weeks per semester. The Exercise Periods shall be notified by or on behalf of the Company to the Beneficiaries.

The Board of Directors shall decide, when required, in accordance with the applicable rules relating to abuse of insider information, to establish closed periods during which the Warrants cannot be exercised.

 

6.4 Conditions of Exercise

Individual Warrants can only be exercised as a whole.

In order to exercise a Warrant, the Warrant Holder needs to submit an appropriate declaration to that effect (the exercise form) to the Board of Directors or to an authorized person designated by the Board of Directors, and to pay the Exercise Price into a bank account designated by the Company and opened in the name of the Company.

On the exercise form, the Warrant Holder needs to mention the number of Warrants he desires to exercise.

In case the bank account is not or not sufficiently credited prior to the end of the Exercise Period, the Warrants will be deemed not to be exercised. The Company will inform the Warrant Holder thereof and will reimburse the amount that was deposited too late or was insufficient as soon as possible within the limits set by law. The Warrants will consequently not be lost and remain exercisable at a later stage insofar as the Exercise Term has not expired.

 

6.5 Exercise of the Warrants in accordance with the Belgian Companies Code

In case a Warrant, that is not exercisable or cannot be exercised in accordance with the issuance conditions (as specified in the Plan), becomes prematurely exercisable pursuant to article 501 of the Belgian Companies Code and is thus also prematurely exercised pursuant to article 501 of the Belgian Companies Code, the New Shares that the Warrant Holders receives as a result of such Exercise will not be transferable, except with the explicit prior consent of the Board of Directors, until such time as the Warrant would have become exercisable in accordance with the Plan.

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 6 of 10


Free translation for information purposes only

LOGO

 

6.6 Change in Control of the Company

Notwithstanding anything to the contrary in this Plan, in the event of a change in Control of the Company, all Warrants that are still outstanding under this Plan at such time shall, in principle, immediately vest (to the extent they had not all vested yet) and become immediately exercisable during an Exercise Period determined by the Board of Directors, provided, however, that in compliance with applicable (tax) laws the Board of Directors is authorized to establish certain conditions for such vesting and/or exercising that will be applicable to some or all of the Warrant Holders involved, and provided further that, in the event a public takeover bid is made on the securities of the Company, the Warrants shall immediately become fully vested and exercisable as from the date of the announcement of such public takeover bid by the FSMA. The Board of Directors shall establish an Exercise Period as soon as practicable following the announcement of such public takeover bid.

 

7 Issuance of New Shares

The Company shall only be obliged to issue New Shares pursuant to the Exercise of Warrants if all exercise conditions set forth in chapter 6 have been complied with.

As soon as these exercise conditions are complied with, the New Shares will be issued, taking into account the time needed to fulfill the required administrative formalities. The Board of Directors shall to this effect timely at a date to be determined by the Board of Directors and at least once per semester have the capital increase established by notary deed.

New Shares participate in the profit of the financial year of the Company that started on the first of January of the year in which the relevant New Shares have been issued.

In view of a rapid delivery of the Shares resulting from the exercise of Warrants, the Company may propose to the Warrant Holders who have complied with the exercise conditions to receive existing Shares awaiting the issuance of New Shares by notary deed. In such case the Warrant Holders will receive an advance of existing Shares subject to the condition that they sign an authorization by which the New Shares will, upon issuance, immediately and directly be delivered to the Company or to any other party who advanced them the existing Shares.

The Board of Directors has granted power of attorney to any two (2) members of the Board of Directors acting jointly, as well as to the managing Director acting individually, with possibility of sub-delegation and the power of subrogation, to take care of the establishment by notary deed of the acceptance of the Warrants offered, the exercise of the Warrants, the issuance of the corresponding number of New Shares, the payment of the exercise price in cash, the corresponding realization of the capital increase, the allocation to the unavailable account “issuance premiums” of the difference between the subscription price for the Shares and the accounting par value, to bring the Articles of Association in accordance with the new situation of the registered capital, to sign and deliver the relevant Euroclear and bank documentation, and to sign and deliver all necessary documents in connection with the delivery of the Shares (acquired as a result of the exercise of the Warrants) to the Beneficiaries.

The Company will take the necessary actions to have the New Shares listed for trading on a regulated market as soon as they have been issued. The Company has not issued VVPR strips and has no intention to do so in the future.

 

8 Cessation of the Employment relationship

 

8.1 Good Leaver Situations

If a Good Leaver Situation arises with respect to a Warrant Holder, the Warrants of said Warrant Holder shall continue to vest as set forth in Section 6.2 (if unvested) and, if and when vested, the Exercise Term of the non-exercised Warrants shall remain unchanged and the Warrant Holder will have the time to exercise his non-exercised Warrants during each Exercise Period within the Exercise Term.

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 7 of 10


Free translation for information purposes only

LOGO

 

As an exception, if the Good Leaver Situation is caused by the decease of the relevant Warrant Holder, all Warrants held by such Warrant Holder shall pass to his Personal Representative(s) and the Personal Representative(s) will be able to exercise the non-exercised Warrants during a six-month period as from the death of the Warrant Holder. All the remaining non-exercised Warrants held by the Personal Representative(s) of the Warrant Holder shall become null and void upon the expiry of such six-month period.

 

8.2 Bad Leaver Situation

 

  8.2.1 After the end of the third calendar year

In case a Bad Leaver Situation occurs after the end of the third calendar year following the calendar year in which the Grant was made, the relevant Warrant Holder will have time to exercise, during an Exercise Period, his non-exercised Warrants until six months after the date of the Bad Leaver Situation. All his remaining non-exercised Warrants shall become null and void upon the expiry of such six-month period.

 

  8.2.2 Before the end of the third calendar year

In case the Bad Leaver Situation occurs before the end of the third calendar year following the calendar year in which the Grant was made, all granted Warrants shall automatically become null and void.

 

8.3 Change of employment

 

  8.3.1 In case of a cessation of the employment agreement or consultancy agreement of the relevant Warrant Holder accompanied by a simultaneous (other) employment or appointment of the relevant Warrant Holder (or a company Controlled by the Warrant Holder) as a Consultant, Employee or Director of the Company or a Subsidiary, the Warrants of said Warrant Holder shall continue to vest as set forth in Section 6.2 (if unvested) and, if and when vested, the Exercise Term of the non-exercised Warrants shall remain unchanged and the Warrant Holder will have the time to exercise his non-exercised Warrants during each Exercise Period within the Exercise Term.

 

  8.3.2 If, however, at any time following such change as described in Section 8.3.1:

 

  (i) the Warrant Holder unilaterally terminates his employment agreement or his mandate as a Director or his consultancy agreement with the Company or a Subsidiary; or

 

  (ii) the Company or a Subsidiary terminates the employment agreement or his mandate as a Director or terminates his consultancy agreement because of a breach or insufficiency by the Warrant Holder in the performance of the employment agreement or a breach by the Warrant Holder of his obligations as a Consultant or Director,

then such termination shall also be deemed to be a Bad Leaver Situation and the rules set forth in Section 8.2 shall apply.

 

8.4 Deviations

The Board of Directors may at its discretion decide to deviate at any time from the provisions set forth in this chapter 8, provided that such provisions comply with compulsory statutory provisions (in particular with article L. 225-183 paragraph 3 of the French Commercial Code).

 

9 Amendments and Modifications

In case of share capital amortization, share capital decrease, change in the distribution of the profits, allocation of free Company’s shares, share capital increase through incorporation of reserves, profits or

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 8 of 10


Free translation for information purposes only

LOGO

 

premiums, distribution of reserves, or any rights issue of shares or other securities in respect of which the existing shareholders are entitled to exercise preferential subscription rights, the Company shall take any necessary measure in order to protect the Beneficiaries’ interests in accordance with the applicable provisions of the French Commercial Code.

The Board of Directors is authorized to take appropriate measures to safeguard the interests of the Warrant Holders in case:

-         a fundamental change in the Control of the Company occurs;

-         a fundamental change in the applicable laws or regulations occurs; or

-         a serious and exceptional circumstance jeopardizing the rights of the Beneficiaries occurs.

In addition, the Board of Directors may amend the provisions of this Plan to the benefit of the Warrant Holders, to the extent that the contemplated amendments comply with all applicable laws.

This Plan may, if required by the circumstances, be amended by the Company. The Beneficiary shall be informed of such amendments and will be bound by them. The amendments may in no event affect the essential provisions of the Plan. The amendments may not harm the rights under this Plan of the existing Warrant Holders. In the event the rights of the existing Warrant Holders under this Plan would be harmed, the amendments may not be made without their agreement.

 

10 Dispute Resolution

All disputes relating to this Plan will be brought to the attention of the Board of Directors, who may propose an amicable settlement for a dispute, as the case may be. If required the dispute will be submitted to Courts and Tribunals competent for the judicial area of Antwerp, department of Mechelen (Belgium) whereby all parties involved shall make election of domicile at the seat of the Company. This Plan is governed by Belgian law.

 

11 Final Provisions

 

11.1 Additional Information

The Company will provide the Beneficiary at his request with a copy of the articles of association of the Company and any amendments thereto.

 

11.2 Taxes and Social Security Treatment

The Company or a Subsidiary shall be entitled, in accordance with the applicable law or customs, to apply a withholding on the cash salary or the compensation for the month in which the taxable moment occurs or on the cash salary or the compensation of any other following month, and/or the Beneficiary shall be obliged to pay to the Company or a Subsidiary (if so required by the Company or by a Subsidiary) the amount of any tax and/or social security contributions due or payable because of the fact of the grant, the acceptance, the fact that Warrants become susceptible of being exercised or of the exercise of the Warrants, or due or payable in respect of the delivery of the New Shares.

The Company or a Subsidiary shall be entitled, in accordance with the applicable law or customs, to prepare the required reports, necessary as a result of grant of the Warrants, the fact that Warrants become susceptible of being exercised, or the delivery of the Shares.

 

11.3 Costs

Stamp duties, stock exchange taxes and similar charges and taxes levied at the occasion of the exercise of the Warrants and/or the delivery of the New Shares or existing Shares shall be borne by the Warrant Holder.

Costs relating to the issue of the Warrants or to the issue of New Shares shall be borne by the Company.

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 9 of 10


Free translation for information purposes only

LOGO

 

11.4 Relation to employment agreement

No person has a right to participate in this Plan and a participation in this Plan does not give the Beneficiaries a right to future grants of additional Warrants. The grant of Warrants under this Plan does not contain a promise of a continuous employment by the Company or its Subsidiaries.

Notwithstanding any provision of the Plan, the rights and obligations of any individual or entity as determined in the provisions of his/her employment agreement concluded with the Company or a Subsidiary shall not be affected by his/her participation in the Plan or by any right that he/she may have to participate therein.

An individual to whom Warrants are granted in accordance with the Plan shall not be entitled to any damages or compensation as a result of the cessation of his mandate or employment agreement with the Company or a Subsidiary, based on any reason whatsoever (with the exception of abusive or unlawful dismissal in accordance with French case law), to the extent that these rights would arise or might arise based on the cessation of the rights he/she might have or the claims he/she could make concerning the exercise of Warrants pursuant to the Plan because of the cessation of such agreement or by reason of the loss or decrease in value of the rights or benefits.

 

11.5 Shareholders’ Meetings

Warrant Holders have the right to participate in the Shareholders’ Meetings of the Company, but without voting right and only with an advisory voice, subject to complying with the formalities set forth in the convocation for the Shareholders’ Meeting.

 

11.6 Communication with Warrant Holders

By accepting Warrants, the Warrant Holder agrees that documentation can be validly communicated by the Company by e-mail, including convocations for Shareholders’ Meetings and documentation pertaining to the exercise of Warrants.

 

11.7 Address Change

Warrant Holders are obliged to keep the Company informed of changes to their address and changes to their e-mail address. Communications sent by the Company to the last known address or e-mail address of the Warrant Holder are validly made.

 

11.8 Language

In case of discrepancies between the French, Dutch and English versions of the present Warrant Plan, the French language version of the Plan shall prevail.

***

 

 

Galapagos NV  |  Warrant Plan 2016 RMV    Page 10 of 10
EX-4.13 3 d333278dex413.htm EX-4.13 EX-4.13

Exhibit 4.13

 

ADDENDUM 13 to the

LEASE AGREEMENT DATED 6/30/99 and 2/21/2001 plus Addenda

 

 

 

    Extension of Mechelen Campus Tower offices    

 

  

Between the undersigned:

 

  1. Intervest Offices & Warehouses NV, Regulated Real Estate Company (Gereglementeerde Vastgoedvennootschap [GVV]), with registered office in 2600 Berchem (Antwerp), Uitbreidingstraat 66, registered in the Register of Legal Entities (Antwerp) under number 0458.623.918, here represented by three Executive Committee members, i.e. 1/ the BVBA Jean-Paul Sols, CEO, represented here by its permanent representative, Mr. Jean-Paul Sols, 2/ Ms. Inge Tas, CFO and 3/ the BVBA Luc Feyaerts, COO, represented here by its permanent representative, Mr. Luc Feyaerts,

further referred to as the “Landlord

and

 

  2. Galapagos NV (previously known as GALAPAGOS GENOMICS NV), with registered office in 2800 Mechelen, Generaal De Wittelaan L11 A3, registered in the Register of Legal Entities (Antwerp, Mechelen department) under number 0466.460.429, represented here by its Managing Director, Mr. Onno van de Stolpe,

further referred to as the “Tenant”,

Will first be outlined as follows:

In the private Lease Agreement of 6/30/1999, followed by the notarial Lease Agreement of 2/21/2001, and Addendum 1 and 2, the Tenant has leased from the then owner, the N.V. Innotech in Mechelen, 1,542m² of office space, with 40 parking spaces, located in the Intercity Business Park in Mechelen-Noord, Generaal De Wittelaan L11 A3, lot 1, on the first floor, for a fixed period of 15 years, commencing on 6/1/2000, to end on 5/31/2015.

The N.V. Innotech merged with Perifund CVA on 6/29/2001, at which time the name was also changed to Intervest Offices N.V.

In the “Addendum 3” Agreement of 2/13/2004 the Tenant additionally leased 322m² of offices plus 7 parking spaces in the same building, commencing on 12/1/2003 to end on 5/31/2015.

In the Addendum 4 of 8/1/2005 the Landlord temporarily made available ± 20m² of floor space to the Tenant located in a larger warehouse in Gen. De Wittelaan 9 in Mechelen.

In the Addendum 5 of 3/23/2006 the provision under Addendum 4 was prematurely terminated, and the Tenant leased an additional warehouse of ± 100m² in the same building in Gen. De Wittelaan L11 A3 in Mechelen, commencing on 3/1/2006 to end on 5/31/2015.

In the Addendum 6 of 2/6/2007 the Tenant leased an additional warehouse space of ± 213m² in the same building, commencing on 2/1/2007 to end on 5/31/2015.

In the Addendum 7 of 1/31/2008 the Tenant leased additional office space and sanitary facilities of ± 513m², reception space of ± 116m², storage space of ± 27m² in the same building, and 24 parking spaces, commencing on 1/1/2008 to end on 5/31/2015.

In the Addendum 8 of 7/14/2009 the Tenant leased additional office space with private kitchen of ± 716m² in the same building, commencing on 7/1/2009 to end on 5/31/2015.

The Tenant has so far leased 3,093m² of offices, 116m² of reception space, 340m² of storage space, and 71 outdoor parking spaces, with a current annual rent of € 432,446.96.

In the Addendum 9 of 9/30/2011 the aforementioned Lease Agreements of 6/30/99 and 2/21/2001 and all the Addenda were extended for nine years, from 6/1/2015 to 5/31/2024, and an additional 458m² of office space on the ground floor was leased, and the lease for 716m² of office space plus the kitchen was prematurely terminated.

 

1


In the Addendum 10 of 9/30/2011 the Tenant leased the following additional spaces, in the adjacent building located in Mechelen, Generaal De Wittelaan 21: 753 m² of laboratory space on the 2nd floor, plus ± 83 m² of the common entrance and hallways on the ground floor, plus 2 technical storage areas of ± 60 m², and +/- 760 m² of laboratory space on the 1st floor, and 10 parking spaces.

In the Addendum 11 of 5/15/2012 the lease of 30 m² storage space was terminated.

In the Addendum 12 of 8/8/2013 the Tenant additionally leased, in the building located in Mechelen, Generaal De Wittelaan 11A: 398 m² of office space, 156 m² of storage space and 20 outdoor parking spaces, commencing on 9/1/2013.

This having been outlined, it is agreed as follows:

Article 1 – Leased Property

In extension of the above leases the Landlord presents the following spaces for lease to the Tenant, who accepts these, in a building located in Mechelen, Schaliënhoevedreef 20T

 

  1. ± 866 m² of office space on the 10th floor, and ± 433 m² on the 9th floor, as indicated on the attached plan (Appendix 1)

 

  2. 30 indoor parking spaces, numbered 445 to 464, and 475 to 484, as indicated on the attached plan (Appendix 2)

 

  3. 10 outdoor parking spaces, numbered 604 to 613, as indicated on the attached plan (Appendix 3)

Further referred to as the “Leased Property”.

The leased areas are not guaranteed more or less in terms of area, thus representing an advantage or disadvantage for the Tenant.

The Leased Property will be leased in the condition it is in and which is known by the Tenant, provided, however, that the Landlord undertakes to carry out the adjustments described in Article 5. The Tenant declares to have viewed and inspected the Leased Property in detail.

An inventory will be made from the commencement of the lease based on joint costs by expert agency Collin Thomas, at the latest within one month after completion of the work specified in Article 5. The fees of the expert agency shall be borne by the Landlord and the Tenant, each for half.

Article 2 – Duration

The present Addendum 13 shall enter into force on June 1, 2016 to end on May 31, 2024, like the other aforementioned contracts plus addenda. Notwithstanding the foregoing:

 

  1. the Landlord will grant the Tenant access to the Landlord’s Property between the date of signing of this Addendum by both parties (the “Signature Date”), in order to allow the Tenant to make the Landlord’s Property ready for use before the effective date of this Addendum; and

 

  2. the current Article 2 and Article 5 come into force from the Signature Date.

The Tenant shall have the right to terminate the lease by 5/31/2020, provided that a notice is sent by registered mail at least six months in advance.

(Please also see Article 6)

Article 3 – Rental Price

The rental price amounts to:

 

  1. for the offices: € 145/m² per annum or € 188,355 per annum;

 

  2. for the indoor parking spaces: € 875/parking space per annum or € 26,250 per annum;

 

  3. for the outdoor parking spaces: € 450/parking space per annum or € 4,500 per annum,

Or in total  219,105 per annum or € 54,776.25 quarterly

The annual indexation of this rental price will take place on June 1 of each year (and for the first time on June 1, 2017), with the base index in May 2016.

 

2


Article 4 – Bank Security Deposit

The Tenant shall, within one month after the signing of this Addendum, increase the amount of the existing bank guarantee with an amount equivalent to 6 months rent or € 109,552.50.

Article 5 – Condition of the Leased Property

The Landlord undertakes to carry out the following work at his own expense within the shortest reasonable time after the signing of this Agreement, and no later than June 1, 2016:

 

    painting fixed walls where necessary, repairing small damages, and thorough cleaning of floors and floor coverings;

 

    installing a patch cabinet on both floors with fiber optic connection between the two, and four wifi connections on each floor;

 

    necessary adjustments to internal walls + doors and floor coverings of the 10th floor in order to make its layout identical to that of the 8th floor

Article 6 – Commercial Compensation

As a commercial title the Landlord grants the following concessions to the Tenant:

1/ to apply a rent-free period of 6 months from the effective date of this contract for the 433 m² of office space on the 9th floor. The joint rental charges and taxes relating to the same Leased Property are payable from the effective date of this contract. Nevertheless, in case the work described in Article 5 would not have been completed by June 1, 2016:

 

  (a) the rent-free period shall be extended by a period equal to the number of days with which the time specified in Article 5 is exceeded; and

 

  (b) the joint rental charges and taxes will only be payable by the Tenant from the completion of the work specified in Article 5.

2/ a budget worth € 133,000 (including VAT), free to use by the Tenant; this budget will be transferred by credit notes on the first rental invoices.

In the event that the Tenant would effectively make use of the termination option by 5/31/2020, they shall pay back 50% of the aforementioned budget or € 66,500 (including VAT) to the Landlord, within a month after the commencement of the termination.

Article 7 – General Provision

For the rest, all the provisions of the aforementioned Lease Agreements of 6/30/1999 and 2/21/2001 and all Addenda will remain fully in force, and also apply to the current Agreement, and this insofar these are not deviated from in the current Addendum.

The Landlord shall register this Addendum, where the registration fees shall be borne by the Tenant.

The registration duties amount to 0.20% and are calculated on the combined amount of the rental price and the joint charges for the whole duration of this Agreement. For the purpose of the tax authorities, these joint charges imposed under this addendum, are estimated at 5% of the additional rent.

****************

[signature page follows]

 

3


Thus, drawn up in triplicate on April 28, 2016, whereby each party acknowledges having received his copy, and one copy is intended for registration.

 

The Landlord         The Tenant   
Intervest Offices & Warehouses NV      Galapagos NV   

/s/ Jean-Paul Sols

       

/s/ Onno van de Stolpe                 

  
        Onno van de Stolpe, CEO   

/s/ Inge Tas

       

/s/ Bart Filius

  
        Bart Filius, CFO   

/s/ Luc Feyaerts

          
          
Appendices:           
1/ Plan of leased property           
2/ Plan of indoor parking spaces        
3/ Plan of outdoor parking spaces        

 

4


Appendix 1: Plan of the Leased Property

 

 

LOGO LOGO

 

5


Appendix 2: Plan of the indoor parking spaces

 

 

LOGO

 

6


Appendix 3: Plan of the outdoor parking spaces

 

 

LOGO

 

7

EX-8.1 4 d333278dex81.htm EX-8.1 EX-8.1

Exhibit 8.1

Subsidiaries of Galapagos NV

 

Name of Subsidiary    Jurisdiction of Incorporation or Organization   

 

Galapagos B.V.

   The Netherlands   

BioFocus DPI AG

   Switzerland   

Inpharmatica Ltd

   United Kingdom   

Galapagos SASU

   France   

Fidelta d.o.o.

   Croatia   

Discovery Partners International GmbH

   Germany   

BioFocus, Inc.

   United States   

Xenometrix, Inc.

   United States   

 

 

Page 1 of 1

EX-12.1 5 d333278dex121.htm EX-12.1 EX-12.1

Exhibit 12.1

Certification by the Principal Executive Officer pursuant to

Securities Exchange Act Rules 13a-14(a) and 15d-14(a)

as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Onno van de Stolpe, certify that:

 

  1. I have reviewed this annual report on Form 20-F of Galapagos NV;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

 

  4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

  5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: March 23, 2017

 

/s/ Onno van de Stolpe

Name:   Onno van de Stolpe
Title:   Chief Executive Officer
(Principal Executive Officer)

 

EX-12.2 6 d333278dex122.htm EX-12.2 EX-12.2

Exhibit 12.2

Certification by the Principal Financial Officer pursuant to

Securities Exchange Act Rules 13a-14(a) and 15d-14(a)

as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Bart Filius, certify that:

 

  1. I have reviewed this annual report on Form 20-F of Galapagos NV;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

 

  4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

  5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: March 23, 2017

 

/s/ Bart Filius

Name:   Bart Filius
Title:   Chief Financial Officer
(Principal Financial Officer)
EX-13.1 7 d333278dex131.htm EX-13.1 EX-13.1

Exhibit 13.1

Certification by the Principal Executive Officer pursuant to

18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Onno van de Stolpe, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 23, 2017

 

/s/ Onno van de Stolpe

Name:   Onno van de Stolpe
Title:   Chief Executive Officer
(Principal Executive Officer)
EX-13.2 8 d333278dex132.htm EX-13.2 EX-13.2

Exhibit 13.2

Certification by the Principal Financial Officer pursuant to

18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the annual report of Galapagos NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Bart Filius, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 23, 2017

 

/s/ Bart Filius

Name:   Bart Filius
Title:   Chief Financial Officer
(Principal Financial Officer)
EX-15.1 9 d333278dex151.htm EX-15.1 EX-15.1

Exhibit 15.1

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (Nos. 333-208697, 333-204567, 333-211834 and 333-215783) and Form F-3 (No. 333-211765) of Galapagos NV (the “Company”) of our report dated March 21, 2017, relating to the consolidated financial statements of the Company and its subsidiaries, appearing in the annual report on Form 20-F of the Company for the year ended December 31, 2016.

Zaventem, March 23, 2017

/s/ Gert Vanhees

DELOITTE Bedrijfsrevisoren/Reviseurs d’Entreprises

BV o.v.v.e. CVBA/SC s.f.d. SCRL

Represented by Gert Vanhees

GRAPHIC 10 g333278g0314072718765.jpg GRAPHIC begin 644 g333278g0314072718765.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#WXGFC)H/6 MDIC%R:,FDHH&+DT9-)10 N31DTE% "Y-&3244 8&L^,]'T&]%I?S2),4#@*A M/!__ %5G?\+.\-?\_,W_ 'Z-<+\51GQ=&,X_T9>?Q-ZV?CK1K]&:V>:15."1&:OVGB&SO+I+>/S1(^=NY,#CFO(?#!>V M2;RF\Z+JG3PT)8?VC?O' MH(Z44@Z45[!P@>M-W#.,C/IFH-0:9-/N7MEW3K&QC'JV.*\BT/4H'UC2&>2Z MN-6DG/VG?.R[#GH5QC&*+BE*UD>RTU)$DSL=6P<'!SBN L/&-S)XPCLGO(WL MY99(]KJJE2.@ZY_/K5FPU&TTX>*9HIT18KC<#$ Q7( SCZT7#G1VX(/0@TM< M+HFOW5SHNNHMS%]HL@TD++M8D;=V3C@\\9JYI&O74LDQN+Z*Y@6P6YDEA08A M<_P\=>.WM0F[:CYUT.NHKE-)U^XN?[20S),8(5FBW%7$-Q= MI,T\*6^\*R*IW^@ YQ1<.9'3T5A6E]2;3D$^WO7- M?\*O\3YSNM,_]=S_ (5[914N*9+IINYY?HO@C7-.AD2YAMY2S9!6;_ZU='I& MB:C:ZI;S36\<<,9))60'L1TKK:*Y'@*+J^VMKZG5&O4C3]FGH*.E% Z45V'. M!ZU"+: 2^:((Q(?X]@S^=3T4#(/LT&_?Y$6[.=VP9SZTHMH!NQ#&-_WL(.?K M4U% BG<:?;SV=Q;"-8UGB,3,B@'!&*=9V4-E9QVT**$1 O"@;L#&35JB@"I- M86\MM) L:Q"1"A:-0" :J:?HL5A<>?OWR"/RP1&$&WWQU-:U% :$2PQ(K*D2 I*K?> 4 'ZTJ1I$FR-%11V48%244#N-HIU% 7&T4ZB@+B#I12T4"/_]D! end GRAPHIC 11 g333278g0321075331294.jpg GRAPHIC begin 644 g333278g0321075331294.jpg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end GRAPHIC 12 g333278g0321075331419.jpg GRAPHIC begin 644 g333278g0321075331419.jpg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end GRAPHIC 13 g333278g0321075331513.jpg GRAPHIC begin 644 g333278g0321075331513.jpg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g333278g0321075331622.jpg GRAPHIC begin 644 g333278g0321075331622.jpg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end GRAPHIC 15 g333278g13j61.jpg GRAPHIC begin 644 g333278g13j61.jpg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�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g333278g15k66.jpg GRAPHIC begin 644 g333278g15k66.jpg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end GRAPHIC 17 g333278g17i47.jpg GRAPHIC begin 644 g333278g17i47.jpg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g333278g32g11.jpg GRAPHIC begin 644 g333278g32g11.jpg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end GRAPHIC 19 g333278g42c15.jpg GRAPHIC begin 644 g333278g42c15.jpg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end GRAPHIC 20 g333278g57q39.jpg GRAPHIC begin 644 g333278g57q39.jpg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g333278g59s81.jpg GRAPHIC begin 644 g333278g59s81.jpg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end GRAPHIC 22 g333278g78x81.jpg GRAPHIC begin 644 g333278g78x81.jpg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end GRAPHIC 23 g333278g79e19.jpg GRAPHIC begin 644 g333278g79e19.jpg M_]C_X 02D9)1@ ! 0(!>@%Z #_X6JA:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2 M1$8@>&UL;G,Z&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN&UP.D-R96%T941A=&4^,C Q-RTP,RTQ M.%0Q,3HT.#HP-BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX M;7 Z365T861A=&%$871E/C(P,3&UP.D-R96%T;W)4;V]L M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z M06QT/@H@(" @(" @(" @(" @(" \&UP1TEM9SIH M96EG:'0^,3@P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @ M/'AM<$=);6&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=% M05-!0DE!040O-U%!#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M( M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX M.&9(>#AF2'@X9DAX.&8O.$%!15%G071!14%!=T52)B-X03M!04E205%-4D%F M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=% M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%! M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455 M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!# M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7 M5G!B6$8Q95@Q4FQ:;61O85=PE1B.' O>D$Q1 M155Y=UI:5$DS-41F>EHU<79N+U56.#DO-% P4%-9=%-V67)(.4E84AG$,K36A*4UDR.7%),D5Y=W5+1FA)2SEF1V@T M5V\V;T,O3'HS64YE)B-X03ME8W9--S8Y9F5J'1(87=Q3&U92TQ2 M;FPO8VAE5S!:04AW9%!B1%@S3DIN2RMF.&(Q5'E0.$%N1F)E8F1C3VY7.6Y" M87 V)B-X03LP,%%I;79&5R]#>$EZ0U)R4F]K<7)&2T52>756-G-!3CAI435/ M4$]*1W8W6&\R0G9D:7)S5F1I$4Q%AZ)B-X03M&2UAL>CAV+T%-='IR;6U0-64Q M>54V,355:DYR4#E5=4QD<'!)=S=!>#-Q0TTX9T1Y5%E,-&1H46ML630T5TM/ M.&9X=6Y8;69Y+S56)B-X03M0;39W,5(Y8FPX=BM:-S)&-T'5D)B-X03M-9S%C=CEF:V=VE)Y>4Q+04=A5C0S53E4 M=&IA3T=),T)P1#)F-6,O;&IR5W-84C O6'!B>2]B5D4X>'HR,79D)B-X03M7 M,&I*2U-7549"1WI#3#DU,S,V9D9HF\X8VI15%AR=TU),#1%33AJ>'=X>7EL)B-X03M5-DY+-T593&)0 M0T8X4C9->',W=3)V8E-#.'1:0DYB6$UA>E%3'HO=T)X.$]L:GI#-V%F87EY)B-X03M85G-S;'5P8U1Y,C921712=VI* M-FM3=59+-VEO2DI03$1X3E@U8F%R6DAA+VQH%8R2W5X5C)+ M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6-#)N-6MF;D(V=VIM M.'1I3TPV>D9%.3!T)B-X03ML9$]&='!05TPS0550=5EL4DMR,TYF-6AH5FQF M;4@X=U!-3VPV-4IP.70U5W5R*S)3-&=T,74T+U9)6DIO*V)4+T)$2DAW1$AH M.79L)B-X03MY0C5"4E-O5DQ025AN>GHY<4]V='!7=F%"3D9B4UA%-&HQ4#!: M417,T(O,V9X,D(K24Y8644T<6I0*U9N*V)4<6LQ<6YK=3E. M=$9E4&(O049K*W5V2T):-#1237$O5GE#4TI'96Y+)B-X03ML1BLQ:7)T93@Q M9FU/=71Y861O.6I'1V$K1G1%C$U#E5=6)L06M6>CAF=TAK1%@T1U)U,VHX.7-64WI29$4Q8GDU-6)U;W!D M5$XY9"MS.7=,:59764%.>$A(:7I%)B-X03LO1E1M,B\R:6-+<#,Y5S%8+VQT M5"]K4U K83A#=2MR87(O>3)P+WE*2"].94MU*W)A4I(+TYE2W4K MEAI$)G1DMF.$AIG)U.4-E1S%D;&(U;G=8<%9V:$=M>3ER8T5J2&@U13EE-S1()B-X03LS M;G5J5EA,,&I0:&]E24$S>G)P*S,X2'5'-DXP-U5$94-1;45X8T148VAG9'E+ M5DAC8V0X>F1(<2]'=C X3F9T*S9T+VLT*V9"-&1B)B-X03LR:DUZ1V@R2W5X M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9+8G9Z M6&]&<&-08EA&,39C>4=25U1H26%')B-X03M'25138FA33F\R0BMN>'EI5W!X M>$Y%-R]!2VAB8DA$26EW161:86I:,W%-.7)*-FEO>DLR>%=H5FEH,EE$.7!# M37-H:T5U5$-54T]A)B-X03M)>6)&,DMU>%8R2W5X5C)+=7A6,DMS5G1V2T=N M-D(U5W9D3W1*<#-J:VMA-$UJ4%(V:TMG1E5#-T)%564O53165&,K5SE)3$9I M:W!:)B-X03MJ56LS13E383AV-2](2T1PGEJ55)'2$1/)B-X03M7 M34-*15-E6%5!;'-W;GA-:U),8T=1968O<')8=BM7-C8O-4=Y9C%Z:'8U8S%V M.$%/+S)-9BM*96PO:WI4+WIF=% V,#AU<&11:3AP)B-X03LR96]P95AF,7EE M67!)>&YL231Q6E)S=&%B.%)M-WHY<&%I3V=X-5),.35+5D4P3UAQ-E9844]U M>#9016162T)(;T5E."]W0D9)+S Q)B-X03MR,R],9&1F.&I:4#8U<% U8S%V M.#GA:9#=6-$5/9$0X1R]V4S=7 M9DPK)B-X03MN859O97!8=6UE=%HS349P239V1E!+2RMH031I1$%S87%N669W M>3-&235-:UEY3FII*S@W=5!Q25)W-%IY>&=2:TE(:U U;S(K5'AR)B-X03LO M2&9N2"]Q-S-0.$%W961*+TIM1"MB.7 O5SA4+TQM61Z;C=3>G@P34UO;#8U4V]M:"]3.'$V0FE0*T\O3U X M03%D-VXO9S@R4#AM65 U=C)N.6)P)B-X03MV-6,Q9C@O-TDO<64O2F\Q%AC:S R8V)$;TTU2CE$9$IO,7,X8DE*4MJ-5EQ.&,X)B-X03MY*V%F3D5/=5@Q=G!U<%1X5S%V4&5X<6IY4U!1 M0E9T-U0T9T4I"3#4T+W=#5C1F;78O=T)42&,O.$1&+WI2;&9I)B-X03M& M;SA76&4Y3C$W>C,U>G10>4@X=65B64YA=6PQ,U5D464Q=3=N;4-':E(W,$%# M36HP=V%224MH9C)F;E=:;65',C!Z4$%#.'DO=T-6)B-X03LT9FUV+W="5$AC M+SA$1B]Z4FM014Q6-'-U.3EO<&\Q%AC:S R8V)$;TUY M2$YD2F\QC8X9T0X.&@T8V5D1#5-=4]896PR=F%&<"MK M*U@Y5G8Y3#E7>75R)B-X03ME>FUL4U-'85%6345$*VM'0EDX;%%M;T@X2S58 M:T%H0U)I0418,V-M94UM56=$=4QE1V8X&9/=61M*UES-S%E-G1M+TM,4DQD6FM.=VPV-U!#1T)C1&QC M-VQE;S9J3E1H+W=!9&XO5B\T;#9()B-X03M5+SA!1UIJ+T%+-2\S-T)-,GIZ M>C9D+U1E:F8X=#ET+WE/5"MU8TDK4]4*W5+=D,O370O M8T1Z1G%485-E9'!*)B-X03MD,V-J>4EO9%-B9CDU<'9X03DY6FMU3T\O=T%B M5EAT5$UE4C,O2#0U=4I)-S=F:CA&33E-1VDR=C5E*V9:63=I3DIB=E,W:3-T M:V%9)B-X03M%=F)7;'1C5S%S5E)M4#)G:&\S-V8R=2M3:4YI>F="=VPX<355 M-'HR6'I09%=Z9C@T=RM58F1::TYW;7)3"]R9CA5-$=0+T=*93DI-9W-),4Q2 MB\X045R M;DY4:"]X,F8X058O-&PV2%4O.%IM3"MU9CDK."]Z8E!04'%R3T5F5UA9<3=& M5T]F;50O=T-3-C@P+SES:2\O=T-O)B-X03MA5$),:WAN.4IF0E=9DQD:3=&6%EQ9TYF M5%P8FM(:U58 M:6562$-(-%-3:#A3=%)T:%90+S!L2B]Y=S-0.$%W2V8X,31&9"MK<% K5T2\Y5CAZ9C54>B]!336)G8VMM M66IK6&1J5FU*,WI,-TQY>6YN;$M2B]!34-N)B-X03LO3F5C22MS=2]356XO3$1C+W=$ M07 O>EAI749G=FLO.$$U54(K M8G8X03%,>B]!4%-282\X05982U!$3&EE1DQU6FXK62MJ87IO2"]/4$AL:E%T M67-P)B-X03M,4%5,4%9M339S63-196]B,E)11VI:=V%P241K<$-O%8S-E-K+S598FXO04E&4"MA.%9D*VMP4"M71S4O-$90*V$X5F0K:W!0 M.$%L:'5F*T)4+T%*DYT7!K369N-U,S0TY)4C8O=TI1%9")B-X03MA,2]X>7)N+T%&4#0T<6IC5F1I#52+W=#+T]T8WAT5G O1FIW M,UC0O.$%K.4YL6&%N.310-G8V4S(Y M;B]19F8K<$HO=T%O)B-X03LO=T1Y65=L9CE(2"]!1D13-51O4#$9+:%8V5#)F.4(Y M+S9K<2]+;C%V.&9A6#9)57EF=C9">5%V.$%V4$I8<%AT;$]G+W9O+T@W:3(V M,RLV4'%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C1T+WIL:"\U M3')4=BLR=D0O=T)1)B-X03LQ>FQE6&LP-2]P9DM'54])+U)J370R3'-69&ER M6Y19C,P9FHY>&)D M6B]D2#1F92MJ.#9.,%1S5E-,>FPU93%(6'1&;3 V>3%35%-N;$%")B-X03MM M:5%/4U9D6$9D,5E$-$]*-'-.:6-644=N*UB]W041B+SA!5DA&6&953'(O<358 M4"]!,B]W1#%2>%8S)B-X03LQ0S8O-G56>B]W041B+SA!5DA&6&953'(O<358 M4"]!,B]W1#%2>%8S,4,V+S9U5GHO=T%$8B\X059(1EAF54QR+W$U6% O03(O M=T0Q)B-X03M2>%8S,4,V+S9U5GHO=T%$8B\X059(1EAF54QR+W$U6% O03(O M=T0Q4GA6,S%#-B\V=59Z+W=!1&(O.$%62$989E5,4A"2TYS)B-X03M*=T5H4EE,+T%. M0VXO;#$O,6-D6"]W0U(Q="\R5%I$=V=W.$-,,7HV:&1F.5A+-2\T1S,O04]Q M3U=.>G9Q1C$O,6-R;B]G8F8O<6II)B-X03MR=G%&,2\Q8W)N+V=B9CA!-F\T M<375F*T)T+RMQ3TMU)B-X03LK;UA8+U9Y=68K0G0O=T1Q:FER>$0X-S1:279. M;&]R>G9/5%E2;FY)14)!.6%B8CDR<40X33!886XY-% V=C93-VIS+S9$-R]! M3E-6)B-X03MF;%-J4#4K,'16:V%*:C8Y2%1I4TM7.&@O841$9C5:5&]0-S90 M>"LT='5T+W5J.%!V9E-/9$&-8,'=G:$QP)B-X03M% M%9/8U9D:7)S5F1ID5Z-D]' M5U9K;'EC3W%L:D9#:TXU9"]+6'DU;T=S,BMR5V1Z95-83G1Z-$I-.%)1*V]J M4FUO5TY$,&9X>4]()B-X03M147AY16=462](8WEY-GEC-#A*05IR;6$T:G-6 M4WI8=DQM:V$W82]6=%1H.6%+:%A:;5$X6'!Z5W%K1VI5,WA6041Y=F]E:656 M6F1+)B-X03LP-C%73WAI2$M/1GE:2TA91&1Y>"M%04%E07A613-9.&]79'A$ M8C--9&Q&4%!)4UK9UEO=$MB8V=H<%A&54IQ,RM&3%=()B-X03M4 M-RM23$M/=V4U-$YC0EDO5&)N1DEQ3'E!;V%Y54$Y.$MQ5FIR+S5A6'IU;'!D M85A+>4-R1#EY2U8O,6=/>$(K4D(V34MQ<58Q<6YK)B-X03M85&12=6AF>5=- M361%5TU-:UI8;7!)9$)12#0V:V9$,4]+15I986PK6#)O4F5R6E1A6F-2+T51 M>4=!,4-J:U=(*U1X*TMV4VTO5$%L)B-X03M%85)P5VI45UIL1FYB4TLP.7AW M9C T,D)55'5&;V%D2V1-2W)T63!F4U4P>31D3$LS5F=M>D-*05(Y24="5W)W M955,2S1G=')Q3WEH)B-X03MU3&PQ:6=I6DEW>D\T67%+53&-G M17A)9&QN8T%D3W=&359D%9Q-TAL0WIU26)E-6IS;W U-49H:6E:22M2:VM$1D9P5&)K14Y+-'%S M;C O47!P3DYL=')A,6MG;6Y98S0P)B-X03MJ6DA545-N<6]O4GE80W%Y,'5V M23$S0DA0061084]65VMI3$Q%:%I%3$)N05E+94DT3G8P,GA61#-K,VLO5')U M4S5V:%I15U5S1G5B)B-X03ME4FMJ-$UZ979)4VQ!46%P2%ABE=6=7@Y M935!)B-X03M*:5$W0V1W0C W05E&9')':C93;6LS75)3&$V:G-O8FDU9%EO26U334UZ=4=+:6Q/)B-X03LO M03!X5EI0<"MH5%,V9$IB5S%R2D1*8T]P94Y),E9GD-' M55)M4#!3,W%"1TE#)B-X03LX9"M7,DMS:G=+-T9867%G=&$O-#56>B]!2VXX M8U99+W(S-5AE54YF,6$T,5!73&53-VUU15=);UI8:E)9=V]2,4%J2T=K9T$U M5D]+)B-X03MR-W9Y6&]-5VIA9C5D:&IK:3 QGIW,3=P1V=7 M5GIAC92*U5C,G)$>6A*1&1Y-C1Z4F%D-C-Q5&-L5SAK<3!H:V-L M6$DY)B-X03MF-'$O13%D=3=!<3E"=F9++VPK9E)R>GDY<3!B6&5I439885%4 M<3593S!6=5IG1TII-&YK3T9F:$A8<&=69VYL4%-0>70X=RMD3$LK)B-X03LX M='G5X3$U35%5N1EAJ=FUX=GEJ M3W$S,VQY-C V-E17;BMS,GE32DY+4W=-<6=V>DY9>'DY851:=#9#;E9L3T98 M<&5T841P1G)O.#!.)B-X03LP2C4W4'DY<#%T8U)+:W!I:VLK<$IC0E%Z249( M>$M..7%9<3@U=&1"+TM$>GIQ:S-L:7=S8G$S=6U62C=I.$5R,5515SEO5E5R M3'E2)B-X03MU4SA53D%2.$YF,G-693$V34M78D-P3DQI-494,5 X07!%;4)7 M.6(O04]/3F8O.$%-3DXO>$$T<6M7="]L<#57,7I86DY:,5-+5S1U)B-X03M( M:6IH5U Q6&I25FI,13!%6E4O2'EO,50R,GA61V%D-64P&(S M.%)K,"M!=WI354-L<4M1>F-K04MT2G,R-$,P-G-P=W$Y4C%,>3=P8V5L>5=& M=S%X2F$V3%E757-,4E-T0DUZ5U!R)B-X03M'36U33&A1+T)88G9I6HO34,W=%!,='99,V-6,F]76#8S-G(X;W91:%9E2D5G2U-$.3 P97=),C5F M=$1&5V%E961-.&Y2)B-X03MA5$1R6&U7,VYU-V5'-FUT1S13>4M%:F$W:VMA M5# P235S1$A866-V-60V66]9,S5B.')F;#,U:75B:GI2;TYR8S)%*VAW36A" M;%IK)B-X03MM8S(P:V1(4U1K4C966%=O<'EQ5"]+8U5V8F-#=7A6,DMO3%=V M*T]68R\V;CAC5E)U2W)8:6ID:UIL0F%.=55:.$=+;&$O8WA'2V]))B-X03LO M;T=05FY9;3%85G!K:E)Y5$=,:#!J-6U)2#ES:&5B.&9M8U929$QE3V)K94MY M>C!88S!,8U%305!'9W)I<4@P>41326]81VU*07-0)B-X03MQ4T=4-G-%-"MO M-VU35W9$.6]Y3WI.-VY&559(1DA%<%=.47%L;5EG9GI/>%IJ.4I.8U91;71F M.&-Q-2\Q4#0T<6IC5E=V1D%965C=0-G=Z2S9E=2]' M2G9I2$DX45A6868V)B-X03MR1G9L:7%&7)&0UDQ M2FU::E!-;U9F,G54$$O;61I>D@V4V$T M<6A.)B-X03MB+S0T,2\X03AW,#,O141I<4YX5F$X56)S:DUO3%)T>6I09WA5 M"LQ5&M+5GA6)B-X03MV M;EEM4C,U>&PS47))95%.56A9:&=F6D=99RM'2V]C86YO369'4F)U,5-Q07$T M:VI&67EW:E5G,2MZ>F]O.3ES5E)S8U5C4VQ9,4-Q)B-X03M76FE"+TTW1FU0 M,&LQ>%9#83,O>'AR+R]!2FAP=BM)2$958FEQ,31O,UI'6E%7:F)L1V9":7!7 M=C--4FER4G0T0U-41VA*3E-3;W%4)B-X03MT=CA!:&EQ;7-L:WDO6$9E3FMM M5D4Y8TU#&EG3E55%91=G)9,TYP3$%'-&U286-U M=$U6)B-X03M6.%9D:7)Z-WHW*U5D=#5N;G5B*S Q3S0P=E9B9TE"8U)5-&=+ M<7AN<'AE=G!Q441Y,DHK:D953&,O:UAP3GE'95183E53-F-"5&-X)B-X03M4 M2W)R4E-O.4UL5TLO84QD9#)*3TEA.;DQ!<$-M M4F%":C!'2W$K2W5X5C5Z1"M396Q2>7AN.4]A;S%V2&)35W$R6FQ143!K-55F M9T4VE)V)B-X03MX4VI30U1G4V5U=SA-0W-W=#=Y,'5B8UA.=E!( M3F)N;%-A3FQD1'A*5G9I0DDR24E/2V]7-W5D4'9T175*;W)Y13)5.$5G1C9( M5F]1)B-X03MP57%8-6%9H0V9K=&\X,'-T+V(K64Y51#-O9UIP;W!O+VEI:%-9 M249B:%=J9E=#>F(W;F9U8TYQ,'8U1F%';#!B;5!7)B-X03M.5&IL935A-FQ+ M4WAR>EHU4DMY1VEF,V4S1&HO04,W63)Q8S9&*U9(;$A43%-70S1T:'%R>7-V M-S8Y5DI'5TY(4U9):V]&0WAR3$=*)B-X03M+9GIK;G9G5FU72W%&.6)'-G-R M:3)$8U1013A98G)4;7!7=C0T<7(T<6@Y47,P=G)#-7-N9#1K=6]N:&%333A8 M55-+5DQ+97I#=3)+)B-X03MV4%4O2F-T3F5V4#5O,59H8S-+,T5F<'EQ:%92 M04EM4FI2<2]'6%E5;T%$4VY5:S)R82]K9G!(,5=3>FLQ'18<&5"5D,K=&ID5U9X8D)U2FYI)B-X03ME M34XQ<'I5%(R66IV M-TIM='!30W9Q16-5-53)K=D-E5"]2=55K2V]H:V=K,TA, M;$EP*THR>%9%5T9L)B-X03LK559N85AE<'@K84A0;%-84W)R4EA*CDW27E3:45554Q+=D9E1E!54#@R,DMQ36YL4#AL2E1(<45(;4&%N<&ML-G!L9#1Y=T1'2E-N2'=(3#=D96U+G5T9#):071F)B-X03MA M=G5Q$,Q1'%#=S0X=4MF0S,S*S)+7)A4V$Q63(Q-4AD4G%W1'!Y355F351"=&TK3&Q11558-THW67%R M='%8;4UC56PQ2W=3+VI8:$Y%2D%S)B-X03M3=C9R2V535I7)B-X03MK84\P:VIL4E,T5VA"<#1N:U9),G!X.3A5<4]N M9510240R>&AS=$YS-6]96EAO1E98.4IY<&E+;V0O5$-O4VEH855865E&43%J M-5@O)B-X03M!0W5706%80EEA6DET:W8Q9&]N4THR06IF9%=,,4I04#=6934S M-C1Q<51E5"]W070P931E9E0Y4&]6:CEA2GA'55%11UIL26I0=W!4)B-X03LV M>DHP2%$T<7)2*U=0>3AGC1C=FQZ*T@U-'%U3W1A M44LO-EI$=$8V-6\V;CDS+T%$.65M2W%I-FYP>DMR%0R9#%B84I';'I$2%580FXU9S@U2DI45E$U1%9:9S%E M,U1P431Q'E5 M-3@U6&%P1W% S)B-X03MS8FDW2WI-040V:D]K869V1'@K M3&HX5SE"5'1T:7%S=6MA,C P>&PX=G%5,4%#2S=);EE-26U337-+;5)I,4-N M5&)U359C=6=A,"]O)B-X03M'-#!Y1S17,E%7.$MY5$UV1T(T>6QX1T655;U P5'%$4'!-5#9M3'!'5T%Y>6-*22]5 M;W9X%9#9C1E,6HQ50O)B-X03M! M3C-)9E5(141M1TIF,4=D<70Q4'--5E)/;394<4U7=#)%DUD:E5';7AP4E9%878U)B-X03M:=7)D;S=N5#E% M:&UM:W$Q=W-D>DMA:FE9,E9N67A&=E935"M8%E"87119$0Y7IDDY/4TM"46YQ4'966#(R;C8Y6G)F>#)V M;'5&;W!P4S!35'5*;$%1=5EZ4C)O5'EC,7!3;FI3;4MQ$(U>54K5TYQ:%ID3#AX45!E M;3,P248W-&\Q-&983'AZ;C%!-35)>FEL1D)!*TQX)B-X03M'.5)25F%03$XO M.$%5,6M444E93&Q&1%)"6D1*5U)1,T)7-5-2+T1Y4F%S97@V9&-656]V2S)Q M,CEJ2D$R:'AZ4T-A-%)+5% V66E9)B-X03M!8S%5>4M76BM#-S=B1'-C5E95 M.'0V>&%8;"]%3DI8.4=83&-:2&IL:V53849'4$976#%'-TQ6:%1C9D0S3TMS M%!):T8O=$4O8G X5T,P<6(K M4B],1%)R1V))56I656I02FE65E152W1384-U+WIR-#0R7%E M2'!#)B-X03MK,&TP9EI"=C!'3G$W+T)F;#4)Q:R]A-6]'2C=M=FEC8E9/3&$S:'1R94LS:%AJ1$-I>'AR56UI)B-X03MO M2T%63R]167%Q67$W1EA9<3=&6&QS6'!E=$HV+W=#;"M8,6XT4'-C4'-(:C9T M3G502&QY$HP-F-U16Y+=$YU5D].93%0<'A6 M9D@K:B]7='$O<'(Q)B-X03M/3"MH-B]';E Q,G!4;CA0<3EE;4MO5%5F.$PO M04M''HK,RLYE-N-#&UL;G,Z>&UP34T](FAT=' Z M+R]N&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O7!E+U)E&UP+F1I9#HQ1# X1#(R,$$P,$)% M-S$Q.#=&040V.4$R0C0R041"0SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @ M(" @/'AM<$U-.DEN&UP+FEI9#HQ1# X1#(R,$$P,$)%-S$Q M.#=&040V.4$R0C0R041"0SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @ M/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.CAF-SDU83-F+6%C9C&UP34TZ3W)I9VEN86Q$;V-U;65N M=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA&UP34TZ4F5N9&ET:6]N0VQA7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,4,P.$0R,C!!,#!"13&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @ M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@"UD969A=6QT(CYG-SEE,3D\+W)D9CIL:3X*(" @(" @(" @ M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D M9CI$97-C&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI02 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$ M97-C&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E M7!E/D]P96X@5'EP93PO3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\ M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @ M(" @(" @/'-T1FYT.G9E7!E/2)297-O=7)C92(^"B @(" @ M(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y486AO;6$M0F]L9#PO3X*(" @(" @(" @(" @(" @ M(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @ M(" @(" @(" @(" @(" \7!E/"]S=$9N M=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \&UP5%!G.E-W871C:$=R;W5P&UP1SIG M&UP1SIG&UP1SIG M&UP5%!G.E-W871C:$=R;W5P65G>7M]76UPH8(38X5%58E)73U"(Q-W5VMADC.4%XM+4D,C,T M-;,:)2=187-TL?_$ !T! 0 " @,! 0 ! @8'! 4( PG_Q !F M$0 ! @,$!0<#"@T/"P0" P ! (#!!$%(3%1!A)!D:$'(F%Q@;'1$\'P"!0R M-#9B#A).6 MTQ@F@L0G16/5UO_: P# 0 "$0,1 #\ [^.$3A$X1.$7(;UZ]OGU0]&/:;[) MZ>,4K5UIZ9M37+47I8PW4; YLYZA6O7^M[3(FKSAJ:S7/:V[5K3F@F^N)6DM).4BU[! MTNFK+\A*1K(DH\CY<"!$,V9:/*RD:.6QA'$,1 Z.\0BZ%JUU&NK4D["MW]J) MM(#VJW01TI::EZOM73#U::,I6WIEN>!%B5J*PKE/W0L83JEA8L,$=#%3PM&K M$N*U,K\YY.9$]3CGAD-MQ>,R489.8C/UVQ8,0LU:@-N\G4.%":@N.!&Q9//Z M7SD/3+1NQI!TG&LBVK.@SSHYAO?&>V.;0+'P8HBM8UCF2T%P#H3C>ZIO ;%. ME.V1V WVB_:*Z-ZEB6K*;TJ]&6N-R7T;9Q-;+P;OEO7VU=84D'#)DY5GGPK M3,Q+G,%CPPL%!GGK-+"P1J<2'D1)'TB2+?6LM$A:[HT=T-M"06\YCW&@H"*% MH-23057!L_3N:&E.E%G6LZ3@6-84K/S+8S(3VS%)6&U[W1G-BOB".6-A MLAM=%C.AM9>0TS9V1_7!UR]HC8=L]0VQZ5K;4W17&L-CKNB@4>J&\[/O,Y@J MMIER5;IEJD"" :D#&\#;0>&UB'!/W5^0+!YB-5X]$C_.=EY>6#(3'/?'H#$. ML-1MV6J#5V(!=4DK $6+"LZ$($3UW,.#Z F.Z, M6.AR[!J1HC(36Q9@ED/5$*(T;F?7\_:>_-F5+55!&R&(3UCMY1H? M&D$9277(@@5&QAP@;-3&X\AR&%#1)Y66W'D.1X;J&'E(X4.'$BNU(;'/<;Z- M%;LSD.DW+-K0M*0LF6=.6E-P).680TQ8[PP%YJ6L8+W1(C@"6PX;7/< 2&FA M6-?39VGW09U=GK'5^GSJ/J-YL52KI*W6 --#W.BSQ]5#.QF3%C\GV)6:FN6# M$KF1/.12#Y3"@(D,NRGFFG$KS]8LI,00#$A.:"=4&YPJSXNH _6+K>5=)QEL!"<6,O,.DS"KTC$1AB+M.=4XVKY#,F0I#46GNB$6<$BRW90S#HGDFG M4F&R[GDT $ZZ"),@FYKA'U7;'%8?=1773U.4'MV>DCHIJNP(@[IOVGJ2':;O M1%TVE391B1L>0*3AG")DQ,C[PI>$ZSX MT M3M)VMY=T(QV7R\&YD5HYN'.=6W.R,[1C>6_ML=J6WU;[DK#FJ.D[8U9ATDR= M!:]UX"UU2GK?U"#STD[8PH6NXFPFA%!K27R=IGSG(R1JWD26W9LUXW#-?'0G2BT;2GM,!;4_",E8LU";+OB0Y65AR MLN8]IMB&)%APX6LT0Y:%5\9SJ:A-07.)SZU-VPG9L[SVL$TEJSJHJ%HV79C+ M5>K8#T8V.$BV$W(R9')'3^N1J@]!%0>@K13[+EK:Y M3]+;+FVU@3EAB$X@ NAN]96*Z%&96[RD&*UD6&34:[&U!%0M6O0;6M\:E[:O MHPZ7NH*4](M/2->[1H6MH>2]E#%&BYW!L@&Z,ER?!)(5LQ*V,3LE1E/I1X*J M;#18[;4*-%8:YQC!L0_"K#8:C81J 'I!*Q#1N#:4EI_8-CVF28 MUB1X]FP:@W2P$_-PRQQO?!B&;?%@$TI!B0VBC6M JVWNA_9/7OVJ_:UZIU+: MY .]4F%O7<0*K)2O$';$^E[@UK#B:P)/XGP8\))V2>:(A9L],L?&M0:ON368 M\?"R4 R8;+R>E0)1YUVAOE#$#X;G:S1&APBX !7< J]>85=;8AYBE84IK%:V3&;CY=B7!#!PCB&JY MP8375VE+F%&,4$NAQB7!U:T<;RVN5+V^]N'L2MLDD*U;'98\9C):T[$AL MEHLN&"#Y25AGR<*8;"HVCVD>1F@!5L<"(_5]<,:L(/NDQEJ/U,=E\:W?'*R> MC>%M*4SMM#+)"0!2UF_ZUE["CEFAR5+65GZLBD< &58R0D0X=E2%2K+93GWL MO]JFQ#H(Y9S,*^Q<&TKL#Z5V5(KL6/;";..$[0/,.AF91TR' MZGV;I-K_ "0]F6MC>3^S4R]J7:^SXN_1KU&C>@EN!M?34C>@VR3M3-K#0*TFC84I0"Y.M3/G*-F6QH1F/* MM@^5 /E:@>5+7^3H'WU+CBW;2NQ<_3"-HS,6#:K-&GV3%M@60X@V/Y!T9MCM MG9 VBR,Z2K#;!];8PY@AWD_*^2;3RJTIZYU/6>J3LT]3:YOG:5]G%I#4VOE> ME:M86S75>J_491;>)DG6"J"DF)/B[&N!@_D@0>=G!11--VB2HJH29GB66F.> MYYA3;W-E9F(]W-UVO)A.:0*;-4 =)&J0:K 963A6QHG)2DSI9HM9TE*_KWK. M-*PH-J2\=CHH?KD/;-1XD76>2Z&Q_K@.!;K74V 'V'(W;X]D%&>MV-@.Q^A+ M2S#M\Q#)#L79QK4/4*VNW8'F6F3$'%D4G)G$,LRT2C8F^)G--RD.IQQV_4^= MYNK^R(G-NYO.A\VZZ["Z[*Y9+$!'*1H.#']=$:-R(,SJO;ZX(D;4!CZL2CV^ M6_;-5X#QK4=?58?=(]!U7M75'W05K+<>[1W3O3;SU!=.8-O;9V$2GU>M6K'4 MOU DJ2Q;V1:5/L5([;!X@!8B;V6X8063D&I;S3(]2\?6*Y['68YD,Q7-A1#J M"@)'DH6L6U^R#:D#:13:NCL66DYV3Y392>M!MEP)BT[+A^O8C7N@PHWT7M)T MN(X9>(,2.V'"BO-&PV/,0D!M5<_2KOC;W11U3="71=M(+V=?7!J\YM37@O5. MPNG%K7FPMDZS>+7N (#WT)LJBBZW:1%F!32B;#+5L"OS)5TKT4Q!D'%M.3BT M*(T.',09B8:9F7>&N+FQ=9C'\V]NJXEI::4YIN=2[ +[6-:,]H_;&CE@3;-% M](9.).2S)*9LH2LS-2AB3+6,F8]O>/S' MUZ,3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3 MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%" ?IKT%7]UV3J0":AH0O?5Q M$H VG;<*O06+V?#-P@8U PI8$-XFRX:8%: 0TL..91B.(@-^#NQT8Q]#%B&& M(1>XPP:AE>:#4FH'62>TKKV639L*T(MJPY&69:4=@A1IUL)HF8D,-AL#'Q?9 M%H;!A-H3@QHV!4TWTI=-=DW6%ZD#VC]:%=]UUN&T$V[,J@MV^C4#H4H9 \FL M7B,3TJB#IDF!'6IU2VH3ODJ%882A"0C11#,(1'"&<65.J:FN&&-ZI$L:RHMH M0[5B6?*/M*$&B'/.@L,RP-:YC:1::US'.:+[FFF"^]*Z7.G76^V[KOJA:8UY M4MS['C%8=\V:"K< ?%3*RY6>CVE+2$K GYH/;,S<.$UL>,( MCV1(@B1!>X/?#8]U<7-!Q"H]5Z/.EJB[D,]0U+T)J^J;PL4L_./[1KU4&B+B M;F6KQF;+(+%X+3#Y!TZZZN255*R[Y=,SB;([\M*7\2Z/&6C2F&I\%W/CH!! MA+4Z!(PF1#D,/)2YBC'OAN#V.! M,0F189(O:[5>" YIO:X4P"Y(,M900 M!+]AD@IKT>1.!-G"[I$I$!SI$2&_.#0I<<9->APW)45U<2/EOZQ)F/& $2*] MX!J 3=7.@H*BIH=BZZS-&[!L>(^-9EE2%$K\F8MS+KKTFFP MU,4^3X]W*G)#;X%QJ0M2U/-N96K.;")3#V53_ "CSN*X;]"]%(D:PS4WE9(S.E;IMG;6H^\Y>D-9KV_K2O0:C MKS8F*F)9L]+JXV&7&C:]62+,=M8?+RT4, M=#$1VHXUR73LO:+K/E/7TI"; E9KR+!&EX+6O8R% M!< -2&UL2(UK&T :]P H59L3H1Z,X(/;M9C=,6E,5[?A 67W.%=U_7Y(W99< M&6+'@A:VPY,-YDJ4"G3I^'$B/B0 MWD:S'N+VD.O5 T1V=?0YTRV_.P-$],&I==WK#4EB+<1=<1.LPMB:TN/-8!FS M;Q,B 9FQG7(LQL)(@(EQ5KC2$N,*RWF8DS,11JQ(KW-^U)H#U@4![5\[.T7T M>LB/ZYLZR)*5F*$".R$'1F!P(<(<2(7OAAP)#A#+01<:BY9B1B$"8]+CQ)T. M4^/>Q'GLQI++[T*0I&'$L2VVEJ7&>RWG"\-/)0O*,X5A/@SX>?"A&S'#I7>! MS7%P:YI+31P!!+3C1P&!I?0KV<*R\DZ?!&1G)I*;$'PVLHP[+G268D9O+KB6 MF\./OK;:1EQU:&T84O'?<6E"?"I6,9*KG-8"Y[FM:,7.(:!6X5)H,5Z\YQC& MKA63A$X M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3 MA$X1.$3A$X1.$3A$X1<66[T=,<3J1^Z+EZ]/T1=P$]-M;D:R8!77,XFS93%$ MGS>K/T:@MFI&9!"%ME,5G9;,=AY=6LWBADAL2XK$3/>,\J85F:P=JF,=:K: MC6'D:W8%E=3,9K0EH?0EMJ\J7K:)+^799,(R@AQ]9XBQ)9S[:\DWRAJ]LZ&B M; !,&-S"&'FK8#U!=4/2+NSL3;17*_UD5\/;]4]'M&$%!^LMYPZ@?([D?Z=; M3%IFE+QYN(-3; QL W5[,.G:TD*R[<7:W/@KCOI@2&^<>'!C,GP3 ):^,X@N MAZP#!%!+VU%!J@MH[97I62VG;%B6AH!&@PK=A,CR=AR\-[)2T6P(CIXV7&$" MSYC5<'11,O@QF.E#?'\DYM#JD+%/JDF=._4#T0]DU;W.K'HT$YT'TSFY177? M4;<;Y&.?*10 ^$UNM#:8D0AW/!&JX8&E" ;Q<5TUL.LRT]']"XYMJP M6?0VR(CGRMJQY@RL]'A6;9\&/*N=)1H43R\M%+=>$V,([8KF4A1*1&+=1T3[ M7V@7[+[IRVATZ])M3!W4Y1AXG5%!J@M%0>::$4(* MS[1^'/9,QH4U%;#B,K-00]D1SF1 M&,U[]=2KU4W31$CHT?1VC<;5FFZML46+%W&CV?:3TZFM;(%1INP@5, ; B1: M-.M92+.I#AD*D>,$S3;@9QAD6]X51'J06Q/+_L77>YI):X,YVJ>:7%IU@+G4 M.-*X[5S;9CV:;"(TI$G(P9ID-D>7C3A,#UVP.FH]IN6P*!U+=5&R >G*V[8]GPJ36;YN0-T] M&YP8B5">5Z\N&S+N"+%I[Q*,C-? QIXA#,ST.R MXCH;GP]:4F)R8A/>[6%84(.82=0.D?J2ZL.J[J6$]F1NKI6=:'6_V-X#K\ 5R[5MJV;69HE:%C5=;#M&[>@S#27", MR9E(39>T7PF#G>NZ0HT2581K"(^$0'&@=+_5E$[+:W=F#IGU$7/INC;$!],E MAL^J(_59LO98'8$<008NS>RC],&4Y"7#11'0 M\*;2#Z[;-Q/*MC:IB@/\BUI;4:NJ'%PJ('DSF*CWP-.=;;=#X^B$C]#8]E-F MH=DQ8TD+9FYN'-"&[UQZ[B2[)>(UD:V_HA"U0',B-;%:6ZHEC#:[8)U"]4O4 M!I7LO.S\N.@MDP]56FY4_1D*Z3^HG86D:=O2P:X#ZA23M;%2M_4C'3I(EMTC MB#!,/+N0]Z8;@+FRPP-9!QUB-QH<*%$FYEL1NL&F)J^2:\PPXOH"1"YX8*_8 MF@VFBR:U+8M.0T0T:F+-FVR<:/ LX3#K4FK.@6C%E&26O'$"/:H^A[YYX:V( M?+L)B-UG0X>L:#7I:NUJZU+NWK:-K7J!&:7"S>E*N[IUW?>I\=TJ=/OK_MLK M95L"625?V]DAR=6,UH*.KN*I"KG3R1I5BL*<9V-!?BP"<2OC^0V3@-UM>'KD M1C#>V%Y:+Y,!K2 TM(())K6*' >QQ!)QB-IK;\P)02EILD(;K&A3\I,VNVQK M,^B<9TW'AQ730FV/@OA0V0A!;!LM\"+$]MM(8]L)E!(]:?4#H/9O5]9-9%P> ML6>H;M#]/5O;NY8I#7K #60HSTRA[.V-"73GPZ5$.48^QX<8,AS$_#BR4#R\7F,F9J'$A,8UU6ZS@YN1 M%&[17JUM]MZ>],[XZ[]!]+-&+:TZ@+>8ZV*JVJT7,\/ MG=/0FT :5/'6*\QJ)"A*+S$J&A7!,HG"99^3I:"&Q'PX$2*X.A-$!WE6%C7- MJY^J#Y0AS@0W6-PO-5V4MI3;4>/9DC:6D5FV-+/E+2COT@@"RIN!:$Q*S?D8 M,F(\1K[+9%AR[V19D2[1KN&K#,-SQ3"+:NW;Y4]0]L,JV=7M.W/9(.]] V(# MH[9NK]+&A.UJU==C].$D;O8'K"Z!CA@741(2PMCP@X)">I\!\J&/3EJM.!I- M7)8QI?(T@NACR<4&(QT0%KFLB5AES2!K$BI)O-"!=:K#-&PS'U[X?.B.KN [+;K.ZS.KG?5FU]N8CY@$]&NHRNH>J\'P>3984D^1MEGK>"P35NF? MF8+'PWB&"V$R2EA%MD)PB<(G")PB<(G")PB<(G")P MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBM3T M$H^))"9Z&U3RLLB6V5E>CPCRDFW/<\;.;(/^1^-F(F._ZR6F2IQ,AS^F]A:O MP\G6==SC=A>;NK)?'UM+U>[R$'6B!P>?),J\.-7!YU:N#C>ZM:F\KSHUQKUN M*_";H=,1#E.QWY,1%7!IBR'X:9"(CS\=,'#3SL5,N4F.XXA2V$R9&&LIP\YA M4ZSOMG;RJ^M)4 M$M+AKB"6^1AT);75)&K0D:QH3A4TQ*^<[6>MR8R*%):^I M! /!F*(PA,ZJ 98R&07A.%SHL!^ Y%CS%X0C"I3+2'U80G&5Y[N/ UG U#G MYU-=Z.E)5S&PW2TNZ&UVLUCH,,L:X_9-:6T#ND"JO5*4H2E"$I0A"<)2E.,) M2E*<>!*4IQX,)2G&,8QC&,8QC'@QRJY"HM@K%:ML% NU5X'9AK#'C\N>#BIS-]*WF^F&[8H;!@M(RVU5%FZPUJ1;@LD->4:>R,G.$QK4VI )38\D]EI3Q""A\>M,2,E\W2DJ[5#I:7<&.+VAT&&=5YQ/\T6RN ;0)\\K MQ3OBO&-]Y7<5CPYY )::M)!S!(/!?2+!@QVZD:%#C,J#J16-B-J,#JO!%1L- M*A>0W1Z596!46QT^K'XP%UMX''-U\258#/,H;;:=%-3HC[8YUI#32&W(:65H M0VVE.<80G& !%#!%@P8@AWPQ$AL>&&X58'-(;&=9U2=9U3B:FIZSBJ&5EG0VP72\!T)A#F0C"AF&TBM"UA;JM(J:$ &\ MK[3:)1R4^25(TVJ$"DR#'&2R4VO")4^4-B/L28H^3,?AN2'X,:3&C2(\1UQ3 M#+\=AUMM+C3:DQK.^V.-<3B<3UE2Z7EWN+W0(+G%H:7.A,+BUI#FM)+22UI M(!- 0"+P%6DB!*2;AI(L+)A1L$W1Z7,/)@N3\->5+AI=2EW$93N6 M<.)PO".]C&>*FE*FF--FY?348'F)J-\H6ZI?JC7+0:AI=36+:WTK2JH[E&I3 MS(2,]3ZL['K,S)&ML.5\2MFOD%.YD*G!&E1,H$S%/YR]F5 3'?R[G+F5]_\ MI<:SK[S?<;S>,CFOGZWER(8,""1!=K0AY)E(3JUUH8U>8ZM]6T-5$?3[TQ:N MZ:6MLYUPP==);OW'<][[+/V@PL\=L6PKRJ%@Q+( MBMJ:B-(R\\IR\2*^+J:U*0V-AL % &MPNSOJ3B5PK,LB3LD3OK41"^T)^/:, MW$C1#$B19J8U?*.UB!JL 8UL.&T!K *-%Y60O/FNS3A$X1.$3A$X1.$3A$X1 M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A M%C!UL;KM/3=T?]3W4#1QX K<=*Z(VEM"K#+5%(S:T0/TBG%["*AGX8DH$*2A M$B; 9:(,#S N8[%4XB//BNY2\@I:*D#,@;RN>![M]^I8)Y4-MFA*+!O.GBO1 M31NH_6=?H^Q;/<\[!W;O/:%*VI&TW#C[!B^DH^YZBK6NMD=.T/+9J1Y1L*!" ML)*Y=],9@OIY,8@W$NI7(-K?U&H/4ML&M.T3,"^S8JG:!;O#4RY.[->JI>B: MTZ=%O2$1$[FV:%UOIW416U7FU9%$=B CMF!UK;MQEKI=:"6B/9V(U7@L $-D MBIJ\[5&-^/0*D]66*H1'M7W:UU"5;IFN'2)O2#LYHAJ6!N:'4'@VT!FG6-XW MFU4[79^28H+9D78JQ@964[ N)=^;65U:EEF%MPC-E$V6MA24NK4;<;L #YZ# MJZJZ\-$=NEN$=2R6PM_ZKC; XU9T\G$>J6M$*X(I5BVOM3J\K%CN^T[3/)V MEFG:H#UW057@9-NB9N(%K-Q8TIS,8\E\45W0P,#M=B1LI2F%]_GV+;9U%]HB M'T1J7IAV6 TW9]S$NJJ!+FT&HT&^:SPU'3"T-:M_R9+]Z(V-JBEPK55J1)IL M[7396"5QEJ=7?/;=87C^WIUB5"P/)^F'>,2]71?3F1U) M0YDZG%IM^IO4MI?86\Z5FWP4ZAOO%U:W[00*7TVD>E*R=$[9[6KNV-#:TGZ'VL#;W?$UV.G.&'1D.Z MZ:V+LW6%EVA6==;IH"V?&T$Y(&U4K$:B&+ Q8"D=K%H UDM4,I.**-4WFZ@Z M<;P+L[SC@IJZ#NTMK_7&8.A8VC=C:;EQM$Z6ZCJEZ9':-9,7;5>['[J-KY>% MBD'#.0T^*:H1R&X%->3%78;@^<]%@O2'H$8CFZNVMY':VE>\+7:9[3OKS1V< M5J[30(ST?XH%TC#WM-:#?UYMRP;)I*C/5)0M(!XUYM8W=849M,VS53-IEV^O MUVL:O= 71%?C0R!& T4'O%.JW6U;ZUO-;L-@I7B;E$^_>V'[0/I[N]4KUCUG MJ>4*#=/-*ZA]P.6WI&ZB=9%J]5[!U:6S1%AG6> CJ2V&0TC3ZY00<>YQ[F<$ M;44:(MI3#KR8Y^"/&%.H*5Z=44(QH"*7"M:TI=UK=_M7J"V*CK Z<.FG4[5: M6+MNG]U]2VUSAB*Y-FE=<:PGZ[H=2HU%DXGQ1XTU=]A[9 SBUEGQRC(:JUD@ MQ%'KF'(\\:5*7$Y$#?4^;THM8FK>UCZI0ZJ)6>IK1#E/OEEV'JAT^&&Z"V_0 M+$/I6P:WKNH$=8U/7NQKU@M:]B/=7&S W3IK';CUA$:EV0%KVR]JB!\@#K(\ MQ,*Q:*T:>(.%]:W4YHJ1>1<+ZK/+5_7$C8'4KJ,4,-5\OTP=5?1R?ZFM'6D@ M$F5&WTHUJ6VZ^KVS:W?,E"&6'!1H+MZEF!;DP<(F5@[7;<&FR2L>8-7!**7$ MY.H>VO@>"A[M1NT,W/T('M0)H%+UY>*_OS7.\*7K-FQ#+'(*R.KH5'HSO3O4 M99$5;P8Z71M@O6"QQC(9F)"/2U /&#+:&0M7>*6-#L32\98;=W;U5H%A;5.V M.ZM]K=#W6EU@:JU5T]NQ^E36.@&I Z[M[.##VMYR=*0MB]6U>E-B#1F7:(^K M;E::?2Z;2$RZ#,5W+"]9=D+?;@(<*=0:S6D^RXMK<>BHKGLN6PCJ'ZI^J#6W M4ET64/6$S0=\KO4;;]?!;AH/T&V!,WT)UC(ADB.\>HR/L =LEFH4[7&I86:^ MU#A636Q2/8#1%%<3;,G3(> T50 6DFMVW9T"E*U)Z?%;5>%5.$3A$X1.$3A$ MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$ M3A$X18G]2FT]2C!MYTQNO6MBO&OK=TV[FV3;(N1M:*TZY46C3J33KOK)<*=: M!Q>9:[&WL\ P.'RA,2KS(X3+L#J[-IK]KZ2+42A:WG&C=>-&@,YO7,L:DY13C)R>W"!2! M;CKD-;+@V"2I&VZ\XYB_ACVJZ6=1=#[&J[_HU%8T!G3FT;!9+5?=8.S*D_1[ M%8K<69/V$L_6WYK@N)+('X[!_OCH\-,0ZTV9@IC$TXEI!+A44I> M-F"C@=TC=FV(+Z^L W6G3U$/ZM>1RH-TG;''X(E%'53K,V.OQ0 ME#TXQ)BZJ#9(U.,)U]$ET: <+5!N'"9:C, 9SX]AIMG*4I4.1W%-87\X7XWB^^O>%$17I3[. M$U7%5(GK+IQD ?-.I D>(F=7([XT=H<$:J^FVPA.,59* 9.N*W9+ !JI +-@ M$!HH@ A5*E.:?P5_P!84"UDI- QR\A+Q1T2XU E2WX\6(VPH5WN4RBHQVSTI=RK>PY,E<)B>W!@2"5ZI]6MIEX5&@N&SX 63+JF MRHC3F%#D=Q37]]ATJ\MR=.W9]=0]_!;1WIK[IQVS?:V$%5H-8[Z[4;))BUT& M>(6@2#B-_HW(+J.QM"IOP81.K-UI+<"YZ^V>,$Q+MK2]02C1+!.IDBU9IMM M@J'.B30:T4\-/&EF(SA6$24.1W)K"E*B_IR_2=ZJE_H/1[M1%X3L.)IFV.;( MBT"%=)9:P '21J/JDY.L^LL**-E6B,!R@68F2LM/D"Y4*17K"0FG!;L8I*?E MK4.1W% X#!PWK&&\]$/1+L,L44>V$)A4C.DM9=-]-U16;AK:O:YUQHNA;,JF MTK1K2H!(@=;K8+=9:CU2M[<=*2R10I1@0^N5SGNYSA&4J'([BHU@,'4K<;]F2B(STS]GC8-96O3!? M7G3K+U3>ME&-Q7&@^6UEBM679]@QE)N[&!T8FRU-.$T9PW+D/=Y#C2&FO%X; M::2A0Y'<4#Z&NL*@4!J+AAW*VE]&_9G.6NB7IS5/3DNXZQ%5<'0;*HL%R8JP M>E%73E4&"YN3?CFX0$N\Z1'QW%.-LRG%N]U6$]:6LO:+1/>ZO_2'%#D=Q2HS&\)ZTM9>T6B> M]U?^D.*'([BE1F-X3UI:R]HM$][J_P#2'%#D=Q2HS&\)ZTM9>T6B>]U?^D.* M'([BE1F-X3UI:R]HM$][J_\ 2'%#D=Q2HS&\)ZTM9>T6B>]U?^D.*'([BE1F M-X3UI:R]HM$][J_](<4.1W%*C,;PGK2UE[1:)[W5_P"D.*'([BE1F-X3UI:R M]HM$][J_](<4.1W%*C,;PGK2UE[1:)[W5_Z0XH MM+67M%HGO=7_ *0XHM+67M%H MGO=7_I#BAR.XI49C>$]:6LO:+1/>ZO\ TAQ0Y'<4J,QO">M+67M%HGO=7_I# MBAR.XI49C>$]:6LO:+1/>ZO_ $AQ0Y'<4J,QO">M+67M%HGO=7_I#BAR.XI4 M9C>$]:6LO:+1/>ZO_2'%#D=Q2HS&\)ZTM9>T6B>]U?\ I#BAR.XI49C>$]:6 MLO:+1/>ZO_2'%#D=Q2HS&\)ZTM9>T6B>]U?^D.*'([BE1F-X3UI:R]HM$][J M_P#2'%#D=Q2HS&\)ZTM9>T6B>]U?^D.*'([BE1F-X7HB['UY.?1%A7RF3)+O M>\5'BV@'(?<[B%.+[C+4Y;B^XVA:U=U.>ZA*E9\"4YSA0Y'<4J,QO"O/D*4X M1.$3A%"NQNGK5&V;$U:+\%/&BC6N;WJ?#,?8.Q 0)VA;,0.3=PTJJUVUB:O, MD&EA@^QHL5E*EQ5*PS&C,M1V&\9[C+#3;3:4MH2G%W M$U%Y]BS;[T*H I@,3LZ2IC] Z/\ RJ>[HC^3Y6IS.\J:#(;@GH'1_@95/=T M1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE* M#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@ M95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5 M.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@G MH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T M1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE* M#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@ M95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5 M.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@G MH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T M1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE* M#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@ M95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5 M.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@G MH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T M1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE* M#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@95/=T1_)\5.9WE*#(;@GH'1_@ M95/=T1_)\5.9WE*#(;@OLQ2Z=%=0_%J=:C/M][N/, A;+J.\G*%=QQN*E:>\ MA2D*\&<>%*LIS^#.<<5.9WI09#<%84_U1&A#-9G2F9#R5SHL%J.TF,P[(5AY3)*0ZE2VVE>+PEE?ASE/>R MG&?#C(=%N6/1C2ZW)71^S9*W(,[-09B,U\[*R,*!";+P(D=PC.@VC'BM<]D) MWDPV$\$EM2T$D=7;&@EL6)9T6TYN/9SY>"^$PMEXTP^*\Q8C(0+&OE83"UKG MC6)>V@K2IH#+O-LK"TX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$ MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$ M3A%%6\=BR-1ZAV)LJ(-C%YE-JQ,U#'SI;@\8_,CM=V(HR1:8DNC 4>0XU).D MVHTEP<(9FS41WE,8:407D#-4/3FT#%UUL>M=N'1,&:==]Q48YFECC!(>>>U# ML:WT.09K 1.2YU3AY%6\LQ5F7SA(4:D2ZO'(GGX#9&<18-+L3U@&O2 E)VN5 M0QL7?*W%P]1;*DL,Y*[YV.9CLN.-U=3*9S,6Z5:76W9,_8%GPIV%*61ZSBN?/R$KY.,9F)&_:YN:@&*-5S+V!H )U8 ME:M6TM =*+&L.SYV6M.:?+OC3OEF!LM,Q=>'Y%C/9P(,35HX&XG'%NU>+PGV M_!W=:[CBKZUM*(VO- ]86AS6 M@4'L9:ZMYJTUH;Q6XW]K6VN4JVPK)9*)MX6$&Q#$DJ2>TUM%4>)'P*EHPZ[X MNJN.---Y5A;J\X6RTC#KCBT)3W^;"Y+^3#3;1K3.R[6MBR84M(P8=I>NIEMI MV7,ZIC6?,P)=C8,">C3!UHL5HHQD2&-9SC2FNL8TPTPT?M:P)R1DIY\:8>Z5 M,*$92CO-/-Y4VXE6=VVQRI\F>C]I3 M5CV[R@Z%V-:TDYC)RS+4TFL:1GY5T6%#CPVS$I,SD./!=$@1845@B,:70XC' MBK7 G +/T*TQM63@VA9FBND-H2,R'.EYR3L:T)F6CAD1T)YA1X,N^'$#8C'P MW%KB ]KFF\%>'[_7IA^&YOY/-A?5CG6_3LY'/]ZG)Y_WCH__ (]*W8XTS.&C'G!.J=GST-$3"I"!,!Q<6I.I1,)J MB2DP(RLX=EJCO880O+:_!E.CFFNA^F#9U^B>E6CNDK+-\A]$'6%;-G6J)'UT M(QEO79DIB,)?RXEI@P?*ZOE!!BZM?)NITMKZ.V_H^99MNV):UCF<\KZT%IV? M-R1F?(^3$7R F(4,Q?)&-"#]36U?*,K36%;>^_UZ8?AN;^3S87U8YBWT[.1S M_>IR>?\ >.C_ /CUW7TN>4#]Y.E?] 6I_A4^_P!>F'X;F_D\V%]6./IVV#+6#&C1Q;\Y,2D$0V>MS+#6+XA<0[7I_*4]W1MG2I2/#GO:5VS_15CN_]]*<*QWL^!7@0VXM"LJQ MC+S>/PHR;Z'\G-36VK5H#L8Z\7X'Z'#"X5(K=75-X."&V.6\CFZ*Z.@EIO=, MP+C[YHMX[*T#7N!-*O;4EM7KG4QU#2#P%JR:6N,"O/%QS)^7$TCMA<^*(7-9 M22DQV$-3$X<:A>.<9\7F>[ESP>"(YE*6W.-.2&@;)6:=)6O:,6;;+QG2D.(U MPA/F!#<8,-[S9\.K71-4.UO)-I_G&@U'.LRUN6"+:-GLM31JPI>S'SLK#M&/ M!F(#IB#)NCL$U&APFVW'&LR!KNAAIF'EW^9>0&ND"T]H'TJ4>9%'7+81.JSY MT-9&%"L-"OX>5+@-DB =R;&8GUIAQZ*@L)*#%OMI4TF>.G1,JP_%>0CI;*T1 MTIMR7?-V-H];-JRK(SI=\S9UG34Y 9'8R'$?!=%@0HC&Q6PXL)[H9(<&1&.( MHYI.5V_RB:!:*3L.SM)],]&-'K0BRS)R%)6U;=G69-1)2)$C08T-Z3+?,D#JKLF;9)\0?**RH8.BWTI*C# M(.$9F$'V(5;><:A1<.-YD25I2RSWT>,6GO8\/7VGH=I78LJ9VU]&[;LN3$1D M(S4_9DW*2XBQ*^3A^6CPF,UWT.JW6JZAH#1=Q87*3R>Z3SXLO1O3?16WK2,& M),"0LBWK-M&<,"#0Q8PEI29BQ3#A!S?*/U-5E1K$57C-=H]T>5PP5K]@VLL( M=!D9H@T&*TV\0"8DJ.D.0R TC!DUUJ3#G0I;+L:7%D-MO1WVW&G4)6A2<!-RFB.D4U*S4&%,2TS+V//1H$Q C,;$@QH,6' 2GI*;TFL>7FI.;E8KH,S*S,O%F MV18$Q C,?"C0HC6OAQ&N8]H<"%3/])OT2^VF'[L7'Z Y]OI<:?\ [R]*/Z#M M'_#KB_3JY'_]Z&@/_=EB?XU2'3NMSIXV'&Q,H5CM5SB*,-5Y,FKZQV4=84>> M'RBS(;#HVJ249*.BX4PBW!PKRE<*+(DI;RRRXM/16MH_;E@Q84&V[)M"R(T> M&8L&%:4I&DHD6$':AB0V3#(;GL#^:7-! =<3599H]I?HKI; F)K1;2.Q=(Y: M4C-EYJ/8EI2EIP9>.]GE&P8T23BQF0HKH9#VL>0XMYP%+U)?KUJOP4W1\@FY MOJ/SJM4YM_EL_.60U'3N/@GKUJOP4W1\@FYOJ/QJG-O\MGYR5'3N/@K*M_5[ MI/7S/E-[F7RFQ\L8D^/L^I-I V?)E2F(.'_&$JA&1XG,V5&B8<\/4K:1GP^!Q:O@9^2&,U %+[XC?'H*_?^D5Z1.^EOUGR/&+:R^AOT M)O7C%LXQG.7D(]'.\MO&$JSE:<93C"%YSGP(5X'KF6_=,OG^WPOST]?R5:>N MH%2*@>4;4C/'!>/;?:3=&N@\B\;PVXG4&3D\N*#>LJHW6E>=2=?A@B!T>.]( MJ\/\LF!X-HK@Q3P=^2AMLC$4[>)$APM7RL6%#UZZOE(K&:VK0&FL MX5H2*KZ19J7@:OEXT.#K5U?*.#-;5IK4UJ5IK-K3"HS4,?Z;/LMOUQ]4_MT_ M^1Y\_74K^ZI;^<0?SU\?HE(?NR6_ZS/%752.UY[.G9EM 4+7?4Y2[U=[40:$ MUFH5*(?L-EL!1_"LLC@P44)E$24UW"%Y;BQ([KR\)5E*,^#/);,2[W!K9B7< MYQH&MCPB2<@ ^I5F3\E$%%A$2:U%*"YD0B/?6SAJ9!DL2F% M.,NMK5+X\"&XLB1X#'BE6OC0FN%145!<"*@UO4Q)Z3A/+(LS!AO%*L?$:UPJ M 14$@BH((S!!5G?Z;/LMOUQ]4_MT_P#D>5]=2O[JEOYQ!_/5/HE(?NR6_P"L MSQ4I:M[4+HO6J_!3='R";F^H_/MJG-O\MGYR^]1T[C MX)Z]:K\%-T?()N;ZC\:IS;_+9^LX>EQ MU::W$'G$;)FME9D..+EYIK#S4R.B*[/5(C+P[!C1'Y^5-MQEN(X5I09F-9MH M0I0TFHDC-0Y8MCM@N$P^!$;!+8H>TPG"*6TB!P+#1P(I5R%],5_7%=4ZO#A0;J5SC MO=S.6JWMS*^ZCN]V2VMX?CP2'NXM+C*\>(8PXRIA651O"J3HSRAX^7GL:4&D M$$D 7AP)G!5[C76:[F %NK4LJ8%MZ'C"%+9WV4^E36K2&RWL6U%".N=C#/$'#, FF"W.*D*TF-(E&'ZY8L MP'_*7,EUH$W!L*P[-B:0VA*V>]DO+2TQ,6C/2T-CISR-7PW M3+XWDHL4ECS5KW%X:Y]3>5@CY2/:]JSL.Q9*8G0Z+'CPH$C*1XCQ+>4H(@@, MAE\.&-=@O: PN:VZX*W?]*?T(>WP)^X[5]"7."6MB&##>&%P:2T.H2 :8*Q/]*?T(>WP)^X M[5]"WPRBNTG:R M[<>\MA0HSWN#&- MC]NR$!\U/6-:DG+0RT/CS,A-0(+"]P8P.B1(36 N>X-:";W$ 7E?"R]I/T:4 MPU+K=NVZBL6 >F(N<$/U&ZB2L-!"%&)05R8$ZO,2F$S!TR).BJ<:3A^))8D- MY4TZA:JS>E&C5GS,63GM(+%DYN 0V-+35J24"/"+FM>T1(46.V(PN8YKP'-% M6N#A<05,KH[;\[ AS4G8EK34M&!,*8E[/FXT&(&N+"61(<)S' .:YI+2:.!! MO!5"_P!*?T(>WP)^X[5]"X1XI4-FO6$354#7+28%4V\31-:;,R78099\E'KKD00DM.9V,7""9R4F)812S5+Q#,:&S7+-=NMJUU M=9M<0LT.=FNO3A$X1.$7EGP()2#,&$X<4B-(Q9$ @/GQV9<&?!ELKCRX'/"*+=#?B78?CHZBOG]V5RSL1\% MGX#5 P[3WE31RJE?&1'CRX[\64PS)BR678\F-(:0]'D1WD*;>8?9<2IMUEUM M2FW6G$J0XA2DJ3E.S*KS$-$ 8_B&U'8J(!EIF M*F.QXA#+*6\--MM8PAM*,-IQC"?!C\3?5361:TSR]\H<>7LNT9B#$G;&+(T& M2F8L)]-&K%:2V(R$YCJ.!::$T<"#>"OT9Y$YV3AT0YCX\) MCFUMFT2*M<\$5!!%1@05CAZ/GOT(7_=LS^#SS_\ 0"W?]BVM_1TY_P"%;3^B M-G_NZ3_G,'\];/>SLK_?&;B2<"=[Q,S7Q >DL-\/BB$%JZ+CS86)C.?%S(;B MTK9DL>!Z.M:5(6C*L9S^C7J"9">D9'E;$[)S#&U!I!K^2BLB:M8EATUM1QU:T-*T MK0TP*UA>CY[]"%_W;,_@\_.7Z 6[_L6UOZ.G/_"O6_T1L_\ =TG_ #F#^>GH M^>_0A?\ =LS^#Q] +=_V+:W]'3G_ (4^B-G_ +ND_P"../@1)$ M^7$@PXLHK(:EE),>,RS()2V(<8V/_ %AT MJ6H_GH=>,5L^[(L? *]7<<<4@PR0^9K*]LRX$^,S,A2F5-C.\U)BR$.,/M*\ M&.\VZA2,^#'AQS1/JBOK<1?X:LKOCKUGZBWZ]DM][%O_ ($JL2.KK\JSJ6^/ MO;O^?C_-C.9@M;+I [$D? G M:EV\[-@PYCHS:@4@.>OT_P#4&>XS3K[YY'\E0UO(YYA7O%.$6NOM.X(K M'3&8+OP8&2K%GJ,&(36-9E%68CIA$N5"@S.[B1&9>\EP]+;PYXEYAEQ.6\OJ M96CK[3-)1_PV9Y]%_H1M756S02+R?]9"Z_9;-N%<-E5S6-]S*<,X5'PX\]Y7 M,6PVXI7<1A+V4+(*5A,IU3>&$.0G.[_04PI&,8E=Y>,5P!O-2XT)Q)K>3MPK MOK0K# $Y9>?3%;\&,/Y1F*U!I]D020YV6VXT)%-FKAF4!)! O+R#< MXBHIB3?JFE+L#3"A57^ZYQ\""(Z!'8<&+#=)%.J @2DXIZQ_P"9_P#KKBWY MCZQ1;,.QM_VHW1#\>U:_]B?SER'MR6^-:N?9?U1D_CV=ZR.^Z*A\ 5VLW4&- M%P88T="JNAX\.! C,PX41AO1FOL(8C18Z&V&&48_ AMIM"$X_!A..?:U?;T; MJA_),7(MWZJ3'5!^0AK2#SKEU"ZLON3@? *=6'4_")P89&&OIU%NKB3HS,N, MMV+M6FRXKBF)"'&E.1I3#,F.O*,J9D,M/-Y2XVA6.ZL/VQ%^)_MM62:->VIC M[G_O&+OFYDRS1.$7CD#X$N1 ERX,.5+%/NRAD#9+\20/?DP'G$*<0HB]G")PBTN=N8/@-=((DHU!AM$YV[->0II%N M,RB=,ACJSLUX?$E2THQ(D1H#I(B["8=<6U%]U4Q_ TW^-2*Y&N>1%Z;5W:__ !\I/^+JW_UF%SER'MZ2^ZY;Y9BX ML][2G/N68^2>M[W;[#X ^\=.*8$&'!3,K^T"$O$.,S&Q*GRS=3FK8DMAF5$E5O:D:5%DM(?CR8[^M+0T\P^RZE3;S+S:E-NM. M)4AQ"E(6G*\J7N+M/XZS_Q^75B]J4PQ%Z]>H2+ M%9:C1HQBF,1X[#:&6&&&=9TIMIEEIO"6VFFFTI0VVA*4(0G"4XPG&,P6 ;01ZK =E""+$%FA-/9F M!SHV&7%R\QB]]EQ\R1Y!F1$?S'E,,R6?&LJ\5(9:>1W7&T*QZ)]3][9TH^(L MGY2T%HWEK]KZ/?'6E^!)+IWYZ76@4X1.$3A$X1.$4+Z&_$NP_'1U%?/[LKEG M8CX+/P&J!AVGO*FCE5*<(G")PB<(G")PB<(G")PB<(G")PBYS>>Z?4S^X&TOOKM#\E6(OR=]7/\ 7>L+^+VQ_P"L.E2U"<]#KQBMI78^ M?ECC_BWO7_M#.:)]45];B+_#5E]\=>L_46_7LEOO8M_\"56'G5U^59U+?'WM MW_/Q_FQN3WW!:$_>GH]^291:5Y9?KN\J/\8>F?\ 6*T5CQS,%K9=)G8?_P!D M.[/C(#?Y88YXM]5![HM&?X%F?QYZ_3_U!GN,TZ^^>1_)4-;O.>85[Q3A%KY[ M3IA4CI.LF,9?PVBVTE;_ (I]#"/%>>FV\8D95X5.-J><:2TVUC*\S-FO#KU:PROQIA0UVTJNIMH5D'C9Y2%7^6.WJIMILJN:%?CG6DR M5*DXR24AEAQ>$QX[<7#O@[K,%/\ K("U(RON375)QG*EXSC.(B+SXQ3@QA.5SV\'@ MSG./_*=/']6<_ASC_P#.?PYYW%N82G_&_N5WFD^$A_S/_P!=<5G,?6)K9AV- MO^U&Z(?CVK7_ +$_G+D/;DM\:U<^R_JC)_'L[UDU]T<_[7+J,_PWHKYC=?<^ MUJ^WHW5"^28N1;OU4F>J#\A#6C7G7+J%U??ZJ8_@:;_&I%7_ZH:-_<=H_ M+2RTUR*^T[?^Z9#Y*97//SSVMWK:!V.GY?FIO[AV?\V]GYM#D<]WUE?<]I_D MZ96O>5+W%VG\=9_X_+JQ.U2_+\ZBO[]J'S;4SG Y5/=_I%\?)_DV27,Y.?<7 M87Q,U^/S:U]!!.V2Z&[M4U3M;MV=YBSJ"-P"%9*G90^!%*;N(W7U MQIQ60W3]:;^;T]-/VWTGN)N);MOQJI.L( 31K=>Z4 V-C#TP5B:6OFP(M2.MQ-'W(FTO;>^) M*Y$>UZO8;:DS-V[ ES1RD3KM&>4^)EO/BY3S;:H/ M8LS^U'0J N^UVG:,RI;]8NR?U?KS[XZC^OW*T&8X^"FKOM>(3UB[)_5^O/OC MJ/Z_<4&8X^"5=]KQ">L79/ZOUY]\=1_7[B@S''P2KOM>(3UB[)_5^O/OCJ/Z M_<4&8X^"5=]KQ">L79/ZOUY]\=1_7[B@S''P2KOM>(3UB[)_5^O/OCJ/Z_<4 M&8X^"5=]KQ">L79/ZOUY]\=1_7[B@S''P2KOM>(3UB[)_5^O/OCJ/Z_<4&8X M^"5=]KQ">L79/ZOUY]\=1_7[B@S''P2KOM>(3UB[)_5^O/OCJ/Z_<4&8X^"5 M=]KQ">L79/ZOUY]\=1_7[B@S''P2KOM>(3UB[)_5^O/OCJ/Z_<4&8X^"5=]K MQ">L79/ZOUY]\=1_7[B@S''P2KOM>(7-EVOYHV=ZG*E+/T\M29C>DZO&;%&" M5<*29$9%TV(Z@@W(K!@U 0PZZ\]&2R]*;F)Z/4T>X&TKZ_^ MZ[0_)5B9K\GO5SU^F[8513_\>V/_ %ATJ6JOGH=>,ELH[*,N8"=6D":#JI.X MSO5_=&L!A) ",EY9<:'>,E>4V,J'&X:8[J>^WY9X]??QXIISP*[NB?5%?6XB MWT_RU9??'R7K+U%WU[):@K_[8M^[_P",JL4.J>5*F]374-,G#9 :;+W=M.3+ M$2WX4F4+DOW>@RY4-UQM2XTAYE2'%;&Y/?<%H5]Z M>CWY)E%I;ED^N[RH[/\ \AZ9_P!8K14#X6*_K2PWAA_ M8 AV1-#'*4*9A/8KC*$Q7FK19 DIUU:,8=PY&8>8PC.$J=PYX48\7>J?]T6C M-X'^19G/]W/R"_3[U!I/ZC-.J"O_ +GD=H'_ .JAK M8:#,\*N^UXA/6+LG]7Z\^^.H_K]Q09CCX)5WVO$+%CK%JF[^H72T[6M3 MT4;&F)MA E6R5ANFL$0H3 F0[(?6UB!>)#JI;Z,^1MX6RMI#4E]W^@\VRO'$ MG)=TQ ,)CV-<7--7:X% ;_8M-:X7BE]=BX-HR\6;EC!AAK7%[':SG4 #34X MUJ+J4VUV+4ICLUNKK#K^4:T"MIRCN,O>GU,%&$*5,6JP(PO"L=Y.&F4L MX3WG%8<[S[N>=/\ 0>8_UDO44H=:,>W]K%.H=)J*KH?H%-U-'2XH &GRD0GI M)YE;KP!6E23=K%?1OLV>KM"VN[KD>PEKO*PZUL2EN2>/9PRQX4- MJ\C0RM*\-^*4^EMUS"9%CS /[9+W>^C&IIMK#N'$TK6\A/H%. ^R@ ;(CR2 M:4O)8*# @#':;R%K]^ZQ+%9SHGH);L>O3U%S"D=2N(JC1FG%L%5/1M!)DIC8 MJEA.YCJ@^(9R_P"6XC(=\L:\D4_XN1XF;=%/6E]?V_/_ /AS32>O[!!&R9OK M7]SKC>YCZQ5;'.R'FSAW:8]%TX:'EV"?&W?7'8H6!)&PYA%W#,[&(T>47F#Q MC#BL9SG"YLV,SC"<]YS&LD?NA4F4, M=JYU"3S-;(5(@[7M))>!%)P4C-BI:TI0FF7')=?)%A3B932$2FL,3G5MMNH0 M^EI]+C2/M:WM^-?6Z%\DS.B^]N?5.8J*70;O^!#6E+G7+J5U)?)#_3U$9?A!BM8%/0F<;(JJ\2WG;0;"1G6E+2EG#<5Y^1A:TJRUAK" MEI[NP_;$:^GZST_;MR61Z-5]=3%!7]CYT_SC%W/^L79/ZOUY]\=1_7[F34&8 MX^"S.KOM>(3UB[)_5^O/OCJ/Z_<4&8X^"5=]KQ">L79/ZOUY]\=1_7[B@S'' MP2KOM>(3UB[)_5^O/OCJ/Z_<4&8X^"5=]KQ">L79/ZOUY]\=1_7[B@S''P2K MOM>(6HOMI[=<#?2,!A'=56:F0L;JIS^#!>P4(G$5(;K-Y0W!Q&K=I,DXR7O!_R](Y_N2T+[QV=JVMR/$_JJF*BG^1I MO;7_ $J17*ESR&O3BNJBK6W=ZDONN6^68N+/>TIS[EF/DGK=[VZ=AL9^Z].R[# M0CE%7&JVP$Q631>IEED4NEJQEU;"JJ>.MLXBJ0A#J9BXZEY>1EC#J4N91OKU M0 M#1J\']AVCA7_ %TKF!BM,\BE?6=OU%/V3(;:_P":F5H8YYZ6\%LC[)[^R?N>U.S_)LRM>\J7N*M.@K^O6==_S\NK)[3,@1*]O:BTVE^6#GDQ3V7VFVY2,Q)S^$MOH0[EM]+K2. M!RJ>[_2+X^3_ "9)+F/@8Q-RRMM2YF([64.*]%>I^ M]LZ47T_6+)S_ -9:&0*T9RV>U]';J_KUIY?:26:ZA.>EEH).$3A$X1.$3A%" M^AOQ+L/QT=17S^[*Y9V(^"S\!J@8=I[RIHY52G")PB<(G")PB<(G")PB<(G" M)PB<(N7+MJORK:7\0U3_ ,][-Y[I]3/[@;2^^NT/R58B_)WU<_UWK"_B]L?^ ML.E2U"<]#KQBMI78^?ECC_BWO7_M#.:)]45];B+_ U9??'7K/U%OU[);[V+ M?_ E5AYU=?E6=2WQ][=_S\?YL;D]]P6A/WIZ/?DF46E>67Z[O*C_ !AZ9_UB MM%8\\4X1.$3A$X1<8/W7S_P"F]G[_ /W=4?\ R_3US'[=_P!%_P"/ M_RC7HB$BHLN3Y4ZZ; M8<;SEK#6$,N]Y>%91A6"BDWIC8,*R9.9EY2,RT9><,6:$4PRR#!F8;F#R M3'NUB8[2+J4::G!9EH/I++:*VQ$M*:EX\S"?(QY00YX.Q@#3^Z=2/,B#8HH\RU$N.'76A\YB6XVWE87",..(:RE&5 M9PGO9QWLXQX>?:6Y"+>@3$O&=;5D%L&-"BN ;.5(AQ&O(%8 %2!05-*KXS'+ M'8T:7CP195I@Q8,6&"72M 7L5+W%VG\=9_X_+JQ.U2_+\ZBO[]J'S;4SG Y5/=_I%\?)_DV M27,Y.?<787Q,U^/S:U]D.2'EBT;Y/]&9NQ;8D+0BP! CR5G2S6.=-6E*1 M!%#Y2(7 0BP-LZ'8]IV>8%C3MLQYTQIUL$0G"'/ M6%9\#R3?)N\H3,!XJ-5CKZ:,>KK\JSJ6^/O;O^?C_/4O)[[@M"?O3T>_),HO M G++]=WE1_C#TS_K%:*QXYF"ULNDSL/_ .R'=GQD!O\ +#'/%OJH/=%HS_ L MS^//7Z?^H,]QFG7WSR/Y*AK=YSS"O>*<(G")PB<(N,'[KY_]-[/W_P#NZH_^ M7Z>N8_;O^B_\?^Y6)Z4?Z#_S/_UUQ2\Q]8FMF'8V_P"U&Z(?CVK7_L3^SO637W1S_ +7+J,_PWHKYC=?<^UJ^WHW5"^28N1;OU4F> MJ#\A#6C7G7+J%U??XNT_CK/_'Y=6)VJ7Y?G45_?M0^;:FB?4_>V=*/B+)^4M!: M-Y:_:^CWQUI?@22Z8.>EUH%.$3A$X1:V^H36?4A>+=E%9!6EHR*TS?XGK8UG M=XNO*M=K#88-P&A]5R*J:W5*LE*ACPDAJ8B[#@!B?/VH5H5FC6.DA*"3S**U MU#W&_#L\+KMJR=Z?JI?JAIZ:$,Q)==/O6[;YBEUVXF$7&12:K8]C7 YK.K'B M0>Q&&)\>N5@B!A.AP=IGCP(]E%5 F71HB!+R53Z>/ICT*Q-+1-ZJJ1W(NP:E M:C8VWOA+R9]/N,A]1%.[=@)+NMN1[S%;3">*XF/#6%-K?C#UQH\F1+DM.RGO MH[5K]E[%N7VH5!K>]Q.>94M^1=0_PETQ[D7C[0>5YGON"GG^]XIY%U#_ ET MQ[D7C[0>.9[[@G/][Q3R+J'^$NF/*>1=0_PETQ[D7C[0 M>.9[[@G/][Q3R+J'^$NF/*>1=0_PETQ[D7C[0>.9[[@G M/][Q3R+J'^$NF/*>1=0_PETQ[D7C[0>.9[[@G/\ >\4\ MBZA_A+ICW(O'V@\/M!XYGON"<_WO%/(NH?X2 MZ8]R+Q]H/',]]P3G^]XIY%U#_"73'N1>/M!XYGON"<_WO%/(NH?X2Z8]R+Q] MH/',]]P3G^]XIY%U#_"73'N1>/M!XYGON"<_WO%/(NH?X2Z8]R+Q]H/',]]P M3G^]XIY%U#_"73'N1>/M!XYGON"<_P![Q7&OU38)IZFNH9)IR"\83N[:>"KH MMF1&&ND<7@YB:X/CRWY4IB$N1XQ45F3)D/MLY0AU]U>%+5^GW)[[@M"OO3T> M_),HOP:Y9/KN\J/\8>F?]8K14#R V68^&>[A2'FGW%.>%6%I3X$\\7>J?U?U1:,UK]19G" MG[N>OT^]0;7]1FG5*>Z>1QK_ +*AK>8N9[[@O>'/] M[Q3R+J'^$NF/*>1=0_PETQ[D7C[0>.9[[@G/][Q3R+J' M^$NF/*>1=0_PETQ[D7C[0>.9[[@G/][Q6ICM2.R,OO:D M,:0C[%WK4-:HT@[L9X.NEZ],RU&E;'11T$$DL'+C.PVD=BBPLP\Q#@3TC#G?)5>]GD]>E TUU]6M:Y:@IUE=9:-F"TO(^4C&%Y'RE-1H=K M>4\G6M2*4U.*U'?_ C0[]!6,>'GU@61"@QH<7RT1WDW!U-5HK3I7WEM'XTEY7(K<$@-$+;SI2A9B^3PR9 M$K,:6F+XE,CQDYY*Y&'%M]QM26T]1:U/7\:F%(6/Q3%CUN5^B;D^ M/\7G+KTAUKQ6%IPUW\I4GN[#IZXC5K^T[/AM61Z-5]=3%*5];[?C&+N?\BZA M_A+ICW(O'V@\R?F>^X+,^?[WBGD74/\ "73'N1>/M!XYGON"<_WO%/(NH?X2 MZ8]R+Q]H/',]]P3G^]XIY%U#_"73'N1>/M!XYGON"<_WO%/(NH?X2Z8]R+Q] MH/',]]P3G^]XIY%U#_"73'N1>/M!XYGON"<_WO%/(NH?X2Z8]R+Q]H/',]]P M3G^]XIY%U#_"73'N1>/M!XYGON"<_P![Q7.-VZC-_9NO3OB^$*>0=S5M@9&K MJ(8T';;;P6K'E*9S9DZ<4\M2_$Y87'=82E.'<.(7G*%8\Q>J I]$-&J5]IVC MC3_72R]!>EO!;(^R819G.N75R*A*!0SV0FQ_)9% MD@D"0A#>-?6/,KRB&,(BICJU1O&IC^+G,I0_EM;F%MI4A6T.1SW?V37#UO:? MY.F5KWE2]Q5ITQ\M9_X_+JR>TS0?;ZY=_(M$@/*/)-U7!"0 AS8 AU7J]J.6 M,PX9&<2F,)Q%\0EU+\Z1G+^'5(7AM2$)X'*I[O\ 2/X^3_)LDN9R<^XJPJX^ M1FOQ^;6"7-?+-ET"=@LW;W+?U&YK4RMQ8*0NLLG$'1I2?+?3F3?L#L"G(!4: MS%4W(\:N:J8U,PZSXMMA#*^\[ST5ZGZGKG2FM?VBR,/C+0Z%HSELKZWT=I3] MNM/'X$DNH3GI9:"3A$X1.$3A$X10OH;\2[#\='45\_NRN6=B/@L_ :H&':>\ MJ:.54IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+A^ZNORK.I;X^]N_Y^/\ M_4#D]]P6A/WIZ/?DF47X,5'^,/3/\ K%:*QXYF"ULNDSL/_P"R'=GQ MD!O\L,<\6^J@]T6C/\"S/X\]?I_Z@SW&:=??/(_DJ&MWG/,*]XIPB<(G")PB M<(G")PB_S,?NCG_:Y=1G^&]%?,;K[F(6K[>C=4+Y)BU];OU4F>J#\A#6C7G7 M+J%U??)', M0QXD)X'*183W M^N9:++@A[HSVC5,0.-6FH%+EC>EG*;+:26'-61#LF/*OF'RSQ'?-0XK6^0F( M<<@L;!83K"'JCG"A-;UI$[5+\OSJ*_OVH?-M3.:1Y5/=_I%\?)_DV26W.3GW M%V%\3-?C\VM?7-?+-ET4?<_/XR]4?]QZE_Y_87/1/J?O;.E'Q%D_*6@M&\M? MM?1[XZTOP))=,'/2ZT"G")PB<(K-*;%U\#/.U4U>Z:(L\>MS;D_7"EG"#SS- M0&J=01M3H>7.:(-UN MA],TXN.D7%4RZE^4WEM>,$58KMDKMO"C[+4CX6T5T MLRJ0*/UTK!-A2;"'7&%O#RHQ^3!F,I>:=94Y&?<0EUMQO*L+0K&"*,=#?B78 M?CHZBOG]V5RSL1\%GX#5 P[3WE31RJE.$3A$X1.$3A$X1.$3A$X1.$3A$X1. M$3A$X18T'^C7I7M1TS9['H;6QFP6(J0.'"\^NQ7YQ0N5E.SB)&8\K^D]*FS' MWI$AU7X5NN+5G\.>9M*M6T^3W1>>M&TIN9GY^=F+,@Q)B;G)N, M^8F9F/$-[XT>-$?%B/-[GN).*I'WB_1]^KIJOW8BB/\ 1,!3'K33>K--#R0K5=#K=#&F)C9 I"K8YH='GS66,1FI4EMK M\#CR&$X:2O/X<(QC',LVT6T)T2T)EYJ4T2T>LO1Z6G8S9F;@67+,EHV(OQ/]MB MR31GVU,?<_\ >,7>US)EFB<(G")PB<(G")PB<(G")PB<(N'SM4OR_.HK^_:A M\VU,YX@Y5/=_I%\?)_DV27KKDY]Q=A?$S7X_-K7US7RS9=%'W/S^,O5'_<>I M?^?V%ST3ZG[VSI1\19/REH+1O+7[7T>^.M+\"273!STNM IPB<(G"+ 3?W2) M?MU$*^VK:O?B5FK7^"Q8[A'<,DCY.XU6Z5Z&(L&O:O$I>L&1HR79 [C]YKP< M-L.?20YK64J>\(NMB,/E(-.'I7S8;=BR.U!K W0]<':N;W'ML^(>6!Y"D(8=6/W;L""Y/+A[%F?VHZ54#I.)RS/0I;]41KVX[H_>5 ^SSE:C('@GJB->W'='[RH'V><5&0X^*4.9X M>">J(U[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./BE#F>'@GJB M->W'='[RH'V><5&0X^*4.9X>">J(U[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW M1^\J!]GG%1D./BE#F>'@GJB->W'='[RH'V><5&0X^*4.9X>">J(U[<=T?O*@ M?9YQ49#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./BE#F>'@GJB->W'='[RH'V><5 M&0X^*4.9X>">J(U[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./B ME#F>'@GJB->W'='[RH'V><5&0X^*4.9X>">J(U[<=T?O*@?9YQ49#CXI0YGA MX)ZHC7MQW1^\J!]GG%1D./BE#F>'@GJB->W'='[RH'V><5&0X^*4.9X>">J( MU[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./BE#F>'@GJB->W'= M'[RH'V><5&0X^*4.9X>">J(U[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW1^\J! M]GG%1D./BE#F>'@GJB->W'='[RH'V><5&0X^*4.9X>">J(U[<=T?O*@?9YQ4 M9#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./BE#F>'@GJB->W'='[RH'V><5&0X^* M4.9X>"_S?/NA4*_7^U;ZA!4@^=LSS%>TDM1FR/#WR\GQ^E*$_A$AP6-$P'<):CLNX M=0C/CN[C*%=W89I,1K@?UG;\-JR31KVU'OI^Q]GQC%W/>J(U[<=T?O*@?9YS M)JC('@GJB->W'='[RH'V><5& M0X^*4.9X>">J(U[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./BE M#F>'@GJB->W'='[RH'V><5&0X^*4.9X>">J(U[<=T?O*@?9YQ49#CXI0YGAX M)ZHC7MQW1^\J!]GG%1D./BE#F>'@GJB->W'='[RH'V><5&0X^*4.9X>">J(U M[<=T?O*@?9YQ49#CXI0YGAX)ZHC7MQW1^\J!]GG%1D./BE#F>'@N,SM,A+H/ MKEW\*?-&+"[$-U7"S)]V$\7FY=U[47\+F.#H R$I36'<,-8CP8Z4L--)RE2T MJ<7X?Y5/=_I%\?)_DR27KODY]Q=A?$S7X_-K!+FOEFRZ!.P6K\@U;^HV4Q9[ M( 2,"ZRR[$!/BVHI?$R3?F4(*H(B23KB8*D>/A9AO0E(>6O+RGVE>*QZ)]3] M[9THNK^L63\I:&2T;RV>U]';Z?KUIY?:268*ZA.>EUH%.$3A$X1.$3A%"^AO MQ+L/QT=17S^[*Y9V(^"S\!J@8=I[RIHY52G")PB<(G")PB<(G")PB<(G")PB M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB_S,?NCG_:Y=1G^&]%?,;K[F(6 MK[>C=4+Y)BU];OU4F>J#\A#6C7G7+J%U??B?4_>V=*/B+)^4M!:-Y:_:^CWQUI?@22Z8.>EUH%.$3A$X10IL MKJ)TYJ \.K&PKB@&?+52TW6"+8!V4]*=KM/8;D%I*TUT,6Q'FR\+(B2<6(4T)[/.KXH%_JVSJQ&N%-FS)P222L07*B(4W7"<(U4;& M6J%H#E0-D'"3H@J!LP(N%)0"8Z))CS8#Z,MY1A"U%"LK0WXEV'XZ.HKY_=E< ML[$?!9^ U0,.T]Y4TBOF-U]S$+5]O1NJ%\DQ:^MW MZJ3/5!^0AK1KSKEU"ZOON2G\KKJ=_P"'&'\YM2YW5B>V(OQ/]MBR31GVU,?< M_P#>,7>US)EFB<(G")PB<(G")PB<(G")PB<(N'SM4OR_.HK^_:A\VU,YX@Y5 M/=_I%\?)_DV27KKDY]Q=A?$S7X_-K7US7RS9=%'W/S^,O5'_ ''J7_G]A<]$ M^I^]LZ4?$63\I:"T;RU^U]'OCK2_ DETP<]+K0*<(G")PBPKV/T$Z)V+8(5L M=E;0J]F'C2(^(5KVU+K+CH6^.L$4'/>K5N*VFGS)5-*68M9ZPS-KLD8Q8)"Y M)0>4B.R(3Q2#3+=U'S+(/7VJ E U_-U\DH.;2M]DO M%SGOO5B!7H([RP[:R^8# 2",:$P M_=_^M'&N[/@/!-1N7$^*?>_ZK_0AKW[O_P!:.-=V? >":C_=_\ K1QKNSX#P34;EQ/BGWO^J_T(:]^[_P#6CC7=GP'@FHW+B?%/ MO?\ 5?Z$->_=_P#K1QKNSX#P34;EQ/BGWO\ JO\ 0AKW[O\ ]:.-=V? >":C M":C< MN)\4^]_U7^A#7OW?_K1QKNSX#P34;EQ/BGWO^J_T(:]^[_\ 6CC7=GP'@FHW M+B?%/O?]5_H0U[]W_P"M'&N[/@/!-1N7$^*?>_ZK_0AKW[O_ -:.-=V? >": MC_P"J_P!"&O?N_P#UHXUW M9\!X)J-RXGQ3[W_5?Z$->_=_^M'&N[/@/!-1N7$^*?>_ZK_0AKW[O_UHXUW9 M\!X)J-RXGQ3[W_5?Z$->_=_^M'&N[/@/!-1N7$^*?>_ZK_0AKW[O_P!:.-=V M? >":CM(M=D(MP(C,""B<(PS'9PAEI"$_!\"!$<7Q($"(\TJY\&&YQH*"KG-)- M !?XT%!5SFDF@ J;@**T_]$SV:7ZD/3G\F MX3^#ROK65_+\8A*L?2'"A0B3" MA0H1(H3#A0V$C&A+6@D5V+Z0Y25@DN@R\&$2*$PX;6$C&A+0"16^BF+[W_5? MZ$->_=_^M'/KKNSX#P7VU&Y<3XI][_JO]"&O?N__ %HXUW9\!X)J-RXGQ3[W M_5?Z$->_=_\ K1QKNSX#P34;EQ/BGWO^J_T(:]^[_P#6CC7=GP'@FHW+B?%/ MO?\ 5?Z$->_=_P#K1QKNSX#P34;EQ/BGWO\ JO\ 0AKW[O\ ]:.-=V? >":C M":C< MN)\4^]_U7^A#7OW?_K1QKNSX#P34;EQ/BGWO^J_T(:]^[_\ 6CC7=GP'@FHW M+B?%/O?]5_H0U[]W_P"M'&N[/@/!-1N7$^*XRNTS BZQUR[^!!6'8PR ;JJ8 MK#\V<0=1A_7M1E.]^82DRYK^5/ONK[TB2ZI.%80G.&TH2GP]RJ>[_2/X^3_) MLDO7G)S[B["^)FOQ^;6"7-?+-ET"=@M4@-DM_4=-,19$B2%"ZR4-<8*%1^&< MD)-^CR_&M#IL1J7AQII&$IF(D)94GQC&&W,Y7GT5ZGXTF=*?B+)Z?\Y:"T9R MV &7T=K_ *ZT_P "274)STLM!)PB<(G")PB<(H7T-^)=A^.CJ*^?W97+.Q'P M6?@-4##M/>5-'*J4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1 M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1>1.4?0_2FTM-;=G9"P+4G)2/&E709F7E(L2#%#)"4AN+'M:0X->QS M#3!S2-B].Z":3Z.R&B=CRD[;5G2LS!A3 BP(TU"AQ89=.S+VA['.!:2QS7"N MP@K"/[PCK3_5?W5[AG/Y;F$?J!TT_>O;7\QC?FK+?U9Z)_OALG^>0?SEO0[$ MOI^W=I$_U$R-O:KO&N&+&'UFR!=MX">$06=&3;NL@W 5,:;Q(7#1.AJD);\. M6L26?(GH_;EAS&D3K7LJ>LULS!LQL SDN^"(QA/GC$$/7 UBP/87 M4PUA7%:?Y6K;LBUX%AMLRT9.?,"+:!C"5C,C&$(C)0,+]0G5URQVK7'5-,%T M [5KZY2\'\8B0Y-;26J!0F*-RF!;DBO.PIY M,:&EKECH91@HBTINW3(RHG8Y+;FL1\AW;F^B#3$V_56(\Y *[PV$3%SFVGRS M:UPR0V7$(0)*4Y9F094>7'6Y'>;<5=P-1]"J",QB=O25+GK]T3[:M2 M_*/3OIGE:'([BIJ,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWT MSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4 MJ,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">O MW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+ M\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F> M*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1 MF-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z M)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E M'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0 MY'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,Q MO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/ MMJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H] M.^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'( M[BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X M3U^Z)]M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M M6I?E'IWTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IW MTSQ0Y'<4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'< M4J,QO">OW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO"> MOW1/MJU+\H].^F>*'([BE1F-X3U^Z)]M6I?E'IWTSQ0Y'<4J,QO"^\;>>DYC MR(T/<6K)+CQM@U)]YSN(4XON--%U+5W6TJ6KNISW4)4K/@QC.>*'([B ME1F-X4I\A2G")PB<(H@ONAM5[0*9+; KDNUNI$$@\8<6M-O=K8Q)8*7K<\R$ MJ2#S=7 W%VO6 V#;O@8/ NT405G#HE@8B27&E$K17I3:15Z!6HM1J@S(\#%D M&)ODTB<1,2YI&Q&"%AL13)S)4V6^^X11 MOH@? 73+#E4*(K.-S=0Z<95&95G"4;[V2A"?#E&?Z*$)2E./ZDI3A./!C&,< ML[$?!9^ U5 %,!B=G25,WFT=^80OV5C^'RJF@R&X*S=C#AZ=?7M28,/&<4VS MYQG$5C&<9P$G9QG&<(\.,XS^'&H(%#<,#L7\UP.'JUY0U*@P\Y MS3*OG.W-KE.>[&9QX4Y++\*<^!'X4Y_WXS^#/^_E MF_9?!*JX"ZX>R&Q3+YM'?F$+]E8_A\JK4&0W!/-H[\PA?LK'\/A*#(;@H:L M^!C?VJT8A1,(5JG>"E)Q&9[JE)M&A\)5E/<\&$YSCPXPI6,?][/AG8> ML=Q44%1<,#LZE,OFT=^80OV5C^'R%-!D-P3S:._,(7[*Q_#X2@R&X*&M;CX" MMA]0>%0HF<(V-54HQF,SG"<9TQK!6<)QE'@3C*E*5G&/!C*LYS_7G/). ZO. M5 ON&.70%,OFT=^80OV5C^'R%-!D-P3S:._,(7[*Q_#X2@R&X*&>G\? 7JT M0I<*(M6;!L'&5*C,JSX,;$M:<8\.49S^#&,8Q_\ ;&,8Q^#'+/\ 9'L[@JM MU1<-NSI4S>;1WYA"_96/X?*JU!D-P4,]0X^ C2.S%HA1$*35IV4J3&92I.?" MW^'&<(QG&?\ \XSR6XCK"@@4-PP.Q3-YM'?F$+]E8_A\A309#<$\VCOS"%^R ML?P^$H,AN"AK; ^ D_HK"8,-.%[FCI5C$9G&%)]6>S5=U7@1^%/>2E7@S^#P MXQG^O&.2,'=7G"JX 4H![(!3+YM'?F$+]E8_A\A6H,AN">;1WYA"_96/X?"4 M&0W!0S+'P/OA@"/(HG#O8QG.,9\'AQC.L=Q44%1<,#LZE,WFT=^80OV5C^'R%-!D-P3S:._,(7[*Q_#X2@R&X*&= M2CX"CV],*A1%81N:6E&%1F4I7@QX,>%6<_UYSRSL&? M!_M.4 "^X8Y= 4S>;1WYA"_96/X?*J:#(;@GFT=^80OV5C^'PE!D-P4,].X^ M O1VK5KA1%J53A&5*5&94I6?$_UYSE&2,>P]Q4$#(8C9TA3-YM'?F$+]E8_A\A309#<$\VCOS"%^RL?P M^$H,AN"AG8P^ G8W3ZE,*)A*[_;L+QB,SC"\8T]L96,*QA'@5C"DX5C&?#C" ML8S_ %XQR1@>KSA00+KACET%3-YM'?F$+]E8_A\A309#<$\VCOS"%^RL?P^$ MH,AN"AFNCX&=^[71F%$RA.L-(J2G,9GNI4NQ;PPK*4]SP8RK"4X5G&/#GNI\ M/A\&.6/L1\)W;1WYA"_96/X?*J:#(;@GFT=^80OV5C^'PE M!D-P4-:9'P%1-D]Z##5W=R;(3CO1F<^!.#7X$X\*/P)Q_NQC\&/]W+.^Q^"% M5H%]P]D=BF7S:._,(7[*Q_#Y56H,AN"LC9@X>G6^P5)@P\9Q2+7G&<16,9QG M &?G&<9PCPXSC/X<9Q_5PE!D-P7IU^.'YH=)SF##SG-1K>>2<3UE0 *"X8#8KN\VCOS"%^RL?P^0IH,AN"PYZ^X,)GI0V@ MXU$BM.)=HW=<;CM(6GP[#JB<^!2485CPISG&?!G\.,YQG\&>69[(=O<55P : M: ;.\+-/E5=.$3A$X1.$3A%AO-N=EUQTF]26PJ7&8F7&AR.M6YU.)*A+)1I5 MEJ^R=R' 4:0.;DPG)[#Y2#%:=A-S(BY3:E,)DL*5F\5NO5FE7!0"_P"Y7YA#9,:+?FV=2V/- M/*U^1#F@6U/7;S318)R2*4Y($(JIN&VM^S'L.!'H,SF-0S>U#NE-OR=I1"K> M8Z+?%HI2RUH;3+A8*7ZO0LIXG;*D((3QX$E%O,J[5\;'9\D5.JP2O&7X[D@F M[.F2,1UCO4.P/4>S%8%SX7561!;(%4EGJ(DBED+.1TL3A&9->9AWTOTSZ+$: M,E,2V"X&+(T)5]Q@-U>DM;)L3*C)=(5BQ7T)8!AI968.)ZSWJ135:>@5&TWF MO"F*K>NF^T+%3*I"$XMXH41IFL%;9G[6BP=BD%;\3=](5'>9*E>=+OX >IW* M?<-GW6I!ZRJ!4UGM;R7Z<,&5>0@9;(4\V_A3*E1VX U_18PKJ(ZB+MMRQ:NW M5$D^3ZV)5O#5*H(V .OMQ+!A&F94BQ"W1DMB11;*4+W"W1JY',744,MZC0.3 M1&8#.OK@759OV7P2JNI1N9<.H8]WGK4U"\LVN=;[P^J.UR/U)M*580AJ:-?O M5BPBN:%,V7?QG>*J'1'O79? M4#6!D$#%DI M85T!6+G/DVN 6FS9V'K'<54BC@.@]XZ MJG(1.$4,:V_M$ZA?C'JGS+:OY)P M'5YRH&)Z_,%K$";6Z_K[!UUL^O5RV2H;VMR1<1$;HH(&!L&S[4 #S15,LMV(WNNNN Q$.+6W .) 06'1!NK-1*#2[T_1MNV<3'=C'@0VH9B'?JJUU.GNQ^;>>RTM$;LV;OSHAVY?-LD0 M\JVNX\E?&@8L/S76D2];ZWLS9@[HG*2]*J@QS!)D*R7=Q8K28%294(:]4!<^7"FZ_AZ5'G6'%PW M;V@NIM8NWC846L/NRF]8@I*':U4*-#KIFZ?>D2+.359R=BL0$/@*>V3U*T<) M*LHXD!@,ZWJ4PZ@Y,CD"ER*>:>C><]^SS46; VPE[=KKHOM=@)MFCUG.:\L) MLPR#GUEDJ7-:*O1(D29K92+")@&9LR2]):"D8<6<+;=3"EQV9##C:9&!ZO.% M\W;/A!9:\A63A%"\O\H@!\2]O_SQ2.3L/6.XJ-HZCWA:ZCFS.M>]V2::K(V^ M1:30NHG<(G)"HZ^ XE( 4DYUL*(T83=9(\X M&B2LQEBJ["O<*=/@#E7&O33CE?T[7'JOL5SF1M\4R'5H":[:G;,.@"QK-6K% MI@VX3"UK!UM:HIXJ1O@NY:^=.V:^R2J'=8H&M6"S5*P'+=<@X6UTP=/+VRL$B>G]?0H=AKHH4:KI8B7"OOH M)080D\'*R7XR&AA&).7'>39V#/@G\-RJ,3U^8+&EPQV@3 .OQ*2"C546,I51G6FC"IYFM43:1J?KES55R#BQA6N32&R!(F!L MV2-\F.Q)R,1@P@>2!SK%$>(2<3UGO56TU1_\>NE+U]QI#KR4-J@BK#&Z0!@U M_ ]R18 <^_GBZW2O5DB^I& MXT\E+)$(D:0^+R4$U"JJ@5VQGR5@F2X]@N<%$>F6:JPH$C'L/<5#A0#&_5/$ M8+;IR$3A%"^R/[2.GOXP+?\ ,YL?DC ]7G"@XCK\Q6$/4-L'JZLUYWCKK2HF MR2@U3G!!<&4 K(X=F"*EZFK%\69#7>5=*Y,,7Q&Q)X2NQJ=C(@+.I1^R2)A5 M;XW,L)"M=3I[?T*0-17SK,+;-HXS85/F0J'(L-KBDB$VH !31344>-N9=.V' M9R42Q+EU7<)(H&T;!*ZX@BV($09;[21]'FW,3$:W)=?V;]HZL=V.>28SR[UX M;F\V>3Y)>J33'F_$OO\ DN9WGS>ODGE/B_\ 6>3^/\7X[N?T_%][N_TO!RQ] M@WX3NYBKM/4.\K #5,KM"H5(UV#<'3Q!914?G8]PO 2=:3UA*$S?2'7K83= MV[<%P8J(^MQ;MU5%80NCE!5'/3=1@[)2ZZ"IIF(%M]58T\.J_HZO3"_NFSJ! MZB+CU/V+3>YG P2-2-=J3-!#@X]HG8[.Q3M#GTVN5%@-%IM8'YF7J[MRYTT] M&JQZ3)KM;J4%)>FW!\H2@I7TI?MIT>FR_)SUXBVW6LZH(V/*%1.LC:'K!@4I MIQVOO4J?6;D'S,OC<=*'Y0@;:258D0H:Y"X3T ILJPUD<"$Z: 4.AYL%OO29TP M?L$A"V3L0PT"/21%2?L1"BU4HQ%KXP_+JOI=45RV=.VX;,NC)6Y7=^]1IG=F MV='[;F"!M+7))$#K^9 M:)0ZAAA$&S-S1SQ12X&_S;_,K[V=C?2DGX6K&MQ289OI5U\- RP[DR-2*_=& M[97_ #C.">:YH0FZ2A4F<;,6-JLE!NQ;&+BR:S2+4&M":DZ)EV)ZRH;[$&[9 M=MP].W-6:/)]HP$UT#9K41>2(&GDXK<&W5V%;S5G,CZ#U$6T48E&[%K#8=AQ\WRL0KNRMT]. M_6RUL&>+Q#INQ*@(IE=%P8VR';W%4>.;N[QW87=]5NVY52G")PB<(G")PBA?0WXEV'XZ M.HKY_=E8REF] M*+NGHV#;\::L/HM1-*%O(?(![?<7WYB6+#78^(A7SRE285J75]-EW7?P*SN MW1_Y;6?QSZX_ZLOEF_9?!*H[['X07EW_ +CSI"EC+5@979V2UQKE0Q.NMRSK MNA5[)]]]&#=VO6*[;,UD,CR?S; DXKI+).T$Z]7\)B9,>7Q*JRQ4Z3>M@_U5 M; JBHE6K=&I9O2-FODFGXN>+7L<.?B6K7 L.Y>A.*E7D4F 7%'S!RA8;)G,; M I!0)=%,@<.MBD%)%/2[L66M@_* U3\5&\O\TZ%Y.P]8[BJ[1U'O"F?D*4X1 M0QK;^T3J%^,>J?,MJ_DG =7G*@8GK\P4S\A2G"*%^GW^RL/_ (@V%\XMKY9_ MLCV=P56>Q';WE:V]D=IV?8INTHM-HFN0-S#:U-6BL%S^Y/*H=>.R:]N*0 U] M< N-895#ZD(A36*/!T^>/EMEY#Y<;C8$?(-QXA57 SK3]&X7XK9)U%?V'[-_ MPK.__P!;Y(Q'6.]5.!ZCW*J[KV7ZG]86K8V1+!KT;8'+\CG%_1X,SYT,C@OG M>S63S:9]&:> \Y>?KG9_,Y;TO*_6J! M715KV/?*]SO3,O9P-1J/5?$:L6LQ>*$"](=52;GHZM24[742"+P1*HIJ MJLI?57U<+Z5S[,!MQNS6>/2[LVQ[@T_% MOUJ0:,]3R>3M5>KM-WEL:ET]ZNV'(L)FS!W:E7@C@^T9#B\V:,I ML]D?$R0\0@H/1T=RBV=>[%J[L_[1LNH9A)M>O>FBZW:LJ))PL=@_5J,9.",S MT98DX5"P0@Q_*L9C2,98[_A8=_\ #5+L3UE0W['L6).T.TDNHFG['F56FT$: M:9U1;BU(M)#9V"&JI5NK%BZK*O#?U]<_5RAW;1VYOZ-KY?75&6"J[5SCRC$5 MHR+0*5-,PK 9FG?LQK@+\>];).H+^RPM_B+7?SCU+DC'L/<50X=H[PIHY"E. M$4+[(_M(Z>_C M_S.;'Y(P/5YPH.(Z_,5-'(4IPBA>N?V_[9^*_2'^8MX\L? M8-^$[N8HVGJ'>5A?F\-32*J)M<.F;8U0*J^*@>01V&,I]F^\E$FH MEBUXJL-I9&GBW41=W*E<,VN4\5(U^;761D'(WSG$JK4N!Z#PKZ;LU.W1QU"6 M/J1K>UKH<8I448)V< !4Z)0;=F^@8-<*=/\ HS8,D>Y.E^9?*7"$4]*;2/,IGN;#MOJ[4K41ZBD]H M%36S:0T&M3='%I#-+,%E%<*%55R*;^&?AG?DLXM:7RQ[2Z+JCLJX>0>E5]Z< MX-OL7FO&<#//-@U[@H1\W^&-#RJ%Y5)<\E7F)%[['<7Y,QWO%)*#B5_-M[%L M6INE'UAU5P,T6%_-T_(ECO MD4PY*HN&5R<3UGO4-P'4%A1<>T;NN&)XZMTJF@BAD#-(5NRG-A^/HDM^L;4E MZU()U:=QK["]Q$MBQ4-[!U&)<@TY%SUK!,6O$P*@:N+)A6ITUZL;QEUW=:RW MZ_\ \DW:/_[:+\XE3Y9GLAV]Q5'^Q/9WA9D\JK)PB<(G")PB<(H7T-^)=A^. MCJ*^?W97+.Q'P6?@-4##M/>5-'*J5X2@V(9&$1$]"G8)6#+&S6TK6TIR).CN M19*$N-Y2MM2V75IPM"L+1G/>3G&<8SPB_@L;$##!P> A34$5 AC83:EK=4W$ M@QVXL9"G',J<<4AEI"+/GC2X M49J.HH:DQXD204G9;2G,F<]%@PX[LEWO.K:BL(4K*6TXP1? ]6Q-D0)068S(@/KRTI/C6VG+%CHC*4,Q8(^#'8B1(S24M,1 MV6VFTX0G&,$7PDUL3+L@>VOL.*-@0U@ C9&'W4MLC;1,KDXPRN.E6&'EOR:H M%6V\XA3C&([B&5(3(>PMT>FWQ3I]-G@J[PB<(H8UM_:)U"_&/5/F6U?R3@.K MSE0,3U^8*9^0I3A%0:U6Q-2#L @;#D8;'DDY;33C[LE>'RY288G*R\^M;BL. M3Y\EU*:SGNX_IMK2K'^[/"*O<(J2% A:W"=' !<$/ M?*'3CT,=&:BQW#%G-D;+8B:VF4I0J::L!8F9)2,X\9+(SYQ(+."A093[:75*3';R/"CVO$,X0UA32W>[XQ MUQ2E:TZ+AO)[R45>X1.$5!K%;$T^O!ZN"8X1.$4+[(_M(Z>_C M_P SFQ^2,#U> M<*#B.OS%31R%*<(J#%K8F'9#-L88<2;/B*^#)R,ONJ;>'5B58)@=I$=2\L,K M8?LYA3CK2$N/X?;2\I:6&<(FMU-@).^G@$Z?3;XJODU5 M=X4JGEAD,V*)AB+:G1Y4N-J6RZM.'$*2M&R';W%5?[$]G>%F3RJLG")P MB<(G")PBA?0WXEV'XZ.HKY_=EHMR')UI.:FK(<-(B:^KLR3 M:=IR](/XIBUF]@1FH%MJM5WU3K*89*Y'59Y;!>OP[.CVN4M\*\7)39U<:>/7F IJZ8.HZ)U$T4*=EU [0[:Y0=7WHY6 MS/FR1$6*VA5L'P)ZLDA14JB?6"@#%&$A+.C(5]TS6Q*),!M7455) MUWGN[&TK1F*P,DCXA,EC:^YJ#JMY0V07G"A"",!BYNDH*2Y44)=E0VFB90=! M7(FL$%_'@*K'S':!::DNP8(BOWZP&S%7H5C!UP'C7KK[? KQE.NNOQ:3M2X! M]<6VR1]/[,FZHMLJ!+ P@.;[&VJ&U_%H(V:7)P#6(V:G@,PI2Z2:16&+T(Z=/1 M_&; M=ECO+XR4QYOD,A3D;RMA*69/BO'-)PA:<<*%4.$3A%"\O\H@!\2]O_SQ2.3L M/6.XJ-HZCWA31R%*<(L>-_\ 42#Z>&J64M-3LQNK6.5?56.RU]P"MBBA->:J MNVVC9PH+)&!YDTVL#12S44=6H10@ZXASNLJD^0PB),5!1'KECP;\>!2=66P) M6M?TZ3.V)Z2GM0A;,.V)/OH>F5G6PUTIMX;3Y)>=!),6IF7!L1H0='&@P<04 M;MC98O6.Q] MBGX]28-V-J?&EU56NB(:P>G4"E0G'L2W:Q-LRV(L><2E]/2\@>?I7PG=H33! M(BSJ-ZWO@*R5T)N8K+ADLUN37@Y+5<[JK;AU6RG )\U,0?/"^D':Y"4]4 ER MK8=R!#B>D,Y1FON&"4RZ.-/%>T-U@[+O=:G-ZLZ=SEPV77;[48-GJ12W5BK" M$ZCM.V]JZR:VO73KI JHG#;D:>MC#P K# V&#(;P&).O%';7TP4R<(G"*%]D?VD=/?Q@6_YG-C\D8'J\X4'$=?F M*FCD*4X16??[P$UK33]ZL?EGF.MPL3R7F]A,J9XC+[,?_41UNL)=7XQY'A3E MU&.[WL^'\'@R18Q%^N;4(:S%*Y*$79,<&JX1C5LE,TL%30Y6H67J.J:A)0[9 M[L"0/<.%NE?;6!9F6PU51T2&!F6ZP5AD]$5@IH?3IIV[0K%?[0O7<\A0U5BG MVJ96BUANH38=I.DM?5P)K^=2M;]1UQFUF4:)7UD'+L[QCIX,#FRS1)6KFPQ! MDU)V-'1('-3"4\W&GBKHB=O2T6V:HA;XY,@_/B$0LR^_AU]"M#6?:'4 M^\8H[5@U+LVE$=@E:-"&#GG*.?\ 1X;? _2NH*>MI /<'8+0R?:NKG5P LD9U 6%58DT@U5Y96N0;E3#B781"J MV< G573SL2QQHTQR7$L<4U7I/4+6H"FB]5#CR<'&9 R;*GP3@X40BGGZ+SX+ M-CA0G"+#;K__ "3=H_\ [:+\XE3Y9GLAV]Q57^Q/9WA9D\JK)PB<(G")PB<( MK4IM2B4L3.$PI4F6S.M=YMKCLK#6'$2[W=#]VGQ48:0A/DT*;8)$.)E6,NYB ML,Y>6M[*UJDFNX#< /,@NX\3577R$3A$X18_;+Z7-%;5KLFO6/7%1C8?E5F: MR8$5:KQS4*14+M(V* PT_,"3X%3)$*7)BNO+9?<0HBJ%"U;K/5<">*UCKVDZ[&%)J"1 M(=1ZL#JD$@0;B1Q["&7\M1?%YF M9B^*7AC$AYET>)/G49]/A17EPI3A%;%QI5.V'7IE1OU4KEVJI%\9*GUNV!1U MA!3)00K!/!94D46C2X+TD.<(N0XPIX>6'P2,1;,R(P\V160+Z?=#A"C)P M+I75 @S'@5H7'*C->5* 1CC*9(I5K;7@-5\Z$GDVUN_8>GS_-7E,M M[%Y99N/C9#KCF;0RR>RK)1EN4DH7T$:,TJ 8CQ0>HM9AXT101<9@91:Q!:87 M6G:8_75M(C#&TMK OZXUZ\'6G&%#7:+3W(>65UL.J&2IS]/0G>O12]+:>UN5 MFG=>:JUS1#9(=%#D"]/I-;K1*:*A-0H\0;*FAAL.3(@QHXP8PS%=<4RA@8-9 M2C#8^&EDIJ3B2I,X4)PB<(K5/%>1KAE"X@P])7 MX6_'^5-OAV&F^Z[AKQ3KO>;4ON*2Z/3;XIMKU\:>"NKA$X16C<-?T3842 /O MU+JEV@"ISY,9!MM>$V*&/(R@Q:N2IT.,7B3&8TN57SQP%)?:0AU\.8*#'5+A M$)3+I%9V.GS0^*]BI8TMJKT6PAE'H[G7]5R%RF/85VUC"AF168:O%6IUVRHR MIK*L'W72_A\X.+D*)5>9/3?T](CDXB-%Z@1$-1F(9>*G6]/3')Q(U/+:]CQI MS& ^&I3#%"/G*4TT\E:&ZH9*5]*<"I\J(Z2IS],>^]59>CM+.Q9$%S4>LW(4 MMHFQ+B+HM87&E,&VM@1S+,AE0O+;S19C;&TF22'$J3.:V1?&Y.'4VX_B>2JJ M],U;K/7,FPS-?:]I-&EVV?DK:950JP.N2+&25+(D%3SCP>##<*S%$#!<@J1. M4^[F>7*SHIPHEH4WX5*>CMH5_06K/&?3X@^9,NCP(\ZN[A$X14BP5\#; M9BL6@**L=;L(R:%/5\Z/B%@IL.2CN1"(HL+GM/PB(Z?$==C3(4MAZ/)8<<9> M;6VM2TRQ82%"K$9@"6K M5*W1LC%PS"9:Q9X]G(QS"93@..:NI*W(0&Q8M>#X>*M03*HXTWB]WC!:$UE,5E%55!O M3WH4/-@$A&E-3BR ID;'&3A^O*E#ECV UNSL 0U"D1Q+;L9 J]J78S$9&U>N04-8B@A;40E3FI M.X1.$45;LU0+W=K.Q:R,E)X8;8U!U2"0M$=R='\S'1AYG#*):'&,^.?&-L.= M]&? TXO*? O"0I3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1 M.$3A$X1.$3A$X1.$3A$X1.$6D2Z]+/6F(G2]D:PM9B<9']2/5WN+7VKSAYIV M&*O][7U/UK6=UL) E8D5^3JW%,:T2W4M?+COL!C6P=@G3\%A]4- ,KW&_H %U093JX[KV(7<@7C6;=T#5M=V7H][7(38D#I[C7&XZ]*;.TJ*WLC; MK0&MN/I>"525OJ966J^0KT5HA#UYU?E)6OQ$K&NGXF*N-V3GIV1'PX+.%L.G)#J+(ZQ.M4IHEU,!7M MZ.GKZ.C!5;I7W-U&6;JNQK'M.RWSHW9>1$*TG'+5-J2#M1KE9D""$"E1G=C6E]>C+IPJH',Z M\[0U.OMBZFJ1CJ)R8)#++5Z(9-E-$IJ;\BQ[1W2SM@Q8[BJ*FWP82=.D=6E] M"D83\27!O\EJ-(:;&0+>+&$YMU>W/PQX4VU5UP ?75>MD@0A>O[G1I(8>Z>B M\@/LYG4'EV9^KNI_HHNK%T])ZL5$$TD)E!%=1!*P4R%6W(L1H#(;*GSQ0A3Q M$0EU^'1CM!SR--^[=APJIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<( MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(H%ZJ M;)::=TP=1]NHTV:-NU5T+N"R4\B-81*(#[2#U[8B=?FP(SK,EN1-BEHL1^*P MY'D(>?;0VMEU*LH44C$5PJL%;EUL=2+8.Y*I^L*.+-ZXV3L/3UIE6T#>"HPG M>]/:8ZCMX6R7610L\!FO4R\U37FBD4*PK+2O-TG;1^.3CFC-/P!(%-/FW@9] M>[%4B5UX[O![48U188.E&;0+N%6&( ($7$=9-U#K:;>'Y8X_4*I MNJ?*/6*5'NXA^5KPB8) JA7C1!ZEDI=6^^O93,])V<:J/JIUS]2E TYK")LU M[5:K//Z#:MNQCS1J04TR[.GJNV75[<%L(Z4+-:KITM M]-=QO4^65N]LT#IRS7$I/C8ASB5J/:[KA2PSYD-+,=,67,+RIDB1&2PQAAYQ M;6&6\)[B2@XFF%5/W"A.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6%]; MF=5 &=$@EASI\>JLTIUHO,0 G/3+//(&21T,88BEQ7F2$.:*/ RUABM$5,C: MS49D&,3G%B[*+VNSJJ3<>NZ=:F>HG#X<7?A?AA0@ M=4C$3610ETL6,>6TR-99C\:$5ABHC;4M^\PGI$::[ET!!#V@6$=>3Y"='5V' M/JVTZHVSARU=,"RU=:A5B 9ZF'%C(4T2(CR) MS-/\X3&@4+S<#@%9%%](YC;[MQER"-B *(WR L6MM4&5"KXT\AW#DEH66B[O M\]-G5Z82OMFQ=2T6I@9*JL#*VUVRU]!4/#M5J1+_U,J(+@/4U MJ5)AU6*8FP(PJ'$RE96+L]CPK/S"68N2HVP5VFQ(HTFX+%CF3B8S$U0C$^EX)OG61S1$B)E^6L M#&L.8@1Y,7=.%_73KSZDO[?-7PZU]:)(ZD8B+),L\'RE+^L,0*PDS)#R9D38 M=*KX:&H@9KP!+$-"-A6LG:R7C1MJ)Q9 (%7F4MUN0^I,R>;QV9=%M-PH>0$DI95>&&,DON1(D68>8WXG%F(3(,YUMP74VJ[$4!!(<;@HVM:Q=G/*@-FTN8MV-4YKEEP!DR_(7 MRJFH\4>B6W-KR%UWIL%V^H2_;EL&7:;R.SKO7D38NIB1&*KC5T@1K[(@@&$Q[A*0B 90,UNETVI:WV)=FL49#<9R"ED$NNX\.CK],9O MZ.CKONQZK[E:0BV]5<1LXN71Y4^6:,52;!7+'U]$>O0D4=EO8D6%!;NV$+C" M[2S%:ID%\AEVQ2E3WI)#,*6^8BSS;K\^V\TV98\ <$\^>S9Z=Z]GI'U3CG"+ M, "D_&S(L2NX#"[9?LVE3?UG.EV/ M7TW=2_4XIOJXBM4'Q"9E2;M,7)>R"80\7,378I#9FLBM?BG%SYL:;Y>/U?Z9 M-&FXBEPI91LB/=8SF6,8RYHKM_0>O;2B&IP-.SJ/CBE>-=21RGV3TSK<>O'D M8HZF8557 03<&JLS/IXBOS)TY\:V6F45#[@IAXG*<%V9Y;>"K7ABM0G-SKCW M7<<>[-??=Z;?F[\0/TZ8Z@4RB8NI@9\0$VEU ,A=(0PJ8C#\*JK@J0_,]+L2 M3! AB9>&)S11MJ:(8"US$]IR7(D23T74^?KZ.KTP7_/Z4&?!4E=XZE8YF6'5 M58Q:0-K39:4@<&@C8TKSQ'VAY,\P7EV$FS&G#"X*CCX@F/ -RI4&65F2XDA4 MAAV&N]+\NKIR2I[:"O;7;V9'P_#=RZI8; R<6K->8P2(-U[(M0UEU^'+*0:" M '%RH=A<5(C1K5:K5:K4TF&PE%0H,^(/8A39,:1/FC=A/=G=AU#M[$O[OG\ M:<5EY"DKEL>.CH?\$9^2UXF6AI,N-GQOC,QGFG%C!"9 M/F/N94MQY]7@SA"4(21?K-< YL:;=D3!S9T!7*X@[XA'G)(%V#O8X15KA%0R]: 'YE<(&A$$G-J!Q=EK$F8PA]T&?IUB%6ZK%FVUXSA,X#9P8@Z,?Q_3BDAT22WG#C*&WDU(N)*IJ)(5,&2H4\&,K+%^0Y#+EFAPM<6O(::A$$R97C9?TJ MT[ *=EU>C$TXJO.!)K49;Z#HV5*NTT(ZL9@N'.A$"C5AB0YS#@O[>A7 S7NHR)LH-/=-G"=9B%"XUV6HA2$#"-:DWRF2D2K6#2S!PB8F@CK M)%#S*<%@EF#SL))'+<.<5<>D2B1%N>5CP[VN/;#T^"2#V(2+F2IX14"I-B'F M@R76YWG,JV)@0*;>G/*[#Q0U_13SU[AX?FX)W:N^29S$+8$ \"RN".')<1]]P:NIT]VSYZBI3N\ M*$>AZ.U^"H"H$IN#/0WKZ6[B:Q714H9+%.%8L\HTJ;8WC(H MT-.A)<>/$@0R0LOW"BX@F;J9GM]..U#6HV#:=O%6SFM]29NKW!2S:>EBS\SR*$=S M.(U&O40W92LIZIU2/36!M?AKLD:.13>(EEFW3,F!D#%K)*2T#*RB* C,21J\ M=INVUONNIAMKT(:T[#LV[!2_MQ4AL!>H812R8^&>FS#+Y(1.B3GVJ6;L(N%- M+V%=@$@4%'@8&>W!C)K3D+-K(OR$099MJ.4DRHXN'&BZ[CB-G17;^@)>!Z9W M])ZC?TIB%U#C*4%AP9AS9>!V*+Z4VX5KQ^;>HSQ0NH3) Y.**N\QBPDKB7"#:_M::+:J,PH7V M [4F#3DZ[*0Y"!L%JMY=&KDM <*=68"E-F.6%W5A7NP4TV^<]&R[IV]/593=7ZBH M\,)'PX?FSAA"BS2;LZW1UC396#K0.))J7('70*8CTYJ[0"DVTPO%9E$W"3!: M#6;+GRN,A=?A2\"XUQZL:8=X44-:UR-.S;V])"OFR)W/+?H]DH[5K4X[2FO. M8>PS*0%AO$GR HA)BWJ#(AR7Q1QP&DE"%3*:(D-"[0Y%:-LNUYN:PY%U]>%> M'S[.E3?Z7#SE68P-ZJW(0*?/+%')$(TPR3'Q6M8"R\JM/66XX)$4PVI!*LN6 MQNH+JL<3$F&I=7;)97,DP\S$/28L\W+JQZ.&/3U)?\^_].':5X1-6ZH6K%85 MJLMHAB2=EV&0'2B!77I/ BNS8]>]!8(^"]$*1VRJI@@HL_'ECI@84P4:;J[@ MY,PJTTJVF&7S[1=?=2F%Z@AVPY_-W7DYW*^=0!]]#K1<'+],F(#EGK"1@()3 M@!X!!GOPJ)$JR*ZS!(JM<>)'S"NCMA$$B$,5E;PAP+EF3*(R,0:4N],?F._H M4BN7=NNR]*J6C=2M-E Q!A*\R Q.+8A1C)BC#)-;\K&C9++[P"7%('+(\N(4 M;3(BSWVB#+GB7FEQ$1949$A<7?I] IZ^%WG6/57K_44$F5_R7-F8$J!TV!9H MMCMM>M\V;?QI1KTKL[LFP&[$^-UD=K\F4PZ,JY ?:DF18R0)K0-EXH^4L:=% M;Z74NRNVC=TJHK=U7]?36^F5.VBHI.S]5<1BCH@I 709(=RQZ%-_ M5?PXC'/O7TQ ZMG"HTC-?/*Q !V09,P*=U-"9FMS1%-G;3"E*;:XJ+^[+HO[ZX787J^R:.IA8 X MS!E^2F\7^4J$38%4 @[Z$NB3ZXK-=K:+U4R#6^62MMN+:Q\!]OQ_ U>ZZ_Y^T'L*BAI3 MCYNS/'H4E;#3M2V"M?E=>P9=?5 (LWHZ+,&LUTH38#9AK@:])QH[K].';U^=1XP(ZKTQI.7K3A"7GV-EU;L\W9=CC79AM MVX%1?UX9#KKU;*<53YM=ZK@LQ VLVV02"NHLA%),[ H!TFV=GWH=Z&O??077]>%.U7( MEGJ8*EY!E$N56A6"CC@^I3$ZUD>$4R2ER8[!F5#C'9'CY4-N&/EY%V/&4PI# MRXSTDM87S\@.6L5%>.CIQ37 M:X[<-H$$&7A0_P BESHP*LPR,OO-D04F(0I\>'4)I".9)#%U-E:9<,,<+^N_ *?3'TQ^:F M*_M=B;QK]OKAHP)MA:ILHFAY8:=88A4C$;+W39/DQ*6@7>'8) BF"6U2VF62 M&G!P.L"[8]F8#EP8V" TO]*X?/EL3+TWW]5]^U?.^Z_WR5O%[D5:QD8=9NCL M<$(=CW<"T8>_.=KNP 8294ZX/L(DW8W"I/SN-)-D*^! M%,,.C''YJ]'5>O\ 3T],>A>#9-/ZE+:S1W11G(,T]776CF:L8)5H)7#,R=2W MIK)AQC8./2!R+$B6YD<;C5(^V^B3&A,!*P_(786 +16HNX[>CJK>.W!0:W4X M79=/7=0KVS@^\95IS:V U]C#UD1L]-83?*^A30T'V=<8@0B33\T>PN^>_WWS;$O[CLPVC'KS%XORJ\(1NB-*MIH; N M,";+@["6B(;N8$TS-F'[L)(:\54PA"Q62L!IE'IF#T$E"D(JH8L2?@#'912( MIJQA!I=ALV=%]<#>>LI?D=MU"*.F%-D2;,_:G//A/S:$B]ZH*@2FQ3DH-6N'?3'PPZ M<4OIYKJ[\!?CCA55DX1.$3A$X1.$3A$X18BFM5;>KL5$33\ZL5A4VSW0 MJ5FO3IOC-!;9E0LQ8A"63C/2(<,"W:#YN_MZ\$OV'?XY=F&U5LQ0=Z6D)L M<4?(C6AQDEJB540X^Q)DRX46L[ R+NO'NZ\^W;T!?U8=.WJ&(],_@.USM\(1UZ_$1!D"Z 2O$I8]^ZN1 MG;1"O1Z"<&#'FH=>BBH[E(AQY 5*/(VQSZ/%*!Q8,)Q46,)'=P!KO*4IQXFO M"]4$QI+>98V5+OW$&Y#*V.9?&1B"-BAS0Y5R5.AL5@<8S+GLCW6:=!J 7;A M0J)"#DAQ(]FEDIDZV3XC7E$:JV\<'V&2CQQRG';57K-98!%N!A68Z!->#>;Y>28N+EV* MB[CTWX=5!W["E#7'TIT])/"[*J@]<[6B7>LFY4]C(0+:=@RTP25C6?:C![3= MK(?3-RV3#RR<@L_6#(RMAO(38C-4R)DPTN$ZZ3D#7)J*&[+N'GOP->C%1?=Q MOP%=YNN5ML4'J8D62.;GVH7"<9*GT0?-1WO0A0(H0UG,DPI,,Q7C.3+$F/6[ MS$#YD^!0Z4?$$%0!S+>1H-=EZ7_-=T;=LFNSC6FSP7]&:\ZDHS)&9)N32RLL M>Z[EI%DF9%2Y,2*:'!X+L"3"FS1;RVU""Y98:PQL/D?^P-G/5C MYL,TH<_3CX=E*5RL4C?*"]*(7NT*(HKEO@%"J@UJP/$SZLG7I6O+&R0R*Y&6 M1G1+;.78"+A BZV2A+96F4Y,BP88E=?0>E:]UR7W<=U.^_\ 0%:%>T?O,"W5 M&(]V!-HK1:NW>2ORRR/MFCT,)3ZX8K:HB)T-IB.0%Q-AJ+GR"C,(\3MH\ZY5 MX!@>W*@R2V^[/ST\V[*Y10]&-:#;A7S[]AO7QNFB]P'KGG;LOK[XVB]S3#3,N9L7T>&3[$S8GI MIZ7330JO;X&KI5&,RR$4^-J82HPSKQE4YJ1/B:SJXB:;#36XC!:-!19D%5)> M*9EEY)*-/+X<1&G0HD>#39Z7GS9*WIP],5#V=7;Y*QZ_%,6&+)AU^4T96.,6 M?)"$9*!P,[%,CR).GIJ8MC@XARQD:*F:B^[':.DWW5 M(P\.E5H<^H5[S2N->"II36?4T?I)D$6N,;!V9"*H!E!UE4)CB6'#=D?&PY2$ M5\F5R>;$RJVPBQLG)ST)$*3&;D/2F'BMA5%1==T]G3U[/FF^ASIN\_I@%_#> MI.HDG%*,-W2+YOF6S8!*&%68A-*@@"+P>=2&X\]JI*<:L,.6_:_.Q!:Y#;KD MV*MY1!I*&X[FY' ;[Z[>I10]=_"HP_\ C6O7M62U=$[%C5P!&(6,4T5C2"KA M=1,4]9)3XQ\N_( C?.D,G6&5$A()4864+J'2$%B#*R*6&\*5B17YOGXJRA?8 M.O-[+)W*?K:S"(*)#DIVAX(F"S:@SUK&QY=I61A^3NPY*1UVK0 J$\<[.C,A MK1#>JD$_ISQZ;J5ZSD**XY5*W/BO6%<>VPB5L MCE =HI+AF[QX4N4WY[>'IQVA1A8]-;_ )@X*""7F'EBH7"N$P!6P&'I>90ZOXND07-D M0X0-B1XZ.#(4Z'8!I":0:LIL84*Y=BN+7+,R"VMXQ^;IZ_3"*&X T Z=E]VW MB:78*L.ZQZAC+->:,[$6U%9L^O91N%$)1H^4 UHL5@MJH4A .;+?+/N,4E M63)(9[T&!-AN)&M29L64JW+/'AY\.C;>IH;^'IAVW^95('3.IMH9$8+7\:HP MAL/",D52X@T MKR=T5+F>0R*M&N61,#,N"@>7)Q<(BQTQH4J''-R/H#YZ;DOV]/?<=W2K-BZ^ MZGWR4LM/MXT<4=D$HXF0(.)?'@Q$EFG2),60..5TNHWY1/@71L"[+=QYM<,A MR4J'&CPVP0E=EZ7Y'J\=I7]^W.G0<.WJH:#TB]>]2,1=BFR+>RN23:)H $?"3#EQ7RPB1"!!+H;EL#;6B-,LAH/'=L4ME!(MF:CTITGJR&' M9L0#,]&/0.-:W_-2XZ92=ZL%:,4V#8UG9P-C#5GR'M>(%>,N2Z>U"6XQ7V*P M/\&(!^.]Y9F3)6N>[.28AXB-H2)'Q=?=Z5Z\O"^\F+[NCIQN/1U;.RX*Q&-* M[;RIZ6VW !KF 3S:1(>^FH<*NRR8#;\)ZNUF3"@QI, /-,7;79%1!E45^7,H M#A^?%B$F@D),U%/0Y;]N^F"FGGZ,>/7G3K4RU8!=@>P_/\JO-MBK,!KM>/98 ML;,W$(F($&B3UF<8;%P%RFE/,P*N[D@^3(*DS(+HC(H/&)^<:[/3H]/.@%.N MZIS5?!ZBB@RPHWRLS.KNQH^4S3K\B.,*R(KD"/6Y-LN M$V8,@MQ ,"9%GJIR*"$$R,%F5CI[1F6DBQ(DS"D^:MRV;S3QKP2AOH=_7?V4 MP[;U9$[6?4^]-"&,6D.0.#50H9,A//NQ8L\0[%(1Y:A <.%'>9RT2)+B)E/- MF$9,FXTR3B;"$240E.;7 TR%],,\=J@@TH,=A]!EA17\*H.]Y%+GC[G)PD%?-@F7+"7IPK808^>(KH^8(%W&D-HK4^7B/*RP_+=>1$PRTK#T5% M;A=\U.&*FAVG=AC7KZ%8UEZ>+B818BPEY='50990V(0&H-:SBU^/% MA'"5#+RHLN-=64F\A\-DJ\,91F6 BMEX\&E]:@XC >E%!%=]1?LI0C M X[0KTME(WZ7L 1,*R#HE5%#: LG$R-GFBH"UTDR?4U*GM$7V$RX JW0& MVWU=XA#)#F#1,EB7*:#+N_N-/-Z8KZ_/U=N>0[;UX+EI[<1>XVB?6;TR%K19 M]]@ TLT9Q+KSG4$%WIY]IS]"9EY"E.$3A$X1.$ M3A$X1.$3A$X1.$3A$X1.$6%":9OI=Q9KS]ZB))0J@-GC"OIO>71:< HU&C')=ZEC2RS,"602JIIL$@R .$ST*-(5:KKX! M4DV0N1 C"D@K -BD"E3'P:@FNA<0*^U#AJ>#*:3"2W+D379UA2E,KZ#8!LVW MUQ2GI7.N['@,EE8.KYV/BONS[L=EO"Q(Z"6B,0:PP*L1"+&RU,+3$O@)AJ(\ M0?5F0Y'''8D=GN-(:;3_ *]3]>SON5EC+%T3M$:1:6(LX8#";F#%%R55+MUF MVWF5!>L;CENMEA9UR0(3",APG#(SJ>.WKVUZ 54P^E]QPI28TO;1AT8^(%0_.>+E<9I8"13KU\%:I\(<3Q) M@6-=ENDI-C'*-SHR:6V*C.5Z.E9*3"B"1EP%]]W5=EBE.GCT8X>F/0O&5T_O MJ=B=,]:4UXL0'1I.&H=^LM8J@\U)>&%"P5L".J9 W(K,4^P5=$E1]PKMH75I M[--=DPXD1))2K49FW#)F0 M2C7V:,<(B=F@E)&OFUE" ,[Z,Q(MP"-9KZ!#,E$0C/D/*BHNV9=] M]_7=FE#G3#;7O'5U\51+3HK:92C!*,"N3(N'"%;!$%I_QNS. MWT;9T!>M@6"YF8EG!>;;?# 5N0 D><1FV\9C93:+PA'>-UWG!NZ<1>JQJS2EUIMW*7^UG M*U8C9VOK &&H,/S='>5%JFL@44BQ(;"MD'8Y*=09C[X$Y*.LUR(490!*.2,V M!RQ16ZGIM\?39(%.[NZ\L.G/&QX/3=;FWLSG8&N1LB2".QI8X*2*,!HT\N%V M^/DAJ_&8I8Y(.GEIVRP</7X84O0 T-<2*5K79U#KQ5B,]-&S( M?B)PZS4^'D9@Y!$U7NS40605E.G[8?%^DH>O@8$%LM9WZA/DH&:VC1T,4H-' M89;\4\N6)&6.WA6E=@KMQ-4IGZ7UQH.C9=2Y7;9M"7Z[VLO:C5H!@TV>36ES MQ()TO.F5I%%(UHM1I8.RRX@]!65634*X6(8Q(K(-A@S=)^7W9T=A"5J@;*X\ M00?-MV=*FF^[LIZ&AIM5J,=-%QQ41X R,U=9; Q)IY(E=GY+T,V22#%UF&0J M"6SFO+NRQ5VI@>1)#N2U%&O)HXF/)K[1)$@VF=85K?MNWWW$=O;>H H*8]?I MEG7J(N4^ Z-816QI=NQ7Z-"A9JX.K0Y0DI)AEWH*$ 5G%GXD2EP(QN7%=%MP MJQ(>)M11@D8Q%@C WGXQAFM;J5/5L[_,I O[*=)PQNKQ4U\A2G")PB<(G")P MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G %")PB_]D! end GRAPHIC 24 g333278g83i96.jpg GRAPHIC begin 644 g333278g83i96.jpg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

C!)5#,Y-V$R371Z37-6,64R,$1SF,X;W!R;UAI)B-X03M4 M4T,T06ET:F%)=VIK5F)93S9.9#%0=VIL,$41W0U9N;6M8)B-X03LQ,C@O,R]*+W=B9C%W,#%C4C

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�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g333278g97h08.jpg GRAPHIC begin 644 g333278g97h08.jpg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end GRAPHIC 26 g333278new1_12a.jpg GRAPHIC begin 644 g333278new1_12a.jpg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